9288106	CD	O	O

Clustering	NN	O	O
of	IN	O	O
missense	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
ataxia	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
gene	NN	O	O
in	IN	O	O
a	DT	O	O
sporadic	JJ	B_Disease	B_Disease
T	NNP	I_Disease	E_Disease
-	:	I_Disease	O
cell	NN	I_Disease	O
leukaemia	NN	E_Disease	O
.	.	O	O

Ataxia	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
is	VBZ	O	O
a	DT	O	O
recessive	JJ	B_Disease	B_Disease
multi	NN	I_Disease	I_Disease
-	:	I_Disease	I_Disease
system	NN	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
ATM	NNP	O	O
gene	NN	O	O
at	IN	O	O
11q22	CD	O	O
-	:	O	O
q23	NN	O	O
(	(	O	O
ref	NN	O	O
.	.	O	O

3	LS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
risk	NN	O	O
of	IN	O	O
cancer	NN	S_Disease	S_Disease
,	,	O	O
especially	RB	O	O
lymphoid	JJ	B_Disease	O
neoplasias	NN	E_Disease	O
,	,	O	O
is	VBZ	O	O
substantially	RB	O	O
elevated	VBN	O	O
in	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
and	CC	O	O
has	VBZ	O	O
long	RB	O	O
been	VBN	O	O
associated	VBN	O	O
with	IN	O	O
chromosomal	JJ	O	O
instability	NN	O	O
.	.	O	O

By	IN	O	O
analysing	VBG	O	O
tumour	JJ	S_Disease	S_Disease
DNA	NN	O	O
from	IN	O	O
patients	NNS	O	O
with	IN	O	O
sporadic	JJ	B_Disease	B_Disease
T	NNP	I_Disease	I_Disease
-	:	I_Disease	I_Disease
cell	NN	I_Disease	I_Disease
prolymphocytic	JJ	I_Disease	O
leukaemia	NN	E_Disease	O
(	(	O	O
T	NNP	B_Disease	O
-	:	I_Disease	O
PLL	NN	E_Disease	O
)	)	O	O
,	,	O	O
a	DT	O	O
rare	JJ	O	O
clonal	JJ	B_Disease	O
malignancy	NN	E_Disease	O
with	IN	O	O
similarities	NNS	O	O
to	TO	O	O
a	DT	O	O
mature	NN	B_Disease	O
T	NNP	I_Disease	O
-	:	I_Disease	O
cell	NN	I_Disease	O
leukaemia	NN	E_Disease	O
seen	VBN	O	O
in	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
,	,	O	O
we	PRP	O	O
demonstrate	VBP	O	O
a	DT	O	O
high	JJ	O	O
frequency	NN	O	O
of	IN	O	O
ATM	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
T	NNP	B_Disease	O
-	:	I_Disease	O
PLL	NN	E_Disease	O
.	.	O	O

In	IN	O	O
marked	VBN	O	O
contrast	NN	O	O
to	TO	O	O
the	DT	O	O
ATM	NNP	O	O
mutation	NN	O	O
pattern	NN	O	O
in	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
,	,	O	O
the	DT	O	O
most	RBS	O	O
frequent	JJ	O	O
nucleotide	NN	O	O
changes	NNS	O	O
in	IN	O	O
this	DT	O	O
leukaemia	NN	S_Disease	O
were	VBD	O	O
missense	JJ	O	O
mutations	NNS	O	O
.	.	O	O

These	DT	O	O
clustered	VBN	O	O
in	IN	O	O
the	DT	O	O
region	NN	O	O
corresponding	VBG	O	O
to	TO	O	O
the	DT	O	O
kinase	NN	O	O
domain	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
highly	RB	O	O
conserved	VBN	O	O
in	IN	O	O
ATM	NNP	O	O
-	:	O	O
related	JJ	O	O
proteins	NNS	O	O
in	IN	O	O
mouse	NN	O	O
,	,	O	O
yeast	NN	O	O
and	CC	O	O
Drosophila	NNP	O	O
.	.	O	O

The	DT	O	O
resulting	VBG	O	O
amino	JJ	O	O
-	:	O	O
acid	NN	O	O
substitutions	NNS	O	O
are	VBP	O	O
predicted	VBN	O	O
to	TO	O	O
interfere	VB	O	O
with	IN	O	O
ATP	NNP	O	O
binding	VBG	O	O
or	CC	O	O
substrate	JJ	O	O
recognition	NN	O	O
.	.	O	O

Two	CD	O	O
of	IN	O	O
seventeen	NN	O	O
mutated	VBN	O	O
T	NNP	B_Disease	O
-	:	I_Disease	O
PLL	NN	E_Disease	O
samples	NNS	O	O
had	VBD	O	O
a	DT	O	O
previously	RB	O	O
reported	VBN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
allele	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
no	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
p53	NN	O	O
gene	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
this	DT	O	O
tumour	NN	S_Disease	S_Disease
suppressor	NN	O	O
is	VBZ	O	O
not	RB	O	O
frequently	RB	O	O
altered	VBN	O	O
in	IN	O	O
this	DT	O	O
leukaemia	NN	S_Disease	O
.	.	O	O

Occasional	JJ	O	O
missense	NN	O	O
mutations	NNS	O	O
in	IN	O	O
ATM	NNP	O	O
were	VBD	O	O
also	RB	O	O
found	VBN	O	O
in	IN	O	O
tumour	JJ	S_Disease	S_Disease
DNA	NN	O	O
from	IN	O	O
patients	NNS	O	O
with	IN	O	O
B	NNP	B_Disease	O
-	:	I_Disease	O
cell	NN	I_Disease	O
non	SYM	I_Disease	O
-	:	I_Disease	I_Disease
Hodgkins	VBZ	I_Disease	I_Disease
lymphomas	FW	E_Disease	E_Disease
(	(	O	O
B	NNP	B_Disease	O
-	:	I_Disease	O
NHL	NN	E_Disease	O
)	)	O	O
and	CC	O	O
a	DT	O	O
B	NNP	B_Disease	O
-	:	I_Disease	O
NHL	NNP	E_Disease	O
cell	NN	O	O
line	NN	O	O
.	.	O	O

The	DT	O	O
evidence	NN	O	O
of	IN	O	O
a	DT	O	O
significant	JJ	O	O
proportion	NN	O	O
of	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutations	NNS	O	O
and	CC	O	O
a	DT	O	O
complete	JJ	O	O
absence	NN	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
copy	NN	O	O
of	IN	O	O
ATM	NNP	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
mutated	JJ	O	O
tumours	NNS	S_Disease	S_Disease
establishes	VBZ	O	O
somatic	JJ	O	O
inactivation	NN	O	O
of	IN	O	O
this	DT	O	O
gene	NN	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
sporadic	JJ	B_Disease	B_Disease
T	NNP	I_Disease	E_Disease
-	:	I_Disease	O
PLL	NN	E_Disease	O
and	CC	O	O
suggests	VBZ	O	O
that	IN	O	O
ATM	NNP	O	O
acts	VBZ	O	O
as	IN	O	O
a	DT	O	O
tumour	NN	S_Disease	S_Disease
suppressor	NN	O	O
.	.	O	O

As	IN	O	O
constitutional	JJ	O	O
DNA	NNP	O	O
was	VBD	O	O
not	RB	O	O
available	JJ	O	O
,	,	O	O
a	DT	O	O
putative	JJ	O	O
hereditary	JJ	O	O
predisposition	NN	O	O
to	TO	O	O
T	NNP	B_Disease	O
-	:	I_Disease	O
PLL	NN	E_Disease	O
will	MD	O	O
require	VB	O	O
further	JJ	O	O
investigation	NN	O	O
.	.	O	O
.	.	O	O

9294109	CD	O	O

Myotonic	NNP	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
protein	NN	O	O
kinase	NN	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
modulation	NN	O	O
of	IN	O	O
the	DT	O	O
Ca2	NNP	O	O
+	NNP	O	O
homeostasis	NN	O	O
in	IN	O	O
skeletal	JJ	O	O
muscle	NN	O	O
cells	NNS	O	O
.	.	O	O

Myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
the	DT	O	O
most	RBS	O	O
prevalent	JJ	O	O
muscular	JJ	B_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
in	IN	O	O
adults	NNS	O	O
,	,	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
n	SYM	O	O
-	:	O	O
repeat	NN	O	O
expansion	NN	O	O
in	IN	O	O
a	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
a	DT	O	O
protein	NN	O	O
kinase	NN	O	O
(	(	O	O
DM	NNP	S_Disease	O
protein	RB	O	O
kinase	VBD	O	O
;	:	O	O
DMPK	NNP	O	O
)	)	O	O
and	CC	O	O
involves	VBZ	O	O
changes	NNS	O	O
in	IN	O	O
cytoarchitecture	NN	O	O
and	CC	O	O
ion	NN	O	O
homeostasis	NN	O	O
.	.	O	O

To	TO	O	O
obtain	VB	O	O
clues	NNS	O	O
to	TO	O	O
the	DT	O	O
normal	JJ	O	O
biological	JJ	O	O
role	NN	O	O
of	IN	O	O
DMPK	NNP	O	O
in	IN	O	O
cellular	JJ	O	O
ion	NN	O	O
homeostasis	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
compared	VBN	O	O
the	DT	O	O
resting	VBG	O	O
[	NNP	O	O
Ca2	NNP	O	O
+	NNP	O	O
]	NNP	O	O
i	NN	O	O
,	,	O	O
the	DT	O	O
amplitude	NN	O	O
and	CC	O	O
shape	NN	O	O
of	IN	O	O
depolarization	NN	O	O
-	:	O	O
induced	JJ	O	O
Ca2	NNP	O	O
+	NN	O	O
transients	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
content	NN	O	O
of	IN	O	O
ATP	NNP	O	O
-	:	O	O
driven	JJ	O	O
ion	NN	O	O
pumps	NNS	O	O
in	IN	O	O
cultured	JJ	O	O
skeletal	JJ	O	O
muscle	NN	O	O
cells	NNS	O	O
of	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
and	CC	O	O
DMPK	NNP	O	O
[	NNP	O	O
-	:	O	O
/	SYM	O	O
-	:	O	O
]	NN	O	O
knockout	NN	O	O
mice	NN	O	O
.	.	O	O

In	IN	O	O
vitro	JJ	O	O
-	:	O	O
differentiated	VBN	O	O
DMPK	NNP	O	O
[	NNP	O	O
-	:	O	O
/	SYM	O	O
-	:	O	O
]	NN	O	O
myotubes	NNS	O	O
exhibit	VBP	O	O
a	DT	O	O
higher	JJR	O	O
resting	NN	O	O
[	JJ	O	O
Ca2	NNP	O	O
+	NNP	O	O
]	NNP	O	O
i	NN	O	O
than	IN	O	O
do	VBP	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
myotubes	NNS	O	O
because	IN	O	O
of	IN	O	O
an	DT	O	O
altered	JJ	O	O
open	JJ	O	O
probability	NN	O	O
of	IN	O	O
voltage	NN	O	O
-	:	O	O
dependent	NN	O	O
l	NN	O	O
-	:	O	O
type	NN	O	O
Ca2	NNP	O	O
+	NNP	O	O
and	CC	O	O
Na	NNP	O	O
+	NNP	O	O
channels	NNS	O	O
.	.	O	O

The	DT	O	O
mutant	JJ	O	O
myotubes	NNS	O	O
exhibit	VBP	O	O
smaller	JJR	O	O
and	CC	O	O
slower	JJR	O	O
Ca2	NNP	O	O
+	NNP	O	O
responses	VBZ	O	O
upon	IN	O	O
triggering	VBG	O	O
by	IN	O	O
acetylcholine	NN	O	O
or	CC	O	O
high	JJ	O	O
external	JJ	O	O
K	NNP	O	O
+	NNP	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
we	PRP	O	O
observed	VBD	O	O
that	IN	O	O
these	DT	O	O
Ca2	NNP	O	O
+	NN	O	O
transients	NNS	O	O
partially	RB	O	O
result	VBP	O	O
from	IN	O	O
an	DT	O	O
influx	NN	O	O
of	IN	O	O
extracellular	JJ	O	O
Ca2	NNP	O	O
+	NNP	O	O
through	IN	O	O
the	DT	O	O
l	NN	O	O
-	:	O	O
type	NN	O	O
Ca2	NNP	O	O
+	NNP	O	O
channel	NN	O	O
.	.	O	O

Neither	CC	O	O
the	DT	O	O
content	NN	O	O
nor	CC	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
Na	NNP	O	O
+	NNP	O	O
/	NNP	O	O
K	NNP	O	O
+	NNP	O	O
ATPase	NNP	O	O
and	CC	O	O
sarcoplasmic	JJ	O	O
reticulum	NN	O	O
Ca2	NNP	O	O
+	NNP	O	O
-	:	O	O
ATPase	NN	O	O
are	VBP	O	O
affected	VBN	O	O
by	IN	O	O
DMPK	NNP	O	O
absence	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
DMPK	NNP	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
modulating	VBG	O	O
the	DT	O	O
initial	JJ	O	O
events	NNS	O	O
of	IN	O	O
excitation	NN	O	O
-	:	O	O
contraction	NN	O	O
coupling	NN	O	O
in	IN	O	O
skeletal	JJ	O	O
muscle	NN	O	O
.	.	O	O
.	.	O	O

9311732	CD	O	O

Constitutional	NNP	O	O
RB1	NNP	O	O
-	:	O	O
gene	NN	O	O
mutations	NNS	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
isolated	JJ	O	O
unilateral	JJ	B_Disease	B_Disease
retinoblastoma	NN	E_Disease	E_Disease
.	.	O	O

In	IN	O	O
most	JJS	O	O
patients	NNS	O	O
with	IN	O	O
isolated	JJ	O	O
unilateral	JJ	B_Disease	B_Disease
retinoblastoma	NN	E_Disease	E_Disease
,	,	O	O
tumor	NN	S_Disease	S_Disease
development	NN	O	O
is	VBZ	O	O
initiated	VBN	O	O
by	IN	O	O
somatic	JJ	O	O
inactivation	NN	O	O
of	IN	O	O
both	DT	O	O
alleles	NNS	O	O
of	IN	O	O
the	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
some	DT	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
can	MD	O	O
transmit	VB	O	O
retinoblastoma	VB	S_Disease	S_Disease
predisposition	NN	O	O
to	TO	O	O
their	PRP$	O	O
offspring	NN	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
the	DT	O	O
frequency	NN	O	O
and	CC	O	O
nature	NN	O	O
of	IN	O	O
constitutional	JJ	O	O
RB1	NNP	O	O
-	:	O	O
gene	NN	O	O
mutations	NNS	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
isolated	JJ	O	O
unilateral	JJ	B_Disease	B_Disease
retinoblastoma	NN	E_Disease	E_Disease
,	,	O	O
we	PRP	O	O
analyzed	VBD	O	O
DNA	NN	O	O
from	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
and	CC	O	O
from	IN	O	O
tumor	NN	S_Disease	S_Disease
tissue	NN	O	O
.	.	O	O

The	DT	O	O
analysis	NN	O	O
of	IN	O	O
tumors	NNS	S_Disease	S_Disease
from	IN	O	O
54	CD	O	O
(	(	O	O
71	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
76	CD	O	O
informative	JJ	O	O
patients	NNS	O	O
showed	VBD	O	O
loss	NN	O	O
of	IN	O	O
constitutional	JJ	O	O
heterozygosity	NN	O	O
(	(	O	O
LOH	NNP	O	O
)	)	O	O
at	IN	O	O
intragenic	JJ	O	O
loci	NN	O	O
.	.	O	O

Three	CD	O	O
of	IN	O	O
13	CD	O	O
uninformative	JJ	O	O
patients	NNS	O	O
had	VBD	O	O
constitutional	JJ	O	O
deletions	NNS	O	O
.	.	O	O

For	IN	O	O
39	CD	O	O
randomly	RB	O	O
selected	VBN	O	O
tumors	NNS	S_Disease	S_Disease
,	,	O	O
SSCP	NNP	O	O
,	,	O	O
hetero	SYM	O	O
-	:	O	O
duplex	JJ	O	O
analysis	NN	O	O
,	,	O	O
sequencing	NN	O	O
,	,	O	O
and	CC	O	O
Southern	NNP	O	O
blot	NN	O	O
analysis	NN	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
identify	VB	O	O
mutations	NNS	O	O
.	.	O	O

Mutations	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
21	CD	O	O
(	(	O	O
91	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
23	CD	O	O
tumors	NNS	S_Disease	S_Disease
with	IN	O	O
LOH	NNP	O	O
.	.	O	O

In	IN	O	O
6	CD	O	O
(	(	O	O
38	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
16	CD	O	O
tumors	NNS	S_Disease	S_Disease
without	IN	O	O
LOH	NNP	O	O
,	,	O	O
one	CD	O	O
mutation	NN	O	O
was	VBD	O	O
detected	VBN	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
9	CD	O	O
(	(	O	O
56	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
tumors	NNS	S_Disease	S_Disease
without	IN	O	O
LOH	NNP	O	O
,	,	O	O
both	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
45	CD	O	O
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
tumors	NNS	S_Disease	S_Disease
of	IN	O	O
36	CD	O	O
patients	NNS	O	O
.	.	O	O

Thirty	NNP	O	O
-	:	O	O
nine	CD	O	O
of	IN	O	O
the	DT	O	O
mutations	NNS	O	O
-	:	O	O
including	VBG	O	O
34	CD	O	O
small	JJ	O	O
mutations	NNS	O	O
,	,	O	O
2	CD	O	O
large	JJ	O	O
structural	JJ	O	O
alterations	NNS	O	O
,	,	O	O
and	CC	O	O
hypermethylation	NN	O	O
in	IN	O	O
3	CD	O	O
tumors	NNS	O	S_Disease
-	:	O	O
were	VBD	O	O
not	RB	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
corresponding	JJ	O	O
peripheral	JJ	O	O
blood	NN	O	O
DNA	NN	O	O
.	.	O	O

In	IN	O	O
6	CD	O	O
(	(	O	O
17	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
36	CD	O	O
patients	NNS	O	O
,	,	O	O
a	DT	O	O
mutation	NN	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
constitutional	JJ	O	O
DNA	NNP	O	O
,	,	O	O
and	CC	O	O
1	CD	O	O
of	IN	O	O
these	DT	O	O
mutations	NNS	O	O
is	VBZ	O	O
known	VBN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
reduced	JJ	O	O
expressivity	NN	O	O
.	.	O	O

The	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
constitutional	JJ	O	O
mutation	NN	O	O
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
early	JJ	O	O
age	NN	O	O
at	IN	O	O
treatment	NN	O	O
.	.	O	O

In	IN	O	O
1	CD	O	O
patient	NN	O	O
,	,	O	O
somatic	JJ	O	O
mosaicism	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
by	IN	O	O
molecular	JJ	O	O
analysis	NN	O	O
of	IN	O	O
DNA	NNP	O	O
and	CC	O	O
RNA	NNP	O	O
from	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
.	.	O	O

In	IN	O	O
2	CD	O	O
patients	NNS	O	O
without	IN	O	O
a	DT	O	O
detectable	JJ	O	O
mutation	NN	O	O
in	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
,	,	O	O
mosaicism	NN	O	O
was	VBD	O	O
suggested	VBN	O	O
because	IN	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
showed	VBD	O	O
multifocal	JJ	O	B_Disease
tumors	NNS	S_Disease	E_Disease
and	CC	O	O
the	DT	O	O
other	JJ	O	O
later	RB	O	O
developed	VBN	O	O
bilateral	JJ	B_Disease	O
retinoblastoma	NN	E_Disease	S_Disease
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
our	PRP$	O	O
results	NNS	O	O
emphasize	VB	O	O
that	IN	O	O
the	DT	O	O
manifestation	NN	O	O
and	CC	O	O
transmissibility	NN	O	O
of	IN	O	O
retinoblastoma	NN	S_Disease	S_Disease
depend	NN	O	O
on	IN	O	O
the	DT	O	O
nature	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
mutation	NN	O	O
,	,	O	O
its	PRP$	O	O
time	NN	O	O
in	IN	O	O
development	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
number	NN	O	O
and	CC	O	O
types	NNS	O	O
of	IN	O	O
cells	NNS	O	O
that	WDT	O	O
are	VBP	O	O
affected	VBN	O	O
.	.	O	O
.	.	O	O

932197	CD	O	O

Hereditary	JJ	B_Disease	B_Disease
deficiency	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
fifth	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
in	IN	O	O
man	NN	O	O
.	.	O	O

I	PRP	O	O
.	.	O	O

Clinical	NNP	O	O
,	,	O	O
immunochemical	JJ	O	O
,	,	O	O
and	CC	O	O
family	NN	O	O
studies	NNS	O	O
.	.	O	O

The	DT	O	O
first	JJ	O	O
recognized	VBN	O	O
human	JJ	O	O
kindred	VBN	O	O
with	IN	O	O
hereditary	JJ	B_Disease	B_Disease
deficiency	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
fifth	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
(	(	O	O
C5	NNP	O	O
)	)	O	O
is	VBZ	O	O
described	VBN	O	O
.	.	O	O

The	DT	O	O
proband	NN	O	O
,	,	O	O
a	DT	O	O
20	CD	O	O
-	:	O	O
year	NN	O	O
-	:	O	O
old	JJ	O	O
black	JJ	O	O
female	NN	O	O
with	IN	O	O
systemic	JJ	B_Disease	B_Disease
lupus	NN	I_Disease	I_Disease
erythematosus	NN	E_Disease	E_Disease
since	IN	O	O
age	NN	O	O
11	CD	O	O
,	,	O	O
lacked	VBD	O	O
serum	JJ	O	O
hemolytic	JJ	O	O
complement	NN	O	O
activity	NN	O	O
,	,	O	O
even	RB	O	O
during	IN	O	O
remission	NN	O	O
.	.	O	O

C5	NNP	O	O
was	VBD	O	O
undetectable	JJ	O	O
in	IN	O	O
her	PRP$	O	O
serum	NN	O	O
by	IN	O	O
both	DT	O	O
immunodiffusion	NN	O	O
and	CC	O	O
hemolytic	JJ	O	O
assays	NNS	O	O
.	.	O	O

Other	JJ	O	O
complement	JJ	O	O
components	NNS	O	O
were	VBD	O	O
normal	JJ	O	O
during	IN	O	O
remission	NN	O	O
of	IN	O	O
lupus	NN	O	S_Disease
,	,	O	O
but	CC	O	O
C1	NNP	O	O
,	,	O	O
C4	NNP	O	O
,	,	O	O
C2	NNP	O	O
,	,	O	O
and	CC	O	O
C3	NNP	O	O
levels	NNS	O	O
fell	VBD	O	O
during	IN	O	O
exacerbations	NNS	O	O
.	.	O	O

A	DT	O	O
younger	JJR	O	O
half	NN	O	O
-	:	O	O
sister	NN	O	O
,	,	O	O
who	WP	O	O
had	VBD	O	O
no	DT	O	O
underlying	JJ	O	O
disease	NN	O	O
,	,	O	O
was	VBD	O	O
also	RB	O	O
found	VBN	O	O
to	TO	O	O
lack	VB	O	O
immunochemically	RB	O	O
detectable	JJ	O	O
C5	NNP	O	O
.	.	O	O

By	IN	O	O
hemolytic	JJ	O	O
assay	NN	O	O
,	,	O	O
she	PRP	O	O
exhibited	VBD	O	O
1	CD	O	O
-	:	O	O
2	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
serum	NN	O	O
C5	NNP	O	O
level	NN	O	O
and	CC	O	O
normal	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
other	JJ	O	O
complement	JJ	O	O
components	NNS	O	O
.	.	O	O

C5	NNP	O	O
levels	NNS	O	O
of	IN	O	O
other	JJ	O	O
family	NN	O	O
members	NNS	O	O
were	VBD	O	O
either	RB	O	O
normal	JJ	O	O
or	CC	O	O
approximately	RB	O	O
half	JJ	O	O
-	:	O	O
normal	JJ	O	O
,	,	O	O
consistent	JJ	O	O
with	IN	O	O
autosomal	JJ	O	O
codominant	JJ	O	O
inheritance	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
determining	VBG	O	O
C5	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O

Normal	NNP	O	O
hemolytic	JJ	O	O
titers	NNS	O	O
were	VBD	O	O
restored	VBN	O	O
to	TO	O	O
both	DT	O	O
homozygous	JJ	O	O
C5	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
deficient	NN	E_Disease	E_Disease
(	(	O	O
C5D	NNP	S_Disease	O
)	)	O	O
sera	NN	O	O
by	IN	O	O
addition	NN	O	O
of	IN	O	O
highly	RB	O	O
purified	VBN	O	O
human	JJ	O	O
C5	NNP	O	O
.	.	O	O

In	IN	O	O
specific	JJ	O	O
C5	NNP	O	O
titrations	NNS	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
noted	VBN	O	O
that	IN	O	O
when	WRB	O	O
limited	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
C5	NNP	O	O
were	VBD	O	O
assayed	VBN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
low	JJ	O	O
dilutions	NNS	O	O
of	IN	O	O
either	DT	O	O
C5D	NNP	S_Disease	O
serum	NN	O	O
,	,	O	O
curving	VBG	O	O
rather	RB	O	O
than	IN	O	O
linear	VB	O	O
dose	JJ	O	O
-	:	O	O
response	NN	O	O
plots	NNS	O	O
were	VBD	O	O
consistently	RB	O	O
obtained	VBN	O	O
,	,	O	O
suggesting	VBG	O	O
some	DT	O	O
inhibitory	JJ	O	O
effect	NN	O	O
.	.	O	O

Further	JJ	O	O
studies	NNS	O	O
suggested	VBD	O	O
that	IN	O	O
low	JJ	O	O
dilutions	NNS	O	O
of	IN	O	O
C5D	NNP	S_Disease	O
serum	NN	O	O
contain	NN	O	O
a	DT	O	O
factor	NN	O	O
(	(	O	O
or	CC	O	O
factors	NNS	O	O
)	)	O	O
interfering	VBG	O	O
at	IN	O	O
some	DT	O	O
step	NN	O	O
in	IN	O	O
the	DT	O	O
hemolytic	JJ	O	O
assay	NN	O	O
of	IN	O	O
C5	NNP	O	O
,	,	O	O
rather	RB	O	O
than	IN	O	O
a	DT	O	O
true	JJ	O	O
C5	NNP	O	O
inhibitor	NN	O	O
or	CC	O	O
inactivator	NN	O	O
.	.	O	O

Of	IN	O	O
clinical	JJ	O	O
interest	NN	O	O
are	VBP	O	O
(	(	O	O
a	DT	O	O
)	)	O	O
the	DT	O	O
documentation	NN	O	O
of	IN	O	O
membranous	JJ	O	O
glomerulonephritis	NN	S_Disease	S_Disease
,	,	O	O
vasculitis	NN	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
arthritis	NN	S_Disease	S_Disease
in	IN	O	O
an	DT	O	O
individual	JJ	O	O
lacking	NN	O	O
C5	NNP	O	O
(	(	O	O
and	CC	O	O
its	PRP$	O	O
biologic	JJ	O	O
functions	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
b	NN	O	O
)	)	O	O
a	DT	O	O
remarkable	JJ	O	O
propensity	NN	O	O
to	TO	O	O
bacterial	JJ	B_Disease	O
infections	NNS	E_Disease	O
in	IN	O	O
the	DT	O	O
proband	NN	O	O
,	,	O	O
even	RB	O	O
during	IN	O	O
periods	NNS	O	O
of	IN	O	O
low	JJ	O	O
-	:	O	O
dose	NN	O	O
or	CC	O	O
alternate	JJ	O	O
-	:	O	O
day	NN	O	O
corticosteroid	JJ	O	O
therapy	NN	O	O
.	.	O	O

Other	JJ	O	O
observations	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
C5D	NNP	S_Disease	O
state	NN	O	O
is	VBZ	O	O
compatible	JJ	O	O
with	IN	O	O
normal	JJ	O	O
coagulation	NN	O	O
function	NN	O	O
and	CC	O	O
the	DT	O	O
capacity	NN	O	O
to	TO	O	O
mount	VB	O	O
a	DT	O	O
neutrophilic	JJ	O	O
leukocytosis	NN	O	O
during	IN	O	O
pyogenic	JJ	B_Disease	O
infection	NN	E_Disease	O
.	.	O	O
.	.	O	O

9336417	CD	O	O

Susceptibility	NN	O	O
to	TO	O	O
ankylosing	VBG	B_Disease	B_Disease
spondylitis	NN	E_Disease	E_Disease
in	IN	O	O
twins	NNS	O	O
:	:	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
genes	NNS	O	O
,	,	O	O
HLA	NNP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
environment	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
To	TO	O	O
determine	VB	O	O
the	DT	O	O
relative	JJ	O	O
effects	NNS	O	O
of	IN	O	O
genetic	JJ	O	O
and	CC	O	O
environmental	JJ	O	O
factors	NNS	O	O
in	IN	O	O
susceptibility	NN	O	O
to	TO	O	O
ankylosing	VBG	B_Disease	B_Disease
spondylitis	NN	E_Disease	E_Disease
(	(	O	O
AS	IN	S_Disease	O
)	)	O	O
.	.	O	O

METHODS	NNP	O	O
Twins	VBZ	O	O
with	IN	O	O
AS	NNP	S_Disease	S_Disease
were	VBD	O	O
identified	VBN	O	O
from	IN	O	O
the	DT	O	O
Royal	NNP	O	O
National	NNP	O	O
Hospital	NNP	O	O
for	IN	O	O
Rheumatic	NNP	B_Disease	O
Diseases	NNP	E_Disease	O
database	NN	O	O
.	.	O	O

Clinical	JJ	O	O
and	CC	O	O
radiographic	JJ	O	O
examinations	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
to	TO	O	O
establish	VB	O	O
diagnoses	NNS	O	O
,	,	O	O
and	CC	O	O
disease	NN	O	O
severity	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
validated	JJ	O	O
scoring	VBG	O	O
systems	NNS	O	O
.	.	O	O

HLA	NNP	O	O
typing	VBG	O	O
for	IN	O	O
HLA	NNP	O	O
-	:	O	O
B27	NNP	O	O
,	,	O	O
HLA	NNP	O	O
-	:	O	O
B60	NNP	O	O
,	,	O	O
and	CC	O	O
HLA	NNP	O	O
-	:	O	O
DR1	NN	O	O
was	VBD	O	O
performed	VBN	O	O
by	IN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
with	IN	O	O
sequence	NN	O	O
-	:	O	O
specific	JJ	O	O
primers	NNS	O	O
,	,	O	O
and	CC	O	O
zygosity	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
using	VBG	O	O
microsatellite	JJ	O	O
markers	NNS	O	O
.	.	O	O

Genetic	JJ	O	O
and	CC	O	O
environmental	JJ	O	O
variance	NN	O	O
components	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
with	IN	O	O
the	DT	O	O
program	NN	O	O
Mx	NNP	O	O
,	,	O	O
using	VBG	O	O
data	NNS	O	O
from	IN	O	O
this	DT	O	O
and	CC	O	O
previous	JJ	O	O
studies	NNS	O	O
of	IN	O	O
twins	NNS	O	O
with	IN	O	O
AS	NNP	S_Disease	S_Disease
.	.	O	O

RESULTS	NNP	O	O
Six	NNP	O	O
of	IN	O	O
8	CD	O	O
monozygotic	JJ	O	O
(	(	O	O
MZ	NNP	O	O
)	)	O	O
twin	VBP	O	O
pairs	NNS	O	O
were	VBD	O	O
disease	JJ	O	O
concordant	NN	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
4	CD	O	O
of	IN	O	O
15	CD	O	O
B27	NNP	O	O
-	:	O	O
positive	JJ	O	O
dizygotic	JJ	O	O
(	(	O	O
DZ	NNP	O	O
)	)	O	O
twin	NN	O	O
pairs	NNS	O	O
(	(	O	O
27	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
4	CD	O	O
of	IN	O	O
32	CD	O	O
DZ	NNP	O	O
twin	NN	O	O
pairs	NNS	O	O
overall	JJ	O	O
(	(	O	O
12	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

Nonsignificant	JJ	O	O
increases	NNS	O	O
in	IN	O	O
similarity	NN	O	O
with	IN	O	O
regard	NN	O	O
to	TO	O	O
age	NN	O	O
at	IN	O	O
disease	NN	O	O
onset	NN	O	O
and	CC	O	O
all	DT	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
severity	NN	O	O
scores	NNS	O	O
assessed	VBN	O	O
were	VBD	O	O
noted	VBN	O	O
in	IN	O	O
disease	NN	O	O
-	:	O	O
concordant	NN	O	O
MZ	NNP	O	O
twins	NNS	O	O
compared	VBN	O	O
with	IN	O	O
concordant	JJ	O	O
DZ	NNP	O	O
twins	NNS	O	O
.	.	O	O

HLA	NNP	O	O
-	:	O	O
B27	NNP	O	O
and	CC	O	O
B60	NNP	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
disease	NN	O	O
in	IN	O	O
probands	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
disease	NN	O	O
concordance	NN	O	O
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
among	IN	O	O
DZ	NNP	O	O
twin	VBP	O	O
pairs	NNS	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
co	NN	O	O
-	:	O	O
twin	NN	O	O
was	VBD	O	O
positive	JJ	O	O
for	IN	O	O
both	DT	O	O
B27	NNP	O	O
and	CC	O	O
DR1	NNP	O	O
.	.	O	O

Additive	NNP	O	O
genetic	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
estimated	VBN	O	O
to	TO	O	O
contribute	VB	O	O
97	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
population	NN	O	O
variance	NN	O	O
.	.	O	O

CONCLUSION	NNP	O	O
Susceptibility	NNP	O	O
to	TO	O	O
AS	NNP	S_Disease	S_Disease
is	VBZ	O	O
largely	RB	O	O
genetically	RB	O	O
determined	VBN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
environmental	JJ	O	O
trigger	NN	O	O
for	IN	O	O
the	DT	O	O
disease	NN	O	O
is	VBZ	O	O
probably	RB	O	O
ubiquitous	JJ	O	O
.	.	O	O

HLA	NNP	O	O
-	:	O	O
B27	NNP	O	O
accounts	NNS	O	O
for	IN	O	O
a	DT	O	O
minority	NN	O	O
of	IN	O	O
the	DT	O	O
overall	JJ	O	O
genetic	JJ	O	O
susceptibility	NN	O	O
to	TO	O	O
AS	NNP	S_Disease	S_Disease
.	.	O	O

9342365	CD	O	O

Cell	NNP	O	O
cycle	NN	O	O
-	:	O	O
dependent	JJ	O	O
colocalization	NN	O	O
of	IN	O	O
BARD1	NNP	O	O
and	CC	O	O
BRCA1	NNP	O	O
proteins	NNS	O	O
in	IN	O	O
discrete	JJ	O	O
nuclear	JJ	O	O
domains	NNS	O	O
.	.	O	O

Germ	NNP	O	O
-	:	O	O
line	NN	O	O
mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
gene	NN	O	O
predispose	JJ	O	O
women	NNS	O	O
to	TO	O	O
early	JJ	O	O
-	:	O	O
onset	NN	O	O
breast	NN	B_Disease	B_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
by	IN	O	O
compromising	VBG	O	O
the	DT	O	O
genes	NNS	O	O
presumptive	JJ	O	O
function	NN	O	O
as	IN	O	O
a	DT	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
biochemical	JJ	O	O
properties	NNS	O	O
of	IN	O	O
BRCA1	NNP	O	O
polypeptides	NNS	O	O
are	VBP	O	O
not	RB	O	O
understood	JJ	O	O
,	,	O	O
their	PRP$	O	O
expression	NN	O	O
pattern	NN	O	O
and	CC	O	O
subcellular	JJ	O	O
localization	NN	O	O
suggest	VBP	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
cell	NN	O	O
-	:	O	O
cycle	NN	O	O
regulation	NN	O	O
.	.	O	O

When	WRB	O	O
resting	VBG	O	O
cells	NNS	O	O
are	VBP	O	O
induced	VBN	O	O
to	TO	O	O
proliferate	VB	O	O
,	,	O	O
the	DT	O	O
steady	JJ	O	O
-	:	O	O
state	NN	O	O
levels	NNS	O	O
of	IN	O	O
BRCA1	NNP	O	O
increase	NN	O	O
in	IN	O	O
late	JJ	O	O
G1	NNP	O	O
and	CC	O	O
reach	VB	O	O
a	DT	O	O
maximum	JJ	O	O
during	IN	O	O
S	NNP	O	O
phase	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
in	IN	O	O
S	NNP	O	O
phase	NN	O	O
cells	NNS	O	O
,	,	O	O
BRCA1	NNP	O	O
polypeptides	NNS	O	O
are	VBP	O	O
hyperphosphorylated	VBN	O	O
and	CC	O	O
accumulate	VB	O	O
into	IN	O	O
discrete	JJ	O	O
subnuclear	JJ	O	O
foci	NN	O	O
termed	VBD	O	O
"	NNP	O	O
BRCA1	NNP	O	O
nuclear	JJ	O	O
dots	NNS	O	O
.	.	O	O

"	JJ	O	O
BRCA1	NNP	O	O
associates	NNS	O	O
in	IN	O	O
vivo	NN	O	O
with	IN	O	O
a	DT	O	O
structurally	RB	O	O
related	JJ	O	O
protein	NN	O	O
termed	VBD	O	O
BARD1	NNP	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
steady	JJ	O	O
-	:	O	O
state	NN	O	O
levels	NNS	O	O
of	IN	O	O
BARD1	NNP	O	O
,	,	O	O
unlike	IN	O	O
those	DT	O	O
of	IN	O	O
BRCA1	NNP	O	O
,	,	O	O
remain	VBP	O	O
relatively	RB	O	O
constant	JJ	O	O
during	IN	O	O
cell	NN	O	O
cycle	NN	O	O
progression	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
immunostaining	VBG	O	O
revealed	VBD	O	O
that	IN	O	O
BARD1	NNP	O	O
resides	NNS	O	O
within	IN	O	O
BRCA1	NNP	O	O
nuclear	JJ	O	O
dots	NNS	O	O
during	IN	O	O
S	NNP	O	O
phase	NN	O	O
of	IN	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
during	IN	O	O
the	DT	O	O
G1	NNP	O	O
phase	NN	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
BARD1	NNP	O	O
polypeptides	NNS	O	O
are	VBP	O	O
found	VBN	O	O
exclusively	RB	O	O
in	IN	O	O
the	DT	O	O
nuclear	JJ	O	O
fractions	NNS	O	O
of	IN	O	O
both	DT	O	O
G1	NNP	O	O
-	:	O	O
and	CC	O	O
S	NNP	O	O
-	:	O	O
phase	NN	O	O
cells	NNS	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
progression	NN	O	O
to	TO	O	O
S	NNP	O	O
phase	NN	O	O
is	VBZ	O	O
accompanied	VBN	O	O
by	IN	O	O
the	DT	O	O
aggregation	NN	O	O
of	IN	O	O
nuclear	JJ	O	O
BARD1	NNP	O	O
polypeptides	NNS	O	O
into	IN	O	O
BRCA1	NNP	O	O
nuclear	JJ	O	O
dots	NNS	O	O
.	.	O	O

This	DT	O	O
cell	NN	O	O
cycle	NN	O	O
-	:	O	O
dependent	JJ	O	O
colocalization	NN	O	O
of	IN	O	O
BARD1	NNP	O	O
and	CC	O	O
BRCA1	NNP	O	O
indicates	VBZ	O	O
a	DT	O	O
role	NN	O	O
for	IN	O	O
BARD1	NNP	O	O
in	IN	O	O
BRCA1	NNP	O	O
-	:	O	O
mediated	VBD	O	O
tumor	JJ	S_Disease	O
suppression	NN	O	O
.	.	O	O

9358014	CD	O	O

Ethnic	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
HFE	NNP	O	O
codon	NN	O	O
282	CD	O	O
(	(	O	O
Cys	NNP	O	O
/	NNP	O	O
Tyr	NNP	O	O
)	)	O	O
polymorphism	NN	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
hereditary	JJ	B_Disease	B_Disease
hemochromatosis	NN	E_Disease	E_Disease
(	(	O	O
HH	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
caused	VBN	O	O
by	IN	O	O
homozygosity	NN	O	O
for	IN	O	O
a	DT	O	O
Cys282Tyr	NNP	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
HFE	NNP	O	O
gene	NN	O	O
located	VBD	O	O
4	CD	O	O
.	.	O	O

5	CD	O	O
Mb	NNP	O	O
telomeric	NN	O	O
to	TO	O	O
HLA	NNP	O	O
-	:	O	O
A	DT	O	O
.	.	O	O

Population	NNP	O	O
studies	NNS	O	O
of	IN	O	O
this	DT	O	O
polymorphism	NN	O	O
are	VBP	O	O
facilitated	VBN	O	O
by	IN	O	O
the	DT	O	O
fact	NN	O	O
that	IN	O	O
the	DT	O	O
Cys282Tyr	NNP	O	O
mutation	NN	O	O
creates	VBZ	O	O
a	DT	O	O
Rsal	NNP	O	O
restriction	NN	O	O
site	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
the	DT	O	O
codon	NN	O	O
282	CD	O	O
(	(	O	O
Cys	NNP	O	O
/	NNP	O	O
Tyr	NNP	O	O
)	)	O	O
polymorphism	NN	O	O
in	IN	O	O
different	JJ	O	O
ethnic	JJ	O	O
groups	NNS	O	O
.	.	O	O

In	IN	O	O
agreement	NN	O	O
with	IN	O	O
previous	JJ	O	O
observations	NNS	O	O
the	DT	O	O
Tyr	NNP	O	O
allele	NN	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
rare	JJ	O	O
or	CC	O	O
absent	NN	O	O
in	IN	O	O
Asiatic	NNP	O	O
(	(	O	O
Indian	JJ	O	O
,	,	O	O
Chinese	JJ	O	O
)	)	O	O
populations	NNS	O	O
.	.	O	O

The	DT	O	O
highest	JJS	O	O
allele	JJ	O	O
frequency	NN	O	O
(	(	O	O
7	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
Swedes	NNP	O	O
.	.	O	O

Saamis	NNP	O	O
(	(	O	O
2	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
Mordvinians	NNPS	O	O
(	(	O	O
1	CD	O	O
.	.	O	O

8	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
frequencies	NNS	O	O
of	IN	O	O
the	DT	O	O
Tyr	NNP	O	O
allele	NN	O	O
.	.	O	O

Comparisons	NNS	O	O
with	IN	O	O
allele	JJ	O	O
frequencies	NNS	O	O
based	VBN	O	O
on	IN	O	O
prevalence	NN	O	O
estimates	NNS	O	O
of	IN	O	O
HH	NNP	S_Disease	S_Disease
showed	VBD	O	O
some	DT	O	O
disagreements	NNS	O	O
with	IN	O	O
the	DT	O	O
RFLP	NNP	O	O
data	NNS	O	O
,	,	O	O
particularly	RB	O	O
in	IN	O	O
Finns	NNP	O	O
.	.	O	O

The	DT	O	O
newly	RB	O	O
described	VBN	O	O
HFE	NNP	O	O
marker	NN	O	O
provides	VBZ	O	O
a	DT	O	O
new	JJ	O	O
approach	NN	O	O
to	TO	O	O
the	DT	O	O
screening	NN	O	O
of	IN	O	O
HH	NNP	S_Disease	S_Disease
as	RB	O	O
well	RB	O	O
as	IN	O	O
studies	NNS	O	O
of	IN	O	O
the	DT	O	O
relationship	NN	O	O
between	IN	O	O
the	DT	O	O
HFE	NNP	O	O
Tyr	NNP	O	O
allele	NN	O	O
and	CC	O	O
different	JJ	O	O
disorders	NNS	O	O
including	VBG	O	O
cancer	NN	S_Disease	S_Disease

9360520	CD	O	O

Autosomal	NNP	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
neurohypophyseal	NN	I_Disease	I_Disease
diabetes	VBZ	I_Disease	I_Disease
insipidus	RB	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
missense	JJ	O	O
mutation	NN	O	O
encoding	VBG	O	O
Gly23	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
Val	NNP	O	O
in	IN	O	O
neurophysin	JJ	O	O
II	NNP	O	O
.	.	O	O

Autosomal	NNP	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
neurohypophyseal	NN	I_Disease	I_Disease
diabetes	NNS	I_Disease	I_Disease
insipidus	VBP	E_Disease	E_Disease
(	(	O	O
ADNDI	NNP	S_Disease	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
inherited	JJ	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
progressive	JJ	O	O
degeneration	NN	O	O
of	IN	O	O
the	DT	O	O
magnocellular	JJ	O	O
neurons	NNS	O	O
of	IN	O	O
the	DT	O	O
hypothalamus	NN	O	O
leading	VBG	O	O
to	TO	O	O
decreased	VBN	O	O
ability	NN	O	O
to	TO	O	O
produce	VB	O	O
the	DT	O	O
hormone	NN	O	O
arginine	NN	O	O
vasopressin	NN	O	O
(	(	O	O
AVP	NNP	O	O
)	)	O	O
.	.	O	O

Affected	JJ	O	O
individuals	NNS	O	O
are	VBP	O	O
not	RB	O	O
symptomatic	JJ	O	O
at	IN	O	O
birth	NN	O	O
,	,	O	O
but	CC	O	O
usually	RB	O	O
develop	VB	O	O
diabetes	NNS	B_Disease	B_Disease
insipidus	VBP	E_Disease	E_Disease
at	IN	O	O
1	CD	O	O
-	:	O	O
6	CD	O	O
yr	NN	O	O
of	IN	O	O
age	NN	O	O
.	.	O	O

The	DT	O	O
genetic	JJ	O	O
locus	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
is	VBZ	O	O
the	DT	O	O
AVP	NNP	O	O
-	:	O	O
neurophysin	NN	O	O
II	NNP	O	O
(	(	O	O
NPII	NNP	O	O
)	)	O	O
gene	NN	O	O
,	,	O	O
and	CC	O	O
mutations	NNS	O	O
that	WDT	O	O
cause	VBP	O	O
ADNDI	NNP	S_Disease	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
in	IN	O	O
both	DT	O	O
the	DT	O	O
signal	JJ	O	O
peptide	NN	O	O
of	IN	O	O
the	DT	O	O
prepro	JJ	O	O
-	:	O	O
AVP	NNP	O	O
-	:	O	O
NPII	NNP	O	O
precursor	NN	O	O
and	CC	O	O
within	IN	O	O
NPII	NNP	O	O
itself	PRP	O	O
.	.	O	O

An	DT	O	O
affected	JJ	O	O
girl	NN	O	O
who	WP	O	O
presented	VBD	O	O
at	IN	O	O
9	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
and	CC	O	O
her	PRP$	O	O
similarly	RB	O	O
affected	JJ	O	O
younger	JJR	O	O
brother	NN	O	O
and	CC	O	O
father	NN	O	O
were	VBD	O	O
all	DT	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
novel	JJ	O	O
missense	NN	O	O
mutation	NN	O	O
(	(	O	O
G1758	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
T	NNP	O	O
)	)	O	O
encoding	VBG	O	O
the	DT	O	O
amino	NN	O	O
acid	JJ	O	O
substitution	NN	O	O
Gly23	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
Val	NNP	O	O
within	IN	O	O
NPII	NNP	O	O
.	.	O	O

The	DT	O	O
mutation	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
restriction	NN	O	O
endonuclease	NN	O	O
analysis	NN	O	O
.	.	O	O

A	DT	O	O
T1	NNP	O	O
-	:	O	O
weighted	VBD	O	O
magnetic	JJ	O	O
resonance	NN	O	O
imaging	NN	O	O
of	IN	O	O
the	DT	O	O
fathers	NNS	O	O
pituitary	JJ	O	B_Disease
gland	NN	O	E_Disease
demonstrates	VBZ	O	O
an	DT	O	O
attenuated	JJ	O	O
posterior	JJ	O	O
pituitary	JJ	O	O
bright	NN	O	O
spot	NN	O	O
.	.	O	O

This	DT	O	O
mutation	NN	O	O
may	MD	O	O
be	VB	O	O
valuable	JJ	O	O
for	IN	O	O
developing	VBG	O	O
models	NNS	O	O
of	IN	O	O
dominantly	RB	B_Disease	B_Disease
inherited	VBN	I_Disease	I_Disease
neurodegeneration	NN	E_Disease	E_Disease
,	,	O	O
as	IN	O	O
the	DT	O	O
early	JJ	O	O
age	NN	O	O
of	IN	O	O
onset	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
suggests	VBZ	O	O
that	IN	O	O
this	DT	O	O
mutation	NN	O	O
may	MD	O	O
be	VB	O	O
particularly	RB	O	O
deleterious	JJ	O	O
to	TO	O	O
the	DT	O	O
magnocellular	JJ	O	O
neuron	NN	O	O
.	.	O	O
.	.	O	O

9371490	CD	O	O

Frequent	JJ	O	O
inactivation	NN	O	O
of	IN	O	O
PTEN	NNP	O	O
/	NNP	O	O
MMAC1	NNP	O	O
in	IN	O	O
primary	JJ	O	O
prostate	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

Sporadic	JJ	B_Disease	B_Disease
prostate	NN	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
male	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
the	DT	O	O
Western	JJ	O	O
world	NN	O	O
,	,	O	O
yet	RB	O	O
many	JJ	O	O
of	IN	O	O
the	DT	O	O
major	JJ	O	O
genetic	JJ	O	O
events	NNS	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
progression	NN	O	O
of	IN	O	O
this	DT	O	O
often	RB	O	O
fatal	JJ	O	O
cancer	NN	S_Disease	S_Disease
remain	NN	O	O
to	TO	O	O
be	VB	O	O
elucidated	VBN	O	O
.	.	O	O

Numerous	JJ	O	O
cytogenetic	JJ	O	O
and	CC	O	O
allelotype	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
reported	VBN	O	O
frequent	JJ	O	O
loss	NN	O	O
of	IN	O	O
heterozygosity	NN	O	O
on	IN	O	O
chromosomal	JJ	O	O
arm	NN	O	O
10q	CD	O	O
in	IN	O	O
sporadic	JJ	B_Disease	B_Disease
prostate	NN	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

Deletion	NN	O	O
mapping	VBG	O	O
studies	NNS	O	O
have	VBP	O	O
unambiguously	RB	O	O
identified	VBN	O	O
a	DT	O	O
region	NN	O	O
of	IN	O	O
chromosome	NN	O	O
10q23	CD	O	O
to	TO	O	O
be	VB	O	O
the	DT	O	O
minimal	JJ	O	O
area	NN	O	O
of	IN	O	O
loss	NN	O	O
.	.	O	O

A	DT	O	O
new	JJ	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
gene	NN	O	O
,	,	O	O
PTEN	NNP	O	O
/	NNP	O	O
MMAC1	NNP	O	O
,	,	O	O
was	VBD	O	O
isolated	VBN	O	O
recently	RB	O	O
at	IN	O	O
this	DT	O	O
region	NN	O	O
of	IN	O	O
chromosome	NN	O	O
10q23	CD	O	O
and	CC	O	O
found	VBD	O	O
to	TO	O	O
be	VB	O	O
inactivated	VBN	O	O
by	IN	O	O
mutation	NN	O	O
in	IN	O	O
three	CD	O	O
prostate	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
cell	NN	O	O
lines	NNS	O	O
.	.	O	O

We	PRP	O	O
screened	VBD	O	O
80	CD	O	O
prostate	NN	B_Disease	B_Disease
tumors	NNS	E_Disease	E_Disease
by	IN	O	O
microsatellite	JJ	O	O
analysis	NN	O	O
and	CC	O	O
found	VBD	O	O
chromosome	RB	O	O
10q23	CD	O	O
to	TO	O	O
be	VB	O	O
deleted	VBN	O	O
in	IN	O	O
23	CD	O	O
cases	NNS	O	O
.	.	O	O

We	PRP	O	O
then	RB	O	O
proceeded	VBD	O	O
with	IN	O	O
sequence	NN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
entire	JJ	O	O
PTEN	NNP	O	O
/	NNP	O	O
MMAC1	NNP	O	O
coding	VBG	O	O
region	NN	O	O
and	CC	O	O
tested	VBN	O	O
for	IN	O	O
homozygous	JJ	O	O
deletion	NN	O	O
with	IN	O	O
new	JJ	O	O
intragenic	JJ	O	O
markers	NNS	O	O
in	IN	O	O
these	DT	O	O
23	CD	O	O
cases	NNS	O	O
with	IN	O	O
10q23	CD	O	O
loss	NN	O	O
of	IN	O	O
heterozygosity	NN	O	O
.	.	O	O

The	DT	O	O
identification	NN	O	O
of	IN	O	O
the	DT	O	O
second	JJ	O	O
mutational	JJ	O	O
event	NN	O	O
in	IN	O	O
10	CD	O	O
(	(	O	O
43	CD	O	O
%	NN	O	O
)	)	O	O
tumors	NNS	S_Disease	S_Disease
establishes	VBP	O	O
PTEN	NNP	O	O
/	NNP	O	O
MMAC1	NNP	O	O
as	IN	O	O
a	DT	O	O
main	JJ	O	O
inactivation	NN	O	O
target	NN	O	O
of	IN	O	O
10q	CD	O	O
loss	NN	O	O
in	IN	O	O
sporadic	JJ	B_Disease	B_Disease
prostate	NN	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O
.	.	O	O

9382108	CD	O	O

Risk	NN	O	O
reversals	NNS	O	O
in	IN	O	O
predictive	JJ	O	O
testing	NN	O	O
for	IN	O	O
Huntington	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
first	JJ	O	O
predictive	JJ	O	O
testing	NN	O	O
for	IN	O	O
Huntington	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
(	(	O	O
HD	NNP	S_Disease	S_Disease
)	)	O	O
was	VBD	O	O
based	VBN	O	O
on	IN	O	O
analysis	NN	O	O
of	IN	O	O
linked	VBN	O	O
polymorphic	JJ	O	O
DNA	NNP	O	O
markers	NNS	O	O
to	TO	O	O
estimate	VB	O	O
the	DT	O	O
likelihood	NN	O	O
of	IN	O	O
inheriting	VBG	O	O
the	DT	O	O
mutation	NN	O	O
for	IN	O	O
HD	NNP	S_Disease	S_Disease
.	.	O	O

Limits	NNS	O	O
to	TO	O	O
accuracy	VB	O	O
included	JJ	O	O
recombination	NN	O	O
between	IN	O	O
the	DT	O	O
DNA	NNP	O	O
markers	NNS	O	O
and	CC	O	O
the	DT	O	O
mutation	NN	O	O
,	,	O	O
pedigree	JJ	O	O
structure	NN	O	O
,	,	O	O
and	CC	O	O
whether	IN	O	O
DNA	NN	O	O
samples	NNS	O	O
were	VBD	O	O
available	JJ	O	O
from	IN	O	O
family	NN	O	O
members	NNS	O	O
.	.	O	O

With	IN	O	O
direct	JJ	O	O
tests	NNS	O	O
for	IN	O	O
the	DT	O	O
HD	NNP	S_Disease	S_Disease
mutation	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
assessed	VBN	O	O
the	DT	O	O
accuracy	NN	O	O
of	IN	O	O
results	NNS	O	O
obtained	VBN	O	O
by	IN	O	O
linkage	NN	O	O
approaches	NNS	O	O
when	WRB	O	O
requested	VBN	O	O
to	TO	O	O
do	VB	O	O
so	RB	O	O
by	IN	O	O
the	DT	O	O
test	NN	O	O
individuals	NNS	O	O
.	.	O	O

For	IN	O	O
six	CD	O	O
such	JJ	O	O
individuals	NNS	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
significant	JJ	O	O
disparity	NN	O	O
between	IN	O	O
the	DT	O	O
tests	NNS	O	O
.	.	O	O

Three	CD	O	O
went	VBD	O	O
from	IN	O	O
a	DT	O	O
decreased	VBN	O	O
risk	NN	O	O
to	TO	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
,	,	O	O
while	IN	O	O
in	IN	O	O
another	DT	O	O
three	CD	O	O
the	DT	O	O
risk	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
.	.	O	O

Knowledge	NNP	O	O
of	IN	O	O
the	DT	O	O
potential	JJ	O	O
reasons	NNS	O	O
for	IN	O	O
these	DT	O	O
changes	NNS	O	O
in	IN	O	O
results	NNS	O	O
and	CC	O	O
impact	NN	O	O
of	IN	O	O
these	DT	O	O
risk	NN	O	O
reversals	NNS	O	O
on	IN	O	O
both	DT	O	O
patients	NNS	O	O
and	CC	O	O
the	DT	O	O
counseling	NN	O	O
team	NN	O	O
can	MD	O	O
assist	VB	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
strategies	NNS	O	O
for	IN	O	O
the	DT	O	O
prevention	NN	O	O
and	CC	O	O
,	,	O	O
where	WRB	O	O
necessary	JJ	O	O
,	,	O	O
management	NN	O	O
of	IN	O	O
a	DT	O	O
risk	NN	O	O
reversal	NN	O	O
in	IN	O	O
any	DT	O	O
predictive	JJ	O	O
testing	NN	O	O
program	NN	O	O
.	.	O	O
.	.	O	O

9385378	CD	O	O

A	DT	O	O
novel	JJ	O	O
common	JJ	O	O
missense	NN	O	O
mutation	NN	O	O
G301C	NNP	O	O
in	IN	O	O
the	DT	O	O
N	NNP	O	O
-	:	O	O
acetylgalactosamine	NN	O	O
-	:	O	O
6	CD	O	O
-	:	O	O
sulfate	NN	O	O
sulfatase	NN	O	O
gene	NN	O	O
in	IN	O	O
mucopolysaccharidosis	NN	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
.	.	O	O

Mucopolysaccharidosis	NN	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
(	(	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	NN	I_Disease	I_Disease
lysosomal	JJ	I_Disease	I_Disease
storage	NN	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
genetic	JJ	B_Disease	O
defect	NN	E_Disease	O
in	IN	O	O
N	NNP	O	O
-	:	O	I_Disease
acetylgalactosamine	NN	O	I_Disease
-	:	O	I_Disease
6	CD	O	I_Disease
-	:	O	I_Disease
sulfate	NN	O	O
sulfatase	NN	O	O
(	(	O	O
GALNS	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
found	VBN	O	O
two	CD	O	O
common	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
Caucasians	NNPS	O	O
and	CC	O	O
Japanese	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

To	TO	O	O
characterize	VB	O	O
the	DT	O	O
mutational	JJ	O	O
spectrum	NN	O	O
in	IN	O	O
various	JJ	O	O
ethnic	JJ	O	O
groups	NNS	O	O
,	,	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
GALNS	NNP	O	O
gene	NN	O	O
in	IN	O	O
Colombian	JJ	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
patients	NNS	O	O
were	VBD	O	O
investigated	VBN	O	O
,	,	O	O
and	CC	O	O
genetic	JJ	O	O
backgrounds	NNS	O	O
were	VBD	O	O
extensively	RB	O	O
analyzed	VBN	O	O
to	TO	O	O
identify	VB	O	O
racial	JJ	O	O
origin	NN	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
mitochondrial	JJ	O	O
DNA	NNP	O	O
(	(	O	O
mtDNA	NN	O	O
)	)	O	O
lineages	VBZ	O	O
.	.	O	O

Three	CD	O	O
novel	JJ	O	O
missense	NN	O	O
mutations	NNS	O	O
never	RB	O	O
identified	VBN	O	O
previously	RB	O	O
in	IN	O	O
other	JJ	O	O
populations	NNS	O	O
and	CC	O	O
found	VBN	O	O
in	IN	O	O
16	CD	O	O
out	IN	O	O
of	IN	O	O
19	CD	O	O
Colombian	JJ	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
unrelated	JJ	O	O
alleles	NNS	O	O
account	VBP	O	O
for	IN	O	O
84	CD	O	O
.	.	O	O

2	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
alleles	NNS	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
.	.	O	O

The	DT	O	O
G301C	NNP	O	O
and	CC	O	O
S162F	NNP	O	O
mutations	NNS	O	O
account	VBP	O	O
for	IN	O	O
68	CD	O	O
.	.	O	O

4	CD	O	O
%	NN	O	O
and	CC	O	O
10	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
of	IN	O	O
mutations	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
remaining	VBG	O	O
F69V	NNP	O	O
is	VBZ	O	O
limited	VBN	O	O
to	TO	O	O
a	DT	O	O
single	JJ	O	O
allele	NN	O	O
.	.	O	O

The	DT	O	O
skewed	JJ	O	O
prevalence	NN	O	O
of	IN	O	O
G301C	NNP	O	O
in	IN	O	O
only	RB	O	O
Colombian	JJ	O	O
patients	NNS	O	O
and	CC	O	O
haplotype	JJ	O	O
analysis	NN	O	O
by	IN	O	O
restriction	NN	O	O
fragment	NN	O	O
length	NN	O	O
polymorphisms	NN	O	O
in	IN	O	O
the	DT	O	O
GALNS	NNP	O	O
gene	NN	O	O
suggest	VBP	O	O
that	IN	O	O
G301C	NNP	O	O
originated	VBD	O	O
from	IN	O	O
a	DT	O	O
common	JJ	O	O
ancestor	NN	O	O
.	.	O	O

Investigation	NN	O	O
of	IN	O	O
the	DT	O	O
genetic	JJ	O	O
background	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
mtDNA	NN	O	O
lineages	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
all	DT	O	O
our	PRP$	O	O
patients	NNS	O	O
are	VBP	O	O
probably	RB	O	O
of	IN	O	O
native	JJ	O	O
American	JJ	O	O
descent	NN	O	O

9391879	CD	O	O

Low	JJ	O	O
frequency	NN	O	O
of	IN	O	O
BRCA1	NNP	O	O
germline	NN	O	O
mutations	NNS	O	O
in	IN	O	O
45	CD	O	O
German	JJ	O	O
breast	NN	B_Disease	B_Disease
/	NNP	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
we	PRP	O	O
investigated	VBD	O	O
45	CD	O	O
German	JJ	O	O
breast	NN	B_Disease	B_Disease
/	NNP	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
for	IN	O	O
germline	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
gene	NN	O	O
.	.	O	O

We	PRP	O	O
identified	VBD	O	O
four	CD	O	O
germline	NN	O	O
mutations	NNS	O	O
in	IN	O	O
three	CD	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
and	CC	O	O
in	IN	O	O
one	CD	O	O
breast	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
family	NN	O	O
.	.	O	O

among	IN	O	O
these	DT	O	O
were	VBD	O	O
one	CD	O	O
frameshift	NN	O	O
mutation	NN	O	O
,	,	O	O
one	CD	O	O
nonsense	NN	O	O
mutation	NN	O	O
,	,	O	O
one	CD	O	O
novel	NN	O	O
splice	NN	O	O
site	NN	O	O
mutation	NN	O	O
,	,	O	O
and	CC	O	O
one	CD	O	O
missense	NN	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
missense	NN	O	O
mutation	NN	O	O
was	VBD	O	O
also	RB	O	O
found	VBN	O	O
in	IN	O	O
2	CD	O	O
.	.	O	O

8	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
general	JJ	O	O
population	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
disease	JJ	O	O
associated	VBN	O	O
.	.	O	O

The	DT	O	O
average	JJ	O	O
age	NN	O	O
of	IN	O	O
disease	NN	O	O
onset	VBN	O	O
in	IN	O	O
those	DT	O	O
families	NNS	O	O
harbouring	VBG	O	O
causative	JJ	O	O
mutations	NNS	O	O
was	VBD	O	O
between	IN	O	O
32	CD	O	O
.	.	O	O

3	CD	O	O
and	CC	O	O
37	CD	O	O
.	.	O	O

4	CD	O	O
years	NNS	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
family	NN	O	O
harbouring	VBG	O	O
the	DT	O	O
missense	NN	O	O
mutation	NN	O	O
had	VBD	O	O
an	DT	O	O
average	JJ	O	O
age	NN	O	O
of	IN	O	O
onset	NN	O	O
of	IN	O	O
51	CD	O	O
.	.	O	O

2	CD	O	O
years	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
show	VBP	O	O
that	IN	O	O
BRCA1	NNP	O	O
is	VBZ	O	O
implicated	VBN	O	O
in	IN	O	O
a	DT	O	O
small	JJ	O	O
fraction	NN	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
/	JJ	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
suggesting	VBG	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
another	DT	O	O
susceptibility	NN	O	O
gene	NN	O	O
(	(	O	O
s	PRP	O	O
)	)	O	O

9391889	CD	O	O

Paternal	JJ	O	O
transmission	NN	O	O
of	IN	O	O
congenital	JJ	B_Disease	B_Disease
myotonic	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
.	.	O	O

We	PRP	O	O
report	VBP	O	O
a	DT	O	O
rare	JJ	O	O
case	NN	O	O
of	IN	O	O
paternally	RB	O	O
transmitted	VBN	O	O
congenital	JJ	B_Disease	B_Disease
myotonic	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

The	DT	O	O
proband	NN	O	O
is	VBZ	O	O
a	DT	O	O
23	CD	O	O
year	NN	O	O
old	JJ	O	O
,	,	O	O
mentally	RB	B_Disease	O
retarded	JJ	E_Disease	O
male	NN	O	O
who	WP	O	O
suffers	VBZ	O	O
severe	JJ	O	O
muscular	JJ	B_Disease	B_Disease
weakness	NN	E_Disease	E_Disease
.	.	O	O

He	PRP	O	O
presented	VBD	O	O
with	IN	O	O
respiratory	NN	O	O
and	CC	O	O
feeding	NN	O	O
difficulties	NNS	O	O
at	IN	O	O
birth	NN	O	O
.	.	O	O

His	PRP$	O	O
two	CD	O	O
sibs	NNS	O	O
suffer	VBP	O	O
from	IN	O	O
childhood	NN	O	O
onset	VBN	O	O
DM	NNP	S_Disease	S_Disease
.	.	O	O

Their	PRP$	O	O
late	JJ	O	O
father	NN	O	O
had	VBD	O	O
the	DT	O	O
adult	NN	O	O
type	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
,	,	O	O
with	IN	O	O
onset	VBN	O	O
around	IN	O	O
30	CD	O	O
years	NNS	O	O
.	.	O	O

Only	RB	O	O
six	CD	O	O
other	JJ	O	O
cases	NNS	O	O
of	IN	O	O
paternal	JJ	O	O
transmission	NN	O	O
of	IN	O	O
congenital	JJ	B_Disease	O
DM	NNP	E_Disease	S_Disease
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
recently	RB	O	O
.	.	O	O

We	PRP	O	O
review	VBP	O	O
the	DT	O	O
sex	NN	O	O
related	JJ	O	O
effects	NNS	O	O
on	IN	O	O
transmission	NN	O	O
of	IN	O	O
congenital	JJ	B_Disease	O
DM	NNP	E_Disease	S_Disease
.	.	O	O

Decreased	VBN	O	O
fertility	NN	O	O
of	IN	O	O
males	NNS	O	O
with	IN	O	O
adult	NN	O	O
onset	VBN	O	O
DM	NNP	S_Disease	S_Disease
and	CC	O	O
contraction	NN	O	O
of	IN	O	O
the	DT	O	O
repeat	NN	O	O
upon	IN	O	O
male	JJ	O	O
transmission	NN	O	O
contribute	NN	O	O
to	TO	O	O
the	DT	O	O
almost	RB	O	O
absent	JJ	O	O
occurrence	NN	O	O
of	IN	O	O
paternal	JJ	O	O
transmission	NN	O	O
of	IN	O	O
congenital	JJ	B_Disease	O
DM	NNP	E_Disease	S_Disease
.	.	O	O

Also	RB	O	O
the	DT	O	O
fathers	NNS	O	O
of	IN	O	O
the	DT	O	O
reported	VBN	O	O
congenitally	RB	O	O
affected	JJ	O	O
children	NNS	O	O
showed	VBD	O	O
,	,	O	O
on	IN	O	O
average	NN	O	O
,	,	O	O
shorter	JJR	O	O
CTG	NNP	O	O
repeat	NN	O	O
lengths	NNS	O	O
and	CC	O	O
hence	RB	O	O
less	JJR	O	O
severe	JJ	O	O
clinical	NN	O	O
symptoms	NNS	O	O
than	IN	O	O
the	DT	O	O
mothers	NNS	O	O
of	IN	O	O
children	NNS	O	O
with	IN	O	O
congenital	JJ	B_Disease	O
DM	NNP	E_Disease	S_Disease
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
paternal	JJ	O	O
transmission	NN	O	O
of	IN	O	O
congenital	JJ	B_Disease	O
DM	NNP	E_Disease	S_Disease
is	VBZ	O	O
rare	JJ	O	O
and	CC	O	O
preferentially	RB	O	O
occurs	VBZ	O	O
with	IN	O	O
onset	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
past	IN	O	O
30	CD	O	O
years	NNS	O	O
in	IN	O	O
the	DT	O	O
father	NN	O	O
.	.	O	O
.	.	O	O

9400934	CD	O	O

The	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
mutation	NN	O	O
in	IN	O	O
a	DT	O	O
child	NN	O	O
with	IN	O	O
ectopic	JJ	B_Disease	O
intracranial	JJ	I_Disease	O
retinoblastoma	NN	E_Disease	S_Disease
.	.	O	O

The	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
mutation	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
in	IN	O	O
a	DT	O	O
child	NN	O	O
with	IN	O	O
ectopic	JJ	B_Disease	O
intracranial	JJ	I_Disease	O
retinoblastoma	NN	E_Disease	S_Disease
using	VBG	O	O
DNA	NNP	O	O
obtained	VBN	O	O
from	IN	O	O
both	CC	O	O
the	DT	O	O
pineal	NN	B_Disease	O
and	CC	I_Disease	O
retinal	JJ	I_Disease	B_Disease
tumours	NN	E_Disease	E_Disease
of	IN	O	O
the	DT	O	O
patient	NN	O	O
.	.	O	O

A	DT	O	O
nonsense	JJ	O	O
mutation	NN	O	O
in	IN	O	O
exon	JJ	O	O
17	CD	O	O
(	(	O	O
codon	VB	O	O
556	CD	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
present	JJ	O	O
homozygously	RB	O	O
in	IN	O	O
both	CC	O	O
the	DT	O	O
retinal	NN	B_Disease	O
and	CC	I_Disease	O
the	DT	I_Disease	O
pineal	NN	I_Disease	O
tumours	NN	E_Disease	S_Disease
.	.	O	O

The	DT	O	O
same	JJ	O	O
mutation	NN	O	O
was	VBD	O	O
present	JJ	O	O
heterozygously	RB	O	O
in	IN	O	O
the	DT	O	O
DNA	NN	O	O
from	IN	O	O
the	DT	O	O
constitutional	JJ	O	O
cells	NNS	O	O
of	IN	O	O
the	DT	O	O
patient	NN	O	O
,	,	O	O
proving	VBG	O	O
it	PRP	O	O
to	TO	O	O
be	VB	O	O
of	IN	O	O
germline	JJ	O	O
origin	NN	O	O
.	.	O	O

The	DT	O	O
initial	JJ	O	O
mutation	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
have	VB	O	O
occurred	VBN	O	O
in	IN	O	O
the	DT	O	O
paternally	RB	O	O
derived	VBN	O	O
RB1	NNP	O	O
allele	NN	O	O
.	.	O	O

The	DT	O	O
mutation	NN	O	O
is	VBZ	O	O
in	IN	O	O
an	DT	O	O
area	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
that	WDT	O	O
encodes	VBZ	O	O
the	DT	O	O
protein	NN	O	O
-	:	O	O
binding	JJ	O	O
region	NN	O	O
known	VBN	O	O
as	IN	O	O
the	DT	O	O
pocket	NN	O	O
region	NN	O	O
and	CC	O	O
has	VBZ	O	O
been	VBN	O	O
detected	VBN	O	O
in	IN	O	O
other	JJ	O	O
cases	NNS	O	O
of	IN	O	O
retinoblastoma	NN	S_Disease	S_Disease
.	.	O	O
.	.	O	O

941901	CD	O	O

Low	JJ	O	O
levels	NNS	O	O
of	IN	O	O
beta	NN	O	O
hexosaminidase	NN	O	O
A	NNP	O	O
in	IN	O	O
healthy	JJ	O	O
individuals	NNS	O	O
with	IN	O	O
apparent	JJ	O	O
deficiency	NN	O	O
of	IN	O	O
this	DT	O	O
enzyme	NN	O	O
.	.	O	O

Appreciable	JJ	O	O
beta	NN	O	O
hexosaminidase	NN	O	O
A	NNP	O	O
(	(	O	O
hex	VB	O	O
A	DT	O	O
)	)	O	O
activity	NN	O	O
has	VBZ	O	O
been	VBN	O	O
detected	VBN	O	O
in	IN	O	O
cultured	JJ	O	O
skin	NN	O	O
fibroblasts	NNS	O	O
and	CC	O	O
melanoma	NNS	S_Disease	S_Disease
tissue	NN	O	O
from	IN	O	O
healthy	JJ	O	O
individuals	NNS	O	O
previously	RB	O	O
reported	VBD	O	O
as	IN	O	O
having	VBG	O	O
deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
hex	NN	I_Disease	O
A	NNP	E_Disease	O
activity	NN	O	O
indistinguishable	NN	O	O
from	IN	O	O
that	DT	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
Tay	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Sachs	NNP	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
(	(	O	O
TSD	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

Identification	NN	O	O
and	CC	O	O
quantitation	NN	O	O
of	IN	O	O
hex	NN	O	O
A	NNP	O	O
,	,	O	O
amounting	VBG	O	O
to	TO	O	O
3	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
-	:	O	O
6	CD	O	O
.	.	O	O

9	CD	O	O
%	NN	O	O
of	IN	O	O
total	JJ	O	O
beta	JJ	O	O
hexosaminidase	NN	O	O
activity	NN	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
obtained	VBN	O	O
by	IN	O	O
cellulose	JJ	O	O
acetate	NN	O	O
gel	NN	O	O
electrophoresis	NN	O	O
,	,	O	O
DEAE	NNP	O	O
-	:	O	O
cellulose	NN	O	O
ion	NN	O	O
-	:	O	O
exchange	NN	O	O
chromatography	NN	O	O
,	,	O	O
radial	JJ	O	O
immunodiffusion	NN	O	O
,	,	O	O
and	CC	O	O
radioimmunoassay	NN	O	O
.	.	O	O

Previous	JJ	O	O
family	NN	O	O
studies	NNS	O	O
suggested	VBD	O	O
that	IN	O	O
these	DT	O	O
individuals	NNS	O	O
may	MD	O	O
be	VB	O	O
compound	VBN	O	O
heterozygotes	NNS	O	O
for	IN	O	O
the	DT	O	O
common	JJ	O	O
mutant	NN	O	O
TSD	NNP	S_Disease	S_Disease
gene	NN	O	O
and	CC	O	O
a	DT	O	O
rare	JJ	O	O
(	(	O	O
allelic	JJ	O	O
)	)	O	O
mutant	JJ	O	O
gene	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
postulated	JJ	O	O
rate	NN	O	O
mutant	JJ	O	O
gene	NN	O	O
appears	VBZ	O	O
to	TO	O	O
code	VB	O	O
for	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
low	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
hex	NN	O	O
A	NNP	O	O
.	.	O	O

Heterozygotes	NNS	O	O
for	IN	O	O
the	DT	O	O
rare	JJ	O	O
mutant	NN	O	O
may	MD	O	O
be	VB	O	O
indistinguishable	JJ	O	O
from	IN	O	O
heterozygotes	NNS	O	O
for	IN	O	O
the	DT	O	O
common	JJ	O	O
TSD	NNP	S_Disease	S_Disease
mutant	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
direct	JJ	O	O
visualization	NN	O	O
and	CC	O	O
quantitation	NN	O	O
of	IN	O	O
hex	NN	O	O
A	NNP	O	O
by	IN	O	O
the	DT	O	O
methods	NNS	O	O
described	VBD	O	O
may	MD	O	O
prevent	VB	O	O
false	JJ	O	O
-	:	O	O
positive	JJ	O	O
prenatal	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
TSD	NNP	S_Disease	S_Disease
in	IN	O	O
fetuses	NNS	O	O
having	VBG	O	O
the	DT	O	O
incomplete	JJ	O	O
hex	NN	B_Disease	O
A	NNP	I_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
of	IN	O	O
the	DT	O	O
type	NN	O	O
described	VBN	O	O
in	IN	O	O
the	DT	O	O
four	CD	O	O
healthy	JJ	O	O
individuals	NNS	O	O

9420335	CD	O	O

The	DT	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
gene	NN	O	O
Smad4	NNP	O	O
/	NNP	O	O
Dpc4	NNP	O	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
gastrulation	NN	O	O
and	CC	O	O
later	RB	O	O
for	IN	O	O
anterior	JJ	O	O
development	NN	O	O
of	IN	O	O
the	DT	O	O
mouse	NN	O	O
embryo	NN	O	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
SMAD4	NNP	O	O
/	NNP	O	O
DPC4	NNP	O	I_Disease
tumor	NN	S_Disease	E_Disease
suppressor	NN	O	O
gene	NN	O	O
,	,	O	O
a	DT	O	O
key	JJ	O	O
signal	JJ	O	O
transducer	NN	O	O
in	IN	O	O
most	JJS	O	O
TGFbeta	NNP	O	O
-	:	O	O
related	JJ	O	O
pathways	NNS	O	O
,	,	O	O
are	VBP	O	O
involved	VBN	O	O
in	IN	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
pancreatic	JJ	B_Disease	B_Disease
cancers	NNS	E_Disease	E_Disease
.	.	O	O

Homozygous	JJ	O	O
Smad4	NNP	O	O
mutant	NN	O	O
mice	NN	O	O
die	NN	O	O
before	IN	O	O
day	NN	O	O
7	CD	O	O
.	.	O	O

5	CD	O	O
of	IN	O	O
embryogenesis	NN	O	O
.	.	O	O

Mutant	NNP	O	O
embryos	NN	O	O
have	VBP	O	O
reduced	VBN	O	O
size	NN	O	O
,	,	O	O
fail	VBP	O	O
to	TO	O	O
gastrulate	VB	O	O
or	CC	O	O
express	VB	O	O
a	DT	O	O
mesodermal	JJ	O	O
marker	NN	O	O
,	,	O	O
and	CC	O	O
show	VB	O	O
abnormal	JJ	O	O
visceral	JJ	O	O
endoderm	NN	O	O
development	NN	O	O
.	.	O	O

Growth	NNP	B_Disease	B_Disease
retardation	NN	E_Disease	E_Disease
of	IN	O	O
the	DT	O	O
Smad4	NNP	O	O
-	:	O	I_Disease
deficient	NN	O	E_Disease
embryos	JJ	O	O
results	NNS	O	O
from	IN	O	O
reduced	VBN	O	O
cell	NN	O	O
proliferation	NN	O	O
rather	RB	O	O
than	IN	O	O
increased	VBN	O	O
apoptosis	NN	O	O
.	.	O	O

Aggregation	NN	O	O
of	IN	O	O
mutant	JJ	O	O
Smad4	NNP	O	O
ES	NNP	O	O
cells	NNS	O	O
with	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
tetraploid	NN	O	O
morulae	NN	O	O
rescues	VBZ	O	O
the	DT	O	O
gastrulation	NN	B_Disease	O
defect	NN	E_Disease	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
Smad4	NNP	O	O
is	VBZ	O	O
initially	RB	O	O
required	VBN	O	O
for	IN	O	O
the	DT	O	O
differentiation	NN	O	O
of	IN	O	O
the	DT	O	O
visceral	JJ	O	O
endoderm	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
gastrulation	NN	B_Disease	O
defect	NN	E_Disease	O
in	IN	O	O
the	DT	O	O
epiblast	NN	O	O
is	VBZ	O	O
secondary	JJ	O	O
and	CC	O	O
non	JJ	O	O
-	:	O	O
cell	NN	O	O
autonomous	JJ	O	O
.	.	O	O

Rescued	VBN	O	O
embryos	JJ	O	O
show	NN	O	O
severe	JJ	O	O
anterior	JJ	O	O
truncations	NNS	O	O
,	,	O	O
indicating	VBG	O	O
a	DT	O	O
second	JJ	O	O
important	JJ	O	O
role	NN	O	O
for	IN	O	O
Smad4	NNP	O	O
in	IN	O	O
anterior	JJ	O	O
patterning	NN	O	O
during	IN	O	O
embryogenesis	NN	O	O
.	.	O	O

9425228	CD	O	O

Prevalence	NN	O	O
of	IN	O	O
p16	NN	O	O
and	CC	O	O
CDK4	NNP	O	O
germline	VBP	O	O
mutations	NNS	O	O
in	IN	O	O
48	CD	O	O
melanoma	NN	S_Disease	S_Disease
-	:	O	O
prone	NN	O	O
families	NNS	O	O
in	IN	O	O
France	NNP	O	O
.	.	O	O

The	DT	O	O
French	JJ	O	O
Familial	NNP	B_Disease	O
Melanoma	NNP	E_Disease	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

Germline	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
p16	NN	O	O
and	CC	O	O
CDK4	NNP	O	O
genes	NNS	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
a	DT	O	O
subset	NN	O	O
of	IN	O	O
melanoma	NN	S_Disease	S_Disease
pedigrees	NNS	O	O
,	,	O	O
but	CC	O	O
their	PRP$	O	O
prevalence	NN	O	O
is	VBZ	O	O
not	RB	O	O
well	RB	O	O
known	VBN	O	O
.	.	O	O

We	PRP	O	O
searched	VBD	O	O
for	IN	O	O
such	JJ	O	O
germline	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
48	CD	O	O
French	JJ	O	O
melanoma	NN	S_Disease	B_Disease
-	:	O	I_Disease
prone	NN	O	O
families	NNS	O	O
selected	VBN	O	O
according	VBG	O	O
to	TO	O	O
two	CD	O	O
major	JJ	O	O
criteria	NNS	O	O
families	NNS	O	O
with	IN	O	O
at	IN	O	O
least	JJS	O	O
three	CD	O	O
affected	JJ	O	O
members	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
20	CD	O	O
)	)	O	O
or	CC	O	O
families	NNS	O	O
with	IN	O	O
two	CD	O	O
affected	JJ	O	O
members	NNS	O	O
,	,	O	O
one	CD	O	O
of	IN	O	O
them	PRP	O	O
affected	VBD	O	O
before	IN	O	O
the	DT	O	O
age	NN	O	O
of	IN	O	O
50	CD	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
28	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
one	CD	O	O
additional	JJ	O	O
minor	JJ	O	O
criterion	NN	O	O
.	.	O	O

Sixteen	JJ	O	O
different	JJ	O	O
p16	NN	O	O
germline	NN	O	O
mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
21	CD	O	O
families	NNS	O	O
,	,	O	O
while	IN	O	O
one	CD	O	O
germline	NN	O	O
mutation	NN	O	O
,	,	O	O
Arg24His	NNP	O	O
,	,	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
CDK4	NNP	O	O
gene	NN	O	O
.	.	O	O

The	DT	O	O
frequency	NN	O	O
of	IN	O	O
p16	JJ	O	O
gene	NN	O	O
mutation	NN	O	O
in	IN	O	O
our	PRP$	O	O
sample	NN	O	O
(	(	O	O
44	CD	O	O
%	NN	O	O
)	)	O	O
is	VBZ	O	O
among	IN	O	O
the	DT	O	O
highest	JJS	O	O
rates	NNS	O	O
yet	RB	O	O
reported	VBN	O	O
and	CC	O	O
the	DT	O	O
CDK4	NNP	O	O
mutation	NN	O	O
is	VBZ	O	O
the	DT	O	O
second	JJ	O	O
mutation	NN	O	O
detected	VBN	O	O
in	IN	O	O
this	DT	O	O
gene	NN	O	O
worldwide	NN	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
our	PRP$	O	O
results	NNS	O	O
show	VBP	O	O
frequent	JJ	O	O
involvement	NN	O	O
of	IN	O	O
the	DT	O	O
p16	JJ	O	O
gene	NN	O	O
in	IN	O	O
familial	JJ	B_Disease	B_Disease
melanoma	NN	E_Disease	E_Disease
and	CC	O	O
confirm	VBP	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
the	DT	O	O
CDK4	NNP	O	O
gene	NN	O	O
as	IN	O	O
a	DT	O	O
melanoma	NN	S_Disease	S_Disease
-	:	O	O
predisposing	NN	O	O
gene	NN	O	O
.	.	O	O
.	.	O	O

9425239	CD	O	O

Progression	NN	O	O
of	IN	O	O
somatic	JJ	O	O
CTG	NNP	O	O
repeat	NN	O	O
length	NN	O	O
heterogeneity	NN	O	O
in	IN	O	O
the	DT	O	O
blood	NN	O	O
cells	NNS	O	O
of	IN	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
patients	NNS	O	O
.	.	O	O

The	DT	O	O
genetic	JJ	O	O
basis	NN	O	O
of	IN	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
the	DT	O	O
expansion	NN	O	O
of	IN	O	O
an	DT	O	O
unstable	JJ	O	O
CTG	NNP	O	O
repeat	NN	O	O
in	IN	O	O
the	DT	O	O
34	CD	O	O
UTR	NNP	O	O
of	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
protein	NN	O	O
kinase	VBD	O	O
gene	NN	O	O
on	IN	O	O
chromosome	NN	O	O
19	CD	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
the	DT	O	O
principal	JJ	O	O
features	NNS	O	O
of	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
mutation	NN	O	O
is	VBZ	O	O
an	DT	O	O
extraordinarily	RB	O	O
high	JJ	O	O
level	NN	O	O
of	IN	O	O
somatic	JJ	O	O
mosaicism	NN	O	O
,	,	O	O
due	JJ	O	O
to	TO	O	O
an	DT	O	O
extremely	RB	O	O
high	JJ	O	O
degree	NN	O	O
of	IN	O	O
somatic	JJ	O	O
instability	NN	O	O
both	DT	O	O
within	IN	O	O
and	CC	O	O
between	IN	O	O
different	JJ	O	O
tissues	NNS	O	O
.	.	O	O

This	DT	O	O
instability	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
biased	VBN	O	O
towards	IN	O	O
further	JJ	O	O
expansion	NN	O	O
and	CC	O	O
continuous	JJ	O	O
throughout	IN	O	O
the	DT	O	O
life	NN	O	O
of	IN	O	O
an	DT	O	O
individual	NN	O	O
,	,	O	O
features	VBZ	O	O
that	DT	O	O
could	MD	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
progressive	JJ	O	O
nature	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O

Although	IN	O	O
increasing	VBG	O	O
measured	VBN	O	O
allele	JJ	O	O
size	NN	O	O
between	IN	O	O
patients	NNS	O	O
clearly	RB	O	O
correlates	VBZ	O	O
with	IN	O	O
an	DT	O	O
increased	JJ	O	O
severity	NN	O	O
of	IN	O	O
symptoms	NNS	O	O
and	CC	O	O
an	DT	O	O
earlier	JJR	O	O
age	NN	O	O
of	IN	O	O
onset	NN	O	O
,	,	O	O
this	DT	O	O
correlation	NN	O	O
is	VBZ	O	O
not	RB	O	O
precise	JJ	O	O
and	CC	O	O
measured	VBD	O	O
allele	NNS	O	O
length	NN	O	O
cannot	NN	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
an	DT	O	O
accurate	JJ	O	O
predictor	NN	O	O
of	IN	O	O
age	NN	O	O
of	IN	O	O
onset	NN	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
further	RBR	O	O
characterize	VB	O	O
the	DT	O	O
dynamics	NNS	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
CTG	NNP	O	O
repeat	NN	O	O
somatic	JJ	O	O
instability	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
repeat	NN	O	O
length	NN	O	O
changes	NNS	O	O
over	IN	O	O
time	NN	O	O
in	IN	O	O
111	CD	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
patients	NNS	O	O
with	IN	O	O
varying	VBG	O	O
clinical	JJ	O	O
severity	NN	O	O
and	CC	O	O
CTG	NNP	O	O
repeat	NN	O	O
size	NN	O	O
over	IN	O	O
time	NN	O	O
intervals	NNS	O	O
of	IN	O	O
1	CD	O	O
-	:	O	O
7	CD	O	O
years	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
found	VBN	O	O
a	DT	O	O
direct	JJ	O	O
progression	NN	O	O
of	IN	O	O
the	DT	O	O
size	NN	O	O
heterogeneity	NN	O	O
over	IN	O	O
time	NN	O	O
related	VBN	O	O
to	TO	O	O
initial	JJ	O	O
CTG	NNP	O	O
repeat	NN	O	O
size	NN	O	O
and	CC	O	O
the	DT	O	O
time	NN	O	O
interval	NN	O	O
and	CC	O	O
always	RB	O	O
biased	VBN	O	O
towards	NNS	O	O
further	JJ	O	O
expansion	NN	O	O
.	.	O	O

Attempts	NNS	O	O
to	TO	O	O
mathematically	RB	O	O
model	VB	O	O
the	DT	O	O
dynamics	NNS	O	O
have	VBP	O	O
proved	VBN	O	O
only	RB	O	O
partially	RB	O	O
successful	JJ	O	O
suggesting	VBG	O	O
that	IN	O	O
individual	JJ	O	O
specific	JJ	O	O
genetic	JJ	O	O
and	CC	O	O
/	NN	O	O
or	CC	O	O
environmental	JJ	O	O
factors	NNS	O	O
also	RB	O	O
play	VBP	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
somatic	JJ	O	O
mosaicism	NN	O	O
.	.	O	O
.	.	O	O

9427148	CD	O	O

Aspartylglucosaminuria	NNP	S_Disease	S_Disease
among	IN	O	O
Palestinian	JJ	O	O
Arabs	NNPS	O	O
.	.	O	O

Aspartylglucosaminuria	NNP	S_Disease	S_Disease
(	(	O	O
AGU	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
a	DT	O	O
rare	JJ	O	O
disorder	NN	B_Disease	O
of	IN	I_Disease	O
glycoprotein	JJ	I_Disease	O
metabolism	NN	E_Disease	O
caused	VBN	O	O
by	IN	O	O
the	DT	O	O
deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
lysosomal	JJ	I_Disease	I_Disease
enzyme	NN	I_Disease	I_Disease
aspartylglucosaminidase	NN	E_Disease	E_Disease
(	(	O	O
AGA	NNP	O	O
)	)	O	O
.	.	O	O

AGU	NNP	S_Disease	S_Disease
is	VBZ	O	O
inherited	VBN	O	O
as	IN	O	O
an	DT	O	O
autosomal	JJ	O	O
recessive	JJ	O	O
trait	NN	O	O
and	CC	O	O
occurs	VBZ	O	O
with	IN	O	O
a	DT	O	O
high	JJ	O	O
frequency	NN	O	O
in	IN	O	O
Finland	NNP	O	O
because	IN	O	O
of	IN	O	O
a	DT	O	O
founder	NN	O	O
effect	NN	O	O
.	.	O	O

While	IN	O	O
very	RB	O	O
few	JJ	O	O
patients	NNS	O	O
with	IN	O	O
AGU	NNP	S_Disease	S_Disease
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
from	IN	O	O
non	JJ	O	O
-	:	O	O
Finnish	JJ	O	O
origin	NN	O	O
,	,	O	O
we	PRP	O	O
diagnosed	VBD	O	O
the	DT	O	O
disorder	NN	O	O
in	IN	O	O
8	CD	O	O
patients	NNS	O	O
originating	VBG	O	O
from	IN	O	O
3	CD	O	O
unrelated	JJ	O	O
families	NNS	O	O
,	,	O	O
all	DT	O	O
Palestinian	JJ	O	O
Arabs	NNP	O	O
from	IN	O	O
the	DT	O	O
region	NN	O	O
of	IN	O	O
Jerusalem	NNP	O	O
.	.	O	O

The	DT	O	O
clinical	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
AGU	NNP	S_Disease	S_Disease
is	VBZ	O	O
often	RB	O	O
difficult	JJ	O	O
,	,	O	O
in	IN	O	O
particular	JJ	O	O
early	JJ	O	O
in	IN	O	O
the	DT	O	O
course	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
,	,	O	O
and	CC	O	O
most	JJS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
are	VBP	O	O
diagnosed	VBN	O	O
after	IN	O	O
the	DT	O	O
age	NN	O	O
of	IN	O	O
5	CD	O	O
years	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
since	IN	O	O
these	DT	O	O
patients	NNS	O	O
excrete	VBP	O	O
early	RB	O	O
large	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
aspartylglucosamine	NN	O	O
in	IN	O	O
urine	NN	O	O
,	,	O	O
biochemical	JJ	O	O
screening	NN	O	O
is	VBZ	O	O
easy	JJ	O	O
by	IN	O	O
urine	JJ	O	O
chromatography	NN	O	O
.	.	O	O
.	.	O	O

9439660	CD	O	O

Detection	NN	O	O
of	IN	O	O
heterozygous	JJ	O	O
carriers	NNS	O	O
of	IN	O	O
the	DT	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
ATM	NNP	O	O
)	)	O	O
gene	NN	O	O
by	IN	O	O
G2	NNP	O	O
phase	NN	O	O
chromosomal	JJ	O	O
radiosensitivity	NN	O	O
of	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
lymphocytes	NNS	O	O
.	.	O	O

In	IN	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
patients	NNS	O	O
,	,	O	O
mutations	NNS	O	O
in	IN	O	O
a	DT	O	O
single	JJ	O	O
gene	NN	O	O
,	,	O	O
ATM	NNP	O	O
,	,	O	O
result	NN	O	O
in	IN	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
that	WDT	O	O
embraces	VBZ	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
clinical	JJ	O	O
features	NNS	O	O
and	CC	O	O
manifests	NNS	O	O
extreme	VBP	O	O
radiosensitivity	NN	O	O
and	CC	O	O
a	DT	O	O
strong	JJ	O	O
pre	NN	O	O
-	:	O	O
disposition	NN	O	O
to	TO	O	O
malignancy	NN	S_Disease	O
.	.	O	O

Heterozygotes	NNS	O	O
for	IN	O	O
the	DT	O	O
ATM	NNP	O	O
gene	NN	O	O
have	VBP	O	O
no	DT	O	O
clinical	JJ	O	O
expression	NN	O	O
of	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
but	CC	O	O
may	MD	O	O
be	VB	O	O
cancer	NN	S_Disease	S_Disease
prone	NN	O	O
with	IN	O	O
a	DT	O	O
moderate	JJ	O	O
increase	NN	O	O
in	IN	O	O
in	IN	O	O
vitro	JJ	O	O
radiosensitivity	NN	O	O
.	.	O	O

We	PRP	O	O
performed	VBD	O	O
a	DT	O	O
blind	NN	O	O
chromosomal	JJ	O	O
analysis	NN	O	O
on	IN	O	O
G2	NNP	O	O
-	:	O	O
phase	NN	O	O
lymphocytes	VBZ	O	O
from	IN	O	O
7	CD	O	O
unrelated	VBD	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
,	,	O	O
13	CD	O	O
obligate	NN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
heterozygotes	NNS	O	O
(	(	O	O
parents	NNS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
14	CD	O	O
normal	JJ	O	O
controls	NNS	O	O
following	VBG	O	O
X	NNP	O	O
-	:	O	O
irradiation	NN	O	O
with	IN	O	O
1	CD	O	O
Gy	NNP	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
evaluate	VB	O	O
this	DT	O	O
cytogenetic	JJ	O	O
method	NN	O	O
as	IN	O	O
a	DT	O	O
tool	NN	O	O
for	IN	O	O
detection	NN	O	O
of	IN	O	O
ATM	NNP	O	S_Disease
carriers	NNS	O	O
.	.	O	O

Both	DT	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
homozygotes	NNS	O	O
and	CC	O	O
heterozygotes	NNS	O	O
showed	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
levels	NNS	O	O
of	IN	O	O
radiation	NN	O	O
-	:	O	O
induced	JJ	O	O
chromatid	JJ	O	O
damage	NN	O	O
relative	NN	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
normal	JJ	O	O
controls	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
G2	NNP	O	O
-	:	O	O
phase	NN	O	O
chromosomal	JJ	O	O
radiosensitivity	NN	O	O
assay	VBP	O	O
can	MD	O	O
be	VB	O	O
used	VBN	O	O
for	IN	O	O
the	DT	O	O
detection	NN	O	O
of	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
heterozygotes	NNS	O	O
.	.	O	O

In	IN	O	O
combination	NN	O	O
with	IN	O	O
molecular	JJ	O	O
genetic	JJ	O	O
analyses	NNS	O	O
,	,	O	O
this	DT	O	O
test	NN	O	O
may	MD	O	O
be	VB	O	O
of	IN	O	O
value	NN	O	O
in	IN	O	O
studies	NNS	O	O
of	IN	O	O
familial	JJ	B_Disease	B_Disease
and	CC	I_Disease	I_Disease
sporadic	JJ	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
aimed	VBN	O	O
at	IN	O	O
determination	NN	O	O
of	IN	O	O
the	DT	O	O
potential	JJ	O	O
involvement	NN	O	O
of	IN	O	O
ATM	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
tumor	NN	S_Disease	S_Disease
risk	NN	O	O
or	CC	O	O
development	NN	O	O
.	.	O	O
.	.	O	O

9443866	CD	O	O

Ataxia	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
:	:	O	O
identification	NN	O	O
and	CC	O	O
detection	NN	O	O
of	IN	O	O
founder	NN	O	O
-	:	O	O
effect	NN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
ATM	NNP	O	O
gene	NN	O	O
in	IN	O	O
ethnic	JJ	O	O
populations	NNS	O	O
.	.	O	O

To	TO	O	O
facilitate	VB	O	O
the	DT	O	O
evaluation	NN	O	O
of	IN	O	O
ATM	NNP	O	O
heterozygotes	NNS	O	O
for	IN	O	O
susceptibility	NN	O	O
to	TO	O	O
other	JJ	O	O
diseases	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
,	,	O	O
we	PRP	O	O
have	VBP	O	O
attempted	VBN	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
their	PRP$	O	O
frequencies	NNS	O	O
in	IN	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
homozygotes	VBZ	O	O
from	IN	O	O
10	CD	O	O
ethnic	JJ	O	O
populations	NNS	O	O
.	.	O	O

Both	DT	O	O
genomic	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
cDNA	NN	O	O
were	VBD	O	O
characterized	VBN	O	O
.	.	O	O

Protein	NNP	O	O
-	:	O	O
truncation	NN	O	O
testing	NN	O	O
of	IN	O	O
the	DT	O	O
entire	JJ	O	O
ATM	NNP	O	O
cDNA	NN	O	O
detected	VBD	O	O
92	CD	O	O
(	(	O	O
66	CD	O	O
%	NN	O	O
)	)	O	O
truncating	VBG	O	O
mutations	NNS	O	O
in	IN	O	O
140	CD	O	O
mutant	JJ	O	O
alleles	NNS	O	O
screened	VBN	O	O
.	.	O	O

The	DT	O	O
haplotyping	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
identical	JJ	O	O
mutations	NNS	O	O
indicates	VBZ	O	O
that	IN	O	O
almost	RB	O	O
all	DT	O	O
of	IN	O	O
these	DT	O	O
represent	JJ	O	O
common	JJ	O	O
ancestry	NN	O	O
and	CC	O	O
that	DT	O	O
very	RB	O	O
few	JJ	O	O
spontaneously	RB	O	O
recurring	VBG	O	O
ATM	NNP	O	O
mutations	NNS	O	O
exist	VBP	O	O
.	.	O	O

Assays	NNS	O	O
requiring	VBG	O	O
minimal	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
genomic	JJ	O	O
DNA	NNP	O	O
were	VBD	O	O
designed	VBN	O	O
to	TO	O	O
allow	VB	O	O
rapid	JJ	O	O
screening	NN	O	O
for	IN	O	O
common	JJ	O	O
ethnic	JJ	O	O
mutations	NNS	O	O
.	.	O	O

These	DT	O	O
rapid	JJ	O	O
assays	NNS	O	O
detected	VBN	O	O
mutations	NNS	O	O
in	IN	O	O
76	CD	O	O
%	NN	O	O
of	IN	O	O
Costa	JJ	O	O
Rican	JJ	O	O
patients	NNS	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
,	,	O	O
50	CD	O	O
%	NN	O	O
of	IN	O	O
Norwegian	JJ	O	O
patients	NNS	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
,	,	O	O
25	CD	O	O
%	NN	O	O
of	IN	O	O
Polish	JJ	O	O
patients	NNS	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
14	CD	O	O
%	NN	O	O
of	IN	O	O
Italian	JJ	O	O
patients	NNS	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
patients	NNS	O	O
of	IN	O	O
Amish	NNP	O	O
/	NNP	O	O
Mennonite	NNP	O	O
and	CC	O	O
Irish	NNP	O	O
English	NNP	O	O
backgrounds	NNS	O	O
.	.	O	O

Additional	JJ	O	O
mutations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
Japanese	JJ	O	O
,	,	O	O
Utah	NNP	O	O
Mormon	NNP	O	O
,	,	O	O
and	CC	O	O
African	JJ	O	O
American	JJ	O	O
patients	NNS	O	O
.	.	O	O

These	DT	O	O
assays	NNS	O	O
should	MD	O	O
facilitate	VB	O	O
screening	VBG	O	O
for	IN	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
heterozygotes	NNS	O	O
in	IN	O	O
the	DT	O	O
populations	NNS	O	O
studied	VBN	O	O
.	.	O	O
.	.	O	O

9448273	CD	O	O

The	DT	O	O
von	NN	B_Disease	B_Disease
Hippel	NNP	I_Disease	I_Disease
-	:	I_Disease	I_Disease
Lindau	NNP	I_Disease	I_Disease
tumor	NN	E_Disease	E_Disease
suppressor	NN	O	O
gene	NN	O	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
cell	NN	O	O
cycle	NN	O	O
exit	NN	O	O
upon	IN	O	O
serum	NN	O	O
withdrawal	NN	O	O
.	.	O	O

The	DT	O	O
inactivation	NN	O	O
of	IN	O	O
the	DT	O	O
von	NN	B_Disease	B_Disease
Hippel	NNP	I_Disease	I_Disease
-	:	I_Disease	I_Disease
Lindau	NNP	I_Disease	I_Disease
(	(	I_Disease	I_Disease
VHL	NNP	I_Disease	I_Disease
)	)	I_Disease	I_Disease
tumor	NN	E_Disease	E_Disease
suppressor	NN	O	O
gene	NN	O	O
predisposes	NNS	O	O
affected	VBD	O	O
individuals	NNS	O	O
to	TO	O	O
the	DT	O	O
human	JJ	O	O
VHL	NNP	B_Disease	B_Disease
cancer	NN	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
and	CC	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
sporadic	JJ	B_Disease	B_Disease
renal	JJ	I_Disease	I_Disease
cell	NN	I_Disease	I_Disease
carcinomas	NN	E_Disease	E_Disease
(	(	O	O
RCC	NNP	S_Disease	S_Disease
)	)	O	O
and	CC	O	O
brain	NN	B_Disease	B_Disease
hemangioblastomas	NN	E_Disease	E_Disease
.	.	O	O

VHL	NNP	O	O
-	:	O	O
negative	JJ	O	O
786	CD	O	O
-	:	O	O
0	CD	O	O
RCC	NNP	S_Disease	S_Disease
cells	NNS	O	O
are	VBP	O	O
tumorigenic	JJ	O	O
in	IN	O	O
nude	JJ	O	O
mice	NN	O	O
which	WDT	O	O
is	VBZ	O	O
suppressed	VBN	O	O
by	IN	O	O
the	DT	O	O
reintroduction	NN	O	O
of	IN	O	O
VHL	NNP	S_Disease	S_Disease
.	.	O	O

Remarkably	RB	O	O
,	,	O	O
this	DT	O	O
occurs	VBZ	O	O
without	IN	O	O
affecting	VBG	O	O
the	DT	O	O
growth	NN	O	O
rate	NN	O	O
and	CC	O	O
cell	NN	O	O
cycle	NN	O	O
profile	NN	O	O
of	IN	O	O
these	DT	O	O
cells	NNS	O	O
in	IN	O	O
culture	NN	O	O
.	.	O	O

The	DT	O	O
786	CD	O	O
-	:	O	O
0	CD	O	O
cell	NN	O	O
line	NN	O	O
,	,	O	O
like	IN	O	O
many	JJ	O	O
cancer	NN	S_Disease	S_Disease
cells	NNS	O	O
,	,	O	O
fails	VBZ	O	O
to	TO	O	O
exit	VB	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
upon	IN	O	O
serum	NN	O	O
withdrawal	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
shown	VBN	O	O
that	IN	O	O
reintroduction	NN	O	O
of	IN	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
VHL	NNP	S_Disease	S_Disease
gene	NN	O	O
restores	VBZ	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
VHL	NNP	O	B_Disease
-	:	O	O
negative	JJ	O	O
RCC	NNP	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
cells	NNS	O	O
to	TO	O	O
exit	VB	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
and	CC	O	O
enter	NN	O	O
G0	NNP	O	O
/	NNP	O	O
quiescence	NN	O	O
in	IN	O	O
low	JJ	O	O
serum	NN	O	O
.	.	O	O

Both	DT	O	O
VHL	NNP	O	O
-	:	O	O
positive	JJ	O	O
and	CC	O	O
VHL	NNP	O	O
-	:	O	O
negative	JJ	O	O
RCC	NNP	S_Disease	S_Disease
cells	NNS	O	O
exit	VBP	O	O
the	DT	O	O
cell	NN	O	O
cycle	NN	O	O
by	IN	O	O
contact	JJ	O	O
inhibition	NN	O	O
.	.	O	O

The	DT	O	O
cyclin	NN	O	O
-	:	O	O
dependent	JJ	O	O
kinase	NN	O	O
inhibitor	NN	O	O
,	,	O	O
p27	NN	O	O
,	,	O	O
accumulates	VBZ	O	O
upon	IN	O	O
serum	NN	O	O
withdrawal	NN	O	O
,	,	O	O
only	RB	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
VHL	NNP	S_Disease	S_Disease
,	,	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
the	DT	O	O
stabilization	NN	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
.	.	O	O

We	PRP	O	O
propose	VBP	O	O
that	IN	O	O
the	DT	O	O
loss	NN	O	O
of	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
VHL	NNP	S_Disease	S_Disease
gene	NN	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
specific	JJ	O	O
cellular	JJ	O	O
defect	NN	O	O
in	IN	O	O
serum	JJ	O	O
-	:	O	O
dependent	JJ	O	O
growth	NN	O	O
control	NN	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
initiate	VB	O	O
tumor	NN	S_Disease	S_Disease
formation	NN	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
corrected	VBN	O	O
by	IN	O	O
the	DT	O	O
reintroduction	NN	O	O
of	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
VHL	NNP	S_Disease	S_Disease
,	,	O	O
implicating	VBG	O	O
VHL	NNP	S_Disease	S_Disease
as	IN	O	O
the	DT	O	O
first	JJ	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
cell	NN	O	O
cycle	NN	O	O
exit	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
consistent	JJ	O	O
with	IN	O	O
its	PRP$	O	O
gatekeeper	NN	O	O
function	NN	O	O
in	IN	O	O
the	DT	O	O
kidney	NN	O	O
.	.	O	O
.	.	O	O

9450866	CD	O	O

Piebaldism	NN	S_Disease	O
with	IN	O	O
deafness	NN	S_Disease	S_Disease
:	:	O	O
molecular	JJ	O	O
evidence	NN	O	O
for	IN	O	O
an	DT	O	O
expanded	JJ	O	B_Disease
syndrome	NN	O	E_Disease
.	.	O	O

In	IN	O	O
a	DT	O	O
South	JJ	O	O
African	JJ	O	O
girl	NN	O	O
of	IN	O	O
Xhosa	NNP	O	O
stock	NN	O	O
with	IN	O	O
severe	JJ	O	O
piebaldism	NN	S_Disease	S_Disease
and	CC	O	O
profound	JJ	O	O
congenital	JJ	O	B_Disease
sensorineural	JJ	B_Disease	I_Disease
deafness	NN	E_Disease	E_Disease
we	PRP	O	O
identified	VBD	O	O
a	DT	O	O
novel	JJ	O	O
missense	NN	O	O
substitution	NN	O	O
at	IN	O	O
a	DT	O	O
highly	RB	O	O
conserved	VBN	O	O
residue	NN	O	O
in	IN	O	O
the	DT	O	O
intracellular	JJ	O	O
kinase	NN	O	O
domain	NN	O	O
of	IN	O	O
the	DT	O	O
KIT	NNP	O	O
proto	NN	O	O
-	:	O	O
oncogene	NN	O	O
,	,	O	O
R796G	NNP	O	O
.	.	O	O

Though	IN	O	O
auditory	JJ	B_Disease	O
anomalies	NNS	E_Disease	O
have	VBP	O	O
been	VBN	O	O
observed	VBN	O	O
in	IN	O	O
mice	NN	O	O
with	IN	O	O
dominant	JJ	O	O
white	JJ	O	O
spotting	NN	O	O
(	(	O	O
W	NNP	O	O
)	)	O	O
due	JJ	O	O
to	TO	O	O
KIT	NNP	O	O
mutations	NNS	O	O
,	,	O	O
deafness	NN	S_Disease	S_Disease
is	VBZ	O	O
not	RB	O	O
typical	JJ	O	O
in	IN	O	O
human	JJ	O	O
piebaldism	NN	S_Disease	S_Disease
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
sensorineural	JJ	B_Disease	B_Disease
deafness	NN	E_Disease	E_Disease
in	IN	O	O
this	DT	O	O
patient	JJ	O	O
extends	VBZ	O	O
considerably	RB	O	O
the	DT	O	O
phenotypic	NN	O	O
range	NN	O	O
of	IN	O	O
piebaldism	NN	S_Disease	S_Disease
due	JJ	O	O
to	TO	O	O
KIT	NNP	O	O
gene	NN	O	O
mutation	NN	O	O
in	IN	O	O
humans	NNS	O	O
and	CC	O	O
tightens	VBZ	O	O
the	DT	O	O
clinical	JJ	O	O
similarity	NN	O	O
between	IN	O	O
piebaldism	NN	S_Disease	S_Disease
and	CC	O	O
the	DT	O	O
various	JJ	O	O
forms	NNS	O	O
of	IN	O	O
Waardenburg	NNP	B_Disease	O
syndrome	NN	E_Disease	O
.	.	O	O
.	.	O	O

9457913	CD	O	O

Cycloheximide	NNP	O	O
facilitates	VBZ	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
aberrant	JJ	O	O
transcripts	NNS	O	O
resulting	VBG	O	O
from	IN	O	O
a	DT	O	O
novel	JJ	O	O
splice	NN	O	O
-	:	O	O
site	NN	O	O
mutation	NN	O	O
in	IN	O	O
COL17A1	NNP	O	O
in	IN	O	O
a	DT	O	O
patient	NN	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
often	RB	O	O
show	VBP	O	O
decreased	JJ	O	O
expression	NN	O	O
of	IN	O	O
type	NN	O	O
XVII	NNP	O	O
collagen	NN	O	O
,	,	O	O
a	DT	O	O
transmembrane	NN	O	O
hemidesmosomal	JJ	O	O
protein	NN	O	O
encoded	VBN	O	O
by	IN	O	O
COL17A1	NNP	O	O
.	.	O	O

This	DT	O	O
report	NN	O	O
documents	NNS	O	O
a	DT	O	O
novel	JJ	O	O
splice	NN	O	O
-	:	O	O
site	NN	O	O
mutation	NN	O	O
in	IN	O	O
COL17A1	NNP	O	O
in	IN	O	O
a	DT	O	O
patient	NN	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
,	,	O	O
and	CC	O	O
applies	VBZ	O	O
a	DT	O	O
new	JJ	O	O
methodology	NN	O	O
to	TO	O	O
define	VB	O	O
and	CC	O	O
characterize	VB	O	O
the	DT	O	O
resulting	VBG	O	O
mRNA	JJ	O	O
splice	NN	O	O
variants	NNS	O	O
.	.	O	O

Mutational	JJ	O	O
analysis	NN	O	O
of	IN	O	O
COL17A1	NNP	O	O
identified	VBD	O	O
a	DT	O	O
maternally	RB	O	O
inherited	VBN	O	O
G	NNP	O	O
-	:	O	O
to	TO	O	O
-	:	O	O
T	VB	O	O
transversion	NN	O	O
at	IN	O	O
the	DT	O	O
-	:	O	O
1	CD	O	O
position	NN	O	O
of	IN	O	O
exon	JJ	O	O
32	CD	O	O
.	.	O	O

This	DT	O	O
acceptor	NN	O	O
splice	NN	O	O
-	:	O	O
site	NN	O	O
mutation	NN	O	O
led	VBD	O	O
to	TO	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
aberrant	JJ	O	O
transcripts	NNS	O	O
present	JJ	O	O
at	IN	O	O
extremely	RB	O	O
low	JJ	O	O
levels	NNS	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
our	PRP$	O	O
recent	JJ	O	O
finding	NN	O	O
that	IN	O	O
cycloheximide	NN	O	O
stabilized	VBD	O	O
mutant	JJ	O	O
COL17A1	NNP	O	O
transcripts	NNS	O	O
in	IN	O	O
keratinocytes	NNS	O	O
homozygous	JJ	O	O
for	IN	O	O
a	DT	O	O
frameshift	NN	O	O
mutation	NN	O	O
,	,	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
splice	NN	O	O
-	:	O	O
site	NN	O	O
mutation	NN	O	O
on	IN	O	O
splicing	NN	O	O
of	IN	O	O
COL17A1	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
reverse	JJ	O	O
transcriptase	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
of	IN	O	O
total	JJ	O	O
RNA	NNP	O	O
from	IN	O	O
keratinocytes	NNS	O	O
incubated	VBN	O	O
for	IN	O	O
2	CD	O	O
.	.	O	O

5	CD	O	O
h	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
or	CC	O	O
absence	NN	O	O
of	IN	O	O
10	CD	O	O
microg	NNS	O	O
cycloheximide	JJ	O	O
per	IN	O	O
ml	NN	O	O
.	.	O	O

Using	VBG	O	O
this	DT	O	O
approach	NN	O	O
,	,	O	O
an	DT	O	O
abnormally	RB	O	O
spliced	JJ	O	O
transcript	NN	O	O
was	VBD	O	O
identified	VBN	O	O
that	IN	O	O
contains	VBZ	O	O
an	DT	O	O
extra	JJ	O	O
264	CD	O	O
bases	NNS	O	O
upstream	RB	O	O
from	IN	O	O
exon	JJ	O	O
32	CD	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
premature	NN	O	O
termination	NN	O	O
codon	VBZ	O	O
27	CD	O	O
bp	NN	O	O
downstream	NN	O	O
from	IN	O	O
the	DT	O	O
cryptic	JJ	O	O
splice	NN	O	O
site	NN	O	O
.	.	O	O

Three	CD	O	O
other	JJ	O	O
splice	NN	O	O
variants	NNS	O	O
,	,	O	O
including	VBG	O	O
one	CD	O	O
derived	VBN	O	O
from	IN	O	O
the	DT	O	O
skipping	NN	O	O
of	IN	O	O
exon	$	O	O
32	CD	O	O
,	,	O	O
were	VBD	O	O
also	RB	O	O
identified	VBN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
the	DT	O	O
usefulness	NN	O	O
of	IN	O	O
cycloheximide	JJ	O	O
treatment	NN	O	O
in	IN	O	O
evaluating	VBG	O	O
the	DT	O	O
abnormal	JJ	O	O
processing	NN	O	O
of	IN	O	O
mRNA	NN	O	O
due	JJ	O	O
to	TO	O	O
splice	VB	O	O
-	:	O	O
site	NN	O	O
mutations	NNS	O	O
,	,	O	O
because	IN	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
aberrant	NN	O	O
splicing	VBG	O	O
often	RB	O	O
generates	VBZ	O	O
a	DT	O	O
premature	JJ	O	O
termination	NN	O	O
codon	NN	O	O
,	,	O	O
(	(	O	O
ii	NN	O	O
)	)	O	O
transcripts	NNS	O	O
with	IN	O	O
premature	JJ	O	O
termination	NN	O	O
codons	NNS	O	O
can	MD	O	O
occur	VB	O	O
at	IN	O	O
low	JJ	O	O
or	CC	O	O
undetectable	JJ	O	O
levels	NNS	O	O
due	JJ	O	O
to	TO	O	O
nonsense	VB	O	O
-	:	O	O
mediated	VBN	O	O
mRNA	NN	O	O
decay	NN	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
iii	NN	O	O
)	)	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
these	DT	O	O
transcripts	NNS	O	O
can	MD	O	O
be	VB	O	O
increased	VBN	O	O
by	IN	O	O
cycloheximide	NN	O	O
.	.	O	O

9457914	CD	O	O

A	DT	O	O
deletion	NN	O	O
mutation	NN	O	O
in	IN	O	O
COL17A1	NNP	O	O
in	IN	O	O
five	CD	O	O
Austrian	JJ	O	O
families	NNS	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
represents	VBZ	O	O
propagation	NN	O	O
of	IN	O	O
an	DT	O	O
ancestral	JJ	O	O
allele	NN	O	O
.	.	O	O

Patients	NNS	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
,	,	O	O
a	DT	O	O
usually	RB	O	O
nonlethal	JJ	O	O
form	NN	O	O
of	IN	O	O
junctional	JJ	B_Disease	O
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
,	,	O	O
have	VBP	O	O
generalized	VBN	O	O
blistering	NN	S_Disease	O
,	,	O	O
nail	JJ	B_Disease	O
dystrophy	NN	E_Disease	E_Disease
,	,	O	O
patchy	NN	B_Disease	O
alopecia	NN	E_Disease	O
,	,	O	O
and	CC	O	O
dental	JJ	B_Disease	B_Disease
abnormalities	NNS	E_Disease	E_Disease
.	.	O	O

Skin	NNP	B_Disease	O
fragility	NN	E_Disease	O
in	IN	O	O
most	JJS	O	O
cases	NNS	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
type	JJ	O	O
XVII	NN	O	O
collagen	NN	O	O
(	(	O	O
COL17A1	NNP	O	O
)	)	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
we	PRP	O	O
reported	VBD	O	O
five	CD	O	O
Austrian	JJ	O	O
families	NNS	O	O
with	IN	O	O
generalized	JJ	O	B_Disease
atrophic	JJ	B_Disease	I_Disease
benign	NN	I_Disease	E_Disease
epidermolysis	NN	I_Disease	O
bullosa	NN	E_Disease	O
who	WP	O	O
share	NN	O	O
the	DT	O	O
same	JJ	O	O
COL17A1	NNP	O	O
mutation	NN	O	O
.	.	O	O

Affected	JJ	O	O
individuals	NNS	O	O
in	IN	O	O
three	CD	O	O
families	NNS	O	O
are	VBP	O	O
homozygous	JJ	O	O
for	IN	O	O
4003delTC	CD	O	O
,	,	O	O
whereas	NNS	O	O
those	DT	O	O
in	IN	O	O
two	CD	O	O
others	NNS	O	O
are	VBP	O	O
compound	JJ	O	O
heterozygotes	NNS	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
if	IN	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
4003delTC	CD	O	O
in	IN	O	O
these	DT	O	O
unrelated	JJ	O	O
families	NNS	O	O
signifies	VBZ	O	O
propagation	NN	O	O
of	IN	O	O
an	DT	O	O
ancestral	JJ	O	O
allele	NN	O	O
or	CC	O	O
a	DT	O	O
mutational	JJ	O	O
hot	JJ	O	O
spot	NN	O	O
,	,	O	O
haplotypes	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
for	IN	O	O
polymorphisms	NNS	O	O
both	DT	O	O
within	IN	O	O
and	CC	O	O
flanking	VBG	O	O
COL17A1	NNP	O	O
.	.	O	O

Five	CD	O	O
intragenic	JJ	O	O
polymorphisms	NNS	O	O
were	VBD	O	O
chosen	VBN	O	O
based	VBN	O	O
on	IN	O	O
their	PRP$	O	O
informativeness	NN	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
these	DT	O	O
,	,	O	O
not	RB	O	O
previously	RB	O	O
reported	VBN	O	O
,	,	O	O
was	VBD	O	O
2988	CD	O	O
A	NNP	O	O
or	CC	O	O
C	NNP	O	O
that	WDT	O	O
introduces	VBZ	O	O
a	DT	O	O
new	JJ	O	O
restriction	NN	O	O
site	NN	O	O
for	IN	O	O
Eco0109	NNP	O	O
I	PRP	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
4003delTC	CD	O	O
alleles	NNS	O	O
showed	VBD	O	O
the	DT	O	O
same	JJ	O	O
haplotype	NN	O	O
for	IN	O	O
these	DT	O	O
five	CD	O	O
polymorphic	JJ	O	O
markers	NNS	O	O
.	.	O	O

Fourteen	NNP	O	O
microsatellite	JJ	O	O
polymorphisms	NNS	O	O
were	VBD	O	O
selected	VBN	O	O
based	VBN	O	O
on	IN	O	O
their	PRP$	O	O
high	JJ	O	O
heterozygosity	NN	O	O
and	CC	O	O
their	PRP$	O	O
location	NN	O	O
within	IN	O	O
10q23	CD	O	O
-	:	O	O
q25	NN	O	O
near	IN	O	O
COL17A1	NNP	O	O
.	.	O	O

Three	CD	O	O
families	NNS	O	O
shared	VBD	O	O
microsatellite	JJ	O	O
polymorphisms	NNS	O	O
covering	VBG	O	O
at	IN	O	O
most	JJS	O	O
19	CD	O	O
cM	NN	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
others	NNS	O	O
shared	VBD	O	O
smaller	JJR	O	O
regions	NNS	O	O
consistent	VBP	O	O
with	IN	O	O
cross	NN	O	O
-	:	O	O
over	IN	O	O
events	NNS	O	O
during	IN	O	O
passage	NN	O	O
of	IN	O	O
this	DT	O	O
mutation	NN	O	O
through	IN	O	O
several	JJ	O	O
generations	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
4003delTC	CD	O	O
occurs	NNS	O	O
on	IN	O	O
a	DT	O	O
single	JJ	O	O
ancestral	JJ	O	O
allele	NN	O	O
.	.	O	O
.	.	O	O

9463309	CD	O	O

The	DT	O	O
haptoglobin	NN	O	O
-	:	O	O
gene	NN	O	O
deletion	NN	O	O
responsible	JJ	O	O
for	IN	O	O
anhaptoglobinemia	NN	S_Disease	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
found	VBN	O	O
an	DT	O	O
allelic	JJ	O	O
deletion	NN	O	O
of	IN	O	O
the	DT	O	O
haptoglobin	NN	O	O
(	(	O	O
Hp	NNP	O	O
)	)	O	O
gene	NN	O	O
from	IN	O	O
an	DT	O	O
individual	NN	O	O
with	IN	O	O
anhaptoglobinemia	NN	S_Disease	O
.	.	O	O

The	DT	O	O
Hp	NNP	O	O
gene	NN	O	O
cluster	NN	O	O
consists	VBZ	O	O
of	IN	O	O
coding	VBG	O	O
regions	NNS	O	O
of	IN	O	O
the	DT	O	O
alpha	NN	O	O
chain	NN	O	O
and	CC	O	O
beta	NN	O	O
chain	NN	O	O
of	IN	O	O
the	DT	O	O
haptoglobin	NN	O	O
gene	NN	O	O
(	(	O	O
Hp	NNP	O	O
)	)	O	O
and	CC	O	O
of	IN	O	O
the	DT	O	O
alpha	NN	O	O
chain	NN	O	O
and	CC	O	O
beta	NN	O	O
chain	NN	O	O
of	IN	O	O
the	DT	O	O
haptoglobin	NN	O	O
-	:	O	O
related	VBN	O	O
gene	NN	O	O
(	(	O	O
Hpr	NNP	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
tandem	NN	O	O
from	IN	O	O
the	DT	O	O
5	CD	O	O
side	NN	O	O
.	.	O	O

Southern	NNP	O	O
blot	NN	O	O
and	CC	O	O
PCR	NNP	O	O
analyses	NNS	O	O
have	VBP	O	O
indicated	VBN	O	O
that	IN	O	O
the	DT	O	O
individual	NN	O	O
with	IN	O	O
anhaptoglobinemia	NN	S_Disease	O
was	VBD	O	O
homozygous	JJ	O	O
for	IN	O	O
the	DT	O	O
gene	NN	O	O
deletion	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
gene	NN	O	O
deletion	NN	O	O
was	VBD	O	O
included	VBN	O	O
at	IN	O	O
least	JJS	O	O
from	IN	O	O
the	DT	O	O
promoter	NN	O	O
region	NN	O	O
of	IN	O	O
Hp	NNP	O	O
to	TO	O	O
Hpr	NNP	O	O
alpha	NN	O	O
but	CC	O	O
not	RB	O	O
to	TO	O	O
Hpr	NNP	O	O
beta	NN	O	O
(	(	O	O
Hpdel	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
seven	CD	O	O
individuals	NNS	O	O
with	IN	O	O
hypohaptoglobinemia	NN	S_Disease	O
in	IN	O	O
three	CD	O	O
families	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
genotypes	NNS	O	O
of	IN	O	O
six	CD	O	O
of	IN	O	O
the	DT	O	O
seven	CD	O	O
individuals	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
Hp2	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
.	.	O	O

The	DT	O	O
phenotypes	NNS	O	O
and	CC	O	O
genotypes	NNS	O	O
in	IN	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
three	CD	O	O
families	NNS	O	O
showed	VBD	O	O
the	DT	O	O
father	NN	O	O
to	TO	O	O
be	VB	O	O
hypohaptoglobinemic	JJ	S_Disease	O
(	(	O	O
Hp2	NNP	O	O
)	)	O	O
and	CC	O	O
Hp2	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
,	,	O	O
the	DT	O	O
mother	NN	O	O
to	TO	O	O
be	VB	O	O
Hp2	NNP	O	O
-	:	O	O
1	CD	O	O
and	CC	O	O
Hp1	NNP	O	O
/	NNP	O	O
Hp2	NNP	O	O
,	,	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
children	NNS	O	O
to	TO	O	O
be	VB	O	O
hypohaptoglobinemic	JJ	S_Disease	O
(	(	O	O
Hp2	NNP	O	O
)	)	O	O
and	CC	O	O
Hp2	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
other	JJ	O	O
child	NN	O	O
to	TO	O	O
be	VB	O	O
Hp1	NNP	O	O
and	CC	O	O
Hp1	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
,	,	O	O
showing	VBG	O	O
an	DT	O	O
anomalous	JJ	O	O
inheritance	NN	O	O
of	IN	O	O
Hp	NNP	O	O
phenotypes	NNS	O	O
in	IN	O	O
the	DT	O	O
child	NN	O	O
with	IN	O	O
Hp1	NNP	O	O
.	.	O	O

The	DT	O	O
Hp2	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
individuals	NNS	O	O
had	VBD	O	O
an	DT	O	O
extremely	RB	O	O
low	JJ	O	O
level	NN	O	O
of	IN	O	O
Hp	NNP	O	O
(	(	O	O
mean	JJ	O	O
+	NNP	O	O
/	NNP	O	O
-	:	O	O
SD	NNP	O	O
=	VBZ	O	O
0	CD	O	O
.	.	O	O

049	CD	O	O
+	JJ	O	O
/	NNP	O	O
-	:	O	O
0	CD	O	O
.	.	O	O

043	CD	O	O
mg	NN	O	O
/	NNP	O	O
ml	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
6	CD	O	O
)	)	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
level	NN	O	O
(	(	O	O
1	CD	O	O
.	.	O	O

64	CD	O	O
+	JJ	O	O
/	NNP	O	O
-	:	O	O
1	CD	O	O
.	.	O	O

07	CD	O	O
mg	NN	O	O
/	NNP	O	O
ml	NN	O	O
)	)	O	O
obtained	VBD	O	O
from	IN	O	O
52	CD	O	O
healthy	JJ	O	O
volunteers	NNS	O	O
having	VBG	O	O
phenotype	NN	O	O
Hp2	NNP	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
serum	NN	O	O
Hp	NNP	O	O
level	NN	O	O
of	IN	O	O
an	DT	O	O
individual	NN	O	O
with	IN	O	O
Hp1	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
was	VBD	O	O
0	CD	O	O
.	.	O	O

50	CD	O	O
mg	NN	O	O
/	NNP	O	O
ml	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
approximately	RB	O	O
half	PDT	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
Hp	NNP	O	O
in	IN	O	O
control	NN	O	O
sera	NN	O	O
from	IN	O	O
the	DT	O	O
Hp1	NNP	O	O
phenotype	NN	O	O
(	(	O	O
1	CD	O	O
.	.	O	O

26	CD	O	O
+	JJ	O	O
/	NNP	O	O
-	:	O	O
0	CD	O	O
.	.	O	O

33	CD	O	O
mg	NN	O	O
/	NNP	O	O
ml	NN	O	O
;	:	O	O
n	CC	O	O
=	VB	O	O
9	CD	O	O
)	)	O	O
,	,	O	O
showing	VBG	O	O
a	DT	O	O
gene	NN	O	O
-	:	O	O
dosage	NN	O	O
effect	NN	O	O
.	.	O	O

The	DT	O	O
other	JJ	O	O
allele	NN	O	O
(	(	O	O
Hp2	NNP	O	O
)	)	O	O
of	IN	O	O
individuals	NNS	O	O
with	IN	O	O
Hp2	NNP	O	O
/	NNP	O	O
Hpdel	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
,	,	O	O
in	IN	O	O
all	DT	O	O
exons	NNS	O	O
,	,	O	O
no	DT	O	O
mutation	NN	O	O
,	,	O	O
by	IN	O	O
DNA	NNP	O	O
sequencing	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
anhaptoglobinemia	NN	S_Disease	O
and	CC	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
anomalous	JJ	O	O
inheritance	NN	O	O
of	IN	O	O
Hp	NNP	O	O
phenotypes	NNS	O	O
were	VBD	O	O
well	RB	O	O
explained	VBN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
hypohaptoglobinemia	NN	S_Disease	O
remains	VBZ	O	O
unknown	JJ	O	O

9463314	CD	O	O

ATM	NNP	O	O
mutations	NNS	O	O
and	CC	O	O
phenotypes	NNS	O	O
in	IN	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
families	NNS	O	O
in	IN	O	O
the	DT	O	O
British	JJ	O	O
Isles	NNS	O	O
:	:	O	O
expression	NN	O	O
of	IN	O	O
mutant	JJ	O	O
ATM	NNP	O	O
and	CC	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
leukemia	NN	S_Disease	S_Disease
,	,	O	O
lymphoma	NN	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

We	PRP	O	O
report	VBP	O	O
the	DT	O	O
spectrum	NN	O	O
of	IN	O	O
59	CD	O	O
ATM	NNP	O	O
mutations	NNS	O	O
observed	VBD	O	O
in	IN	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
British	JJ	O	O
Isles	NNP	O	O
.	.	O	O

Of	IN	O	O
51	CD	O	O
ATM	NNP	O	O
mutations	NNS	O	O
identified	VBN	O	O
in	IN	O	O
families	NNS	O	O
native	VBP	O	O
to	TO	O	O
the	DT	O	O
British	JJ	O	O
Isles	NNP	O	O
,	,	O	O
11	CD	O	O
were	VBD	O	O
founder	NN	O	O
mutations	NNS	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
of	IN	O	O
these	DT	O	O
11	CD	O	O
conferred	VBD	O	O
a	DT	O	O
milder	NN	O	O
clinical	JJ	O	O
phenotype	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
both	DT	O	O
cerebellar	JJ	B_Disease	B_Disease
degeneration	NN	E_Disease	E_Disease
and	CC	O	O
cellular	JJ	O	O
features	NNS	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
,	,	O	O
in	IN	O	O
two	CD	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
families	NNS	O	O
,	,	O	O
an	DT	O	O
ATM	NNP	O	O
mutation	NN	O	O
(	(	O	O
7271T	CD	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
)	)	O	O
that	WDT	O	O
may	MD	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
both	DT	O	O
homozygotes	NNS	O	O
and	CC	O	O
heterozygotes	NNS	O	O
(	(	O	O
relative	JJ	O	O
risk	NN	O	O
12	CD	O	O
.	.	O	O

7	CD	O	O
;	:	O	O
P	NNP	O	O
=	NNP	O	O
.	.	O	O

0025	CD	O	O
)	)	O	O
,	,	O	O
although	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
less	RBR	O	O
severe	JJ	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
phenotype	NN	O	O
in	IN	O	O
terms	NNS	O	O
of	IN	O	O
the	DT	O	O
degree	NN	O	O
of	IN	O	O
cerebellar	JJ	B_Disease	B_Disease
degeneration	NN	E_Disease	E_Disease
.	.	O	O

This	DT	O	O
mutation	NN	O	O
(	(	O	O
7271T	CD	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
)	)	O	O
also	RB	O	O
allows	VBZ	O	O
expression	NN	O	O
of	IN	O	O
full	JJ	O	O
-	:	O	O
length	NN	O	O
ATM	NNP	O	O
protein	NN	O	O
at	IN	O	O
a	DT	O	O
level	NN	O	O
comparable	JJ	O	O
with	IN	O	O
that	DT	O	O
in	IN	O	O
unaffected	JJ	O	O
individuals	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
18	CD	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
,	,	O	O
in	IN	O	O
15	CD	O	O
families	NNS	O	O
,	,	O	O
who	WP	O	O
developed	VBD	O	O
leukemia	NN	S_Disease	S_Disease
,	,	O	O
lymphoma	NN	S_Disease	S_Disease
,	,	O	O
preleukemic	JJ	O	O
T	NNP	O	O
-	:	O	O
cell	NN	O	O
proliferation	NN	O	O
,	,	O	O
or	CC	O	O
Hodgkin	NNP	B_Disease	O
lymphoma	NN	E_Disease	S_Disease
,	,	O	O
mostly	RB	O	O
in	IN	O	O
childhood	NN	O	O
.	.	O	O

A	DT	O	O
wide	JJ	O	O
variety	NN	O	O
of	IN	O	O
ATM	NNP	O	O
mutation	NN	O	O
types	NNS	O	O
,	,	O	O
including	VBG	O	O
missense	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
in	IN	O	O
-	:	O	O
frame	NN	O	O
deletions	NNS	O	O
,	,	O	O
were	VBD	O	O
seen	VBN	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
show	VBP	O	O
that	IN	O	O
25	CD	O	O
%	NN	O	O
of	IN	O	O
all	PDT	O	O
A	DT	B_Disease	O
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
carried	VBD	O	O
in	IN	O	O
-	:	O	O
frame	NN	O	O
deletions	NNS	O	O
or	CC	O	O
missense	NN	O	O
mutations	NNS	O	O
,	,	O	O
many	JJ	O	O
of	IN	O	O
which	WDT	O	O
were	VBD	O	O
also	RB	O	O
associated	VBN	O	O
with	IN	O	O
expression	NN	O	O
of	IN	O	O
mutant	JJ	O	O
ATM	NNP	O	O
protein	NN	O	O
.	.	O	O

9463318	CD	O	O

The	DT	O	O
DMPK	NNP	O	O
gene	NN	O	O
of	IN	O	O
severely	RB	O	O
affected	JJ	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
patients	NNS	O	O
is	VBZ	O	O
hypermethylated	VBN	O	O
proximal	JJ	O	O
to	TO	O	O
the	DT	O	O
largely	RB	O	O
expanded	JJ	O	O
CTG	NNP	O	O
repeat	NN	O	O
.	.	O	O

Using	VBG	O	O
methylation	NN	O	O
-	:	O	O
sensitive	JJ	O	O
restriction	NN	O	O
enzymes	NNS	O	O
,	,	O	O
we	PRP	O	O
characterized	VBD	O	O
the	DT	O	O
methylation	NN	O	O
pattern	NN	O	O
on	IN	O	O
the	DT	O	O
5	CD	O	O
side	NN	O	O
of	IN	O	O
the	DT	O	O
CTG	NNP	O	O
repeat	NN	O	O
in	IN	O	O
the	DT	O	O
DMPK	NNP	O	O
gene	NN	O	O
of	IN	O	O
normal	JJ	O	O
individuals	NNS	O	O
and	CC	O	O
of	IN	O	O
patients	NNS	O	O
affected	VBN	O	O
with	IN	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
,	,	O	O
showing	VBG	O	O
expansions	NNS	O	O
of	IN	O	O
the	DT	O	O
repetitive	JJ	O	O
sequence	NN	O	O
.	.	O	O

The	DT	O	O
gene	NN	O	O
segment	NN	O	O
analyzed	VBD	O	O
corresponds	NNS	O	O
to	TO	O	O
the	DT	O	O
genomic	JJ	O	O
SacI	NNP	O	O
-	:	O	O
HindIII	NNP	O	O
fragment	NN	O	O
carrying	VBG	O	O
exons	NNS	O	O
11	CD	O	O
-	:	O	O
15	CD	O	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
constitutive	JJ	O	O
methylation	NN	O	O
in	IN	O	O
intron	NN	O	O
12	CD	O	O
at	IN	O	O
restriction	NN	O	O
sites	NNS	O	O
of	IN	O	O
SacII	NNP	O	O
and	CC	O	O
HhaI	NNP	O	O
,	,	O	O
localized	VBD	O	O
1	CD	O	O
,	,	O	O
159	CD	O	O
-	:	O	O
1	CD	O	O
,	,	O	O
232	CD	O	O
bp	NN	O	O
upstream	NN	O	O
of	IN	O	O
the	DT	O	O
CTG	NNP	O	O
repeat	NN	O	O
,	,	O	O
whereas	IN	O	O
most	JJS	O	O
,	,	O	O
if	IN	O	O
not	RB	O	O
all	DT	O	O
,	,	O	O
of	IN	O	O
the	DT	O	O
other	JJ	O	O
sites	NNS	O	O
of	IN	O	O
SacII	NNP	O	O
,	,	O	O
HhaI	NNP	O	O
,	,	O	O
and	CC	O	O
HpaII	NNP	O	O
in	IN	O	O
this	DT	O	O
region	NN	O	O
are	VBP	O	O
unmethylated	VBN	O	O
,	,	O	O
in	IN	O	O
normal	JJ	O	O
individuals	NNS	O	O
and	CC	O	O
most	JJS	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
young	JJ	O	O
and	CC	O	O
severely	RB	O	O
affected	JJ	O	O
patients	NNS	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
complete	JJ	O	O
methylation	NN	O	O
of	IN	O	O
these	DT	O	O
restriction	NN	O	O
sites	NNS	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
mutated	JJ	O	O
allele	NN	O	O
.	.	O	O

In	IN	O	O
most	JJS	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
,	,	O	O
the	DT	O	O
onset	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
was	VBD	O	O
congenital	JJ	O	O
.	.	O	O

Preliminary	JJ	O	O
in	IN	O	O
vivo	JJ	O	O
footprinting	VBG	O	O
data	NNS	O	O
gave	VBD	O	O
evidence	NN	O	O
for	IN	O	O
protein	NN	O	O
-	:	O	O
DNA	NN	O	O
contact	NN	O	O
in	IN	O	O
normal	JJ	O	O
genes	NNS	O	O
at	IN	O	O
an	DT	O	O
Sp1	NNP	O	O
consensus	NN	O	O
binding	VBG	O	O
site	NN	O	O
upstream	NN	O	O
of	IN	O	O
the	DT	O	O
CTG	NNP	O	O
repeat	NN	O	O
and	CC	O	O
for	IN	O	O
a	DT	O	O
significant	JJ	O	O
reduction	NN	O	O
of	IN	O	O
this	DT	O	O
interaction	NN	O	O
in	IN	O	O
cells	NNS	O	O
with	IN	O	O
a	DT	O	O
hypermethylated	VBN	O	O
DMPK	NNP	O	O
gene	NN	O	O
.	.	O	O
.	.	O	O

9465039	CD	O	O

The	DT	O	O
hemochromatosis	NN	S_Disease	S_Disease
gene	NN	O	O
product	NN	O	O
complexes	NNS	O	O
with	IN	O	O
the	DT	O	O
transferrin	NN	O	O
receptor	NN	O	O
and	CC	O	O
lowers	VBZ	O	O
its	PRP$	O	O
affinity	NN	O	O
for	IN	O	O
ligand	NN	O	O
binding	NN	O	O
.	.	O	O

We	PRP	O	O
recently	RB	O	O
reported	VBD	O	O
the	DT	O	O
positional	JJ	O	O
cloning	NN	O	O
of	IN	O	O
a	DT	O	O
candidate	NN	O	O
gene	NN	O	O
for	IN	O	O
hereditary	JJ	B_Disease	B_Disease
hemochromatosis	NN	E_Disease	E_Disease
called	VBN	O	O
HFE	NNP	O	O
.	.	O	O

The	DT	O	O
gene	NN	O	O
product	NN	O	O
,	,	O	O
a	DT	O	O
member	NN	O	O
of	IN	O	O
the	DT	O	O
major	JJ	O	O
histocompatibility	NN	O	O
complex	JJ	O	O
class	NN	O	O
I	PRP	O	O
-	:	O	O
like	IN	O	O
family	NN	O	O
,	,	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
mutation	NN	O	O
,	,	O	O
Cys	NNP	O	O
-	:	O	O
282	CD	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
Tyr	NNP	O	O
(	(	O	O
C282Y	NNP	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
85	CD	O	O
%	NN	O	O
of	IN	O	O
patient	JJ	O	O
chromosomes	NNS	O	O
.	.	O	O

This	DT	O	O
mutation	NN	O	O
eliminates	VBZ	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
HFE	NNP	O	O
to	TO	O	O
associate	VB	O	O
with	IN	O	O
beta2	JJ	O	O
-	:	O	O
microglobulin	NN	O	O
(	(	O	O
beta2m	NN	O	O
)	)	O	O
and	CC	O	O
prevents	NNS	O	O
cell	VBP	O	O
-	:	O	O
surface	NN	O	O
expression	NN	O	O
.	.	O	O

A	DT	O	O
second	JJ	O	O
mutation	NN	O	O
that	WDT	O	O
has	VBZ	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
beta2m	NN	O	O
association	NN	O	O
,	,	O	O
H63D	NNP	O	O
,	,	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
eight	CD	O	O
out	IN	O	O
of	IN	O	O
nine	CD	O	O
patients	NNS	O	O
heterozygous	JJ	O	O
for	IN	O	O
the	DT	O	O
C282Y	NNP	O	O
mutant	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
report	NN	O	O
,	,	O	O
we	PRP	O	O
demonstrate	VBP	O	O
in	IN	O	O
cultured	JJ	O	O
293	CD	O	O
cells	NNS	O	O
overexpressing	VBG	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
or	CC	O	O
mutant	JJ	O	O
HFE	NNP	O	O
proteins	VBZ	O	O
that	IN	O	O
both	DT	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
and	CC	O	O
H63D	NNP	O	O
HFE	NNP	O	O
proteins	VBZ	O	O
form	VB	O	O
stable	JJ	O	O
complexes	NNS	O	O
with	IN	O	O
the	DT	O	O
transferrin	NN	O	O
receptor	NN	O	O
(	(	O	O
TfR	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
C282Y	NNP	O	O
mutation	NN	O	O
nearly	RB	O	O
completely	RB	O	O
prevents	VBZ	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
the	DT	O	O
mutant	JJ	O	O
HFE	NNP	O	O
protein	NN	O	O
with	IN	O	O
the	DT	O	O
TfR	NNP	O	O
.	.	O	O

Studies	NNS	O	O
on	IN	O	O
cell	NN	O	O
-	:	O	O
associated	VBN	O	O
transferrin	NN	O	O
at	IN	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
overexpressed	JJ	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
HFE	NNP	O	O
protein	NN	O	O
decreases	VBZ	O	O
the	DT	O	O
affinity	NN	O	O
of	IN	O	O
the	DT	O	O
TfR	NNP	O	O
for	IN	O	O
transferrin	NN	O	O
.	.	O	O

The	DT	O	O
overexpressed	JJ	O	O
H63D	NNP	O	O
protein	NN	O	O
does	VBZ	O	O
not	RB	O	O
have	VB	O	O
this	DT	O	O
effect	NN	O	O
,	,	O	O
providing	VBG	O	O
the	DT	O	O
first	JJ	O	O
direct	JJ	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
functional	JJ	O	O
consequence	NN	O	O
of	IN	O	O
the	DT	O	O
H63D	NNP	O	O
mutation	NN	O	O
.	.	O	O

Addition	NN	O	O
of	IN	O	O
soluble	JJ	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
HFE	NNP	O	O
/	NNP	O	O
beta2m	NN	O	O
heterodimers	NNS	O	O
to	TO	O	O
cultured	VB	O	O
cells	NNS	O	O
also	RB	O	O
decreased	VBD	O	O
the	DT	O	O
apparent	JJ	O	O
affinity	NN	O	O
of	IN	O	O
the	DT	O	O
TfR	NNP	O	O
for	IN	O	O
its	PRP$	O	O
ligand	NN	O	O
under	IN	O	O
steady	JJ	O	O
-	:	O	O
state	NN	O	O
conditions	NNS	O	O
,	,	O	O
both	DT	O	O
in	IN	O	O
293	CD	O	O
cells	NNS	O	O
and	CC	O	O
in	IN	O	O
HeLa	NNP	O	O
cells	NNS	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
at	IN	O	O
4	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
the	DT	O	O
added	JJ	O	O
soluble	JJ	O	O
complex	NN	O	O
of	IN	O	O
HFE	NNP	O	O
/	NNP	O	O
beta2m	NN	O	O
inhibited	VBD	O	O
binding	NN	O	O
of	IN	O	O
transferrin	NN	O	O
to	TO	O	O
HeLa	NNP	O	O
cell	NN	O	O
TfR	NNP	O	O
in	IN	O	O
a	DT	O	O
concentration	NN	O	O
-	:	O	O
dependent	JJ	O	O
manner	NN	O	O
.	.	O	O

Scatchard	NNP	O	O
plots	NNS	O	O
of	IN	O	O
these	DT	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
added	JJ	O	O
heterodimer	NN	O	O
substantially	RB	O	O
reduced	VBD	O	O
the	DT	O	O
affinity	NN	O	O
of	IN	O	O
TfR	NNP	O	O
for	IN	O	O
transferrin	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
establish	VB	O	O
a	DT	O	O
molecular	JJ	O	O
link	NN	O	O
between	IN	O	O
HFE	NNP	O	O
and	CC	O	O
a	DT	O	O
key	JJ	O	O
protein	NN	O	O
involved	VBN	O	O
in	IN	O	O
iron	NN	O	O
transport	NN	O	O
,	,	O	O
the	DT	O	O
TfR	NNP	O	O
,	,	O	O
and	CC	O	O
raise	VB	O	O
the	DT	O	O
possibility	NN	O	O
that	IN	O	O
alterations	NNS	O	O
in	IN	O	O
this	DT	O	O
regulatory	JJ	O	O
mechanism	NN	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
hereditary	JJ	B_Disease	B_Disease
hemochromatosis	NN	E_Disease	E_Disease
.	.	O	O
.	.	O	O

9465301	CD	O	O

Genomic	NNP	O	O
organization	NN	O	O
of	IN	O	O
the	DT	O	O
UBE3A	NNP	O	O
/	NNP	O	O
E6	NNP	O	O
-	:	O	O
AP	NNP	O	O
gene	NN	O	O
and	CC	O	O
related	JJ	O	O
pseudogenes	NNS	O	O
.	.	O	O

The	DT	O	O
UBE3A	NNP	O	O
gene	NN	O	O
encodes	VBZ	O	O
the	DT	O	O
E6	NNP	O	O
-	:	O	O
AP	NNP	O	O
ubiquitin	JJ	O	O
-	:	O	O
protein	NN	O	O
ligase	NN	O	O
and	CC	O	O
has	VBZ	O	O
recently	RB	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
mutated	VBN	O	O
in	IN	O	O
Angelman	NNP	B_Disease	B_Disease
syndrome	JJ	E_Disease	E_Disease
patients	NNS	O	O
who	WP	O	O
lack	VBP	O	O
15q11	CD	O	O
-	:	O	O
q13	NN	O	O
deletions	NNS	O	O
or	CC	O	O
chromosome	VB	O	O
15	CD	O	O
paternal	JJ	O	O
uniparental	JJ	B_Disease	B_Disease
disomy	NN	E_Disease	E_Disease
.	.	O	O

Previous	JJ	O	O
UBE3A	NNP	O	O
cDNA	NN	O	O
analysis	NN	O	O
has	VBZ	O	O
shown	VBN	O	O
a	DT	O	O
coding	VBG	O	O
region	NN	O	O
of	IN	O	O
approximately	RB	O	O
2	CD	O	O
.	.	O	O

6	CD	O	O
kb	NN	O	O
and	CC	O	O
a	DT	O	O
3	CD	O	O
-	:	O	O
untranslated	JJ	O	O
region	NN	O	O
(	(	O	O
UTR	NNP	O	O
)	)	O	O
of	IN	O	O
<	$	O	O
50	CD	O	O
bp	NN	O	O
,	,	O	O
whereas	JJ	O	O
Northern	NNP	O	O
analysis	NN	O	O
has	VBZ	O	O
indicated	VBN	O	O
mRNA	JJ	O	O
sizes	NNS	O	O
of	IN	O	O
5	CD	O	O
-	:	O	O
8	CD	O	O
kb	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
analyzed	VBN	O	O
additional	JJ	O	O
cDNA	NN	O	O
clones	NNS	O	O
and	CC	O	O
provide	VB	O	O
evidence	NN	O	O
for	IN	O	O
an	DT	O	O
additional	JJ	O	O
0	CD	O	O
.	.	O	O

5	CD	O	O
kb	NN	O	O
of	IN	O	O
5	CD	O	O
-	:	O	O
UTR	NN	O	O
and	CC	O	O
>	$	O	O
2	CD	O	O
kb	NN	O	O
of	IN	O	O
3	CD	O	O
-	:	O	O
UTR	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
established	VBN	O	O
the	DT	O	O
genomic	JJ	O	O
organization	NN	O	O
of	IN	O	O
UBE3A	NNP	O	O
and	CC	O	O
the	DT	O	O
sequence	NN	O	O
of	IN	O	O
intron	NN	O	O
-	:	O	O
exon	NN	O	O
borders	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
also	RB	O	O
mapped	VBN	O	O
two	CD	O	O
highly	RB	O	O
homologous	JJ	O	O
processed	VBN	O	O
pseudogenes	NNS	O	O
,	,	O	O
UBE3AP1	NNP	O	O
and	CC	O	O
UBE3AP2	NNP	O	O
,	,	O	O
to	TO	O	O
chromosomes	VB	O	O
2	CD	O	O
and	CC	O	O
21	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
determined	VBD	O	O
their	PRP$	O	O
genomic	JJ	O	O
organization	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
will	MD	O	O
form	VB	O	O
the	DT	O	O
basis	NN	O	O
for	IN	O	O
studies	NNS	O	O
of	IN	O	O
mutation	NN	O	O
and	CC	O	O
imprinting	NN	O	O
of	IN	O	O
UBE3A	NNP	O	O
.	.	O	O

9467011	CD	O	O

Mutation	NNP	O	O
spectrum	NN	O	O
and	CC	O	O
genotype	NN	O	O
-	:	O	O
phenotype	NN	O	O
analyses	NNS	O	O
in	IN	O	O
Cowden	NNP	B_Disease	O
disease	NN	E_Disease	O
and	CC	O	O
Bannayan	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Zonana	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
,	,	O	O
two	CD	O	O
hamartoma	NN	B_Disease	O
syndromes	NNS	E_Disease	O
with	IN	O	O
germline	NN	O	O
PTEN	NNP	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
tumour	NN	S_Disease	S_Disease
suppressor	NN	O	O
gene	NN	O	O
PTEN	NNP	O	O
,	,	O	O
which	WDT	O	O
maps	VBZ	O	O
to	TO	O	O
10q23	CD	O	O
.	.	O	O

3	CD	O	O
and	CC	O	O
encodes	VBZ	O	O
a	DT	O	O
403	CD	O	O
amino	NN	O	O
acid	JJ	O	O
dual	JJ	O	O
specificity	NN	O	O
phosphatase	NN	O	O
(	(	O	O
protein	JJ	O	O
tyrosine	NN	O	O
phosphatase	NN	O	O
;	:	O	O
PTPase	NNP	O	O
)	)	O	O
,	,	O	O
was	VBD	O	O
shown	VBN	O	O
recently	RB	O	O
to	TO	O	O
play	VB	O	O
a	DT	O	O
broad	JJ	O	O
role	NN	O	O
in	IN	O	O
human	JJ	O	O
malignancy	NN	S_Disease	O
.	.	O	O

Somatic	JJ	O	O
PTEN	NNP	O	O
deletions	NNS	O	O
and	CC	O	O
mutations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
sporadic	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
,	,	I_Disease	I_Disease
brain	NN	I_Disease	E_Disease
,	,	I_Disease	O
prostate	NN	I_Disease	B_Disease
and	CC	I_Disease	I_Disease
kidney	NN	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
cell	NN	O	O
lines	NNS	O	O
and	CC	O	O
in	IN	O	O
several	JJ	O	O
primary	JJ	O	B_Disease
tumours	NNS	S_Disease	E_Disease
such	JJ	O	O
as	IN	O	O
endometrial	JJ	B_Disease	B_Disease
carcinomas	NN	E_Disease	E_Disease
,	,	O	O
malignant	JJ	B_Disease	B_Disease
melanoma	NN	E_Disease	E_Disease
and	CC	O	O
thyroid	JJ	B_Disease	B_Disease
tumours	NN	E_Disease	E_Disease
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
PTEN	NNP	O	O
was	VBD	O	O
identified	VBN	O	O
as	IN	O	O
the	DT	O	O
susceptibility	NN	O	O
gene	NN	O	O
for	IN	O	O
two	CD	O	O
hamartoma	NN	B_Disease	O
syndromes	NNS	E_Disease	O
Cowden	NNP	B_Disease	O
disease	NN	E_Disease	E_Disease
(	(	O	O
CD	NN	S_Disease	S_Disease
;	:	O	O
MIM	NNP	O	O
158350	CD	O	O
)	)	O	O
and	CC	O	O
Bannayan	NNP	B_Disease	O
-	:	I_Disease	O
Zonana	NNP	I_Disease	O
(	(	I_Disease	O
BZS	NNP	I_Disease	O
)	)	I_Disease	O
or	CC	I_Disease	O
Ruvalcaba	NNP	I_Disease	O
-	:	I_Disease	O
Riley	NNP	I_Disease	O
-	:	I_Disease	I_Disease
Smith	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
MIM	NNP	O	O
153480	CD	O	O
)	)	O	O
.	.	O	O

Constitutive	JJ	O	O
DNA	NN	O	O
from	IN	O	O
37	CD	O	O
CD	NN	S_Disease	O
families	NNS	O	O
and	CC	O	O
seven	CD	O	O
BZS	NNP	S_Disease	O
families	NNS	O	O
was	VBD	O	O
screened	VBN	O	O
for	IN	O	O
germline	NN	O	O
PTEN	NNP	O	O
mutations	NNS	O	O
.	.	O	O

PTEN	NNP	O	O
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
30	CD	O	O
of	IN	O	O
37	CD	O	O
(	(	O	O
81	CD	O	O
%	NN	O	O
)	)	O	O
CD	NN	S_Disease	S_Disease
families	NNS	O	O
,	,	O	O
including	VBG	O	O
missense	NN	O	O
and	CC	O	O
nonsense	JJ	O	O
point	NN	O	O
mutations	NNS	O	O
,	,	O	O
deletions	NNS	O	O
,	,	O	O
insertions	NNS	O	O
,	,	O	O
a	DT	O	O
deletion	NN	O	O
/	POS	O	O
insertion	NN	O	O
and	CC	O	O
splice	NN	O	O
site	NN	O	O
mutations	NNS	O	O
.	.	O	O

These	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
scattered	VBN	O	O
over	IN	O	O
the	DT	O	O
entire	JJ	O	O
length	NN	O	O
of	IN	O	O
PTEN	NNP	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
exception	NN	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
,	,	O	O
fourth	JJ	O	O
and	CC	O	O
last	JJ	O	O
exons	NNS	O	O
.	.	O	O

A	DT	O	O
hot	JJ	O	O
spot	NN	O	O
for	IN	O	O
PTEN	NNP	O	O
mutation	NN	O	O
in	IN	O	O
CD	NN	S_Disease	O
was	VBD	O	O
identified	VBN	O	O
in	IN	O	O
exon	CC	O	O
5	CD	O	O
that	WDT	O	O
contains	VBZ	O	O
the	DT	O	O
PTPase	NNP	O	O
core	NN	O	O
motif	NN	O	O
,	,	O	O
with	IN	O	O
13	CD	O	O
of	IN	O	O
30	CD	O	O
(	(	O	O
43	CD	O	O
%	NN	O	O
)	)	O	O
CD	NN	S_Disease	O
mutations	NNS	O	O
identified	VBN	O	O
in	IN	O	O
this	DT	O	O
exon	NN	O	O
.	.	O	O

Seven	NNP	O	O
of	IN	O	O
30	CD	O	O
(	(	O	O
23	CD	O	O
%	NN	O	O
)	)	O	O
were	VBD	O	O
within	IN	O	O
the	DT	O	O
core	NN	O	O
motif	NN	O	O
,	,	O	O
the	DT	O	O
majority	NN	O	O
(	(	O	O
five	CD	O	O
of	IN	O	O
seven	CD	O	O
)	)	O	O
of	IN	O	O
which	WDT	O	O
were	VBD	O	O
missense	JJ	O	O
mutations	NNS	O	O
,	,	O	O
possibly	RB	O	O
pointing	VBG	O	O
to	TO	O	O
the	DT	O	O
functional	JJ	O	O
significance	NN	O	O
of	IN	O	O
this	DT	O	O
region	NN	O	O
.	.	O	O

Germline	NNP	O	O
PTEN	NNP	O	O
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
four	CD	O	O
of	IN	O	O
seven	CD	O	O
(	(	O	O
57	CD	O	O
%	NN	O	O
)	)	O	O
BZS	NNP	S_Disease	O
families	NNS	O	O
studied	VBD	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
none	NN	O	O
of	IN	O	O
these	DT	O	O
mutations	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
PTPase	NNP	O	O
core	NN	O	O
motif	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
also	RB	O	O
worthy	JJ	O	O
of	IN	O	O
note	NN	O	O
that	IN	O	O
a	DT	O	O
single	JJ	O	O
nonsense	NN	O	O
point	NN	O	O
mutation	NN	O	O
,	,	O	O
R233X	NNP	O	O
,	,	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
the	DT	O	O
germline	NN	O	O
DNA	NN	O	O
from	IN	O	O
two	CD	O	O
unrelated	JJ	O	O
CD	NN	S_Disease	S_Disease
families	NNS	O	O
and	CC	O	O
one	CD	O	O
BZS	NNP	S_Disease	O
family	NN	O	O
.	.	O	O

Genotype	NNP	O	O
-	:	O	O
phenotype	NN	O	O
studies	NNS	O	O
were	VBD	O	O
not	RB	O	O
performed	VBN	O	O
on	IN	O	O
this	DT	O	O
small	JJ	O	O
group	NN	O	O
of	IN	O	O
BZS	NNP	S_Disease	O
families	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
genotype	JJ	O	O
-	:	O	O
phenotype	NN	O	O
analysis	NN	O	O
inthe	NN	O	O
group	NN	O	O
of	IN	O	O
CD	NNP	S_Disease	S_Disease
families	NNS	O	O
revealed	VBD	O	O
two	CD	O	O
possible	JJ	O	O
associations	NNS	O	O
worthy	NN	O	O
of	IN	O	O
follow	JJ	O	O
-	:	O	O
up	RB	O	O
in	IN	O	O
independent	JJ	O	O
analyses	NNS	O	O
.	.	O	O

The	DT	O	O
first	JJ	O	O
was	VBD	O	O
an	DT	O	O
association	NN	O	O
noted	VBD	O	O
in	IN	O	O
the	DT	O	O
group	NN	O	O
of	IN	O	O
CD	NNP	S_Disease	S_Disease
families	NNS	O	O
with	IN	O	O
breast	NN	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

A	DT	O	O
correlation	NN	O	O
was	VBD	O	O
observed	VBN	O	O
between	IN	O	O
the	DT	O	O
presence	NN	O	O
/	NNP	O	O
absence	NN	O	O
of	IN	O	O
a	DT	O	O
PTEN	NNP	O	O
mutation	NN	O	O
and	CC	O	O
the	DT	O	O
type	NN	O	O
of	IN	O	O
breast	NN	O	B_Disease
involvement	NN	O	E_Disease
(	(	O	O
unaffected	JJ	O	O
versus	NN	O	O
benign	NN	O	O
versus	NN	O	O
malignant	NN	O	S_Disease
)	)	O	O
.	.	O	O

Specifically	RB	O	O
and	CC	O	O
more	RBR	O	O
directly	RB	O	O
,	,	O	O
an	DT	O	O
association	NN	O	O
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
between	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
PTEN	NNP	O	O
mutation	NN	O	O
and	CC	O	O
malignant	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

Secondly	RB	O	O
,	,	O	O
there	EX	O	O
appeared	VBD	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
interdependent	JJ	O	O
association	NN	O	O
between	IN	O	O
mutations	NNS	O	O
upstream	RB	O	O
and	CC	O	O
within	IN	O	O
the	DT	O	O
PTPase	NNP	O	O
core	NN	O	O
motif	NN	O	O
,	,	O	O
the	DT	O	O
core	NN	O	O
motif	NN	O	O
containing	VBG	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
missense	JJ	O	O
mutations	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
all	DT	O	O
major	JJ	O	O
organ	JJ	O	O
systems	NNS	O	O
(	(	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
,	,	O	O
thyroid	NN	O	B_Disease
,	,	O	I_Disease
breast	NN	O	I_Disease
,	,	O	I_Disease
skin	NN	O	E_Disease
and	CC	O	O
gastrointestinal	JJ	O	O
tract	NN	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
these	DT	O	O
observations	NNS	O	O
would	MD	O	O
need	VB	O	O
to	TO	O	O
be	VB	O	O
confirmed	VBN	O	O
by	IN	O	O
studying	VBG	O	O
a	DT	O	O
larger	JJR	O	O
number	NN	O	O
of	IN	O	O
CD	NNP	S_Disease	S_Disease
families	NNS	O	O
.	.	O	O

9472666	CD	O	O

Molecular	JJ	O	B_Disease
defects	NNS	O	E_Disease
leading	VBG	O	O
to	TO	O	O
human	JJ	O	B_Disease
complement	NN	B_Disease	I_Disease
component	NN	I_Disease	I_Disease
C6	NNP	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
an	DT	O	O
African	JJ	O	O
-	:	O	O
American	JJ	O	O
family	NN	O	O
.	.	O	O

Complement	JJ	B_Disease	B_Disease
component	NN	I_Disease	I_Disease
C6	NNP	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
(	(	O	O
C6D	NNP	S_Disease	O
)	)	O	O
was	VBD	O	O
diagnosed	VBN	O	O
in	IN	O	O
a	DT	O	O
16	CD	O	O
-	:	O	O
year	NN	O	O
-	:	O	O
old	JJ	O	O
African	JJ	O	O
-	:	O	O
American	JJ	O	O
male	NN	O	O
with	IN	O	O
meningococcal	JJ	B_Disease	B_Disease
meningitis	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
patients	NNS	O	O
father	RB	O	O
and	CC	O	O
two	CD	O	O
brothers	NNS	O	O
also	RB	O	O
had	VBD	O	O
C6D	NNP	S_Disease	O
,	,	O	O
but	CC	O	O
gave	VBD	O	O
no	DT	O	O
history	NN	O	O
of	IN	O	O
meningitis	NN	S_Disease	S_Disease
or	CC	O	O
other	JJ	O	O
neisserial	JJ	B_Disease	B_Disease
infection	NN	E_Disease	E_Disease
.	.	O	O

By	IN	O	O
using	VBG	O	O
exon	JJ	O	O
-	:	O	O
specific	JJ	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	(	O	O
PCR	NNP	O	O
)	)	O	O
/	VBP	O	O
single	JJ	O	O
-	:	O	O
strand	NN	O	O
conformation	NN	O	O
polymorphism	NN	O	O
as	IN	O	O
a	DT	O	O
screening	JJ	O	O
step	NN	O	O
and	CC	O	O
nucleotide	JJ	O	O
sequencing	NN	O	O
of	IN	O	O
target	NN	O	O
exons	NNS	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
that	IN	O	O
the	DT	O	O
proband	NN	O	O
was	VBD	O	O
a	DT	O	O
compound	NN	O	O
heterozygote	NN	O	O
for	IN	O	O
two	CD	O	O
C6	NNP	O	O
gene	NN	O	O
mutations	NNS	O	O
.	.	O	O

The	DT	O	O
first	JJ	O	O
,	,	O	O
1195delC	CD	O	O
located	VBN	O	O
in	IN	O	O
exon	JJ	O	O
7	CD	O	O
,	,	O	O
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
mutation	NN	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
second	JJ	O	O
,	,	O	O
1936delG	CD	O	O
in	IN	O	O
exon	NN	O	O
12	CD	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
described	VBN	O	O
before	IN	O	O
to	TO	O	O
cause	VB	O	O
C6D	NNP	S_Disease	O
in	IN	O	O
an	DT	O	O
unrelated	JJ	O	O
African	JJ	O	O
-	:	O	O
American	JJ	O	O
individual	NN	O	O
.	.	O	O

Both	DT	O	O
mutations	NNS	O	O
result	VBP	O	O
in	IN	O	O
premature	NN	O	O
termination	NN	O	O
codons	NNS	O	O
and	CC	O	O
C6	NNP	O	O
null	JJ	O	O
alleles	NNS	O	O
.	.	O	O

Allele	NNP	O	O
-	:	O	O
specific	JJ	O	O
PCR	NNP	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
probands	NNS	O	O
two	CD	O	O
brothers	NNS	O	O
also	RB	O	O
inherited	VBD	O	O
the	DT	O	O
1195delC	CD	O	O
mutation	NN	O	O
from	IN	O	O
their	PRP$	O	O
heterozygous	JJ	O	O
mother	NN	O	O
and	CC	O	O
the	DT	O	O
1936delG	CD	O	O
mutation	NN	O	O
from	IN	O	O
their	PRP$	O	O
homozygous	JJ	O	O
father	NN	O	O
.	.	O	O
.	.	O	O

9482572	CD	O	O

PAX6	NNP	O	O
mutations	NNS	O	O
reviewed	VBD	O	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
PAX6	NNP	O	O
are	VBP	O	O
responsible	JJ	O	O
for	IN	O	O
human	JJ	O	O
aniridia	NN	S_Disease	S_Disease
and	CC	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
found	VBN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
Peters	NNP	B_Disease	B_Disease
anomaly	VBP	E_Disease	E_Disease
,	,	O	O
with	IN	O	O
congenital	JJ	B_Disease	B_Disease
cataracts	NNS	E_Disease	E_Disease
,	,	O	O
with	IN	O	O
autosomal	JJ	B_Disease	O
dominant	JJ	I_Disease	O
keratitis	NN	E_Disease	O
,	,	O	O
and	CC	O	O
with	IN	O	O
isolated	JJ	B_Disease	O
foveal	NN	I_Disease	B_Disease
hypoplasia	NN	E_Disease	E_Disease
.	.	O	O

No	DT	O	O
locus	NN	O	O
other	JJ	O	O
than	IN	O	O
chromosome	NN	O	O
11p13	CD	O	O
has	VBZ	O	O
been	VBN	O	O
implicated	VBN	O	O
in	IN	O	O
aniridia	NN	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
PAX6	NNP	O	O
is	VBZ	O	O
clearly	RB	O	O
the	DT	O	O
major	JJ	O	O
,	,	O	O
if	IN	O	O
not	RB	O	O
only	RB	O	O
,	,	O	O
gene	NN	O	O
responsible	JJ	O	O
.	.	O	O

Twenty	NNP	O	O
-	:	O	O
eight	CD	O	O
percent	NN	O	O
of	IN	O	O
identified	JJ	O	O
PAX6	NNP	O	O
mutations	NNS	O	O
are	VBP	O	O
C	NNP	O	O
-	:	O	O
T	NN	O	O
changes	NNS	O	O
at	IN	O	O
CpG	NNP	O	O
dinucleotides	NNS	O	O
,	,	O	O
20	CD	O	O
%	NN	O	O
are	VBP	O	O
splicing	VBG	O	O
errors	NNS	O	O
,	,	O	O
and	CC	O	O
more	JJR	O	O
than	IN	O	O
30	CD	O	O
%	NN	O	O
are	VBP	O	O
deletion	NN	O	O
or	CC	O	O
insertion	NN	O	O
events	NNS	O	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
a	DT	O	O
noticeably	RB	O	O
elevated	JJ	O	O
level	NN	O	O
of	IN	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
paired	JJ	O	O
domain	NN	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
rest	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
.	.	O	O

Increased	VBN	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
homeodomain	NN	O	O
is	VBZ	O	O
accounted	VBN	O	O
for	IN	O	O
by	IN	O	O
the	DT	O	O
hypermutable	JJ	O	O
CpG	NNP	O	O
dinucleotide	NN	O	O
in	IN	O	O
codon	NN	O	O
240	CD	O	O
.	.	O	O

Very	RB	O	O
nearly	RB	O	O
all	DT	O	O
mutations	NNS	O	O
appear	VBP	O	O
to	TO	O	O
cause	VB	O	O
loss	NN	O	O
of	IN	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
mutant	JJ	O	O
allele	NN	O	O
,	,	O	O
and	CC	O	O
more	JJR	O	O
than	IN	O	O
80	CD	O	O
%	NN	O	O
of	IN	O	O
exonic	JJ	O	O
substitutions	NNS	O	O
result	VBP	O	O
in	IN	O	O
nonsense	JJ	O	O
codons	NNS	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
gene	NN	O	O
with	IN	O	O
such	JJ	O	O
extraordinarily	RB	O	O
high	JJ	O	O
sequence	NN	O	O
conservation	NN	O	O
throughout	IN	O	O
evolution	NN	O	O
,	,	O	O
there	EX	O	O
are	VBP	O	O
presumed	VBN	O	O
undiscovered	JJ	O	O
missense	NN	O	O
mutations	NNS	O	O
,	,	O	O
these	DT	O	O
are	VBP	O	O
hypothesized	VBN	O	O
to	TO	O	O
exist	VB	O	O
in	IN	O	O
as	IN	O	O
-	:	O	O
yet	RB	O	O
unidentified	JJ	O	O
phenotypes	NNS	O	O
.	.	O	O
.	.	O	O

9497246	CD	O	O

Genetic	JJ	O	O
heterogeneity	NN	O	O
and	CC	O	O
penetrance	NN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
genes	NNS	O	O
in	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
.	.	O	O

The	DT	O	O
Breast	NNP	B_Disease	B_Disease
Cancer	NNP	E_Disease	E_Disease
Linkage	NNP	O	O
Consortium	NNP	O	O
.	.	O	O

The	DT	O	O
contribution	NN	O	O
of	IN	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
to	TO	O	O
inherited	VB	B_Disease	O
breast	NN	I_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
linkage	NN	O	O
and	CC	O	O
mutation	NN	O	O
analysis	NN	O	O
in	IN	O	O
237	CD	O	O
families	NNS	O	O
,	,	O	O
each	DT	O	O
with	IN	O	O
at	IN	O	O
least	JJS	O	O
four	CD	O	O
cases	NNS	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
,	,	O	O
collected	VBN	O	O
by	IN	O	O
the	DT	O	O
Breast	NNP	B_Disease	B_Disease
Cancer	NNP	E_Disease	E_Disease
Linkage	NNP	O	O
Consortium	NNP	O	O
.	.	O	O

Families	NNS	O	O
were	VBD	O	O
included	VBN	O	O
without	IN	O	O
regard	NN	O	O
to	TO	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
ovarian	JJ	B_Disease	B_Disease
or	CC	I_Disease	I_Disease
other	JJ	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
.	.	O	O

Overall	JJ	O	O
,	,	O	O
disease	NN	O	O
was	VBD	O	O
linked	VBN	O	O
to	TO	O	O
BRCA1	NNP	O	O
in	IN	O	O
an	DT	O	O
estimated	JJ	O	O
52	CD	O	O
%	NN	O	O
of	IN	O	O
families	NNS	O	O
,	,	O	O
to	TO	O	O
BRCA2	NNP	O	O
in	IN	O	O
32	CD	O	O
%	NN	O	O
of	IN	O	O
families	NNS	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
neither	DT	O	O
gene	NN	O	O
in	IN	O	O
16	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NNP	O	O
CI	NNP	O	O
]	VBD	O	O
6	CD	O	O
%	NN	O	O
-	:	O	O
28	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
suggesting	VBG	O	O
other	JJ	O	O
predisposition	NN	O	O
genes	NNS	O	O
.	.	O	O

The	DT	O	O
majority	NN	O	O
(	(	O	O
81	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
breast	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
were	VBD	O	O
due	JJ	O	O
to	TO	O	O
BRCA1	NNP	O	O
,	,	O	O
with	IN	O	O
most	JJS	O	O
others	NNS	O	O
(	(	O	O
14	CD	O	O
%	NN	O	O
)	)	O	O
due	JJ	O	O
to	TO	O	O
BRCA2	NNP	O	O
.	.	O	O

Conversely	RB	O	O
,	,	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
families	NNS	O	O
with	IN	O	O
male	NN	B_Disease	O
and	CC	I_Disease	O
female	JJ	I_Disease	B_Disease
breast	NN	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
were	VBD	O	O
due	JJ	O	O
to	TO	O	O
BRCA2	NNP	O	O
(	(	O	O
76	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
largest	JJS	O	O
proportion	NN	O	O
(	(	O	O
67	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
families	NNS	O	O
due	JJ	O	O
to	TO	O	O
other	JJ	O	O
genes	NNS	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
families	NNS	O	O
with	IN	O	O
four	CD	O	O
or	CC	O	O
five	CD	O	O
cases	NNS	O	O
of	IN	O	O
female	JJ	O	B_Disease
breast	NN	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
only	RB	O	O
.	.	O	O

These	DT	O	O
estimates	NNS	O	O
were	VBD	O	O
not	RB	O	O
substantially	RB	O	O
affected	VBN	O	O
either	RB	O	O
by	IN	O	O
changing	VBG	O	O
the	DT	O	O
assumed	JJ	O	O
penetrance	NN	O	O
model	NN	O	O
for	IN	O	O
BRCA1	NNP	O	O
or	CC	O	O
by	IN	O	O
including	VBG	O	O
or	CC	O	O
excluding	VBG	O	O
BRCA1	NNP	O	O
mutation	NN	O	O
data	NNS	O	O
.	.	O	O

Among	IN	O	O
those	DT	O	O
families	NNS	O	O
with	IN	O	O
disease	NN	O	O
due	JJ	O	O
to	TO	O	O
BRCA1	VB	O	O
that	WDT	O	O
were	VBD	O	O
tested	VBN	O	O
by	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
standard	JJ	O	O
screening	NN	O	O
methods	NNS	O	O
,	,	O	O
mutations	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
coding	NN	O	O
sequence	NN	O	O
or	CC	O	O
splice	NN	O	O
sites	NNS	O	O
in	IN	O	O
an	DT	O	O
estimated	JJ	O	O
63	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
51	CD	O	O
%	NN	O	O
-	:	O	O
77	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
estimated	JJ	O	O
sensitivity	NN	O	O
was	VBD	O	O
identical	JJ	O	O
for	IN	O	O
direct	JJ	O	O
sequencing	NN	O	O
and	CC	O	O
other	JJ	O	O
techniques	NNS	O	O
.	.	O	O

The	DT	O	O
penetrance	NN	O	O
of	IN	O	O
BRCA2	NNP	O	O
was	VBD	O	O
estimated	VBN	O	O
by	IN	O	O
maximizing	VBG	O	O
the	DT	O	O
LOD	NNP	O	O
score	NN	O	O
in	IN	O	O
BRCA2	NNP	O	O
-	:	O	O
mutation	NN	O	O
families	NNS	O	O
,	,	O	O
over	IN	O	O
all	DT	O	O
possible	JJ	O	O
penetrance	NN	O	O
functions	NNS	O	O
.	.	O	O

The	DT	O	O
estimated	VBN	O	O
cumulative	JJ	O	O
risk	NN	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
reached	VBD	O	O
28	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
9	CD	O	O
%	NN	O	O
-	:	O	O
44	CD	O	O
%	NN	O	O
)	)	O	O
by	IN	O	O
age	NN	O	O
50	CD	O	O
years	NNS	O	O
and	CC	O	O
84	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
43	CD	O	O
%	NN	O	O
-	:	O	O
95	CD	O	O
%	NN	O	O
)	)	O	O
by	IN	O	O
age	NN	O	O
70	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
corresponding	JJ	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
risks	NNS	O	O
were	VBD	O	O
0	CD	O	O
.	.	O	O

4	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0	CD	O	O
%	NN	O	O
-	:	O	O
1	CD	O	O
%	NN	O	O
)	)	O	O
by	IN	O	O
age	NN	O	O
50	CD	O	O
years	NNS	O	O
and	CC	O	O
27	CD	O	O
%	NN	O	O
(	(	O	O
95	CD	O	O
%	NN	O	O
CI	NNP	O	O
0	CD	O	O
%	NN	O	O
-	:	O	O
47	CD	O	O
%	NN	O	O
)	)	O	O
by	IN	O	O
age	NN	O	O
70	CD	O	O
years	NNS	O	O
.	.	O	O

The	DT	O	O
lifetime	NN	O	O
risk	NN	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
appears	VBZ	O	O
similar	JJ	O	O
to	TO	O	O
the	DT	O	O
risk	NN	O	O
in	IN	O	O
BRCA1	NNP	O	O
carriers	NNS	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
was	VBD	O	O
some	DT	O	O
suggestion	NN	O	O
of	IN	O	O
a	DT	O	O
lower	JJR	O	O
risk	NN	O	O
in	IN	O	O
BRCA2	NNP	O	O
carriers	NNS	O	O
<	VBP	O	O
50	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
.	.	O	O

9506545	CD	O	O

Eye	NNP	B_Disease	B_Disease
movement	NN	I_Disease	I_Disease
abnormalities	NNS	E_Disease	E_Disease
correlate	VBP	O	O
with	IN	O	O
genotype	NN	O	O
in	IN	O	O
autosomal	JJ	O	B_Disease
dominant	JJ	O	I_Disease
cerebellar	JJ	B_Disease	I_Disease
ataxia	NN	I_Disease	I_Disease
type	NN	I_Disease	I_Disease
I	PRP	E_Disease	E_Disease
.	.	O	O

We	PRP	O	O
compared	VBN	O	O
horizontal	JJ	O	O
eye	NN	O	O
movements	NNS	O	O
(	(	O	O
visually	RB	O	O
guided	VBN	O	O
saccades	NNS	O	O
,	,	O	O
antisaccades	NNS	O	O
,	,	O	O
and	CC	O	O
smooth	VB	O	O
pursuit	NN	O	O
)	)	O	O
in	IN	O	O
control	NN	O	O
subjects	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
14	CD	O	O
)	)	O	O
and	CC	O	O
patients	NNS	O	O
with	IN	O	O
three	CD	O	O
forms	NNS	O	O
of	IN	O	O
autosomal	JJ	O	O
dominant	JJ	O	O
cerebellar	JJ	B_Disease	B_Disease
ataxias	NN	I_Disease	I_Disease
type	NN	I_Disease	I_Disease
I	PRP	E_Disease	I_Disease
spinocerebellar	VBP	B_Disease	I_Disease
ataxias	JJ	I_Disease	O
1	CD	I_Disease	O
and	CC	I_Disease	O
2	CD	E_Disease	O
(	(	O	O
SCA1	NNP	S_Disease	O
,	,	O	O
n	JJ	O	O
=	VBP	O	O
11	CD	O	O
;	:	O	O
SCA2	NNP	S_Disease	O
,	,	O	O
n	JJ	O	O
=	NNP	O	O
10	CD	O	O
)	)	O	O
and	CC	O	O
SCA3	NNP	S_Disease	B_Disease
/	NNP	O	I_Disease
Machado	NNP	B_Disease	I_Disease
-	:	I_Disease	I_Disease
Joseph	NNP	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
(	(	O	O
MJD	NNP	S_Disease	S_Disease
)	)	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
16	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
SCA1	NNP	S_Disease	O
,	,	O	O
saccade	VBD	O	O
amplitude	NN	O	O
was	VBD	O	O
significantly	RB	O	O
increased	VBN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
hypermetria	NN	S_Disease	O
.	.	O	O

The	DT	O	O
smooth	JJ	O	O
pursuit	NN	O	O
gain	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
.	.	O	O

In	IN	O	O
SCA2	NNP	S_Disease	O
,	,	O	O
saccade	VBD	O	O
velocity	NN	O	O
was	VBD	O	O
markedly	RB	O	O
decreased	VBN	O	O
.	.	O	O

The	DT	O	O
percentage	NN	O	O
of	IN	O	O
errors	NNS	O	O
in	IN	O	O
antisaccades	NNS	O	O
was	VBD	O	O
greatly	RB	O	O
increased	JJ	O	O
and	CC	O	O
was	VBD	O	O
significantly	RB	O	O
correlated	VBN	O	O
with	IN	O	O
age	NN	O	O
at	IN	O	O
disease	NN	O	O
onset	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
a	DT	O	O
correlation	NN	O	O
between	IN	O	O
smooth	JJ	O	O
pursuit	NN	O	O
gain	NN	O	O
and	CC	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
trinucleotide	JJ	O	O
repeats	NNS	O	O
was	VBD	O	O
found	VBN	O	O
.	.	O	O

In	IN	O	O
SCA3	NNP	S_Disease	O
,	,	O	O
gaze	SYM	B_Disease	O
-	:	I_Disease	O
evoked	JJ	I_Disease	I_Disease
nystagmus	NN	E_Disease	E_Disease
was	VBD	O	O
often	RB	O	O
present	JJ	O	O
as	IN	O	O
was	VBD	O	O
saccade	VBN	O	O
hypometria	NN	O	O
and	CC	O	O
smooth	JJ	O	O
pursuit	NN	O	O
gain	NN	O	O
was	VBD	O	O
markedly	RB	O	O
decreased	VBN	O	O
.	.	O	O

Three	CD	O	O
major	JJ	O	O
criteria	NNS	O	O
,	,	O	O
saccade	JJ	O	O
amplitude	NN	O	O
,	,	O	O
saccade	JJ	O	O
velocity	NN	O	O
,	,	O	O
and	CC	O	O
presence	NN	O	O
of	IN	O	O
gaze	JJ	B_Disease	O
-	:	I_Disease	O
evoked	JJ	I_Disease	O
nystagmus	NN	E_Disease	E_Disease
,	,	O	O
permitted	VBD	O	O
the	DT	O	O
correct	JJ	O	O
assignment	NN	O	O
of	IN	O	O
90	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
SCA1	NNP	S_Disease	O
,	,	O	O
90	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
SCA2	NNP	S_Disease	O
,	,	O	O
and	CC	O	O
93	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
with	IN	O	O
SCA3	NNP	S_Disease	O
to	TO	O	O
their	PRP$	O	O
genetically	RB	O	O
confirmed	VBN	O	O
patient	NN	O	O
group	NN	O	O
and	CC	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
may	MD	O	O
help	VB	O	O
orient	VB	O	O
diagnoses	NNS	O	O
of	IN	O	O
SCA1	NNP	S_Disease	O
,	,	O	O
SCA2	NNP	S_Disease	O
,	,	O	O
and	CC	O	O
SCA3	NNP	S_Disease	O
at	IN	O	O
early	RB	O	O
clinical	JJ	O	O
stages	NNS	O	O
of	IN	O	O
the	DT	O	O
diseases	NNS	O	O
.	.	O	O
.	.	O	O

9521325	CD	O	O

Genetic	JJ	O	O
basis	NN	O	O
and	CC	O	O
molecular	JJ	O	O
mechanism	NN	O	O
for	IN	O	O
idiopathic	JJ	B_Disease	B_Disease
ventricular	JJ	I_Disease	I_Disease
fibrillation	NN	E_Disease	E_Disease
.	.	O	O

Ventricular	JJ	B_Disease	O
fibrillation	NN	E_Disease	S_Disease
causes	VBZ	O	O
more	JJR	O	O
than	IN	O	O
300	CD	O	O
,	,	O	O
000	CD	O	O
sudden	JJ	O	O
deaths	NNS	O	O
each	DT	O	O
year	NN	O	O
in	IN	O	O
the	DT	O	O
USA	NNP	O	O
alone	RB	O	O
.	.	O	O

In	IN	O	O
approximately	RB	O	O
5	CD	O	O
-	:	O	O
12	CD	O	O
%	NN	O	O
of	IN	O	O
these	DT	O	O
cases	NNS	O	O
,	,	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
demonstrable	JJ	O	O
cardiac	NN	O	O
or	CC	O	O
non	JJ	O	O
-	:	O	O
cardiac	JJ	O	O
causes	NNS	O	O
to	TO	O	O
account	VB	O	O
for	IN	O	O
the	DT	O	O
episode	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
therefore	RB	O	O
classified	JJ	O	O
as	IN	O	O
idiopathic	JJ	B_Disease	B_Disease
ventricular	JJ	I_Disease	I_Disease
fibrillation	NN	E_Disease	E_Disease
(	(	O	O
IVF	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

A	DT	O	O
distinct	JJ	O	O
group	NN	O	O
of	IN	O	O
IVF	NNP	S_Disease	S_Disease
patients	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
present	VB	O	O
with	IN	O	O
a	DT	O	O
characteristic	JJ	O	O
electrocardiographic	JJ	O	O
pattern	NN	O	O
.	.	O	O

Because	IN	O	O
of	IN	O	O
the	DT	O	O
small	JJ	O	O
size	NN	O	O
of	IN	O	O
most	JJS	O	O
pedigrees	NNS	O	O
and	CC	O	O
the	DT	O	O
high	JJ	O	O
incidence	NN	O	O
of	IN	O	O
sudden	JJ	B_Disease	B_Disease
death	NN	E_Disease	E_Disease
,	,	O	O
however	RB	O	O
,	,	O	O
molecular	JJ	O	O
genetic	JJ	O	O
studies	NNS	O	O
of	IN	O	O
IVF	NNP	S_Disease	S_Disease
have	VBP	O	O
not	RB	O	O
yet	RB	O	O
been	VBN	O	O
done	VBN	O	O
.	.	O	O

Because	IN	O	O
IVF	NNP	S_Disease	O
causes	VBZ	O	O
cardiac	JJ	O	O
rhythm	NN	O	O
disturbance	NN	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
whether	IN	O	O
malfunction	NN	O	O
of	IN	O	O
ion	NN	O	O
channels	NNS	O	O
could	MD	O	O
cause	VB	O	O
the	DT	O	O
disorder	NN	O	O
by	IN	O	O
studying	VBG	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
cardiac	JJ	O	O
sodium	NN	O	O
channel	NN	O	O
gene	NN	O	O
SCN5A	NNP	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
now	RB	O	O
identified	VBN	O	O
a	DT	O	O
missense	NN	O	O
mutation	NN	O	O
,	,	O	O
a	DT	O	O
splice	NN	O	O
-	:	O	O
donor	NN	O	O
mutation	NN	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
frameshift	JJ	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
coding	JJ	O	O
region	NN	O	O
of	IN	O	O
SCN5A	NNP	O	O
in	IN	O	O
three	CD	O	O
IVF	NNP	S_Disease	S_Disease
families	NNS	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
that	IN	O	O
sodium	NN	O	O
channels	NNS	O	O
with	IN	O	O
the	DT	O	O
missense	NN	O	O
mutation	NN	O	O
recover	NN	O	O
from	IN	O	O
inactivation	NN	O	O
more	RBR	O	O
rapidly	RB	O	O
than	IN	O	O
normal	JJ	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
frameshift	NN	O	O
mutation	NN	O	O
causes	VBZ	O	O
the	DT	O	O
sodium	NN	O	O
channel	NN	O	O
to	TO	O	O
be	VB	O	O
non	JJ	O	O
-	:	O	O
functional	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
mutations	NNS	O	O
in	IN	O	O
cardiac	JJ	O	O
ion	NN	O	O
-	:	O	O
channel	NN	O	O
genes	NNS	O	O
contribute	VBP	O	O
to	TO	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
developing	VBG	O	O
IVF	NNP	S_Disease	S_Disease
.	.	O	O
.	.	O	O

9521421	CD	O	O

Molecular	JJ	O	O
heterogeneity	NN	O	O
in	IN	O	O
mucopolysaccharidosis	NN	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
in	IN	O	O
Australia	NNP	O	O
and	CC	O	O
Northern	NNP	O	O
Ireland	NNP	O	O
:	:	O	O
nine	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
including	VBG	O	O
T312S	NNP	O	O
,	,	O	O
a	DT	O	O
common	JJ	O	O
allele	NN	O	O
that	IN	O	O
confers	VBZ	O	O
a	DT	O	O
mild	JJ	O	O
phenotype	NN	O	O
.	.	O	O

Mucopolysaccharidosis	NN	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
(	(	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	NN	I_Disease	I_Disease
lysosomal	JJ	I_Disease	I_Disease
storage	NN	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
genetic	JJ	B_Disease	O
defect	NN	E_Disease	O
in	IN	O	O
N	NNP	O	O
-	:	O	I_Disease
acetylgalactosamine	NN	O	I_Disease
-	:	O	I_Disease
6	CD	O	I_Disease
-	:	O	I_Disease
sulfate	NN	O	O
sulfatase	NN	O	O
(	(	O	O
GALNS	NNP	O	O
)	)	O	O
.	.	O	O

Previous	JJ	O	O
studies	NNS	O	O
of	IN	O	O
patients	NNS	O	O
from	IN	O	O
a	DT	O	O
British	JJ	O	O
-	:	O	O
Irish	JJ	O	O
population	NN	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
I113F	NNP	O	O
mutation	NN	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
single	JJ	O	O
mutation	NN	O	O
among	IN	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
patients	NNS	O	O
and	CC	O	O
produces	VBZ	O	O
a	DT	O	O
severe	JJ	O	O
clinical	JJ	O	O
phenotype	NN	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
GALNS	NNP	O	O
gene	NN	O	O
from	IN	O	O
23	CD	O	O
additional	JJ	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
patients	NNS	O	O
(	(	O	O
15	CD	O	O
from	IN	O	O
Australia	NNP	O	O
,	,	O	O
8	CD	O	O
from	IN	O	O
Northern	NNP	O	O
Ireland	NNP	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
various	JJ	O	O
clinical	JJ	O	O
phenotypes	NNS	O	O
(	(	O	O
severe	JJ	O	O
,	,	O	O
16	CD	O	O
cases	NNS	O	O
;	:	O	O
intermediate	VB	O	O
,	,	O	O
4	CD	O	O
cases	NNS	O	O
;	:	O	O
mild	VB	O	O
,	,	O	O
3	CD	O	O
cases	NNS	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
two	CD	O	O
common	JJ	O	O
mutations	NNS	O	O
that	IN	O	O
together	RB	O	O
accounted	VBD	O	O
for	IN	O	O
32	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
44	CD	O	O
unrelated	JJ	O	O
alleles	NNS	O	O
in	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

One	CD	O	O
is	VBZ	O	O
the	DT	O	O
T312S	NNP	O	O
mutation	NN	O	O
,	,	O	O
a	DT	O	O
novel	JJ	O	O
mutation	NN	O	O
found	VBD	O	O
exclusively	RB	O	O
in	IN	O	O
milder	NN	O	S_Disease
patients	NNS	O	O
.	.	O	O

The	DT	O	O
other	JJ	O	O
is	VBZ	O	O
the	DT	O	O
previously	RB	O	O
described	VBN	O	O
I113F	NNP	O	O
that	WDT	O	O
produces	VBZ	O	O
a	DT	O	O
severe	JJ	O	O
phenotype	NN	O	O
.	.	O	O

The	DT	O	O
I113F	NNP	O	O
and	CC	O	O
T312S	NNP	O	O
mutations	NNS	O	O
accounted	VBD	O	O
for	IN	O	O
8	CD	O	O
(	(	O	O
18	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
6	CD	O	O
(	(	O	O
14	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
44	CD	O	O
unrelated	JJ	O	O
alleles	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
relatively	RB	O	O
high	JJ	O	O
residual	JJ	O	O
GALNS	NNP	O	O
activity	NN	O	O
seen	VBN	O	O
when	WRB	O	O
the	DT	O	O
T312S	NNP	O	O
mutant	NN	O	O
cDNA	NN	O	O
is	VBZ	O	O
overexpressed	VBN	O	O
in	IN	O	O
mutant	JJ	O	O
cells	NNS	O	O
provides	VBZ	O	O
an	DT	O	O
explanation	NN	O	O
for	IN	O	O
the	DT	O	O
mild	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
this	DT	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
distribution	NN	O	O
and	CC	O	O
relative	JJ	O	O
frequencies	NNS	O	O
of	IN	O	O
the	DT	O	O
I113F	NNP	O	O
and	CC	O	O
T312S	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
Australia	NNP	O	O
corresponded	VBD	O	O
to	TO	O	O
those	DT	O	O
observed	VBN	O	O
in	IN	O	O
Northern	NNP	O	O
Ireland	NNP	O	O
and	CC	O	O
are	VBP	O	O
unique	JJ	O	O
to	TO	O	O
these	DT	O	O
two	CD	O	O
populations	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
both	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
probably	RB	O	O
introduced	VBN	O	O
to	TO	O	O
Australia	NNP	O	O
by	IN	O	O
Irish	JJ	O	O
migrants	NNS	O	O
during	IN	O	O
the	DT	O	O
19th	JJ	O	O
century	NN	O	O
.	.	O	O

Haplotype	NNP	O	O
analysis	NN	O	O
using	VBG	O	O
6	CD	O	O
RFLPs	NNP	O	O
provides	VBZ	O	O
additional	JJ	O	O
data	NNS	O	O
that	IN	O	O
the	DT	O	O
I113F	NNP	O	O
mutation	NN	O	O
originated	VBD	O	O
from	IN	O	O
a	DT	O	O
common	JJ	O	O
ancestor	NN	O	O
.	.	O	O

The	DT	O	O
other	JJ	O	O
9	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
identified	VBN	O	O
in	IN	O	O
these	DT	O	O
23	CD	O	O
patients	NNS	O	O
were	VBD	O	O
each	DT	O	O
limited	VBN	O	O
to	TO	O	O
a	DT	O	O
single	JJ	O	O
family	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
provide	VBP	O	O
further	JJ	O	O
evidence	NN	O	O
for	IN	O	O
extensive	JJ	O	O
allelic	JJ	O	O
heterogeneity	NN	O	O
in	IN	O	O
MPS	NNP	B_Disease	B_Disease
IVA	NNP	E_Disease	E_Disease
in	IN	O	O
British	NNP	O	O
-	:	O	O
Irish	JJ	O	O
patients	NNS	O	O
and	CC	O	O
provide	VB	O	O
evidence	NN	O	O
for	IN	O	O
their	PRP$	O	O
transmission	NN	O	O
to	TO	O	O
Australia	NNP	O	O
by	IN	O	O
British	NNP	O	O
-	:	O	O
Irish	JJ	O	O
migrants	NNS	O	O
.	.	O	O
.	.	O	O

9529364	CD	O	O

Identification	NN	O	O
of	IN	O	O
constitutional	JJ	O	O
WT1	NNP	O	O
mutations	NNS	O	O
,	,	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
isolated	JJ	O	O
diffuse	NN	B_Disease	O
mesangial	JJ	I_Disease	B_Disease
sclerosis	NN	E_Disease	E_Disease
,	,	O	O
and	CC	O	O
analysis	NN	O	O
of	IN	O	O
genotype	NN	O	O
/	NNP	O	O
phenotype	NN	O	O
correlations	NNS	O	O
by	IN	O	O
use	NN	O	O
of	IN	O	O
a	DT	O	O
computerized	JJ	O	O
mutation	NN	O	O
database	NN	O	O
.	.	O	O

Constitutional	JJ	O	O
mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
WT1	NNP	O	O
gene	NN	O	O
,	,	O	O
encoding	VBG	O	O
a	DT	O	O
zinc	NN	O	O
-	:	O	O
finger	NN	O	O
transcription	NN	O	O
factor	NN	O	O
involved	VBN	O	O
in	IN	O	O
renal	JJ	O	O
and	CC	O	O
gonadal	JJ	O	O
development	NN	O	O
,	,	O	O
are	VBP	O	O
found	VBN	O	O
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
with	IN	O	O
Denys	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Drash	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
DDS	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
or	CC	O	O
diffuse	VB	B_Disease	O
mesangial	JJ	I_Disease	B_Disease
sclerosis	NN	E_Disease	E_Disease
(	(	O	O
DMS	NNP	S_Disease	O
)	)	O	O
associated	VBN	O	O
with	IN	O	O
pseudohermaphroditism	NN	S_Disease	S_Disease
and	CC	O	O
/	NN	O	O
or	CC	O	O
Wilms	NNP	B_Disease	B_Disease
tumor	NN	E_Disease	E_Disease
(	(	O	O
WT	NNP	S_Disease	O
)	)	O	O
.	.	O	O

Most	JJS	O	O
mutations	NNS	O	O
in	IN	O	O
DDS	NNP	S_Disease	S_Disease
patients	NNS	O	O
lie	VBP	O	O
in	IN	O	O
exon	$	O	O
8	CD	O	O
or	CC	O	O
exon	VB	O	O
9	CD	O	O
,	,	O	O
encoding	VBG	O	O
zinc	NN	O	O
finger	NN	O	O
2	CD	O	O
or	CC	O	O
zinc	VB	O	O
finger	JJR	O	O
3	CD	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
hot	JJ	O	O
spot	NN	O	O
(	(	O	O
R394W	NNP	O	O
)	)	O	O
in	IN	O	O
exon	$	O	O
9	CD	O	O
.	.	O	O

We	PRP	O	O
analyzed	VBD	O	O
a	DT	O	O
series	NN	O	O
of	IN	O	O
24	CD	O	O
patients	NNS	O	O
,	,	O	O
10	CD	O	O
with	IN	O	O
isolated	JJ	B_Disease	O
DMS	NNP	E_Disease	O
(	(	O	O
IDMS	NNP	S_Disease	O
)	)	O	O
,	,	O	O
10	CD	O	O
with	IN	O	O
DDS	NNP	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
4	CD	O	O
with	IN	O	O
urogenital	JJ	B_Disease	B_Disease
abnormalities	NNS	E_Disease	E_Disease
and	CC	O	O
/	NN	O	O
or	CC	O	O
WT	NNP	S_Disease	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
WT1	NNP	O	O
heterozygous	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
16	CD	O	O
patients	NNS	O	O
,	,	O	O
4	CD	O	O
of	IN	O	O
whom	WP	O	O
presented	VBN	O	O
with	IN	O	O
IDMS	NNP	S_Disease	O
.	.	O	O

One	CD	O	O
male	NN	O	O
and	CC	O	O
two	CD	O	O
female	JJ	O	O
IDMS	NNP	S_Disease	O
patients	NNS	O	O
with	IN	O	O
WT1	NNP	O	O
mutations	NNS	O	O
underwent	JJ	O	O
normal	JJ	O	O
puberty	NN	O	O
.	.	O	O

Two	CD	O	O
mutations	NNS	O	O
associated	VBN	O	O
with	IN	O	O
IDMS	NNP	S_Disease	O
are	VBP	O	O
different	JJ	O	O
from	IN	O	O
those	DT	O	O
described	VBN	O	O
in	IN	O	O
DDS	NNP	S_Disease	S_Disease
patients	NNS	O	O
.	.	O	O

No	DT	O	O
WT1	NNP	O	O
mutations	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
six	CD	O	O
other	JJ	O	O
IDMS	NNP	S_Disease	O
patients	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
genetic	JJ	O	O
heterogeneity	NN	O	O
of	IN	O	O
this	DT	O	O
disease	NN	O	O
.	.	O	O

We	PRP	O	O
analyzed	VBD	O	O
genotype	JJ	O	O
/	NNP	O	O
phenotype	NN	O	O
correlations	NNS	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
constitution	NN	O	O
of	IN	O	O
a	DT	O	O
WT1	NNP	O	O
mutation	NN	O	O
database	NN	O	O
of	IN	O	O
84	CD	O	O
germ	JJ	O	O
-	:	O	O
line	NN	O	O
mutations	NNS	O	O
,	,	O	O
to	TO	O	O
compare	VB	O	O
the	DT	O	O
distribution	NN	O	O
and	CC	O	O
type	NN	O	O
of	IN	O	O
mutations	NNS	O	O
,	,	O	O
according	VBG	O	O
to	TO	O	O
the	DT	O	O
different	JJ	O	O
symptoms	NNS	O	O
.	.	O	O

This	DT	O	O
demonstrated	VBD	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
mutations	NNS	O	O
in	IN	O	O
exons	NNS	O	O
8	CD	O	O
and	CC	O	O
9	CD	O	O
and	CC	O	O
DMS	NNP	S_Disease	O
;	:	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
among	IN	O	O
patients	NNS	O	O
with	IN	O	O
DMS	NNP	S_Disease	O
,	,	O	O
a	DT	O	O
higher	JJR	O	O
frequency	NN	O	O
of	IN	O	O
exon	$	O	O
8	CD	O	O
mutations	NNS	O	O
among	IN	O	O
46	CD	O	O
,	,	O	O
XY	NN	O	S_Disease
patients	NNS	O	O
with	IN	O	O
female	JJ	O	O
phenotype	NN	O	O
than	IN	O	O
among	IN	O	O
46	CD	O	O
,	,	O	O
XY	NN	O	O
patients	NNS	O	O
with	IN	O	O
sexual	JJ	O	O
ambiguity	NN	O	O
or	CC	O	O
male	JJ	O	O
phenotype	NN	O	O
;	:	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
statistically	RB	O	O
significant	JJ	O	O
evidence	NN	O	O
that	IN	O	O
mutations	NNS	O	O
in	IN	O	O
exons	NNS	O	O
8	CD	O	O
and	CC	O	O
9	CD	O	O
preferentially	RB	O	O
affect	JJ	O	O
amino	NN	O	O
acids	NNS	O	O
with	IN	O	O
different	JJ	O	O
functions	NNS	O	O
.	.	O	O
.	.	O	O

9536083	CD	O	O

The	DT	O	O
185delAG	CD	O	O
BRCA1	NNP	O	O
mutation	NN	O	O
originated	VBD	O	O
before	IN	O	O
the	DT	O	O
dispersion	NN	O	O
of	IN	O	O
Jews	NNP	O	O
in	IN	O	O
the	DT	O	O
diaspora	NN	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
limited	VBN	O	O
to	TO	O	O
Ashkenazim	NNP	O	O
.	.	O	O

The	DT	O	O
185delAG	CD	O	O
mutation	NN	O	O
in	IN	O	O
BRCA1	NNP	O	O
is	VBZ	O	O
detected	VBN	O	O
in	IN	O	O
Ashkenazi	NNP	O	O
Jews	NNP	O	O
both	DT	O	O
in	IN	O	O
familial	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
in	IN	O	O
the	DT	O	O
general	JJ	O	O
population	NN	O	O
.	.	O	O

All	DT	O	O
tested	VBD	O	O
Ashkenazi	NNP	O	O
mutation	NN	O	O
carriers	NNS	O	O
share	NN	O	O
the	DT	O	O
same	JJ	O	O
allelic	JJ	O	O
pattern	NN	O	O
at	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
locus	NN	O	O
.	.	O	O

Our	PRP$	O	O
previous	JJ	O	O
study	NN	O	O
showed	VBD	O	O
that	IN	O	O
this	DT	O	O
Ashkenazi	NNP	O	O
mutation	NN	O	O
also	RB	O	O
occurs	VBZ	O	O
in	IN	O	O
Iraqi	NNP	O	O
Jews	NNP	O	O
with	IN	O	O
a	DT	O	O
similar	JJ	O	O
allelic	JJ	O	O
pattern	NN	O	O
.	.	O	O

We	PRP	O	O
extended	VBD	O	O
our	PRP$	O	O
analysis	NN	O	O
to	TO	O	O
other	JJ	O	O
non	JJ	O	O
-	:	O	O
Ashkenazi	NNP	O	O
subsets	VBZ	O	O
354	CD	O	O
of	IN	O	O
Moroccan	NNP	O	O
origin	NN	O	O
,	,	O	O
200	CD	O	O
Yemenites	NNS	O	O
and	CC	O	O
150	CD	O	O
Iranian	JJ	O	O
Jews	NNPS	O	O
.	.	O	O

Heteroduplex	NNP	O	O
analysis	NN	O	O
complemented	VBN	O	O
by	IN	O	O
direct	JJ	O	O
DNA	NNP	O	O
sequencing	NN	O	O
of	IN	O	O
abnormally	RB	O	O
migrating	VBG	O	O
bands	NNS	O	O
were	VBD	O	O
employed	VBN	O	O
.	.	O	O

Four	CD	O	O
of	IN	O	O
Moroccan	NNP	O	O
origin	NN	O	O
(	(	O	O
1	CD	O	O
.	.	O	O

1	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
none	NN	O	O
of	IN	O	O
the	DT	O	O
Yemenites	NNS	O	O
or	CC	O	O
Iranians	NNP	O	O
was	VBD	O	O
a	DT	O	O
carrier	NN	O	O
of	IN	O	O
the	DT	O	O
185delAG	CD	O	O
mutation	NN	O	O
.	.	O	O

BRCA1	NNP	O	O
allelic	JJ	O	O
patterns	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
for	IN	O	O
four	CD	O	O
of	IN	O	O
these	DT	O	O
individuals	NNS	O	O
and	CC	O	O
for	IN	O	O
12	CD	O	O
additional	JJ	O	O
non	NN	O	O
-	:	O	O
Ashkenazi	$	O	O
185delAG	CD	O	O
mutation	NN	O	O
carriers	NNS	O	O
who	WP	O	O
had	VBD	O	O
breast	VBN	B_Disease	B_Disease
/	JJ	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

Six	NNP	O	O
non	SYM	O	O
-	:	O	O
Ashkenazi	JJ	O	O
individuals	NNS	O	O
shared	VBD	O	O
the	DT	O	O
common	JJ	O	O
Ashkenazi	NNP	O	O
haplotype	NN	O	O
,	,	O	O
four	CD	O	O
had	VBD	O	O
a	DT	O	O
closely	RB	O	O
related	JJ	O	O
pattern	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
rest	NN	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
6	CD	O	O
)	)	O	O
displayed	VBD	O	O
a	DT	O	O
distinct	JJ	O	O
BRCA1	NNP	O	O
allelic	NN	O	O
pattern	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
185delAG	CD	O	O
BRCA1	NNP	O	O
mutation	NN	O	O
occurs	VBZ	O	O
in	IN	O	O
some	DT	O	O
non	JJ	O	O
-	:	O	O
Ashkenazi	JJ	O	O
populations	NNS	O	O
at	IN	O	O
rates	NNS	O	O
comparable	JJ	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
Ashkenazim	NNP	O	O
.	.	O	O

The	DT	O	O
majority	NN	O	O
of	IN	O	O
Jewish	JJ	O	O
185delAG	CD	O	O
mutation	NN	O	O
carriers	NNS	O	O
have	VBP	O	O
a	DT	O	O
common	JJ	O	O
allelic	JJ	O	O
pattern	NN	O	O
,	,	O	O
supporting	VBG	O	O
the	DT	O	O
founder	NN	O	O
effect	NN	O	O
notion	NN	O	O
,	,	O	O
but	CC	O	O
dating	VBG	O	O
the	DT	O	O
mutations	NNS	O	O
origin	VBP	O	O
to	TO	O	O
an	DT	O	O
earlier	JJR	O	O
date	NN	O	O
than	IN	O	O
currently	RB	O	O
estimated	VBN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
different	JJ	O	O
allelic	JJ	O	O
pattern	NN	O	O
at	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
locus	VBD	O	O
even	RB	O	O
in	IN	O	O
some	DT	O	O
Jewish	JJ	O	O
mutation	NN	O	O
carriers	NNS	O	O
,	,	O	O
might	MD	O	O
suggest	VB	O	O
that	IN	O	O
the	DT	O	O
mutation	NN	O	O
arose	VBD	O	O
independently	RB	O	O
.	.	O	O
.	.	O	O

9546397	CD	O	O

Crystal	JJ	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
hemochromatosis	NN	S_Disease	S_Disease
protein	NN	O	O
HFE	NNP	O	O
and	CC	O	O
characterization	NN	O	O
of	IN	O	O
its	PRP$	O	O
interaction	NN	O	O
with	IN	O	O
transferrin	JJ	O	O
receptor	NN	O	O
.	.	O	O

HFE	NNP	O	O
is	VBZ	O	O
an	DT	O	O
MHC	NNP	O	O
-	:	O	O
related	JJ	O	O
protein	NN	O	O
that	WDT	O	O
is	VBZ	O	O
mutated	VBN	O	O
in	IN	O	O
the	DT	O	O
iron	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
overload	NN	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
hereditary	JJ	B_Disease	B_Disease
hemochromatosis	NN	E_Disease	E_Disease
.	.	O	O

HFE	NNP	O	O
binds	VBZ	O	O
to	TO	O	O
transferrin	VB	O	O
receptor	NN	O	O
(	(	O	O
TfR	NNP	O	O
)	)	O	O
and	CC	O	O
reduces	VBZ	O	O
its	PRP$	O	O
affinity	NN	O	O
for	IN	O	O
iron	NN	O	O
-	:	O	O
loaded	JJ	O	O
transferrin	NN	O	O
,	,	O	O
implicating	VBG	O	O
HFE	NNP	O	O
in	IN	O	O
iron	NN	O	O
metabolism	NN	O	O
.	.	O	O

The	DT	O	O
2	CD	O	O
.	.	O	O

6	CD	O	O
A	NNP	O	O
crystal	JJ	O	O
structure	NN	O	O
of	IN	O	O
HFE	NNP	O	O
reveals	VBZ	O	O
the	DT	O	O
locations	NNS	O	O
of	IN	O	O
hemochromatosis	NN	S_Disease	S_Disease
mutations	NNS	O	O
and	CC	O	O
a	DT	O	O
patch	NN	O	O
of	IN	O	O
histidines	NNS	O	O
that	WDT	O	O
could	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
pH	JJ	O	O
-	:	O	O
dependent	JJ	O	O
interactions	NNS	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
demonstrate	VBP	O	O
that	IN	O	O
soluble	JJ	O	O
TfR	NNP	O	O
and	CC	O	O
HFE	NNP	O	O
bind	VBP	O	O
tightly	RB	O	O
at	IN	O	O
the	DT	O	O
basic	JJ	O	O
pH	NN	O	O
of	IN	O	O
the	DT	O	O
cell	NN	O	O
surface	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
at	IN	O	O
the	DT	O	O
acidic	JJ	O	O
pH	NN	O	O
of	IN	O	O
intracellular	JJ	O	O
vesicles	NNS	O	O
.	.	O	O

TfR	NNP	O	O
HFE	NNP	O	O
stoichiometry	NN	O	O
(	(	O	O
2	CD	O	O
1	CD	O	O
)	)	O	O
differs	NNS	O	O
from	IN	O	O
TfR	NNP	O	O
transferrin	NN	O	O
stoichiometry	NN	O	O
(	(	O	O
2	CD	O	O
2	CD	O	O
)	)	O	O
,	,	O	O
implying	VBG	O	O
a	DT	O	O
different	JJ	O	O
mode	NN	O	O
of	IN	O	O
binding	VBG	O	O
for	IN	O	O
HFE	NNP	O	O
and	CC	O	O
transferrin	NN	O	O
to	TO	O	O
TfR	NNP	O	O
,	,	O	O
consistent	NN	O	O
with	IN	O	O
our	PRP$	O	O
demonstration	NN	O	O
that	IN	O	O
HFE	NNP	O	O
,	,	O	O
transferrin	NN	O	O
,	,	O	O
and	CC	O	O
TfR	NNP	O	O
form	VBP	O	O
a	DT	O	O
ternary	JJ	O	O
complex	NN	O	O
.	.	O	O

9554743	CD	O	O

Identification	NN	O	O
of	IN	O	O
three	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
a	DT	O	O
high	JJ	O	O
frequency	NN	O	O
of	IN	O	O
the	DT	O	O
Arg778Leu	NNP	O	O
mutation	NN	O	O
in	IN	O	O
Korean	JJ	O	O
patients	NNS	O	O
with	IN	O	O
Wilson	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

Four	CD	O	O
mutations	NNS	O	O
-	:	O	O
-	:	O	O
R778L	NN	O	O
,	,	O	O
A874V	NNP	O	O
,	,	O	O
L1083F	NNP	O	O
,	,	O	O
and	CC	O	O
2304delC	CD	O	O
-	:	O	O
-	:	O	O
in	IN	O	O
the	DT	O	O
copper	NN	O	O
-	:	O	O
transporting	NN	O	O
enzyme	NN	O	O
,	,	O	O
P	NNP	O	O
-	:	O	O
type	NN	O	O
ATPase	NNP	O	O
(	(	O	O
ATP7B	NNP	O	O
)	)	O	O
,	,	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
Korean	JJ	O	O
Patients	NNS	O	O
with	IN	O	O
Wilson	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

Arg778Leu	NNP	O	O
,	,	O	O
the	DT	O	O
most	RBS	O	O
frequently	RB	O	O
reported	VBN	O	O
mutation	NN	O	O
of	IN	O	O
this	DT	O	O
enzyme	NN	O	O
,	,	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
six	CD	O	O
of	IN	O	O
eight	CD	O	O
unrelated	JJ	O	O
patients	NNS	O	O
studied	VBN	O	O
,	,	O	O
an	DT	O	O
allele	JJ	O	O
frequency	NN	O	O
of	IN	O	O
37	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
considerably	RB	O	O
higher	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
other	JJ	O	O
Asian	JJ	O	O
populations	NNS	O	O
.	.	O	O

The	DT	O	O
novel	JJ	O	O
single	JJ	O	O
nucleotide	NN	O	O
deletion	NN	O	O
,	,	O	O
2304delC	CD	O	O
,	,	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
one	CD	O	O
patient	NN	O	O
.	.	O	O

Since	IN	O	O
a	DT	O	O
mutation	NN	O	O
at	IN	O	O
cDNA	NN	O	O
nucleotide	NN	O	O
2302	CD	O	O
(	(	O	O
2302insC	CD	O	O
)	)	O	O
had	VBD	O	O
been	VBN	O	O
previously	RB	O	O
described	VBN	O	O
,	,	O	O
this	DT	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
ATP7B	NNP	O	O
gene	NN	O	O
may	MD	O	O
be	VB	O	O
susceptible	JJ	O	O
to	TO	O	O
gene	NN	O	O
rearrangements	NNS	O	O
causing	VBG	O	O
Wilson	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

9563950	CD	O	O

Disruption	NN	O	O
of	IN	O	O
splicing	VBG	O	O
regulated	VBN	O	O
by	IN	O	O
a	DT	O	O
CUG	NNP	O	O
-	:	O	O
binding	VBG	O	O
protein	NN	O	O
in	IN	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
.	.	O	O

Myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
CTG	NNP	O	O
expansion	NN	O	O
in	IN	O	O
the	DT	O	O
3	CD	O	O
untranslated	JJ	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

One	CD	O	O
model	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
pathogenesis	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
RNAs	NNP	O	O
from	IN	O	O
the	DT	O	O
expanded	VBN	O	O
allele	NN	O	O
create	VB	O	O
a	DT	O	O
gain	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutation	NN	O	O
by	IN	O	O
the	DT	O	O
inappropriate	JJ	O	O
binding	NN	O	O
of	IN	O	O
proteins	NNS	O	O
to	TO	O	O
the	DT	O	O
CUG	NNP	O	O
repeats	NNS	O	O
.	.	O	O

Data	NNS	O	O
presented	VBN	O	O
here	RB	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
conserved	VBN	O	O
heterogeneous	JJ	O	O
nuclear	JJ	O	O
ribonucleoprotein	NN	O	O
,	,	O	O
CUG	NNP	O	O
-	:	O	O
binding	NN	O	O
protein	NN	O	O
(	(	O	O
CUG	NNP	O	O
-	:	O	O
BP	NNP	O	O
)	)	O	O
,	,	O	O
may	MD	O	O
mediate	VB	O	O
the	DT	O	O
trans	NNS	O	O
-	:	O	O
dominant	JJ	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
RNA	NNP	O	O
.	.	O	O

CUG	NNP	O	O
-	:	O	O
BP	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
bind	VB	O	O
to	TO	O	O
the	DT	O	O
human	JJ	O	O
cardiac	JJ	O	O
troponin	NN	O	O
T	NNP	O	O
(	(	O	O
cTNT	NN	O	O
)	)	O	O
pre	VBZ	O	O
-	:	O	O
messenger	NN	O	O
RNA	NNP	O	O
and	CC	O	O
regulate	VB	O	O
its	PRP$	O	O
alternative	JJ	O	O
splicing	NN	O	O
.	.	O	O

Splicing	VBG	O	O
of	IN	O	O
cTNT	NN	O	O
was	VBD	O	O
disrupted	VBN	O	O
in	IN	O	O
DM	NNP	S_Disease	O
striated	VBD	O	O
muscle	NN	O	O
and	CC	O	O
in	IN	O	O
normal	JJ	O	O
cells	NNS	O	O
expressing	VBG	O	O
transcripts	NNS	O	O
that	WDT	O	O
contain	VBP	O	O
CUG	NNP	O	O
repeats	NNS	O	O
.	.	O	O

Altered	NNP	O	O
expression	NN	O	O
of	IN	O	O
genes	NNS	O	O
regulated	VBN	O	O
posttranscriptionally	RB	O	O
by	IN	O	O
CUG	NNP	O	O
-	:	O	O
BP	NNP	O	O
therefore	NN	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
DM	NNP	S_Disease	S_Disease
pathogenesis	NN	O	O
.	.	O	O
.	.	O	O

9580132	CD	O	O

Identification	NN	O	O
of	IN	O	O
a	DT	O	O
novel	JJ	O	O
nonsense	JJ	O	O
mutation	NN	O	O
and	CC	O	O
a	DT	O	O
missense	JJ	O	O
substitution	NN	O	O
in	IN	O	O
the	DT	O	O
vasopressin	NN	O	O
-	:	O	O
neurophysin	NN	O	O
II	NNP	O	O
gene	NN	O	O
in	IN	O	O
two	CD	O	O
Spanish	JJ	O	O
kindreds	NNS	O	O
with	IN	O	O
familial	JJ	B_Disease	B_Disease
neurohypophyseal	NN	I_Disease	I_Disease
diabetes	VBZ	I_Disease	I_Disease
insipidus	NN	E_Disease	E_Disease
.	.	O	O

Familial	JJ	B_Disease	B_Disease
neurohypophyseal	NN	I_Disease	I_Disease
diabetes	NNS	I_Disease	I_Disease
insipidus	VBP	E_Disease	E_Disease
(	(	O	O
FNDI	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
deficiency	NN	O	B_Disease
in	IN	O	O
the	DT	O	O
antidiuretic	JJ	O	O
hormone	NN	O	I_Disease
arginine	NN	O	I_Disease
vasopressin	NN	O	E_Disease
(	(	O	O
AVP	NNP	O	O
)	)	O	O
encoded	VBN	O	O
by	IN	O	O
the	DT	O	O
AVP	NNP	O	O
-	:	O	O
neurophysin	NN	O	O
II	NNP	O	O
(	(	O	O
AVP	NNP	O	O
-	:	O	O
NPII	NN	O	O
)	)	O	O
gene	NN	O	O
on	IN	O	O
chromosome	NN	O	O
20p13	CD	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
analyzed	VBD	O	O
two	CD	O	O
families	NNS	O	O
with	IN	O	O
FNDI	NNP	S_Disease	S_Disease
using	VBG	O	O
direct	JJ	O	O
automated	VBN	O	O
fluorescent	NN	O	O
,	,	O	O
solid	JJ	O	O
phase	NN	O	O
,	,	O	O
single	JJ	O	O
-	:	O	O
stranded	VBD	O	O
DNA	NNP	O	O
sequencing	NN	O	O
of	IN	O	O
PCR	NNP	O	O
-	:	O	O
amplified	VBD	O	O
AVP	NNP	O	O
-	:	O	O
NPII	NNP	O	O
DNA	NNP	O	O
.	.	O	O

In	IN	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
families	NNS	O	O
,	,	O	O
affected	JJ	O	O
individuals	NNS	O	O
presented	VBD	O	O
a	DT	O	O
novel	JJ	O	O
nonsense	JJ	O	O
mutation	NN	O	O
in	IN	O	O
exon	JJ	O	O
3	CD	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
,	,	O	O
consisting	VBG	O	O
in	IN	O	O
a	DT	O	O
G	NNP	O	O
to	TO	O	O
T	VB	O	O
transition	NN	O	O
at	IN	O	O
nucleotide	JJ	O	O
2101	CD	O	O
,	,	O	O
which	WDT	O	O
produces	VBZ	O	O
a	DT	O	O
stop	JJ	O	O
signal	NN	O	O
in	IN	O	O
codon	NN	O	O
82	CD	O	O
(	(	O	O
Glu	NNP	O	O
)	)	O	O
of	IN	O	O
NPII	NNP	O	O
.	.	O	O

The	DT	O	O
premature	NN	O	O
termination	NN	O	O
eliminates	VBZ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
C	NNP	O	O
-	:	O	O
terminal	JJ	O	O
domain	NN	O	O
of	IN	O	O
NPII	NNP	O	O
,	,	O	O
including	VBG	O	O
a	DT	O	O
cysteine	NN	O	O
residue	NN	O	O
in	IN	O	O
position	NN	O	O
85	CD	O	O
,	,	O	O
which	WDT	O	O
could	MD	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
correct	JJ	O	O
folding	NN	O	O
of	IN	O	O
the	DT	O	O
prohormone	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
second	JJ	O	O
family	NN	O	O
,	,	O	O
a	DT	O	O
G279A	NNP	O	O
substitution	NN	O	O
at	IN	O	O
position	NN	O	O
-	:	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
signal	JJ	O	O
peptide	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
all	DT	O	O
affected	JJ	O	O
individuals	NNS	O	O
.	.	O	O

This	DT	O	O
missense	NN	O	O
mutation	NN	O	O
,	,	O	O
which	WDT	O	O
replaces	VBZ	O	O
Ala	NNP	O	O
with	IN	O	O
Thr	NNP	O	O
,	,	O	O
is	VBZ	O	O
frequent	JJ	O	O
among	IN	O	O
FNDI	JJ	S_Disease	S_Disease
patients	NNS	O	O
and	CC	O	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
reduce	VB	O	O
the	DT	O	O
efficiency	NN	O	O
of	IN	O	O
cleavage	NN	O	O
by	IN	O	O
signal	JJ	O	O
peptidases	NNS	O	O
.	.	O	O
.	.	O	O

9585583	CD	O	O

Genetic	JJ	O	O
heterogeneity	NN	O	O
of	IN	O	O
Saethre	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Chotzen	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
,	,	O	O
due	JJ	O	O
to	TO	O	O
TWIST	NNP	O	O
and	CC	O	O
FGFR	NNP	O	O
mutations	NNS	O	O
.	.	O	O

Thirty	SYM	O	O
-	:	O	O
two	CD	O	O
unrelated	JJ	O	O
patients	NNS	O	O
with	IN	O	O
features	NNS	O	O
of	IN	O	O
Saethre	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Chotzen	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
,	,	O	O
a	DT	O	O
common	JJ	O	O
autosomal	JJ	B_Disease	O
dominant	JJ	I_Disease	O
condition	NN	E_Disease	O
of	IN	O	O
craniosynostosis	NN	S_Disease	S_Disease
and	CC	O	O
limb	NN	B_Disease	B_Disease
anomalies	NNS	E_Disease	E_Disease
,	,	O	O
were	VBD	O	O
screened	VBN	O	O
for	IN	O	O
mutations	NNS	O	O
in	IN	O	O
TWIST	NNP	O	O
,	,	O	O
FGFR2	NNP	O	O
,	,	O	O
and	CC	O	O
FGFR3	NNP	O	O
.	.	O	O

Nine	NNP	O	O
novel	NN	O	O
and	CC	O	O
three	CD	O	O
recurrent	NN	O	O
TWIST	NNP	O	O
mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
12	CD	O	O
families	NNS	O	O
.	.	O	O

Seven	JJ	O	O
families	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
the	DT	O	O
FGFR3	NNP	O	O
P250R	NNP	O	O
mutation	NN	O	O
,	,	O	O
and	CC	O	O
one	CD	O	O
individual	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
FGFR2	NNP	O	O
VV269	NNP	O	O
-	:	O	O
270	CD	O	O
deletion	NN	O	O
.	.	O	O

To	TO	O	O
date	NN	O	O
,	,	O	O
our	PRP$	O	O
detection	NN	O	O
rate	NN	O	O
for	IN	O	O
TWIST	NNP	O	O
or	CC	O	O
FGFR	NNP	O	O
mutations	NNS	O	O
is	VBZ	O	O
68	CD	O	O
%	NN	O	O
in	IN	O	O
our	PRP$	O	O
Saethre	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Chotzen	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
patients	NNS	O	O
,	,	O	O
including	VBG	O	O
our	PRP$	O	O
five	CD	O	O
patients	NNS	O	O
elsewhere	RB	O	O
reported	VBN	O	O
with	IN	O	O
TWIST	NNP	O	O
mutations	NNS	O	O
.	.	O	O

More	JJR	O	O
than	IN	O	O
35	CD	O	O
different	JJ	O	O
TWIST	NNP	O	O
mutations	NNS	O	O
are	VBP	O	O
now	RB	O	O
known	VBN	O	O
in	IN	O	O
the	DT	O	O
literature	NN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
common	JJ	O	O
phenotypic	NN	O	O
features	NNS	O	O
,	,	O	O
present	JJ	O	O
in	IN	O	O
more	JJR	O	O
than	IN	O	O
a	DT	O	O
third	JJ	O	O
of	IN	O	O
our	PRP$	O	O
patients	NNS	O	O
with	IN	O	O
TWIST	NNP	O	O
mutations	NNS	O	O
,	,	O	O
are	VBP	O	O
coronal	JJ	B_Disease	O
synostosis	NN	E_Disease	O
,	,	O	O
brachycephaly	NN	S_Disease	O
,	,	O	O
low	JJ	B_Disease	O
frontal	JJ	I_Disease	O
hairline	NN	E_Disease	O
,	,	O	O
facial	JJ	B_Disease	O
asymmetry	NN	E_Disease	O
,	,	O	O
ptosis	NN	S_Disease	O
,	,	O	O
hypertelorism	NN	S_Disease	S_Disease
,	,	O	O
broad	JJ	B_Disease	O
great	JJ	I_Disease	O
toes	NNS	E_Disease	O
,	,	O	O
and	CC	O	O
clinodactyly	NN	S_Disease	O
.	.	O	O

Significant	JJ	O	O
intra	JJ	O	O
-	:	O	O
and	CC	O	O
interfamilial	JJ	O	O
phenotypic	NN	O	O
variability	NN	O	O
is	VBZ	O	O
present	JJ	O	O
for	IN	O	O
either	DT	O	O
TWIST	NNP	O	O
mutations	NNS	O	O
or	CC	O	O
FGFR	NNP	O	O
mutations	NNS	O	O
.	.	O	O

The	DT	O	O
overlap	NN	O	O
in	IN	O	O
clinical	JJ	O	O
features	NNS	O	O
and	CC	O	O
the	DT	O	O
presence	NN	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
genes	NNS	O	O
,	,	O	O
of	IN	O	O
mutations	NNS	O	O
for	IN	O	O
more	JJR	O	O
than	IN	O	O
one	CD	O	O
craniosynostotic	JJ	B_Disease	O
condition	NN	E_Disease	O
-	:	O	O
such	JJ	O	O
as	IN	O	O
Saethre	NNP	B_Disease	O
-	:	I_Disease	O
Chotzen	NNP	I_Disease	O
,	,	I_Disease	O
Crouzon	NNP	I_Disease	O
,	,	I_Disease	O
and	CC	I_Disease	O
Pfeiffer	NNP	I_Disease	O
syndromes	VBZ	E_Disease	O
-	:	O	O
support	NN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
TWIST	NNP	O	O
and	CC	O	O
FGFRs	NNP	O	O
are	VBP	O	O
components	NNS	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
molecular	JJ	O	O
pathway	NN	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
modulation	NN	O	O
of	IN	O	O
craniofacial	JJ	O	B_Disease
and	CC	O	I_Disease
limb	JJ	O	O
development	NN	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O
.	.	O	O

9585605	CD	O	O

Mutation	NNP	O	O
analysis	NN	O	O
of	IN	O	O
UBE3A	NNP	O	O
in	IN	O	O
Angelman	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
patients	NNS	O	O
.	.	O	O

Angelman	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
AS	IN	S_Disease	O
)	)	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
chromosome	NN	O	O
15q11	CD	O	O
-	:	O	O
q13	NN	O	O
deletions	NNS	O	O
of	IN	O	O
maternal	JJ	O	O
origin	NN	O	O
,	,	O	O
by	IN	O	O
paternal	JJ	O	O
uniparental	JJ	B_Disease	B_Disease
disomy	NN	E_Disease	E_Disease
(	(	O	O
UPD	NNP	S_Disease	S_Disease
)	)	O	O
15	CD	O	O
,	,	O	O
by	IN	O	O
imprinting	VBG	O	O
defects	NNS	O	O
,	,	O	O
and	CC	O	O
by	IN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
UBE3A	NNP	O	O
gene	NN	O	O
.	.	O	O

UBE3A	NNP	O	O
encodes	VBZ	O	O
a	DT	O	O
ubiquitin	JJ	O	O
-	:	O	O
protein	NN	O	O
ligase	NN	O	O
and	CC	O	O
shows	VBZ	O	O
brain	NN	O	O
-	:	O	O
specific	JJ	O	O
imprinting	NN	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
describe	VBP	O	O
UBE3A	NNP	O	O
coding	VBG	O	O
-	:	O	O
region	NN	O	O
mutations	NNS	O	O
detected	VBN	O	O
by	IN	O	O
SSCP	NNP	O	O
analysis	NN	O	O
in	IN	O	O
13	CD	O	O
AS	IN	S_Disease	O
individuals	NNS	O	O
or	CC	O	O
families	NNS	O	O
.	.	O	O

Two	CD	O	O
identical	JJ	O	O
de	FW	O	O
novo	FW	O	O
5	CD	O	O
-	:	O	O
bp	NN	O	O
duplications	NNS	O	O
in	IN	O	O
exon	JJ	O	O
16	CD	O	O
were	VBD	O	O
found	VBN	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
other	JJ	O	O
11	CD	O	O
unique	JJ	O	O
mutations	NNS	O	O
,	,	O	O
8	CD	O	O
were	VBD	O	O
small	JJ	O	O
deletions	NNS	O	O
or	CC	O	O
insertions	NNS	O	O
predicted	VBN	O	O
to	TO	O	O
cause	VB	O	O
frameshifts	NNS	O	O
,	,	O	O
1	CD	O	O
was	VBD	O	O
a	DT	O	O
mutation	NN	O	O
to	TO	O	O
a	DT	O	O
stop	NN	O	O
codon	NN	O	O
,	,	O	O
1	CD	O	O
was	VBD	O	O
a	DT	O	O
missense	JJ	O	O
mutation	NN	O	O
,	,	O	O
and	CC	O	O
1	CD	O	O
was	VBD	O	O
predicted	VBN	O	O
to	TO	O	O
cause	VB	O	O
insertion	NN	O	O
of	IN	O	O
an	DT	O	O
isoleucine	NN	O	O
in	IN	O	O
the	DT	O	O
hect	NN	O	O
domain	NN	O	O
of	IN	O	O
the	DT	O	O
UBE3A	NNP	O	O
protein	NN	O	O
,	,	O	O
which	WDT	O	O
functions	NNS	O	O
in	IN	O	O
E2	NNP	O	O
binding	NN	O	O
and	CC	O	O
ubiquitin	JJ	O	O
transfer	NN	O	O
.	.	O	O

Eight	CD	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
were	VBD	O	O
familial	JJ	O	O
,	,	O	O
and	CC	O	O
five	CD	O	O
were	VBD	O	O
sporadic	NNS	O	O
.	.	O	O

In	IN	O	O
two	CD	O	O
familial	JJ	O	O
cases	NNS	O	O
and	CC	O	O
one	CD	O	O
sporadic	JJ	O	O
case	NN	O	O
,	,	O	O
mosaicism	NN	O	O
for	IN	O	O
UBE3A	NNP	O	O
mutations	NNS	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
the	DT	O	O
mother	NN	O	O
of	IN	O	O
three	CD	O	O
AS	IN	S_Disease	O
sons	NNS	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
maternal	JJ	O	O
grandfather	NN	O	O
of	IN	O	O
two	CD	O	O
AS	IN	S_Disease	O
first	JJ	O	O
cousins	NNS	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
mother	NN	O	O
of	IN	O	O
an	DT	O	O
AS	NNP	S_Disease	S_Disease
daughter	NN	O	O
.	.	O	O

The	DT	O	O
frequencies	NNS	O	O
with	IN	O	O
which	WDT	O	O
we	PRP	O	O
detected	VBD	O	O
mutations	NNS	O	O
were	VBD	O	O
5	CD	O	O
(	(	O	O
14	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
35	CD	O	O
in	IN	O	O
sporadic	JJ	O	O
cases	NNS	O	O
and	CC	O	O
8	CD	O	O
(	(	O	O
80	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
10	CD	O	O
in	IN	O	O
familial	JJ	O	O
cases	NNS	O	O
.	.	O	O
.	.	O	O

9585606	CD	O	O

The	DT	O	O
hemochromatosis	NN	S_Disease	S_Disease
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
and	CC	O	O
187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
mutations	NNS	O	O
:	:	O	O
prevalence	NN	O	O
in	IN	O	O
non	JJ	O	O
-	:	O	O
Caucasian	JJ	O	O
populations	NNS	O	O
.	.	O	O

Hemochromatosis	NN	S_Disease	O
,	,	O	O
the	DT	O	O
inherited	JJ	B_Disease	B_Disease
disorder	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
iron	NN	I_Disease	I_Disease
metabolism	NN	E_Disease	E_Disease
,	,	O	O
leads	VBZ	O	O
,	,	O	O
if	IN	O	O
untreated	VBN	O	O
,	,	O	O
to	TO	O	O
progressive	VB	O	O
iron	NN	B_Disease	B_Disease
overload	NN	E_Disease	E_Disease
and	CC	O	O
premature	JJ	B_Disease	B_Disease
death	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
hemochromatosis	NN	S_Disease	S_Disease
gene	NN	O	O
,	,	O	O
HFE	NNP	O	O
,	,	O	O
recently	RB	O	O
has	VBZ	O	O
been	VBN	O	O
identified	VBN	O	O
,	,	O	O
and	CC	O	O
characterization	NN	O	O
of	IN	O	O
this	DT	O	O
gene	NN	O	O
has	VBZ	O	O
shown	VBN	O	O
that	IN	O	O
it	PRP	O	O
contains	VBZ	O	O
two	CD	O	O
mutations	NNS	O	O
that	WDT	O	O
result	VBP	O	O
in	IN	O	O
amino	NN	O	O
acid	NN	O	O
substitutions	NNS	O	O
-	:	O	O
cDNA	NN	O	O
nucleotides	VBZ	O	O
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	NNP	O	O
(	(	O	O
C282Y	NNP	O	O
)	)	O	O
and	CC	O	O
187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
(	(	O	O
H63D	NNP	O	O
)	)	O	O
.	.	O	O

Although	IN	O	O
hemochromatosis	NN	S_Disease	S_Disease
is	VBZ	O	O
common	JJ	O	O
in	IN	O	O
Caucasians	NNPS	O	O
,	,	O	O
affecting	VBG	O	O
>	JJ	O	O
=	$	O	O
1	CD	O	O
/	$	O	O
300	CD	O	O
individuals	NNS	O	O
of	IN	O	O
northern	JJ	O	O
European	JJ	O	O
origin	NN	O	O
,	,	O	O
it	PRP	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
recognized	VBN	O	O
in	IN	O	O
other	JJ	O	O
populations	NNS	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
used	VBN	O	O
PCR	NNP	O	O
and	CC	O	O
restriction	NN	O	O
-	:	O	O
enzyme	NN	O	O
digestion	NN	O	O
to	TO	O	O
analyze	VB	O	O
the	DT	O	O
frequency	NN	O	O
of	IN	O	O
the	DT	O	O
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
and	CC	O	O
187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
HLA	NNP	O	O
-	:	O	O
typed	VBD	O	O
samples	NNS	O	O
from	IN	O	O
non	JJ	O	O
-	:	O	O
Caucasian	JJ	O	O
populations	NNS	O	O
,	,	O	O
comprising	VBG	O	O
Australian	JJ	O	O
Aboriginal	NNP	O	O
,	,	O	O
Chinese	NNP	O	O
,	,	O	O
and	CC	O	O
Pacific	NNP	O	O
Islanders	NNP	O	O
.	.	O	O

Results	NNS	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
mutation	NN	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
these	DT	O	O
populations	NNS	O	O
(	(	O	O
allele	JJ	O	O
frequency	NN	O	O
0	CD	O	O
.	.	O	O

32	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
,	,	O	O
furthermore	RB	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
always	RB	O	O
seen	VBN	O	O
in	IN	O	O
conjunction	NN	O	O
with	IN	O	O
HLA	NNP	O	O
haplotypes	NNS	O	O
common	JJ	O	O
in	IN	O	O
Caucasians	NNPS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
may	MD	O	O
have	VB	O	O
been	VBN	O	O
introduced	VBN	O	O
into	IN	O	O
these	DT	O	O
populations	NNS	O	O
by	IN	O	O
Caucasian	JJ	O	O
admixture	NN	O	O
.	.	O	O

187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
was	VBD	O	O
present	JJ	O	O
at	IN	O	O
an	DT	O	O
allele	JJ	O	O
frequency	NN	O	O
of	IN	O	O
2	CD	O	O
.	.	O	O

68	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
populations	NNS	O	O
analyzed	VBN	O	O
(	(	O	O
Australian	JJ	O	O
Aboriginal	NNP	O	O
and	CC	O	O
Chinese	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
Australian	JJ	O	O
Aboriginal	NNP	O	O
samples	NNS	O	O
,	,	O	O
187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
associated	VBN	O	O
with	IN	O	O
HLA	NNP	O	O
haplotypes	NNS	O	O
common	JJ	O	O
in	IN	O	O
Caucasians	NNPS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
it	PRP	O	O
was	VBD	O	O
introduced	VBN	O	O
by	IN	O	O
recent	JJ	O	O
admixture	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
Chinese	JJ	O	O
samples	NNS	O	O
analyzed	VBN	O	O
,	,	O	O
187	CD	O	O
C	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
G	NNP	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
a	DT	O	O
wide	JJ	O	O
variety	NN	O	O
of	IN	O	O
HLA	NNP	O	O
haplotypes	NNS	O	O
,	,	O	O
showing	VBG	O	O
this	DT	O	O
mutation	NN	O	O
to	TO	O	O
be	VB	O	O
widespread	JJ	O	O
and	CC	O	O
likely	JJ	O	O
to	TO	O	O
predate	VB	O	O
the	DT	O	O
more	RBR	O	O
genetically	RB	O	O
restricted	VBN	O	O
845	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
mutation	NN	O	O
.	.	O	O

9585611	CD	O	O

Genotype	NNP	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
in	IN	O	O
attenuated	JJ	B_Disease	O
adenomatous	JJ	I_Disease	B_Disease
polyposis	NN	I_Disease	I_Disease
coli	NN	E_Disease	E_Disease
.	.	O	O

Germ	NNP	O	O
-	:	O	O
line	NN	O	O
mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
APC	NNP	O	S_Disease
are	VBP	O	O
implicated	VBN	O	O
in	IN	O	O
attenuated	JJ	B_Disease	O
adenomatous	JJ	I_Disease	B_Disease
polyposis	NN	I_Disease	I_Disease
coli	NN	E_Disease	E_Disease
(	(	O	O
AAPC	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
a	DT	O	O
variant	NN	O	O
of	IN	O	O
familial	JJ	B_Disease	B_Disease
adenomatous	JJ	I_Disease	I_Disease
polyposis	NN	E_Disease	E_Disease
(	(	O	O
FAP	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

AAPC	NNP	S_Disease	O
is	VBZ	O	O
recognized	VBN	O	O
by	IN	O	O
the	DT	O	O
occurrence	NN	O	O
of	IN	O	O
<	$	O	O
100	CD	O	O
colonic	JJ	B_Disease	B_Disease
adenomas	NN	E_Disease	E_Disease
and	CC	O	O
a	DT	O	O
later	JJ	O	O
onset	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
(	(	O	O
age	NN	O	O
>	VBZ	O	O
40	CD	O	O
years	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
genotype	JJ	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
in	IN	O	O
AAPC	NNP	S_Disease	S_Disease
families	NNS	O	O
.	.	O	O

By	IN	O	O
protein	SYM	O	O
-	:	O	O
truncation	NN	O	O
test	NN	O	O
(	(	O	O
PTT	NNP	O	O
)	)	O	O
assay	VBP	O	O
,	,	O	O
the	DT	O	O
entire	JJ	O	O
coding	NN	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
was	VBD	O	O
screened	VBN	O	O
in	IN	O	O
affected	JJ	O	O
individuals	NNS	O	O
from	IN	O	O
11	CD	O	O
AAPC	NNP	S_Disease	S_Disease
kindreds	NNS	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
phenotypic	NN	O	O
differences	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
.	.	O	O

Five	CD	O	O
novel	JJ	O	O
germ	NN	O	O
-	:	O	O
line	NN	O	O
APC	NNP	S_Disease	S_Disease
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
seven	CD	O	O
kindreds	NNS	O	O
.	.	O	O

Mutations	NNS	O	O
were	VBD	O	O
located	VBN	O	O
in	IN	O	O
three	CD	O	O
different	JJ	O	O
regions	NNS	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
at	IN	O	O
the	DT	O	O
5	CD	O	O
end	NN	O	O
spanning	VBG	O	O
exons	NNS	O	O
4	CD	O	O
and	CC	O	O
5	CD	O	O
,	,	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
within	IN	O	O
exon	$	O	O
9	CD	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
at	IN	O	O
the	DT	O	O
3	CD	O	O
distal	JJ	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
.	.	O	O

Variability	NN	O	O
in	IN	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
adenomas	NN	E_Disease	E_Disease
was	VBD	O	O
most	RBS	O	O
apparent	JJ	O	O
in	IN	O	O
individuals	NNS	O	O
with	IN	O	O
mutations	NNS	O	O
in	IN	O	O
region	NN	O	O
1	CD	O	O
,	,	O	O
and	CC	O	O
upper	JJ	O	O
-	:	O	O
gastrointestinal	JJ	O	O
manifestations	NNS	O	O
were	VBD	O	O
more	RBR	O	O
severe	JJ	O	O
in	IN	O	O
them	PRP	O	O
.	.	O	O

In	IN	O	O
individuals	NNS	O	O
with	IN	O	O
mutations	NNS	O	O
in	IN	O	O
either	DT	O	O
region	NN	O	O
2	CD	O	O
or	CC	O	O
region	NN	O	O
3	CD	O	O
,	,	O	O
the	DT	O	O
average	JJ	O	O
number	NN	O	O
of	IN	O	O
adenomas	NN	S_Disease	S_Disease
tended	VBN	O	O
to	TO	O	O
be	VB	O	O
lower	JJR	O	O
than	IN	O	O
those	DT	O	O
in	IN	O	O
individuals	NNS	O	O
with	IN	O	O
mutations	NNS	O	O
in	IN	O	O
region	NN	O	O
1	CD	O	O
,	,	O	O
although	IN	O	O
age	NN	O	O
at	IN	O	O
diagnosis	NN	O	O
was	VBD	O	O
similar	JJ	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
AAPC	NNP	S_Disease	S_Disease
kindreds	NNS	O	O
,	,	O	O
a	DT	O	O
predominance	NN	O	O
of	IN	O	O
right	JJ	O	O
-	:	O	I_Disease
sided	VBD	O	I_Disease
colorectal	JJ	B_Disease	I_Disease
adenomas	NN	E_Disease	E_Disease
and	CC	O	O
rectal	JJ	B_Disease	O
polyp	NN	E_Disease	O
sparing	NN	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

No	DT	O	O
desmoid	JJ	B_Disease	B_Disease
tumors	NNS	E_Disease	E_Disease
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
these	DT	O	O
kindreds	NNS	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
,	,	O	O
in	IN	O	O
AAPC	NNP	S_Disease	S_Disease
families	NNS	O	O
,	,	O	O
the	DT	O	O
location	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
mutation	NN	O	O
may	MD	O	O
partially	RB	O	O
predict	VB	O	O
specific	JJ	O	O
phenotypic	NN	O	O
expression	NN	O	O
.	.	O	O

This	DT	O	O
should	MD	O	O
help	VB	O	O
in	IN	O	O
the	DT	O	O
design	NN	O	O
of	IN	O	O
tailored	JJ	O	O
clinical	JJ	O	O
-	:	O	O
management	NN	O	O
protocols	NNS	O	O
in	IN	O	O
this	DT	O	O
subset	NN	O	O
of	IN	O	O
FAP	NNP	S_Disease	S_Disease
patients	NNS	O	O
.	.	O	O
.	.	O	O

9590178	CD	O	O

Wilms	NNP	B_Disease	B_Disease
'	POS	I_Disease	I_Disease
tumor	NN	E_Disease	E_Disease
1	CD	O	O
and	CC	O	O
Dax	NNP	O	O
-	:	O	O
1	CD	O	O
modulate	NN	O	O
the	DT	O	O
orphan	JJ	O	O
nuclear	JJ	O	O
receptor	NN	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
in	IN	O	O
sex	NN	O	O
-	:	O	O
specific	JJ	O	O
gene	NN	O	O
expression	NN	O	O
.	.	O	O

Products	NNS	O	O
of	IN	O	O
steroidogenic	JJ	O	O
factor	NN	O	O
1	CD	O	O
(	(	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
)	)	O	O
and	CC	O	O
Wilms	NNP	B_Disease	B_Disease
tumor	NN	E_Disease	E_Disease
1	CD	O	O
(	(	O	O
WT1	NNP	O	O
)	)	O	O
genes	NNS	O	O
are	VBP	O	O
essential	JJ	O	O
for	IN	O	O
mammalian	JJ	O	O
gonadogenesis	NN	O	O
prior	RB	O	O
to	TO	O	O
sexual	JJ	O	O
differentiation	NN	O	O
.	.	O	O

In	IN	O	O
males	NNS	O	O
,	,	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
participates	NNS	O	O
in	IN	O	O
sexual	JJ	O	O
development	NN	O	O
by	IN	O	O
regulating	VBG	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
polypeptide	NN	O	O
hormone	NN	O	O
Mullerian	JJ	O	O
inhibiting	NN	O	O
substance	NN	O	O
(	(	O	O
MIS	NNP	O	O
)	)	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
WT1	NNP	O	O
-	:	O	O
KTS	NNP	O	O
isoforms	NNS	O	O
associate	VBP	O	O
and	CC	O	O
synergize	VBP	O	O
with	IN	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
to	TO	O	O
promote	VB	O	O
MIS	NNP	O	O
expression	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
WT1	NNP	O	O
missense	NN	O	O
mutations	NNS	O	O
,	,	O	O
associated	VBN	O	O
with	IN	O	O
male	JJ	B_Disease	B_Disease
pseudohermaphroditism	NN	E_Disease	E_Disease
in	IN	O	O
Denys	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Drash	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
,	,	O	O
fail	VBP	O	O
to	TO	O	O
synergize	VB	O	O
with	IN	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
the	DT	O	O
X	NNP	O	O
-	:	O	O
linked	VBN	O	O
,	,	O	O
candidate	JJ	O	O
dosage	NN	O	O
-	:	O	O
sensitive	JJ	O	O
sex	NN	O	O
-	:	O	O
reversal	NN	O	O
gene	NN	O	O
,	,	O	O
Dax	NNP	O	O
-	:	O	O
1	CD	O	O
,	,	O	O
antagonizes	VBZ	O	O
synergy	NN	O	O
between	IN	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
and	CC	O	O
WT1	NNP	O	O
,	,	O	O
most	JJS	O	O
likely	RB	O	O
through	IN	O	O
a	DT	O	O
direct	JJ	O	O
interaction	NN	O	O
with	IN	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
.	.	O	O

We	PRP	O	O
propose	VBP	O	O
that	IN	O	O
WT1	NNP	O	O
and	CC	O	O
Dax	NNP	O	O
-	:	O	O
1	CD	O	O
functionally	RB	O	O
oppose	VBP	O	O
each	DT	O	O
other	JJ	O	O
in	IN	O	O
testis	NN	O	O
development	NN	O	O
by	IN	O	O
modulating	VBG	O	O
SF	NNP	O	O
-	:	O	O
1	CD	O	O
-	:	O	O
mediated	VBN	O	O
transactivation	NN	O	O
.	.	O	O
.	.	O	O

9590284	CD	O	O

A	DT	O	O
mouse	NN	O	O
model	NN	O	O
for	IN	O	O
Prader	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Willi	NNP	I_Disease	I_Disease
syndrome	VBP	E_Disease	E_Disease
imprinting	VBG	O	O
-	:	O	O
centre	NN	O	O
mutations	NNS	O	O
.	.	O	O

Imprinting	VBG	O	O
in	IN	O	O
the	DT	O	O
15q11	CD	O	O
-	:	O	O
q13	JJ	O	O
region	NN	O	O
involves	VBZ	O	O
an	DT	O	O
imprinting	NN	O	O
centre	NN	O	O
(	(	O	O
IC	NNP	O	O
)	)	O	O
,	,	O	O
mapping	VBG	O	O
in	IN	O	O
part	NN	O	O
to	TO	O	O
the	DT	O	O
promoter	NN	O	O
and	CC	O	O
first	JJ	O	O
exon	NN	O	O
of	IN	O	O
SNRPN	NNP	O	O
.	.	O	O

Deletion	NN	O	O
of	IN	O	O
this	DT	O	O
IC	NNP	O	O
abolishes	VBZ	O	O
local	JJ	O	O
paternally	RB	O	O
derived	VBN	O	O
gene	NN	O	O
expression	NN	O	O
and	CC	O	O
results	NNS	O	O
in	IN	O	O
Prader	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Willi	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
PWS	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
created	VBN	O	O
two	CD	O	O
deletion	NN	O	O
mutations	NNS	O	O
in	IN	O	O
mice	NN	O	O
to	TO	O	O
understand	VB	O	O
PWS	NNP	S_Disease	S_Disease
and	CC	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
this	DT	O	O
IC	NNP	O	O
.	.	O	O

Mice	NNP	O	O
harbouring	VBG	O	O
an	DT	O	O
intragenic	JJ	O	O
deletion	NN	O	O
in	IN	O	O
Snrpn	NNP	O	O
are	VBP	O	O
phenotypically	RB	O	O
normal	JJ	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
mutations	NNS	O	O
of	IN	O	O
SNRPN	NNP	O	O
are	VBP	O	O
not	RB	O	O
sufficient	JJ	O	O
to	TO	O	O
induce	VB	O	O
PWS	NNP	S_Disease	S_Disease
.	.	O	O

Mice	NNP	O	O
with	IN	O	O
a	DT	O	O
larger	JJR	O	O
deletion	NN	O	O
involving	VBG	O	O
both	DT	O	O
Snrpn	NNP	O	O
and	CC	O	O
the	DT	O	O
putative	JJ	O	O
PWS	NNP	O	S_Disease
-	:	O	O
IC	NNP	O	O
lack	VBP	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
imprinted	JJ	O	O
genes	NNS	O	O
Zfp127	NNP	O	O
(	(	O	O
mouse	IN	O	O
homologue	NN	O	O
of	IN	O	O
ZNF127	NNP	O	O
)	)	O	O
,	,	O	O
Ndn	NNP	O	O
and	CC	O	O
Ipw	NNP	O	O
,	,	O	O
and	CC	O	O
manifest	JJS	O	O
several	JJ	O	O
phenotypes	NNS	O	O
common	JJ	O	O
to	TO	O	O
PWS	NNP	S_Disease	S_Disease
infants	NNS	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
demonstrate	NN	O	O
that	IN	O	O
both	CC	O	O
the	DT	O	O
position	NN	O	O
of	IN	O	O
the	DT	O	O
IC	NNP	O	O
and	CC	O	O
its	PRP$	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
coordinate	JJ	O	O
expression	NN	O	O
of	IN	O	O
genes	NNS	O	O
is	VBZ	O	O
conserved	VBN	O	O
between	IN	O	O
mouse	NN	O	O
and	CC	O	O
human	NN	O	O
,	,	O	O
and	CC	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
mouse	NN	O	O
is	VBZ	O	O
a	DT	O	O
suitable	JJ	O	O
model	NN	O	O
system	NN	O	O
in	IN	O	O
which	WDT	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
molecular	JJ	O	O
mechanisms	NN	O	O
of	IN	O	O
imprinting	VBG	O	O
in	IN	O	O
this	DT	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
genome	NN	O	O
.	.	O	O
.	.	O	O

9600235	CD	O	O

Mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
ATM	NNP	O	O
gene	NN	O	O
detected	VBD	O	O
in	IN	O	O
Japanese	JJ	O	O
ataxia	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
patients	NNS	O	O
:	:	O	O
possible	JJ	O	O
preponderance	NN	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
founder	NN	O	O
mutations	NNS	O	O
4612del165	CD	O	O
and	CC	O	O
7883del5	CD	O	O
.	.	O	O

The	DT	O	O
ATM	NNP	O	O
(	(	O	O
A	NNP	O	B_Disease
-	:	O	I_Disease
T	NN	O	E_Disease
,	,	O	O
mutated	VBN	O	O
)	)	O	O
gene	NN	O	O
on	IN	O	O
human	JJ	O	O
chromosome	NN	O	O
11q22	CD	O	O
.	.	O	O

3	CD	O	O
has	VBZ	O	O
recently	RB	O	O
been	VBN	O	O
identified	VBN	O	O
as	IN	O	O
the	DT	O	O
gene	NN	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
human	JJ	O	O
recessive	JJ	B_Disease	O
disease	NN	E_Disease	O
ataxia	SYM	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
types	NNS	O	O
of	IN	O	O
disease	NN	O	O
-	:	O	O
causing	NN	O	O
ATM	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
Japanese	JJ	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
to	TO	O	O
look	VB	O	O
for	IN	O	O
possible	JJ	O	O
mutational	JJ	O	O
hotspots	NNS	O	O
,	,	O	O
reverse	VB	O	O
-	:	O	O
transcribed	NN	O	O
RNA	NNP	O	O
derived	VBD	O	O
from	IN	O	O
ten	JJ	O	O
patients	NNS	O	O
belonging	VBG	O	O
to	TO	O	O
eight	CD	O	O
unrelated	JJ	O	O
Japanese	PDT	O	O
A	DT	B_Disease	O
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
families	NNS	O	O
was	VBD	O	O
analyzed	VBN	O	O
for	IN	O	O
mutations	NNS	O	O
by	IN	O	O
the	DT	O	O
restriction	NN	O	O
endonuclease	NN	O	O
fingerprinting	VBG	O	O
method	NN	O	O
.	.	O	O

As	IN	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
by	IN	O	O
others	NNS	O	O
,	,	O	O
mutations	NNS	O	O
that	WDT	O	O
lead	VBP	O	O
to	TO	O	O
exon	VB	O	O
skipping	VBG	O	O
or	CC	O	O
premature	JJ	O	O
protein	JJ	O	O
truncation	NN	O	O
were	VBD	O	O
also	RB	O	O
predominant	JJ	O	O
in	IN	O	O
our	PRP$	O	O
mutants	NNS	O	O
.	.	O	O

Six	CD	O	O
different	JJ	O	O
mutations	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
on	IN	O	O
12	CD	O	O
of	IN	O	O
the	DT	O	O
16	CD	O	O
alleles	NNS	O	O
examined	VBN	O	O
.	.	O	O

Four	CD	O	O
were	VBD	O	O
deletions	NNS	O	O
involving	VBG	O	O
a	DT	O	O
loss	NN	O	O
of	IN	O	O
a	DT	O	O
single	JJ	O	O
exon	NN	O	O
exon	VBD	O	O
7	CD	O	O
,	,	O	O
exon	RB	O	O
16	CD	O	O
,	,	O	O
exon	VBZ	O	O
33	CD	O	O
or	CC	O	O
exon	VB	O	O
35	CD	O	O
.	.	O	O

The	DT	O	O
others	NNS	O	O
were	VBD	O	O
minute	JJ	O	O
deletions	NNS	O	O
,	,	O	O
4649delA	CD	O	O
in	IN	O	O
exon	JJ	O	O
33	CD	O	O
and	CC	O	O
7883del5	CD	O	O
in	IN	O	O
exon	JJ	O	O
55	CD	O	O
.	.	O	O

The	DT	O	O
mutations	NNS	O	O
4612del165	CD	O	O
and	CC	O	O
7883del5	CD	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
more	JJR	O	O
than	IN	O	O
two	CD	O	O
unrelated	JJ	O	O
families	NNS	O	O
;	:	O	O
44	CD	O	O
%	NN	O	O
(	(	O	O
7	CD	O	O
of	IN	O	O
16	CD	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
mutant	JJ	O	O
alleles	NNS	O	O
had	VBD	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
mutations	NNS	O	O
.	.	O	O

The	DT	O	O
4612del165	CD	O	O
mutations	NNS	O	O
in	IN	O	O
three	CD	O	O
different	JJ	O	O
families	NNS	O	O
were	VBD	O	O
all	DT	O	O
ascribed	VBN	O	O
to	TO	O	O
the	DT	O	O
same	JJ	O	O
T	NNP	O	O
-	:	O	O
-	:	O	O
>	VB	O	O
A	DT	O	O
substitution	NN	O	O
at	IN	O	O
the	DT	O	O
splice	NN	O	O
donor	NN	O	O
site	NN	O	O
in	IN	O	O
intron	NN	O	O
33	CD	O	O
.	.	O	O

Microsatellite	NNP	O	O
genotyping	VBG	O	O
around	IN	O	O
the	DT	O	O
ATM	NNP	O	O
locus	NN	O	O
also	RB	O	O
indicated	VBD	O	O
that	IN	O	O
a	DT	O	O
common	JJ	O	O
haplotype	NN	O	O
was	VBD	O	O
shared	VBN	O	O
by	IN	O	O
the	DT	O	O
mutant	JJ	O	O
alleles	NNS	O	O
in	IN	O	O
both	DT	O	O
mutations	NNS	O	O
.	.	O	O

This	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
these	DT	O	O
two	CD	O	O
founder	NN	O	O
mutations	NNS	O	O
may	MD	O	O
be	VB	O	O
predominant	JJ	O	O
among	IN	O	O
Japanese	JJ	O	O
ATM	NNP	O	O
mutant	JJ	O	O
alleles	NNS	O	O
.	.	O	O

9603435	CD	O	O

W474C	NNP	O	O
amino	NN	O	O
acid	NN	O	O
substitution	NN	O	O
affects	VBZ	O	O
early	JJ	O	O
processing	NN	O	O
of	IN	O	O
the	DT	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
of	IN	O	O
beta	NN	O	O
-	:	O	O
hexosaminidase	NN	O	O
A	DT	O	O
and	CC	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
subacute	NN	O	O
G	NNP	B_Disease	O
(	(	I_Disease	O
M2	NNP	I_Disease	O
)	)	I_Disease	O
gangliosidosis	NN	E_Disease	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
HEXA	NNP	O	O
gene	NN	O	O
,	,	O	O
encoding	VBG	O	O
the	DT	O	O
alpha	NN	O	O
-	:	O	O
subunit	NN	O	O
of	IN	O	O
beta	NN	O	O
-	:	O	O
hexosaminidase	NN	O	O
A	NNP	O	O
(	(	O	O
Hex	NNP	O	O
A	NNP	O	O
)	)	O	O
,	,	O	O
that	IN	O	O
abolish	JJ	O	O
Hex	NNP	O	O
A	NNP	O	O
enzyme	NN	O	O
activity	NN	O	O
cause	NN	O	O
Tay	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Sachs	NNP	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
(	(	O	O
TSD	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
the	DT	O	O
fatal	JJ	O	O
infantile	JJ	B_Disease	B_Disease
form	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
G	NNP	I_Disease	I_Disease
(	(	I_Disease	I_Disease
M2	NNP	I_Disease	O
)	)	I_Disease	O
gangliosidosis	NN	I_Disease	O
,	,	I_Disease	O
Type	NNP	I_Disease	O
1	CD	E_Disease	O
.	.	O	O

Less	RBR	O	O
severe	JJ	O	O
,	,	O	O
subacute	JJ	O	O
(	(	O	O
juvenile	JJ	O	B_Disease
-	:	O	I_Disease
onset	NN	O	E_Disease
)	)	O	O
and	CC	O	O
chronic	JJ	O	O
(	(	O	O
adult	JJ	O	O
-	:	O	O
onset	NN	O	O
)	)	O	O
variants	NNS	O	O
are	VBP	O	O
characterized	VBN	O	O
by	IN	O	O
a	DT	O	O
broad	JJ	O	O
spectrum	NN	O	O
of	IN	O	O
clinical	JJ	O	O
manifestations	NNS	O	O
and	CC	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
residual	JJ	O	O
levels	NNS	O	O
of	IN	O	O
Hex	NNP	O	O
A	NNP	O	O
enzyme	NN	O	O
activity	NN	O	O
.	.	O	O

We	PRP	O	O
identified	VBD	O	O
a	DT	O	O
1422	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
C	NNP	O	O
(	(	O	O
amino	JJ	O	O
acid	VBP	O	O
W474C	NNP	O	O
)	)	O	O
substitution	NN	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
position	NN	O	O
of	IN	O	O
exon	JJ	O	O
13	CD	O	O
of	IN	O	O
HEXA	NNP	O	O
of	IN	O	O
a	DT	O	O
non	JJ	O	O
-	:	O	O
Jewish	JJ	O	O
proband	NN	O	O
who	WP	O	O
manifested	VBD	O	O
a	DT	O	O
subacute	JJ	O	O
variant	NN	O	O
of	IN	O	O
G	NNP	B_Disease	O
(	(	I_Disease	O
M2	NNP	I_Disease	O
)	)	I_Disease	O
gangliosidosis	NN	E_Disease	O
.	.	O	O

On	IN	O	O
the	DT	O	O
second	JJ	O	O
maternally	RB	O	O
inherited	VBN	O	O
allele	RB	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
the	DT	O	O
common	JJ	O	O
infantile	NN	O	B_Disease
disease	NN	O	E_Disease
-	:	O	O
causing	VBG	O	O
4	CD	O	O
-	:	O	O
bp	NN	O	O
insertion	NN	O	O
,	,	O	O
+	NNP	O	O
TATC	NNP	O	O
1278	CD	O	O
,	,	O	O
in	IN	O	O
exon	JJ	O	O
11	CD	O	O
.	.	O	O

Pulse	NNP	O	O
-	:	O	O
chase	NN	O	O
analysis	NN	O	O
using	VBG	O	O
proband	NN	O	O
fibroblasts	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
W474C	NNP	O	O
-	:	O	O
containing	VBG	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
precursor	NN	O	O
was	VBD	O	O
normally	RB	O	O
synthesized	VBN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
phosphorylated	VBD	O	O
or	CC	O	O
secreted	VBN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
mature	NN	O	O
lysosomal	JJ	O	O
alpha	SYM	O	O
-	:	O	O
subunit	NN	O	O
was	VBD	O	O
not	RB	O	O
detected	VBN	O	O
.	.	O	O

When	WRB	O	O
the	DT	O	O
W474C	NNP	O	O
-	:	O	O
containing	VBG	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
was	VBD	O	O
transiently	RB	O	O
co	JJ	O	O
-	:	O	O
expressed	VBN	O	O
with	IN	O	O
the	DT	O	O
beta	NN	O	O
-	:	O	O
subunit	NN	O	O
to	TO	O	O
produce	VB	O	O
Hex	NNP	O	O
A	NNP	O	O
(	(	O	O
alphabeta	NN	O	O
)	)	O	O
in	IN	O	O
COS	NNP	O	O
-	:	O	O
7	CD	O	O
cells	NNS	O	O
,	,	O	O
the	DT	O	O
mature	NN	O	O
alpha	SYM	O	O
-	:	O	O
subunit	NN	O	O
was	VBD	O	O
present	JJ	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
level	NN	O	O
was	VBD	O	O
much	RB	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
from	IN	O	O
normal	JJ	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
transfections	NNS	O	O
,	,	O	O
although	IN	O	O
higher	JJR	O	O
than	IN	O	O
in	IN	O	O
those	DT	O	O
cells	NNS	O	O
transfected	VBN	O	O
with	IN	O	O
an	DT	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
associated	VBN	O	O
with	IN	O	O
infantile	JJ	O	O
TSD	NNP	S_Disease	S_Disease
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
precursor	NN	O	O
level	NN	O	O
of	IN	O	O
the	DT	O	O
W474C	NNP	O	O
alpha	SYM	O	O
-	:	O	O
subunit	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
accumulate	VB	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
the	DT	O	O
normal	JJ	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
precursor	NN	O	O
levels	NNS	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
1422	CD	O	O
G	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
C	NNP	O	O
mutation	NN	O	O
is	VBZ	O	O
the	DT	O	O
cause	NN	O	O
of	IN	O	O
Hex	NNP	B_Disease	B_Disease
A	NNP	I_Disease	I_Disease
enzyme	JJ	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
the	DT	O	O
proband	NN	O	O
.	.	O	O

The	DT	O	O
resulting	VBG	O	O
W474C	NNP	O	O
substitution	NN	O	O
clearly	RB	O	O
interferes	VBZ	O	O
with	IN	O	O
alpha	JJ	O	O
-	:	O	O
subunit	NN	O	O
processing	NN	O	O
,	,	O	O
but	CC	O	O
because	IN	O	O
the	DT	O	O
base	NN	O	O
substitution	NN	O	O
falls	VBZ	O	O
at	IN	O	O
the	DT	O	O
first	JJ	O	O
position	NN	O	O
of	IN	O	O
exon	JJ	O	O
13	CD	O	O
,	,	O	O
aberrant	JJ	O	O
splicing	NN	O	O
may	MD	O	O
also	RB	O	O
contribute	VB	O	O
to	TO	O	O
Hex	VB	B_Disease	O
A	DT	I_Disease	O
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
this	DT	O	O
proband	NN	O	O
.	.	O	O
.	.	O	O

9618166	CD	O	O

Two	CD	O	O
frequent	JJ	O	O
missense	NN	O	O
mutations	NNS	O	O
in	IN	O	O
Pendred	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
.	.	O	O

Pendred	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
characterized	VBN	O	O
by	IN	O	O
early	JJ	O	O
childhood	NN	O	B_Disease
deafness	NN	S_Disease	E_Disease
and	CC	O	O
goiter	NN	S_Disease	S_Disease
.	.	O	O

A	DT	O	O
century	NN	O	O
after	IN	O	O
its	PRP$	O	O
recognition	NN	O	O
as	IN	O	O
a	DT	O	O
syndrome	NN	O	O
by	IN	O	O
Vaughan	NNP	O	O
Pendred	NNP	O	S_Disease
,	,	O	O
the	DT	O	O
disease	NN	O	O
gene	NN	O	O
(	(	O	O
PDS	NNP	O	S_Disease
)	)	O	O
was	VBD	O	O
mapped	VBN	O	O
to	TO	O	O
chromosome	VB	O	O
7q22	CD	O	O
-	:	O	O
q31	NN	O	O
.	.	O	O

1	CD	O	O
and	CC	O	O
,	,	O	O
recently	RB	O	O
,	,	O	O
found	VBD	O	O
to	TO	O	O
encode	VB	O	O
a	DT	O	O
putative	JJ	O	O
sulfate	NN	O	O
transporter	NN	O	O
.	.	O	O

We	PRP	O	O
performed	VBD	O	O
mutation	NN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
PDS	NNP	S_Disease	S_Disease
gene	NN	O	O
in	IN	O	O
patients	NNS	O	O
from	IN	O	O
14	CD	O	O
Pendred	NNP	S_Disease	S_Disease
families	NNS	O	O
originating	VBG	O	O
from	IN	O	O
seven	CD	O	O
countries	NNS	O	O
and	CC	O	O
identified	VBD	O	O
all	DT	O	O
mutations	NNS	O	O
.	.	O	O

The	DT	O	O
mutations	NNS	O	O
include	VBP	O	O
three	CD	O	O
single	JJ	O	O
base	NN	O	O
deletions	NNS	O	O
,	,	O	O
one	CD	O	O
splice	NN	O	O
site	NN	O	O
mutation	NN	O	O
and	CC	O	O
10	CD	O	O
missense	NN	O	O
mutations	NNS	O	O
.	.	O	O

One	CD	O	O
missense	NN	O	O
mutation	NN	O	O
(	(	O	O
L236P	NNP	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
a	DT	O	O
homozygous	JJ	O	O
state	NN	O	O
in	IN	O	O
two	CD	O	O
consanguineous	JJ	O	O
families	NNS	O	O
and	CC	O	O
in	IN	O	O
a	DT	O	O
heterozygous	JJ	O	O
state	NN	O	O
in	IN	O	O
five	CD	O	O
additional	JJ	O	O
non	NN	O	O
-	:	O	O
consanguineous	JJ	O	O
families	NNS	O	O
.	.	O	O

Another	DT	O	O
missense	NN	O	O
mutation	NN	O	O
(	(	O	O
T416P	NNP	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
a	DT	O	O
homozygous	JJ	O	O
state	NN	O	O
in	IN	O	O
one	CD	O	O
family	NN	O	O
and	CC	O	O
in	IN	O	O
a	DT	O	O
heterozygous	JJ	O	O
state	NN	O	O
in	IN	O	O
four	CD	O	O
families	NNS	O	O
.	.	O	O

Pendred	JJ	S_Disease	S_Disease
patients	NNS	O	O
in	IN	O	O
three	CD	O	O
non	SYM	O	O
-	:	O	O
consanguineous	JJ	O	O
families	NNS	O	O
were	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
compound	VBN	O	O
heterozygotes	NNS	O	O
for	IN	O	O
L236P	NNP	O	O
and	CC	O	O
T416P	NNP	O	O
.	.	O	O

In	IN	O	O
total	JJ	O	O
,	,	O	O
one	CD	O	O
or	CC	O	O
both	DT	O	O
of	IN	O	O
these	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
nine	CD	O	O
of	IN	O	O
the	DT	O	O
14	CD	O	O
families	NNS	O	O
analyzed	VBN	O	O
.	.	O	O

The	DT	O	O
identification	NN	O	O
of	IN	O	O
two	CD	O	O
frequent	JJ	O	O
PDS	NNP	S_Disease	S_Disease
mutations	NNS	O	O
will	MD	O	O
facilitate	VB	O	O
the	DT	O	O
molecular	JJ	O	O
diagnosis	NN	O	O
of	IN	O	O
Pendred	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
.	.	O	O

9618170	CD	O	O

Insertional	JJ	O	O
mutation	NN	O	O
by	IN	O	O
transposable	JJ	O	O
element	NN	O	O
,	,	O	O
L1	NNP	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
DMD	NNP	S_Disease	S_Disease
gene	NN	O	O
results	NNS	O	O
in	IN	O	O
X	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
linked	VBN	I_Disease	I_Disease
dilated	JJ	I_Disease	I_Disease
cardiomyopathy	NN	E_Disease	E_Disease
.	.	O	O

X	LS	B_Disease	B_Disease
-	:	I_Disease	I_Disease
linked	VBN	I_Disease	I_Disease
dilated	VBN	I_Disease	I_Disease
cardiomyopathy	NN	E_Disease	E_Disease
(	(	O	O
XLDCM	NNP	S_Disease	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
clinical	JJ	O	O
phenotype	NN	O	O
of	IN	O	O
dystrophinopathy	NN	S_Disease	O
which	WDT	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
preferential	JJ	O	O
myocardial	JJ	B_Disease	B_Disease
involvement	NN	E_Disease	E_Disease
without	IN	O	O
any	DT	O	O
overt	JJ	O	O
clinical	JJ	O	O
signs	NNS	O	O
of	IN	O	O
skeletal	JJ	B_Disease	B_Disease
myopathy	NN	E_Disease	E_Disease
.	.	O	O

To	TO	O	O
date	NN	O	O
,	,	O	O
several	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
Duchenne	NNP	B_Disease	B_Disease
muscular	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
gene	NN	O	O
,	,	O	O
DMD	NNP	O	S_Disease
,	,	O	O
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
XLDCM	NNP	S_Disease	O
,	,	O	O
but	CC	O	O
a	DT	O	O
pathogenic	JJ	O	O
correlation	NN	O	O
of	IN	O	O
these	DT	O	O
cardiospecific	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
DMD	NNP	O	S_Disease
with	IN	O	O
the	DT	O	O
XLDCM	NNP	S_Disease	O
phenotype	NN	O	O
has	VBZ	O	O
remained	VBN	O	O
to	TO	O	O
be	VB	O	O
elucidated	VBN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
here	RB	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
a	DT	O	O
unique	JJ	O	O
de	FW	O	O
novo	FW	O	O
L1	NNP	O	O
insertion	NN	O	O
in	IN	O	O
the	DT	O	O
muscle	NN	O	O
exon	VBD	O	O
1	CD	O	O
in	IN	O	O
DMD	NNP	O	S_Disease
in	IN	O	O
three	CD	O	O
XLDCM	NN	S_Disease	O
patients	NNS	O	O
from	IN	O	O
two	CD	O	O
unrelated	JJ	O	O
Japanese	JJ	O	O
families	NNS	O	O
.	.	O	O

The	DT	O	O
insertion	NN	O	O
was	VBD	O	O
a	DT	O	O
5	CD	O	O
-	:	O	O
truncated	JJ	O	O
form	NN	O	O
of	IN	O	O
human	JJ	O	O
L1	NNP	O	O
inversely	RB	O	O
integrated	VBD	O	O
in	IN	O	O
the	DT	O	O
5	CD	O	O
-	:	O	O
untranslated	JJ	O	O
region	NN	O	O
in	IN	O	O
the	DT	O	O
muscle	NN	O	O
exon	VBZ	O	O
1	CD	O	O
,	,	O	O
which	WDT	O	O
affected	VBD	O	O
the	DT	O	O
transcription	NN	O	O
or	CC	O	O
the	DT	O	O
stability	NN	O	O
of	IN	O	O
the	DT	O	O
muscle	NN	O	O
form	NN	O	O
of	IN	O	O
dystrophin	JJ	O	O
transcripts	NNS	O	O
but	CC	O	O
not	RB	O	O
that	IN	O	O
of	IN	O	O
the	DT	O	O
brain	NN	O	O
or	CC	O	O
Purkinje	NNP	O	O
cell	NN	O	O
form	NN	O	O
,	,	O	O
probably	RB	O	O
due	JJ	O	O
to	TO	O	O
its	PRP$	O	O
unique	JJ	O	O
site	NN	O	O
of	IN	O	O
integration	NN	O	O
.	.	O	O

We	PRP	O	O
speculate	VBP	O	O
that	IN	O	O
this	DT	O	O
insertion	NN	O	O
of	IN	O	O
an	DT	O	O
L1	NNP	O	O
sequence	NN	O	O
in	IN	O	O
DMD	NNP	O	S_Disease
is	VBZ	O	O
responsible	JJ	O	O
for	IN	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
population	NN	O	O
of	IN	O	O
Japanese	JJ	O	O
patients	NNS	O	O
with	IN	O	O
XLDCM	NNP	S_Disease	O
.	.	O	O
.	.	O	O

9620771	CD	O	O

Severe	RB	O	O
early	JJ	O	O
-	:	O	O
onset	NN	O	O
obesity	NN	S_Disease	S_Disease
,	,	O	O
adrenal	JJ	B_Disease	B_Disease
insufficiency	NN	E_Disease	E_Disease
and	CC	O	O
red	JJ	O	B_Disease
hair	NN	O	I_Disease
pigmentation	NN	O	E_Disease
caused	VBN	O	O
by	IN	O	O
POMC	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O

Sequential	JJ	O	O
cleavage	NN	O	O
of	IN	O	O
the	DT	O	O
precursor	NN	O	O
protein	NN	O	O
pre	SYM	O	O
-	:	O	O
pro	JJ	O	O
-	:	O	O
opiomelanocortin	NN	O	O
(	(	O	O
POMC	NNP	O	O
)	)	O	O
generates	VBZ	O	O
the	DT	O	O
melanocortin	NN	O	O
peptides	NNS	O	O
adrenocorticotrophin	VBP	O	O
(	(	O	O
ACTH	NNP	O	O
)	)	O	O
,	,	O	O
melanocyte	SYM	O	O
-	:	O	O
stimulating	NN	O	O
hormones	NNS	O	O
(	(	O	O
MSH	NNP	O	O
)	)	O	O
alpha	NN	O	O
,	,	O	O
beta	NN	O	O
and	CC	O	O
gamma	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
opioid	JJ	O	O
-	:	O	O
receptor	NN	O	O
ligand	NN	O	O
beta	SYM	O	O
-	:	O	O
endorphin	NN	O	O
.	.	O	O

While	IN	O	O
a	DT	O	O
few	JJ	O	O
cases	NNS	O	O
of	IN	O	O
isolated	JJ	O	O
ACTH	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
(	(	O	O
OMIM	NNP	O	O
201400	CD	O	O
)	)	O	O
,	,	O	O
an	DT	O	O
inherited	JJ	O	B_Disease
POMC	NNP	O	I_Disease
defect	NN	O	E_Disease
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
described	VBN	O	O
so	RB	O	O
far	RB	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
in	IN	O	O
animal	JJ	O	O
models	NNS	O	O
elucidated	VBD	O	O
a	DT	O	O
central	JJ	O	O
role	NN	O	O
of	IN	O	O
alpha	JJ	O	O
-	:	O	O
MSH	NN	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
food	NN	O	O
intake	NN	O	O
by	IN	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
brain	NN	O	O
melanocortin	SYM	O	O
-	:	O	O
4	CD	O	O
-	:	O	O
receptor	NN	O	O
(	(	O	O
MC4	NNP	O	O
-	:	O	O
R	NN	O	O
;	:	O	O
refs	CC	O	O
3	CD	O	O
-	:	O	O
5	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
linkage	NN	O	O
of	IN	O	O
human	JJ	O	O
obesity	NN	S_Disease	O
to	TO	O	O
chromosome	VB	O	O
2	CD	O	O
in	IN	O	O
close	JJ	O	O
proximity	NN	O	O
to	TO	O	O
the	DT	O	O
POMC	NNP	O	O
locus	NN	O	O
,	,	O	O
led	VBN	O	O
to	TO	O	O
the	DT	O	O
proposal	NN	O	O
of	IN	O	O
an	DT	O	O
association	NN	O	O
of	IN	O	O
POMC	NNP	O	O
with	IN	O	O
human	JJ	O	O
obesity	NN	S_Disease	S_Disease
.	.	O	O

The	DT	O	O
dual	JJ	O	O
role	NN	O	O
of	IN	O	O
alpha	JJ	O	O
-	:	O	O
MSH	NN	O	O
in	IN	O	O
regulating	VBG	O	O
food	NN	O	O
intake	NN	O	O
and	CC	O	O
influencing	VBG	O	O
hair	NN	O	O
pigmentation	NN	O	O
predicts	VBZ	O	O
that	IN	O	O
the	DT	O	O
phenotype	NN	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
defect	NN	O	O
in	IN	O	O
POMC	NNP	O	O
function	NN	O	O
would	MD	O	O
include	VB	O	O
obesity	NN	S_Disease	S_Disease
,	,	O	O
alteration	NN	O	O
in	IN	O	O
pigmentation	NN	O	O
and	CC	O	O
ACTH	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
observation	NN	O	O
of	IN	O	O
these	DT	O	O
symptoms	NNS	O	O
in	IN	O	O
two	CD	O	O
probands	NNS	O	O
prompted	VBD	O	O
us	PRP	O	O
to	TO	O	O
search	VB	O	O
for	IN	O	O
mutations	NNS	O	O
within	IN	O	O
their	PRP$	O	O
POMC	NNP	O	O
genes	NNS	O	O
.	.	O	O

Patient	JJ	O	O
1	CD	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
compound	NN	O	O
heterozygote	NN	O	O
for	IN	O	O
two	CD	O	O
mutations	NNS	O	O
in	IN	O	O
exon	JJ	O	O
3	CD	O	O
(	(	O	O
G7013T	NNP	O	O
,	,	O	O
C7133delta	NNP	O	O
)	)	O	O
which	WDT	O	O
interfere	VBP	O	O
with	IN	O	O
appropriate	JJ	O	O
synthesis	NN	O	O
of	IN	O	O
ACTH	NNP	O	O
and	CC	O	O
alpha	SYM	O	O
-	:	O	O
MSH	NN	O	O
.	.	O	O

Patient	JJ	O	O
2	CD	O	O
was	VBD	O	O
homozygous	JJ	O	O
for	IN	O	O
a	DT	O	O
mutation	NN	O	O
in	IN	O	O
exon	JJ	O	O
2	CD	O	O
(	(	O	O
C3804A	NNP	O	O
)	)	O	O
which	WDT	O	O
abolishes	VBZ	O	O
POMC	NNP	O	O
translation	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
represent	VBP	O	O
the	DT	O	O
first	JJ	O	O
examples	NNS	O	O
of	IN	O	O
a	DT	O	O
genetic	JJ	B_Disease	O
defect	NN	E_Disease	O
within	IN	O	O
the	DT	O	O
POMC	NNP	O	O
gene	NN	O	O
and	CC	O	O
define	VB	O	O
a	DT	O	O
new	JJ	O	O
monogenic	JJ	B_Disease	O
endocrine	NN	I_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
resulting	VBG	O	O
in	IN	O	O
early	JJ	O	O
-	:	O	O
onset	NN	O	O
obesity	NN	S_Disease	S_Disease
,	,	O	O
adrenal	JJ	B_Disease	B_Disease
insufficiency	NN	E_Disease	E_Disease
and	CC	O	O
red	JJ	O	O
hair	NN	O	O
pigmentation	NN	O	O
.	.	O	O
.	.	O	O

9634518	CD	O	O

A	DT	O	O
European	JJ	O	O
multicenter	NN	O	O
study	NN	O	O
of	IN	O	O
phenylalanine	JJ	B_Disease	B_Disease
hydroxylase	NN	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
:	:	O	O
classification	NN	O	O
of	IN	O	O
105	CD	O	O
mutations	NNS	O	O
and	CC	O	O
a	DT	O	O
general	JJ	O	O
system	NN	O	O
for	IN	O	O
genotype	NN	O	O
-	:	O	O
based	VBN	O	O
prediction	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
phenotype	NN	O	O
.	.	O	O

Phenylketonuria	NNP	S_Disease	S_Disease
(	(	O	O
PKU	NNP	S_Disease	S_Disease
)	)	O	O
and	CC	O	O
mild	JJ	B_Disease	B_Disease
hyperphenylalaninemia	NN	E_Disease	E_Disease
(	(	O	O
MHP	NNP	S_Disease	S_Disease
)	)	O	O
are	VBP	O	O
allelic	JJ	B_Disease	B_Disease
disorders	NNS	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
phenylalanine	JJ	O	O
hydroxylase	NN	O	O
(	(	O	O
PAH	NNP	O	O
)	)	O	O
.	.	O	O

Previous	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
suggested	VBN	O	O
that	IN	O	O
the	DT	O	O
highly	RB	O	O
variable	JJ	O	O
metabolic	JJ	O	O
phenotypes	NNS	O	O
of	IN	O	O
PAH	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
correlate	NN	O	O
with	IN	O	O
PAH	NNP	O	O
genotypes	NNS	O	O
.	.	O	O

We	PRP	O	O
identified	VBD	O	O
both	DT	O	O
causative	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
686	CD	O	O
patients	NNS	O	O
from	IN	O	O
seven	CD	O	O
European	JJ	O	O
centers	NNS	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
phenotypic	NN	O	O
characteristics	NNS	O	O
of	IN	O	O
297	CD	O	O
functionally	RB	O	O
hemizygous	JJ	O	O
patients	NNS	O	O
,	,	O	O
105	CD	O	O
of	IN	O	O
the	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
assigned	VBN	O	O
to	TO	O	O
one	CD	O	O
of	IN	O	O
four	CD	O	O
arbitrary	JJ	O	O
phenotype	NN	O	O
categories	NNS	O	O
.	.	O	O

We	PRP	O	O
proposed	VBD	O	O
and	CC	O	O
tested	VBD	O	O
a	DT	O	O
simple	JJ	O	O
model	NN	O	O
for	IN	O	O
correlation	NN	O	O
between	IN	O	O
genotype	NN	O	O
and	CC	O	O
phenotypic	NN	O	O
outcome	NN	O	O
.	.	O	O

The	DT	O	O
observed	JJ	O	O
phenotype	NN	O	O
matched	VBD	O	O
the	DT	O	O
predicted	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
79	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
only	RB	O	O
5	CD	O	O
of	IN	O	O
184	CD	O	O
patients	NNS	O	O
was	VBD	O	O
the	DT	O	O
observed	JJ	O	O
phenotype	NN	O	O
more	JJR	O	O
than	IN	O	O
one	CD	O	O
category	NN	O	O
away	RB	O	O
from	IN	O	O
that	DT	O	O
expected	VBN	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
seven	CD	O	O
contributing	NN	O	O
centers	NNS	O	O
,	,	O	O
the	DT	O	O
proportion	NN	O	O
of	IN	O	O
patients	NNS	O	O
for	IN	O	O
whom	WP	O	O
the	DT	O	O
observed	JJ	O	O
phenotype	NN	O	O
did	VBD	O	O
not	RB	O	O
match	VB	O	O
the	DT	O	O
predicted	JJ	O	O
phenotype	NN	O	O
was	VBD	O	O
4	CD	O	O
%	NN	O	O
-	:	O	O
23	CD	O	O
%	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
.	.	O	O

0001	CD	O	O
)	)	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
differences	NNS	O	O
in	IN	O	O
methods	NNS	O	O
used	VBN	O	O
for	IN	O	O
mutation	NN	O	O
detection	NN	O	O
or	CC	O	O
phenotype	JJ	O	O
classification	NN	O	O
may	MD	O	O
account	VB	O	O
for	IN	O	O
a	DT	O	O
considerable	JJ	O	O
proportion	NN	O	O
of	IN	O	O
genotype	JJ	O	O
-	:	O	O
phenotype	NN	O	O
inconsistencies	NNS	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
PAH	NNP	O	O
-	:	O	O
mutation	NN	O	O
genotype	NN	O	O
is	VBZ	O	O
the	DT	O	O
main	JJ	O	O
determinant	NN	O	O
of	IN	O	O
metabolic	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
most	JJS	O	O
patients	NNS	O	O
with	IN	O	O
PAH	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
classification	NN	O	O
of	IN	O	O
105	CD	O	O
PAH	NNP	O	O
mutations	NNS	O	O
may	MD	O	O
allow	VB	O	O
the	DT	O	O
prediction	NN	O	O
of	IN	O	O
the	DT	O	O
biochemical	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
>	JJ	O	O
10	CD	O	O
,	,	O	O
000	CD	O	O
genotypes	NNS	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
be	VB	O	O
useful	JJ	O	O
for	IN	O	O
the	DT	O	O
management	NN	O	O
of	IN	O	O
hyperphenylalaninemia	NN	S_Disease	S_Disease
in	IN	O	O
newborns	NNS	O	O
.	.	O	O

9668171	CD	O	O

Somatic	JJ	O	O
instability	NN	O	O
of	IN	O	O
the	DT	O	O
CTG	NNP	O	O
repeat	NN	O	O
in	IN	O	O
mice	NN	O	O
transgenic	NN	O	O
for	IN	O	O
the	DT	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
region	NN	O	O
is	VBZ	O	O
age	NN	O	O
dependent	JJ	O	O
but	CC	O	O
not	RB	O	O
correlated	VBN	O	O
to	TO	O	O
the	DT	O	O
relative	JJ	O	O
intertissue	NN	O	O
transcription	NN	O	O
levels	NNS	O	O
and	CC	O	O
proliferative	JJ	O	O
capacities	NNS	O	O
.	.	O	O

A	DT	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
nexpansion	NN	O	O
in	IN	O	O
the	DT	O	O
3	CD	O	O
-	:	O	O
untranslated	JJ	O	O
region	NN	O	O
(	(	O	O
UTR	NNP	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
DM	NNP	O	O
protein	NN	O	O
kinase	NN	O	O
gene	NN	O	O
(	(	O	O
DMPK	NNP	O	O
)	)	O	O
is	VBZ	O	O
responsible	JJ	O	O
for	IN	O	O
causing	VBG	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

Major	JJ	O	O
instability	NN	O	O
,	,	O	O
with	IN	O	O
very	RB	O	O
large	JJ	O	O
expansions	NNS	O	O
between	IN	O	O
generations	NNS	O	O
and	CC	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
somatic	JJ	O	O
mosaicism	NN	O	O
,	,	O	O
is	VBZ	O	O
observed	VBN	O	O
in	IN	O	O
patients	NNS	O	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
a	DT	O	O
good	JJ	O	O
correlation	NN	O	O
between	IN	O	O
repeat	NN	O	O
size	NN	O	O
(	(	O	O
at	IN	O	O
least	JJS	O	O
in	IN	O	O
leucocytes	NNS	O	O
)	)	O	O
,	,	O	O
clinical	JJ	O	O
severity	NN	O	O
and	CC	O	O
age	NN	O	O
of	IN	O	O
onset	NN	O	O
.	.	O	O

The	DT	O	O
trinucleotide	JJ	O	O
repeat	NN	O	O
instability	NN	O	O
mechanisms	NNS	O	O
involved	VBN	O	O
in	IN	O	O
DM	NNP	S_Disease	S_Disease
and	CC	O	O
other	JJ	O	O
human	JJ	O	O
genetic	JJ	B_Disease	B_Disease
diseases	NNS	E_Disease	E_Disease
are	VBP	O	O
unknown	JJ	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
somatic	JJ	O	O
instability	NN	O	O
by	IN	O	O
measuring	VBG	O	O
the	DT	O	O
CTG	NNP	O	O
repeat	NN	O	O
length	NN	O	O
at	IN	O	O
several	JJ	O	O
ages	NNS	O	O
in	IN	O	O
various	JJ	O	O
tissues	NNS	O	O
of	IN	O	O
transgenic	JJ	O	O
mice	NN	O	O
carrying	VBG	O	O
a	DT	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
55expansion	CD	O	O
surrounded	VBN	O	O
by	IN	O	O
45	CD	O	O
kb	NNS	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
DM	NNP	S_Disease	S_Disease
region	NN	O	O
,	,	O	O
using	VBG	O	O
small	JJ	O	O
-	:	O	O
pool	NN	O	O
PCR	NNP	O	O
.	.	O	O

These	DT	O	O
mice	NNS	O	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
reproduce	VB	O	O
the	DT	O	O
intergenerational	JJ	O	O
and	CC	O	O
somatic	JJ	O	O
instability	NN	O	O
of	IN	O	O
the	DT	O	O
55	CD	O	O
CTG	NNP	O	O
repeat	NN	O	O
suggesting	VBG	O	O
that	IN	O	O
surrounding	VBG	O	O
sequences	NNS	O	O
and	CC	O	O
the	DT	O	O
chromatin	NN	O	O
environment	NN	O	O
are	VBP	O	O
involved	VBN	O	O
in	IN	O	O
instability	NN	O	O
mechanisms	NNS	O	O
.	.	O	O

As	IN	O	O
observed	VBN	O	O
in	IN	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
tissues	NNS	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
patients	NNS	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
tendency	NN	O	O
for	IN	O	O
repeat	NN	O	O
length	NN	O	O
and	CC	O	O
somatic	JJ	O	O
mosaicism	NN	O	O
to	TO	O	O
increase	VB	O	O
with	IN	O	O
the	DT	O	O
age	NN	O	O
of	IN	O	O
the	DT	O	O
mouse	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
we	PRP	O	O
observed	VBD	O	O
no	DT	O	O
correlation	NN	O	O
between	IN	O	O
the	DT	O	O
somatic	JJ	O	O
mutation	NN	O	O
rate	NN	O	O
and	CC	O	O
tissue	NN	O	O
proliferation	NN	O	O
capacity	NN	O	O
.	.	O	O

The	DT	O	O
somatic	JJ	O	O
mutation	NN	O	O
rates	NNS	O	O
in	IN	O	O
different	JJ	O	O
tissues	NNS	O	O
were	VBD	O	O
also	RB	O	O
not	RB	O	O
correlated	VBN	O	O
to	TO	O	O
the	DT	O	O
relative	JJ	O	O
inter	NN	O	O
-	:	O	O
tissue	NN	O	O
difference	NN	O	O
in	IN	O	O
transcriptional	JJ	O	O
levels	NNS	O	O
of	IN	O	O
the	DT	O	O
three	CD	O	O
genes	NNS	O	O
(	(	O	O
DMAHP	NNP	O	O
,	,	O	O
DMPK	NNP	O	O
and	CC	O	O
59	CD	O	O
)	)	O	O
surrounding	VBG	O	O
the	DT	O	O
repeat	NN	O	O
.	.	O	O
.	.	O	O

9671401	CD	O	O

A	DT	O	O
novel	JJ	O	O
missense	NN	O	O
mutation	NN	O	O
in	IN	O	O
patients	NNS	O	O
from	IN	O	O
a	DT	O	O
retinoblastoma	NN	S_Disease	S_Disease
pedigree	NN	O	O
showing	VBG	O	O
only	RB	O	O
mild	JJ	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
tumor	NN	S_Disease	S_Disease
phenotype	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
used	VBN	O	O
single	JJ	O	O
strand	NN	O	O
conformation	NN	O	O
polymorphism	NN	O	O
analysis	NN	O	O
to	TO	O	O
study	VB	O	O
the	DT	O	O
27	CD	O	O
exons	NNS	O	O
of	IN	O	O
the	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
in	IN	O	O
individuals	NNS	O	O
from	IN	O	O
a	DT	O	O
family	NN	O	O
showing	VBG	O	O
mild	JJ	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
retinoblastoma	NN	S_Disease	S_Disease
phenotype	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
family	NN	O	O
affected	VBD	O	O
individuals	NNS	O	O
developed	VBD	O	O
unilateral	JJ	B_Disease	B_Disease
tumors	NNS	E_Disease	E_Disease
and	CC	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
linkage	NN	O	O
analysis	NN	O	O
,	,	O	O
unaffected	JJ	O	O
mutation	NN	O	O
carriers	NNS	O	O
were	VBD	O	O
also	RB	O	O
identified	VBN	O	O
within	IN	O	O
the	DT	O	O
pedigree	NN	O	O
.	.	O	O

A	DT	O	O
single	JJ	O	O
band	NN	O	O
shift	NN	O	O
using	VBG	O	O
SSCP	NNP	O	O
was	VBD	O	O
identified	VBN	O	O
in	IN	O	O
exon	NN	O	O
21	CD	O	O
which	WDT	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
missense	JJ	O	O
mutation	NN	O	O
converting	VBG	O	O
a	DT	O	O
cys	NN	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
arg	NN	O	O
at	IN	O	O
nucleotide	JJ	O	O
position	NN	O	O
28	CD	O	O
in	IN	O	O
the	DT	O	O
exon	NN	O	O
.	.	O	O

The	DT	O	O
mutation	NN	O	O
destroyed	VBD	O	O
an	DT	O	O
NdeI	NNP	O	O
restriction	NN	O	O
enzyme	NN	O	O
site	NN	O	O
.	.	O	O

Analysis	NN	O	O
of	IN	O	O
all	DT	O	O
family	NN	O	O
members	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
the	DT	O	O
missense	NN	O	O
mutation	NN	O	O
co	SYM	O	O
-	:	O	O
segregated	VBN	O	O
with	IN	O	O
patients	NNS	O	O
with	IN	O	O
tumors	NNS	S_Disease	S_Disease
or	CC	O	O
who	WP	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
linkage	NN	O	O
analysis	NN	O	O
had	VBD	O	O
been	VBN	O	O
predicted	VBN	O	O
to	TO	O	O
carry	VB	O	O
the	DT	O	O
predisposing	NN	O	O
mutation	NN	O	O
.	.	O	O

These	DT	O	O
observations	NNS	O	O
point	NN	O	O
to	TO	O	O
another	DT	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
RB1	NNP	O	O
gene	NN	O	O
where	WRB	O	O
mutations	NNS	O	O
only	RB	O	O
modify	VBP	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
and	CC	O	O
raise	VB	O	O
important	JJ	O	O
questions	NNS	O	O
for	IN	O	O
genetic	JJ	O	O
counseling	NN	O	O
in	IN	O	O
families	NNS	O	O
with	IN	O	O
these	DT	O	O
distinctive	JJ	O	O
phenotypes	NNS	O	O
.	.	O	O
.	.	O	O

9674903	CD	O	O

Maternal	JJ	B_Disease	B_Disease
disomy	NN	E_Disease	E_Disease
and	CC	O	O
Prader	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Willi	NNP	I_Disease	I_Disease
syndrome	JJ	E_Disease	E_Disease
consistent	NN	O	O
with	IN	O	O
gamete	JJ	O	O
complementation	NN	O	O
in	IN	O	O
a	DT	O	O
case	NN	O	O
of	IN	O	O
familial	JJ	O	O
translocation	NN	O	O
(	(	O	O
3	CD	O	O
;	:	O	O
15	CD	O	O
)	)	O	O
(	(	O	O
p25	NN	O	O
;	:	O	O
q11	NN	O	O
.	.	O	O
2	CD	O	O
)	)	O	O
.	.	O	O

Maternal	NNP	B_Disease	B_Disease
uniparental	JJ	I_Disease	B_Disease
disomy	NN	I_Disease	E_Disease
(	(	I_Disease	O
UPD	NNP	I_Disease	S_Disease
)	)	I_Disease	O
for	IN	I_Disease	O
chromosome	NN	I_Disease	O
15	CD	E_Disease	O
is	VBZ	O	O
responsible	JJ	O	O
for	IN	O	O
an	DT	O	O
estimated	JJ	O	O
30	CD	O	O
%	NN	O	O
of	IN	O	O
cases	NNS	O	O
of	IN	O	O
Prader	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Willi	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
PWS	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
on	IN	O	O
an	DT	O	O
unusual	JJ	O	O
case	NN	O	O
of	IN	O	O
maternal	JJ	B_Disease	O
disomy	NN	I_Disease	O
15	CD	E_Disease	O
in	IN	O	O
PWS	NNP	S_Disease	S_Disease
that	WDT	O	O
is	VBZ	O	O
most	RBS	O	O
consistent	JJ	O	O
with	IN	O	O
adjacent	JJ	O	O
-	:	O	O
1	CD	O	O
segregation	NN	O	O
of	IN	O	O
a	DT	O	O
paternal	JJ	O	O
t	NN	O	O
(	(	O	O
3	CD	O	O
;	:	O	O
15	CD	O	O
)	)	O	O
(	(	O	O
p25	NN	O	O
;	:	O	O
q11	NN	O	O
.	.	O	O

2	CD	O	O
)	)	O	O
with	IN	O	O
simultaneous	JJ	O	O
maternal	JJ	O	O
meiotic	JJ	O	O
nondisjunction	NN	O	O
for	IN	O	O
chromosome	NN	O	O
15	CD	O	O
.	.	O	O

The	DT	O	O
patient	NN	O	O
(	(	O	O
J	NNP	O	O
.	.	O	O

B	NNP	O	O
.	.	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
17	CD	O	O
-	:	O	O
year	NN	O	O
-	:	O	O
old	JJ	O	O
white	JJ	O	O
male	NN	O	O
with	IN	O	O
PWS	NNP	S_Disease	S_Disease
,	,	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
47	CD	O	O
chromosomes	NNS	O	O
with	IN	O	O
a	DT	O	O
supernumerary	JJ	O	O
,	,	O	O
paternal	JJ	O	O
der	NN	O	O
(	(	O	O
15	CD	O	O
)	)	O	O
consisting	NN	O	O
of	IN	O	O
the	DT	O	O
short	JJ	O	O
arm	NN	O	O
and	CC	O	O
the	DT	O	O
proximal	JJ	O	O
long	JJ	O	O
arm	NN	O	O
of	IN	O	O
chromosome	NN	O	O
15	CD	O	O
,	,	O	O
and	CC	O	O
distal	JJ	O	O
chromosome	NN	O	O
arm	NN	O	O
3p	CD	O	O
.	.	O	O

The	DT	O	O
t	NN	O	O
(	(	O	O
3	CD	O	O
;	:	O	O
15	CD	O	O
)	)	O	O
was	VBD	O	O
present	JJ	O	O
in	IN	O	O
the	DT	O	O
balanced	JJ	O	O
state	NN	O	O
in	IN	O	O
the	DT	O	O
patients	NNS	O	O
father	NN	O	O
and	CC	O	O
a	DT	O	O
sister	NN	O	O
.	.	O	O

Fluorescent	NN	O	O
in	IN	O	O
situ	JJ	O	O
hybridization	NN	O	O
analysis	NN	O	O
demonstrated	VBD	O	O
that	IN	O	O
the	DT	O	O
PWS	NNP	S_Disease	S_Disease
critical	JJ	O	O
region	NN	O	O
resided	VBD	O	O
on	IN	O	O
the	DT	O	O
derivative	JJ	O	O
chromosome	NN	O	O
3	CD	O	O
and	CC	O	O
that	IN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
deletion	NN	O	O
of	IN	O	O
the	DT	O	O
PWS	NNP	S_Disease	S_Disease
region	NN	O	O
on	IN	O	O
the	DT	O	O
normal	JJ	O	O
pair	NN	O	O
of	IN	O	O
15s	CD	O	O
present	JJ	O	O
in	IN	O	O
J	NNP	O	O
.	.	O	O

B	NNP	O	O
.	.	O	O

Methylation	NN	O	O
analysis	NN	O	O
at	IN	O	O
exon	JJ	O	O
alpha	NN	O	O
of	IN	O	O
the	DT	O	O
small	JJ	O	O
nuclear	JJ	O	O
ribonucleoprotein	NN	O	O
-	:	O	O
associated	VBN	O	O
polypeptide	IN	O	O
N	NNP	O	O
(	(	O	O
SNRPN	NNP	O	O
)	)	O	O
gene	NN	O	O
showed	VBD	O	O
a	DT	O	O
pattern	JJ	O	O
characteristic	NN	O	O
of	IN	O	O
only	RB	O	O
the	DT	O	O
maternal	JJ	O	O
chromosome	NN	O	O
15	CD	O	O
in	IN	O	O
J	NNP	O	O
.	.	O	O

B	NNP	O	O
.	.	O	O

Maternal	JJ	B_Disease	B_Disease
disomy	NN	E_Disease	E_Disease
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
analysis	NN	O	O
of	IN	O	O
microsatellite	JJ	O	O
repeats	NNS	O	O
at	IN	O	O
the	DT	O	O
gamma	NN	O	O
-	:	O	O
aminobutyric	JJ	O	O
acid	NN	O	O
receptor	NN	O	O
beta3	NN	O	O
subunit	NN	O	O
(	(	O	O
GABRB3	NNP	O	O
)	)	O	O
locus	NN	O	O
.	.	O	O

A	DT	O	O
niece	NN	O	O
(	(	O	O
B	NNP	O	O
.	.	O	O

B	NNP	O	O
.	.	O	O
)	)	O	O
with	IN	O	O
45	CD	O	O
chromosomes	NNS	O	O
and	CC	O	O
the	DT	O	O
derivative	JJ	O	O
3	CD	O	O
but	CC	O	O
without	IN	O	O
the	DT	O	O
der	NN	O	O
(	(	O	O
15	CD	O	O
)	)	O	O
demonstrated	VBD	O	O
a	DT	O	O
phenotype	JJ	O	O
consistent	NN	O	O
with	IN	O	O
that	DT	O	O
reported	VBD	O	O
for	IN	O	O
haploinsufficiency	NN	O	O
of	IN	O	O
distal	JJ	O	O
3	CD	O	O
p	NN	O	O
.	.	O	O

Uniparental	JJ	B_Disease	B_Disease
disomy	NN	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
unbalanced	JJ	O	O
segregation	NN	O	O
of	IN	O	O
non	JJ	O	O
-	:	O	O
Robertsonian	JJ	O	O
translocations	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
previously	RB	O	O
but	CC	O	O
has	VBZ	O	O
not	RB	O	O
,	,	O	O
to	TO	O	O
our	PRP$	O	O
knowledge	NN	O	O
,	,	O	O
been	VBN	O	O
observed	VBN	O	O
in	IN	O	O
a	DT	O	O
case	NN	O	O
of	IN	O	O
PWS	NNP	S_Disease	S_Disease
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
our	PRP$	O	O
findings	NNS	O	O
are	VBP	O	O
best	RB	O	O
interpreted	VBN	O	O
as	IN	O	O
true	JJ	O	O
gamete	JJ	O	O
complementation	NN	O	O
resulting	VBG	O	O
in	IN	O	O
maternal	JJ	B_Disease	O
UPD	NNP	I_Disease	S_Disease
15	CD	E_Disease	O
and	CC	O	O
PWS	NNP	S_Disease	S_Disease

9674906	CD	O	O

Schwartz	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Jampel	NNP	I_Disease	I_Disease
syndrome	VBD	I_Disease	I_Disease
type	JJ	I_Disease	I_Disease
2	CD	E_Disease	I_Disease
and	CC	O	O
Stuve	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Wiedemann	JJ	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
:	:	O	O
a	DT	O	O
case	NN	O	O
for	IN	O	O
"	NNP	O	O
lumping	VBG	O	O
"	NN	O	O
.	.	O	O

Recent	JJ	O	O
studies	NNS	O	O
demonstrated	VBD	O	O
the	DT	O	O
existence	NN	O	O
of	IN	O	O
a	DT	O	O
genetically	RB	O	O
distinct	JJ	O	O
,	,	O	O
usually	RB	O	O
lethal	JJ	O	O
form	NN	O	O
of	IN	O	O
the	DT	O	O
Schwartz	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Jampel	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
SJS	NNP	S_Disease	S_Disease
)	)	O	O
of	IN	O	O
myotonia	NN	S_Disease	S_Disease
and	CC	O	O
skeletal	JJ	B_Disease	B_Disease
dysplasia	NN	E_Disease	E_Disease
,	,	O	O
which	WDT	O	O
we	PRP	O	O
called	VBD	O	O
SJS	NNP	B_Disease	S_Disease
type	NN	I_Disease	O
2	CD	E_Disease	O
.	.	O	O

This	DT	O	O
disorder	NN	O	O
is	VBZ	O	O
reminiscent	JJ	O	O
of	IN	O	O
another	DT	O	O
rare	JJ	O	O
condition	NN	O	O
,	,	O	O
the	DT	O	O
Stuve	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Wiedemann	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
SWS	NNP	S_Disease	O
)	)	O	O
,	,	O	O
which	WDT	O	O
comprises	VBZ	O	O
campomelia	NN	S_Disease	O
at	IN	O	O
birth	NN	O	O
with	IN	O	O
skeletal	JJ	B_Disease	B_Disease
dysplasia	NN	E_Disease	E_Disease
,	,	O	O
contractures	NNS	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
early	JJ	B_Disease	O
death	NN	E_Disease	E_Disease
.	.	O	O

To	TO	O	O
test	VB	O	O
for	IN	O	O
possible	JJ	O	O
nosologic	JJ	O	O
identity	NN	O	O
between	IN	O	O
these	DT	O	O
disorders	NNS	O	O
,	,	O	O
we	PRP	O	O
reviewed	VBD	O	O
the	DT	O	O
literature	NN	O	O
and	CC	O	O
obtained	VBD	O	O
a	DT	O	O
follow	JJ	O	O
-	:	O	O
up	IN	O	O
of	IN	O	O
the	DT	O	O
only	JJ	O	O
two	CD	O	O
surviving	VBG	O	O
patients	NNS	O	O
,	,	O	O
one	CD	O	O
with	IN	O	O
SJS	NNP	B_Disease	S_Disease
type	NN	I_Disease	O
2	CD	E_Disease	O
at	IN	O	O
age	NN	O	O
10	CD	O	O
years	NNS	O	O
and	CC	O	O
another	DT	O	O
with	IN	O	O
SWS	NNP	S_Disease	O
at	IN	O	O
age	NN	O	O
7	CD	O	O
years	NNS	O	O
.	.	O	O

Patients	NNS	O	O
reported	VBD	O	O
as	IN	O	O
having	VBG	O	O
either	CC	O	O
neonatal	JJ	O	O
SJS	NNP	S_Disease	S_Disease
or	CC	O	O
SWS	NNP	S_Disease	O
presented	VBD	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
a	DT	O	O
severe	JJ	O	O
,	,	O	O
prenatal	JJ	O	O
-	:	O	O
onset	NN	O	O
neuromuscular	JJ	B_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
(	(	O	O
with	IN	O	O
congenital	JJ	B_Disease	B_Disease
joint	NN	I_Disease	I_Disease
contractures	NNS	E_Disease	E_Disease
,	,	O	O
respiratory	NN	O	O
and	CC	O	O
feeding	NN	O	O
difficulties	NNS	O	O
,	,	O	O
tendency	NN	O	O
to	TO	O	O
hyperthermia	VB	S_Disease	O
,	,	O	O
and	CC	O	O
frequent	JJ	O	O
death	NN	O	O
in	IN	O	O
infancy	NN	O	O
)	)	O	O
with	IN	O	O
a	DT	O	O
distinct	JJ	O	O
campomelic	JJ	B_Disease	O
-	:	I_Disease	O
metaphyseal	NN	I_Disease	O
skeletal	JJ	I_Disease	B_Disease
dysplasia	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
similarity	NN	O	O
of	IN	O	O
the	DT	O	O
clinical	JJ	O	O
and	CC	O	O
radiographic	JJ	O	O
findings	NNS	O	O
is	VBZ	O	O
so	RB	O	O
extensive	JJ	O	O
that	IN	O	O
these	DT	O	O
disorders	NNS	O	O
appear	VBP	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
single	JJ	O	O
entity	NN	O	O
.	.	O	O

The	DT	O	O
follow	NN	O	O
-	:	O	O
up	IN	O	O
observation	NN	O	O
of	IN	O	O
an	DT	O	O
identical	JJ	O	O
and	CC	O	O
unique	JJ	O	O
pattern	NN	O	O
of	IN	O	O
progressive	JJ	O	O
bone	NN	B_Disease	B_Disease
dysplasia	NN	E_Disease	E_Disease
in	IN	O	O
the	DT	O	O
two	CD	O	O
patients	NNS	O	O
(	(	O	O
one	CD	O	O
with	IN	O	O
SJS	NNP	B_Disease	S_Disease
type	NN	I_Disease	O
2	CD	E_Disease	O
,	,	O	O
one	CD	O	O
with	IN	O	O
SWS	NNP	S_Disease	O
)	)	O	O
surviving	VBG	O	O
beyond	IN	O	O
infancy	NN	O	O
adds	VBZ	O	O
to	TO	O	O
the	DT	O	O
evidence	NN	O	O
in	IN	O	O
favor	NN	O	O
of	IN	O	O
identity	NN	O	O
.	.	O	O

The	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
SWS	NNP	S_Disease	O
and	CC	O	O
SJS	NNP	B_Disease	S_Disease
type	NN	I_Disease	O
2	CD	E_Disease	O
are	VBP	O	O
the	DT	O	O
same	JJ	O	O
disorder	NN	O	O
should	MD	O	O
be	VB	O	O
testable	JJ	O	O
by	IN	O	O
molecular	JJ	O	O
methods	NNS	O	O
.	.	O	O
.	.	O	O

9689113	CD	O	O

A	DT	O	O
mouse	NN	O	O
model	NN	O	O
of	IN	O	O
severe	JJ	O	O
von	NN	B_Disease	B_Disease
Willebrand	NNP	I_Disease	I_Disease
disease	NN	E_Disease	I_Disease
:	:	O	I_Disease
defects	NNS	O	E_Disease
in	IN	O	O
hemostasis	NN	O	O
and	CC	O	O
thrombosis	NN	S_Disease	O
.	.	O	O

von	NN	B_Disease	B_Disease
Willebrand	NNP	I_Disease	I_Disease
factor	NN	I_Disease	I_Disease
(	(	I_Disease	I_Disease
vWf	NN	I_Disease	I_Disease
)	)	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
causes	VBZ	O	O
severe	JJ	O	O
von	NN	B_Disease	B_Disease
Willebrand	NNP	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
in	IN	O	O
humans	NNS	O	O
.	.	O	O

We	PRP	O	O
generated	VBD	O	O
a	DT	O	O
mouse	NN	O	O
model	NN	O	O
for	IN	O	O
this	DT	O	O
disease	NN	O	O
by	IN	O	O
using	VBG	O	O
gene	NN	O	O
targeting	VBG	O	O
.	.	O	O

vWf	SYM	B_Disease	O
-	:	I_Disease	O
deficient	NN	E_Disease	O
mice	RB	O	O
appeared	VBD	O	O
normal	JJ	O	O
at	IN	O	O
birth	NN	O	O
;	:	O	O
they	PRP	O	O
were	VBD	O	O
viable	JJ	O	O
and	CC	O	O
fertile	JJ	O	O
.	.	O	O

Neither	DT	O	O
vWf	NN	O	O
nor	CC	O	O
vWf	JJ	O	O
propolypeptide	NN	O	O
(	(	O	O
von	JJ	B_Disease	B_Disease
Willebrand	NNP	E_Disease	I_Disease
antigen	NN	O	O
II	NNP	O	O
)	)	O	O
were	VBD	O	O
detectable	JJ	O	O
in	IN	O	O
plasma	NN	O	O
,	,	O	O
platelets	NNS	O	O
,	,	O	O
or	CC	O	O
endothelial	JJ	O	O
cells	NNS	O	O
of	IN	O	O
the	DT	O	O
homozygous	JJ	O	O
mutant	JJ	O	O
mice	NN	O	O
.	.	O	O

The	DT	O	O
mutant	JJ	O	O
mice	NN	O	O
exhibited	VBD	O	O
defects	NNS	O	O
in	IN	O	O
hemostasis	NN	O	O
with	IN	O	O
a	DT	O	O
highly	RB	O	O
prolonged	JJ	O	O
bleeding	NN	O	O
time	NN	O	O
and	CC	O	O
spontaneous	JJ	O	O
bleeding	VBG	O	O
events	NNS	O	O
in	IN	O	O
approximately	RB	O	O
10	CD	O	O
%	NN	O	O
of	IN	O	O
neonates	NNS	O	O
.	.	O	O

As	IN	O	O
in	IN	O	O
the	DT	O	O
human	JJ	O	O
disease	NN	O	O
,	,	O	O
the	DT	O	O
factor	NN	O	O
VIII	NNP	O	O
level	NN	O	O
in	IN	O	O
these	DT	O	O
mice	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
strongly	RB	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
protection	NN	O	O
provided	VBN	O	O
by	IN	O	O
vWf	NN	O	O
.	.	O	O

Defective	JJ	O	B_Disease
thrombosis	NN	S_Disease	E_Disease
in	IN	O	O
mutant	JJ	O	O
mice	NN	O	O
was	VBD	O	O
also	RB	O	O
evident	JJ	O	O
in	IN	O	O
an	DT	O	O
in	IN	O	O
vivo	JJ	O	O
model	NN	O	O
of	IN	O	O
vascular	JJ	B_Disease	B_Disease
injury	NN	E_Disease	E_Disease
.	.	O	O

In	IN	O	O
this	DT	O	O
model	NN	O	O
,	,	O	O
the	DT	O	O
exteriorized	JJ	O	O
mesentery	NN	O	O
was	VBD	O	O
superfused	VBN	O	O
with	IN	O	O
ferric	JJ	O	O
chloride	NN	O	O
and	CC	O	O
the	DT	O	O
accumulation	NN	O	O
of	IN	O	O
fluorescently	RB	O	O
labeled	VBN	O	O
platelets	NNS	O	O
was	VBD	O	O
observed	VBN	O	O
by	IN	O	O
intravital	JJ	O	O
microscopy	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
these	DT	O	O
mice	NNS	O	O
very	RB	O	O
closely	RB	O	O
mimic	JJ	O	O
severe	JJ	O	O
human	JJ	O	O
von	NN	B_Disease	B_Disease
Willebrand	NNP	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
and	CC	O	O
will	MD	O	O
be	VB	O	O
very	RB	O	O
useful	JJ	O	O
for	IN	O	O
investigating	VBG	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
vWf	NN	O	O
in	IN	O	O
normal	JJ	O	O
physiology	NN	O	O
and	CC	O	O
in	IN	O	O
disease	NN	O	O
models	NNS	O	O
.	.	O	O
.	.	O	O

9700175	CD	O	O

Oral	JJ	O	O
contraceptives	NNS	O	O
and	CC	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
hereditary	JJ	B_Disease	B_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

Hereditary	JJ	B_Disease	B_Disease
Ovarian	JJ	I_Disease	I_Disease
Cancer	NNP	E_Disease	E_Disease
Clinical	NNP	O	O
Study	NNP	O	O
Group	NNP	O	O
.	.	O	O

BACKGROUND	NNP	O	O
Women	NNP	O	O
with	IN	O	O
mutations	NNS	O	O
in	IN	O	O
either	CC	O	O
the	DT	O	O
BRCA1	NNP	O	O
or	CC	O	O
the	DT	O	O
BRCA2	NNP	O	O
gene	NN	O	O
have	VBP	O	O
a	DT	O	O
high	JJ	O	O
lifetime	NN	O	O
risk	NN	O	O
of	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

Oral	JJ	O	O
contraceptives	NNS	O	O
protect	VBP	O	O
against	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
general	JJ	O	O
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
whether	IN	O	O
they	PRP	O	O
also	RB	O	O
protect	VBP	O	O
against	IN	O	O
hereditary	JJ	B_Disease	B_Disease
forms	NNS	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

METHODS	NNP	O	O
We	PRP	O	O
enrolled	VBD	O	O
207	CD	O	O
women	NNS	O	O
with	IN	O	O
hereditary	JJ	B_Disease	B_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
161	CD	O	O
of	IN	O	O
their	PRP$	O	O
sisters	NNS	O	O
as	IN	O	O
controls	NNS	O	O
in	IN	O	O
a	DT	O	O
case	NN	O	O
-	:	O	O
control	NN	O	O
study	NN	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
patients	NNS	O	O
carried	VBD	O	O
a	DT	O	O
pathogenic	JJ	O	O
mutation	NN	O	O
in	IN	O	O
either	DT	O	O
BRCA1	NNP	O	O
(	(	O	O
179	CD	O	O
women	NNS	O	O
)	)	O	O
or	CC	O	O
BRCA2	NNP	O	O
(	(	O	O
28	CD	O	O
women	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
control	NN	O	O
women	NNS	O	O
were	VBD	O	O
enrolled	JJ	O	O
regardless	NN	O	O
of	IN	O	O
whether	IN	O	O
or	CC	O	O
not	RB	O	O
they	PRP	O	O
had	VBD	O	O
either	DT	O	O
mutation	NN	O	O
.	.	O	O

Lifetime	NNP	O	O
histories	NNS	O	O
of	IN	O	O
oral	JJ	O	O
-	:	O	O
contraceptive	NN	O	O
use	NN	O	O
were	VBD	O	O
obtained	VBN	O	O
by	IN	O	O
interview	NN	O	O
or	CC	O	O
by	IN	O	O
written	VBN	O	O
questionnaire	NN	O	O
and	CC	O	O
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
patients	NNS	O	O
and	CC	O	O
control	VB	O	O
women	NNS	O	O
,	,	O	O
after	IN	O	O
adjustment	NN	O	O
for	IN	O	O
year	NN	O	O
of	IN	O	O
birth	NN	O	O
and	CC	O	O
parity	NN	O	O
.	.	O	O

RESULTS	VB	O	O
The	DT	O	O
adjusted	JJ	O	O
odds	NNS	O	O
ratio	NN	O	O
for	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
any	DT	O	O
past	JJ	O	O
use	NN	O	O
of	IN	O	O
oral	JJ	O	O
contraceptives	NNS	O	O
was	VBD	O	O
0	CD	O	O
.	.	O	O

5	CD	O	O
(	(	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0	CD	O	O
.	.	O	O

3	CD	O	O
to	TO	O	O
0	CD	O	O
.	.	O	O

8	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
risk	NN	O	O
decreased	VBD	O	O
with	IN	O	O
increasing	VBG	O	O
duration	NN	O	O
of	IN	O	O
use	NN	O	O
(	(	O	O
P	NNP	O	O
for	IN	O	O
trend	NN	O	O
,	,	O	O
<	RB	O	O
0	CD	O	O
.	.	O	O

001	CD	O	O
)	)	O	O
;	:	O	O
use	NN	O	O
for	IN	O	O
six	CD	O	O
or	CC	O	O
more	JJR	O	O
years	NNS	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
60	CD	O	O
percent	NN	O	O
reduction	NN	O	O
in	IN	O	O
risk	NN	O	O
.	.	O	O

Oral	NNP	O	O
-	:	O	O
contraceptive	NN	O	O
use	NN	O	O
protected	VBN	O	O
against	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
both	DT	O	O
for	IN	O	O
carriers	NNS	O	O
of	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
mutation	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
0	CD	O	O
.	.	O	O

5	CD	O	O
;	:	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0	CD	O	O
.	.	O	O

3	CD	O	O
to	TO	O	O
0	CD	O	O
.	.	O	O

9	CD	O	O
)	)	O	O
and	CC	O	O
for	IN	O	O
carriers	NNS	O	O
of	IN	O	O
the	DT	O	O
BRCA2	NNP	O	O
mutation	NN	O	O
(	(	O	O
odds	NNS	O	O
ratio	NN	O	O
,	,	O	O
0	CD	O	O
.	.	O	O

4	CD	O	O
;	:	O	O
95	CD	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	,	O	O
0	CD	O	O
.	.	O	O

2	CD	O	O
to	TO	O	O
1	CD	O	O
.	.	O	O

1	CD	O	O
)	)	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Oral	NNP	O	O
-	:	O	O
contraceptive	NN	O	O
use	NN	O	O
may	MD	O	O
reduce	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
women	NNS	O	O
with	IN	O	O
pathogenic	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
or	CC	O	O
BRCA2	NNP	O	O
gene	NN	O	O

9702690	CD	O	O

A	DT	O	O
Japanese	JJ	O	O
family	NN	O	O
with	IN	O	O
adrenoleukodystrophy	NN	S_Disease	S_Disease
with	IN	O	O
a	DT	O	O
codon	NN	O	O
291	CD	O	O
deletion	NN	O	O
:	:	O	O
a	DT	O	O
clinical	JJ	O	O
,	,	O	O
biochemical	JJ	O	O
,	,	O	O
pathological	JJ	O	O
,	,	O	O
and	CC	O	O
genetic	JJ	O	O
report	NN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
a	DT	O	O
Japanese	JJ	O	O
family	NN	O	O
with	IN	O	O
adrenoleukodystrophy	NN	S_Disease	S_Disease
(	(	O	O
ALD	NNP	S_Disease	S_Disease
)	)	O	O
with	IN	O	O
a	DT	O	O
three	CD	O	O
base	NN	O	O
pair	NN	O	O
deletion	NN	O	O
(	(	O	O
delGAG	JJ	O	O
291	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
ALD	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

A	DT	O	O
variety	NN	O	O
of	IN	O	O
phenotypes	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
within	IN	O	O
this	DT	O	O
family	NN	O	O
.	.	O	O

While	IN	O	O
the	DT	O	O
proband	NN	O	O
(	(	O	O
patient	JJ	O	O
1	CD	O	O
)	)	O	O
was	VBD	O	O
classified	VBN	O	O
as	IN	O	O
having	VBG	O	O
a	DT	O	O
rare	JJ	O	O
intermediate	JJ	O	O
type	NN	O	O
of	IN	O	O
adult	JJ	O	O
cerebral	JJ	O	O
and	CC	O	O
cerebello	JJ	O	O
-	:	O	O
brain	NN	O	O
stem	NN	O	O
forms	NNS	O	O
,	,	O	O
his	PRP$	O	O
younger	JJR	O	O
brother	NN	O	O
(	(	O	O
patient	JJ	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
nephew	$	O	O
(	(	O	O
patient	JJ	O	O
3	CD	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
childhood	NN	O	O
ALD	NNP	S_Disease	S_Disease
type	NN	O	O
.	.	O	O

Another	DT	O	O
nephew	NN	O	O
(	(	O	O
patient	JJ	O	O
4	CD	O	O
)	)	O	O
of	IN	O	O
patient	NN	O	O
1	CD	O	O
was	VBD	O	O
classified	VBN	O	O
as	IN	O	O
having	VBG	O	O
an	DT	O	O
adolescent	JJ	O	O
form	NN	O	O
.	.	O	O

The	DT	O	O
tau	JJ	O	O
level	NN	O	O
in	IN	O	O
the	DT	O	O
cerebrospinal	JJ	O	O
fluid	NN	O	O
(	(	O	O
CSF	NNP	O	O
)	)	O	O
in	IN	O	O
patient	NN	O	O
1	CD	O	O
was	VBD	O	O
as	RB	O	O
high	JJ	O	O
as	IN	O	O
that	DT	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
Alzheimers	NNP	B_Disease	O
disease	NN	E_Disease	O
(	(	O	O
AD	NNP	S_Disease	O
)	)	O	O
.	.	O	O

His	PRP$	O	O
brain	NN	O	O
magnetic	JJ	O	O
resonance	NN	O	O
image	NN	O	O
(	(	O	O
MRI	NNP	O	O
)	)	O	O
showed	VBD	O	O
abnormalities	NNS	B_Disease	O
in	IN	I_Disease	O
the	DT	I_Disease	O
bilateral	JJ	I_Disease	B_Disease
cerebellar	NN	I_Disease	E_Disease
hemispheres	NNS	E_Disease	O
and	CC	O	O
brain	NN	O	O
stem	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
cerebral	JJ	O	O
white	JJ	O	O
matter	NN	O	O
,	,	O	O
where	WRB	O	O
marked	JJ	O	O
reductions	NNS	O	O
of	IN	O	O
the	DT	O	O
cerebral	JJ	O	O
blood	NN	O	O
flow	NN	O	O
and	CC	O	O
oxygen	NN	O	O
metabolism	NN	O	O
were	VBD	O	O
clearly	RB	O	O
demonstrated	VBN	O	O
by	IN	O	O
positron	NN	O	O
emission	NN	O	O
tomography	NN	O	O
(	(	O	O
PET	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
,	,	O	O
the	DT	O	O
autopsy	NN	O	O
findings	NNS	O	O
showed	VBD	O	O
massive	JJ	O	O
demyelination	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	O
cerebral	JJ	I_Disease	O
white	JJ	I_Disease	O
matter	NN	E_Disease	O
with	IN	O	O
sparing	NN	O	O
of	IN	O	O
the	DT	O	O
U	NNP	O	O
-	:	O	O
fibers	NNS	O	O
,	,	O	O
compatible	JJ	O	O
with	IN	O	O
the	DT	O	O
findings	NNS	O	O
of	IN	O	O
childhood	NN	O	O
ALD	NNP	S_Disease	S_Disease
.	.	O	O

Oleic	NNP	O	O
and	CC	O	O
erucic	JJ	O	O
acids	NNS	O	O
(	(	O	O
Lorenzos	NNP	O	O
Oil	NNP	O	O
)	)	O	O
were	VBD	O	O
administered	VBN	O	O
to	TO	O	O
patients	NNS	O	O
1	CD	O	O
and	CC	O	O
4	CD	O	O
,	,	O	O
but	CC	O	O
sufficient	JJ	O	O
effectiveness	NN	O	O
was	VBD	O	O
not	RB	O	O
obtained	VBN	O	O
.	.	O	O

The	DT	O	O
findings	NNS	O	O
in	IN	O	O
this	DT	O	O
family	NN	O	O
suggest	VBP	O	O
that	IN	O	O
delGAG291	NN	O	O
is	VBZ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
cause	NN	O	O
of	IN	O	O
Japanese	JJ	O	O
ALD	NNP	S_Disease	S_Disease
with	IN	O	O
phenotypic	JJ	O	O
variations	NNS	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
although	IN	O	O
the	DT	O	O
scale	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
is	VBZ	O	O
limited	VBN	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
possibility	NN	O	O
that	IN	O	O
PET	NNP	O	O
can	MD	O	O
detect	VB	O	O
an	DT	O	O
insidious	JJ	B_Disease	O
lesion	NN	E_Disease	O
which	WDT	O	O
is	VBZ	O	O
undetectable	JJ	O	O
by	IN	O	O
computed	JJ	O	O
tomogram	NN	O	O
(	(	O	O
CT	NNP	O	O
)	)	O	O
or	CC	O	O
MRI	NNP	O	O
analysis	NN	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
higher	JJR	O	O
level	NN	O	O
of	IN	O	O
tau	NN	O	O
reflects	VBZ	O	O
the	DT	O	O
process	NN	O	O
of	IN	O	O
neuronal	JJ	B_Disease	B_Disease
degeneration	NN	E_Disease	E_Disease
in	IN	O	O
ALD	NNP	S_Disease	S_Disease
.	.	O	O

Lorenzos	NNP	O	O
Oil	NNP	O	O
should	MD	O	O
be	VB	O	O
given	VBN	O	O
in	IN	O	O
the	DT	O	O
early	JJ	O	O
stage	NN	O	O
.	.	O	O
.	.	O	O

9703418	CD	O	O

Nonsense	NNP	O	O
mutation	NN	O	O
in	IN	O	O
exon	JJ	O	O
4	CD	O	O
of	IN	O	O
human	JJ	O	O
complement	NN	O	O
C9	NNP	O	O
gene	NN	O	O
is	VBZ	O	O
the	DT	O	O
major	JJ	O	O
cause	NN	O	O
of	IN	O	O
Japanese	JJ	O	B_Disease
complement	NN	B_Disease	I_Disease
C9	NNP	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O

Deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
ninth	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
human	JJ	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
(	(	O	O
C9	NNP	O	O
)	)	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
complement	NN	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
Japan	NNP	O	O
but	CC	O	O
is	VBZ	O	O
rare	JJ	O	O
in	IN	O	O
other	JJ	O	O
countries	NNS	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
the	DT	O	O
molecular	JJ	O	O
basis	NN	O	O
of	IN	O	O
C9	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
four	CD	O	O
Japanese	JJ	O	O
C9	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
deficient	NN	E_Disease	E_Disease
patients	NNS	O	O
who	WP	O	O
had	VBD	O	O
suffered	VBN	O	O
from	IN	O	O
meningococcal	JJ	B_Disease	B_Disease
meningitis	NN	E_Disease	E_Disease
.	.	O	O

Direct	JJ	O	O
sequencing	NN	O	O
of	IN	O	O
amplified	JJ	O	O
C9	NNP	O	O
cDNA	NN	O	O
and	CC	O	O
DNA	NNP	O	O
revealed	VBD	O	O
a	DT	O	O
nonsense	JJ	O	O
substitution	NN	O	O
(	(	O	O
CGA	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
TGA	NNP	O	O
)	)	O	O
at	IN	O	O
codon	$	O	O
95	CD	O	O
in	IN	O	O
exon	JJ	O	O
4	CD	O	O
in	IN	O	O
the	DT	O	O
four	CD	O	O
C9	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
deficient	NN	E_Disease	E_Disease
individuals	NNS	O	O
.	.	O	O

An	DT	O	O
allele	JJ	O	O
-	:	O	O
specific	JJ	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
system	NN	O	O
designed	VBN	O	O
to	TO	O	O
detect	VB	O	O
exclusively	RB	O	O
only	RB	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
and	CC	O	O
mutant	JJ	O	O
alleles	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
all	PDT	O	O
the	DT	O	O
four	CD	O	O
patients	NNS	O	O
were	VBD	O	O
homozygous	JJ	O	O
for	IN	O	O
the	DT	O	O
mutation	NN	O	O
in	IN	O	O
exon	CC	O	O
4	CD	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
parents	NNS	O	O
of	IN	O	O
patient	JJ	O	O
2	CD	O	O
were	VBD	O	O
heterozygous	JJ	O	O
.	.	O	O

The	DT	O	O
common	JJ	O	O
mutation	NN	O	O
at	IN	O	O
codon	NN	O	O
95	CD	O	O
in	IN	O	O
exon	JJ	O	O
4	CD	O	O
might	MD	O	O
be	VB	O	O
responsible	JJ	O	O
for	IN	O	O
most	JJS	O	O
Japanese	JJ	O	O
C9	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O
.	.	O	O

9703501	CD	O	O

BRCA1	NNP	O	O
required	VBD	O	O
for	IN	O	O
transcription	NN	O	O
-	:	O	O
coupled	VBN	O	O
repair	NN	O	O
of	IN	O	O
oxidative	JJ	O	O
DNA	NNP	O	O
damage	NN	O	O
.	.	O	O

The	DT	O	O
breast	NN	B_Disease	B_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
susceptibility	NN	O	O
gene	NN	O	O
BRCA1	NNP	O	O
encodes	VBZ	O	O
a	DT	O	O
zinc	NN	O	O
finger	NN	O	O
protein	NN	O	O
of	IN	O	O
unknown	JJ	O	O
function	NN	O	O
.	.	O	O

Association	NNP	O	O
of	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
protein	NN	O	O
with	IN	O	O
the	DT	O	O
DNA	NNP	O	O
repair	NN	O	O
protein	NN	O	O
Rad51	NNP	O	O
and	CC	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
phosphorylation	NN	O	O
and	CC	O	O
cellular	JJ	O	O
localization	NN	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
after	IN	O	O
exposure	NN	O	O
to	TO	O	O
DNA	NNP	O	O
-	:	O	O
damaging	NN	O	O
agents	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
a	DT	O	O
role	NN	O	O
for	IN	O	O
BRCA1	NNP	O	O
in	IN	O	O
DNA	NNP	O	O
repair	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
shown	VBN	O	O
that	IN	O	O
mouse	NN	O	O
embryonic	JJ	O	O
stem	NN	O	O
cells	NNS	O	O
deficient	NN	B_Disease	O
in	IN	I_Disease	O
BRCA1	NNP	E_Disease	O
are	VBP	O	O
defective	JJ	O	O
in	IN	O	O
the	DT	O	O
ability	NN	O	O
to	TO	O	O
carry	VB	O	O
out	RP	O	O
transcription	NN	O	O
-	:	O	O
coupled	VBN	O	O
repair	NN	O	O
of	IN	O	O
oxidative	JJ	O	O
DNA	NNP	O	O
damage	NN	O	O
,	,	O	O
and	CC	O	O
are	VBP	O	O
hypersensitive	JJ	O	O
to	TO	O	O
ionizing	VBG	O	O
radiation	NN	O	O
and	CC	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
BRCA1	NNP	O	O
participates	NNS	O	O
,	,	O	O
directly	RB	O	O
or	CC	O	O
indirectly	RB	O	O
,	,	O	O
in	IN	O	O
transcription	NN	O	O
-	:	O	O
coupled	VBN	O	O
repair	NN	O	O
of	IN	O	O
oxidative	JJ	O	O
DNA	NNP	O	O
damage	NN	O	O
.	.	O	O
.	.	O	O

9705283	CD	O	O

Truncation	NN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
transactivation	NN	O	O
region	NN	O	O
of	IN	O	O
PAX6	NNP	O	O
result	NN	O	O
in	IN	O	O
dominant	JJ	O	O
-	:	O	O
negative	JJ	O	O
mutants	NNS	O	O
.	.	O	O

PAX6	NNP	O	O
is	VBZ	O	O
a	DT	O	O
transcription	NN	O	O
factor	NN	O	O
with	IN	O	O
two	CD	O	O
DNA	NNP	O	O
-	:	O	O
binding	NN	O	O
domains	NNS	O	O
(	(	O	O
paired	VBN	O	O
box	NN	O	O
and	CC	O	O
homeobox	NN	O	O
)	)	O	O
and	CC	O	O
a	DT	O	O
proline	JJ	O	O
-	:	O	O
serine	NN	O	O
-	:	O	O
threonine	NN	O	O
(	(	O	O
PST	NNP	O	O
)	)	O	O
-	:	O	O
rich	JJ	O	O
transactivation	NN	O	O
domain	NN	O	O
.	.	O	O

PAX6	NNP	O	O
regulates	VBZ	O	O
eye	NN	O	O
development	NN	O	O
in	IN	O	O
animals	NNS	O	O
ranging	VBG	O	O
from	IN	O	O
jellyfish	NN	O	O
to	TO	O	O
Drosophila	NNP	O	O
to	TO	O	O
humans	NNS	O	O
.	.	O	O

Heterozygous	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
human	JJ	O	O
PAX6	NNP	O	O
gene	NN	O	O
result	NN	O	O
in	IN	O	O
various	JJ	O	O
phenotypes	NNS	O	O
,	,	O	O
including	VBG	O	O
aniridia	NN	S_Disease	S_Disease
,	,	O	O
Peters	NNP	B_Disease	B_Disease
anomaly	VBP	E_Disease	E_Disease
,	,	O	O
autosomal	JJ	B_Disease	O
dominant	JJ	I_Disease	O
keratitis	NN	E_Disease	O
,	,	O	O
and	CC	O	O
familial	JJ	B_Disease	B_Disease
foveal	NN	I_Disease	I_Disease
dysplasia	NN	E_Disease	E_Disease
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
believed	VBN	O	O
that	IN	O	O
the	DT	O	O
mutated	JJ	O	O
allele	NN	O	O
of	IN	O	O
PAX6	NNP	O	O
produces	VBZ	O	O
an	DT	O	O
inactive	JJ	O	O
protein	NN	O	O
and	CC	O	O
aniridia	NN	S_Disease	S_Disease
is	VBZ	O	O
caused	VBN	O	O
due	JJ	O	O
to	TO	O	O
genetic	JJ	O	O
haploinsufficiency	NN	O	E_Disease
.	.	O	O

However	RB	O	O
,	,	O	O
several	JJ	O	O
truncation	NN	O	O
mutations	NNS	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
occur	VB	O	O
in	IN	O	O
the	DT	O	O
C	NNP	O	O
-	:	O	O
terminal	JJ	O	O
half	NN	O	O
of	IN	O	O
PAX6	NNP	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
Aniridia	NNP	S_Disease	S_Disease
resulting	VBG	O	O
in	IN	O	O
mutant	JJ	O	O
proteins	NNS	O	O
that	WDT	O	O
retain	VBP	O	O
the	DT	O	O
DNA	NNP	O	O
-	:	O	O
binding	NN	O	O
domains	NNS	O	O
but	CC	O	O
have	VBP	O	O
lost	VBN	O	O
most	JJS	O	O
of	IN	O	O
the	DT	O	O
transactivation	NN	O	O
domain	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
not	RB	O	O
clear	JJ	O	O
whether	IN	O	O
such	JJ	O	O
mutants	NNS	O	O
really	RB	O	O
behave	VBP	O	O
as	IN	O	O
loss	NN	O	O
-	:	O	O
of	IN	O	O
-	:	O	O
function	NN	O	O
mutants	NNS	O	O
as	IN	O	O
predicted	VBN	O	O
by	IN	O	O
haploinsufficiency	NN	O	S_Disease
.	.	O	O

Contrary	JJ	O	O
to	TO	O	O
this	DT	O	O
theory	NN	O	O
,	,	O	O
our	PRP$	O	O
data	NNS	O	O
showed	VBD	O	O
that	IN	O	O
these	DT	O	O
mutants	NNS	O	O
are	VBP	O	O
dominant	JJ	O	O
-	:	O	O
negative	JJ	O	O
in	IN	O	O
transient	JJ	O	O
transfection	NN	O	O
assays	NNS	O	O
when	WRB	O	O
they	PRP	O	O
are	VBP	O	O
coexpressed	VBN	O	O
with	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
PAX6	NNP	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
the	DT	O	O
dominant	JJ	O	O
-	:	O	O
negative	JJ	O	O
effects	NNS	O	O
result	VBP	O	O
from	IN	O	O
the	DT	O	O
enhanced	JJ	O	O
DNA	NNP	O	O
binding	VBG	O	O
ability	NN	O	O
of	IN	O	O
these	DT	O	O
mutants	NNS	O	O
.	.	O	O

Kinetic	JJ	O	O
studies	NNS	O	O
of	IN	O	O
binding	NN	O	O
and	CC	O	O
dissociation	NN	O	O
revealed	VBD	O	O
that	IN	O	O
various	JJ	O	O
truncation	NN	O	O
mutants	NNS	O	O
have	VBP	O	O
3	CD	O	O
-	:	O	O
5	CD	O	O
-	:	O	O
fold	NN	O	O
higher	JJR	O	O
affinity	NN	O	O
to	TO	O	O
various	JJ	O	O
DNA	NNP	O	O
-	:	O	O
binding	NN	O	O
sites	NNS	O	O
when	WRB	O	O
compared	VBN	O	O
with	IN	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
PAX6	NNP	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
provide	VBP	O	O
a	DT	O	O
new	JJ	O	O
insight	NN	O	O
into	IN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
mutant	JJ	O	O
PAX6	NNP	O	O
in	IN	O	O
causing	VBG	O	O
aniridia	NN	S_Disease	S_Disease
.	.	O	O
.	.	O	O

9709714	CD	O	O

Reversal	NNP	O	O
of	IN	O	O
severe	JJ	O	O
hypertrophic	JJ	B_Disease	B_Disease
cardiomyopathy	NN	E_Disease	E_Disease
and	CC	O	O
excellent	JJ	O	O
neuropsychologic	JJ	O	O
outcome	NN	O	O
in	IN	O	O
very	RB	B_Disease	O
-	:	I_Disease	O
long	JJ	I_Disease	O
-	:	I_Disease	O
chain	NN	I_Disease	O
acyl	IN	I_Disease	O
-	:	I_Disease	O
coenzyme	NN	I_Disease	O
A	DT	I_Disease	O
dehydrogenase	NN	I_Disease	O
deficiency	NN	E_Disease	E_Disease
.	.	O	O

Very	RB	B_Disease	B_Disease
-	:	I_Disease	I_Disease
long	JJ	I_Disease	I_Disease
-	:	I_Disease	I_Disease
chain	NN	I_Disease	I_Disease
acyl	IN	I_Disease	I_Disease
-	:	I_Disease	I_Disease
coenzyme	NN	I_Disease	I_Disease
A	DT	I_Disease	I_Disease
dehydrogenase	NN	I_Disease	I_Disease
(	(	I_Disease	O
VLCAD	NNP	I_Disease	B_Disease
)	)	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
is	VBZ	O	O
a	DT	O	O
disorder	NN	O	O
of	IN	O	O
fatty	JJ	O	O
acid	JJ	O	O
beta	NN	O	O
oxidation	NN	O	O
that	WDT	O	O
reportedly	RB	O	O
has	VBZ	O	O
high	JJ	O	O
rates	NNS	O	O
of	IN	O	O
morbidity	NN	O	O
and	CC	O	O
mortality	NN	O	O
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
the	DT	O	O
outcome	NN	O	O
of	IN	O	O
a	DT	O	O
5	CD	O	O
-	:	O	O
year	NN	O	O
-	:	O	O
old	JJ	O	O
girl	NN	O	O
with	IN	O	O
VLCAD	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
who	WP	O	O
was	VBD	O	O
first	RB	O	O
seen	VBN	O	O
at	IN	O	O
5	CD	O	O
months	NNS	O	O
of	IN	O	O
age	NN	O	O
with	IN	O	O
severe	JJ	O	O
hypertrophic	JJ	B_Disease	B_Disease
cardiomyopathy	NN	E_Disease	E_Disease
,	,	O	O
hepatomegaly	NN	S_Disease	S_Disease
,	,	O	O
encephalopathy	NN	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
hypotonia	NN	S_Disease	S_Disease
.	.	O	O

Biochemical	JJ	O	O
studies	NNS	O	O
indicated	VBD	O	O
VLCAD	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
stable	JJ	O	O
yet	RB	O	O
inactive	JJ	O	O
enzyme	NN	O	O
.	.	O	O

Molecular	JJ	O	O
genetic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
her	PRP$	O	O
VLCAD	NNP	O	O
gene	NN	O	O
revealed	VBD	O	O
a	DT	O	O
T1372C	NNP	O	O
(	(	O	O
F458L	NNP	O	O
)	)	O	O
missense	NN	O	O
mutation	NN	O	O
and	CC	O	O
a	DT	O	O
1668	CD	O	O
ACAG	NNP	O	O
1669	CD	O	O
splice	NN	O	O
site	NN	O	O
mutation	NN	O	O
.	.	O	O

After	IN	O	O
initial	JJ	O	O
treatment	NN	O	O
with	IN	O	O
intravenous	JJ	O	O
glucose	NNS	O	O
and	CC	O	O
carnitine	NN	O	O
,	,	O	O
the	DT	O	O
patient	NN	O	O
has	VBZ	O	O
thrived	VBN	O	O
on	IN	O	O
a	DT	O	O
low	JJ	O	O
-	:	O	O
fat	NN	O	O
diet	JJ	O	O
supplemented	VBN	O	O
with	IN	O	O
medium	NN	O	O
-	:	O	O
chain	NN	O	O
triglyceride	JJ	O	O
oil	NN	O	O
and	CC	O	O
carnitine	NN	O	O
and	CC	O	O
avoidance	NN	O	O
of	IN	O	O
fasting	NN	O	O
.	.	O	O

Her	PRP$	O	O
ventricular	JJ	O	B_Disease
hypertrophy	NN	O	E_Disease
resolved	VBD	O	O
significantly	RB	O	O
over	IN	O	O
1	CD	O	O
year	NN	O	O
,	,	O	O
and	CC	O	O
cognitively	RB	O	O
,	,	O	O
she	PRP	O	O
is	VBZ	O	O
in	IN	O	O
the	DT	O	O
superior	JJ	O	O
range	NN	O	O
for	IN	O	O
age	NN	O	O
.	.	O	O

Clinical	JJ	O	O
recognition	NN	O	O
of	IN	O	O
VLCAD	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
is	VBZ	O	O
important	JJ	O	O
because	IN	O	O
it	PRP	O	O
is	VBZ	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
few	JJ	O	O
directly	RB	O	O
treatable	JJ	O	O
causes	NNS	O	O
of	IN	O	O
cardiomyopathy	NN	S_Disease	S_Disease
in	IN	O	O
children	NNS	O	O
.	.	O	O
.	.	O	O

9714764	CD	O	O

Cloning	NN	O	O
of	IN	O	O
a	DT	O	O
novel	JJ	O	O
member	NN	O	O
of	IN	O	O
the	DT	O	O
low	JJ	O	O
-	:	O	O
density	NN	O	O
lipoprotein	NN	O	O
receptor	NN	O	O
family	NN	O	O
.	.	O	O

A	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
a	DT	O	O
novel	JJ	O	O
transmembrane	NN	O	O
protein	NN	O	O
was	VBD	O	O
identified	VBN	O	O
by	IN	O	O
DNA	NNP	O	O
sequence	NN	O	O
analysis	NN	O	O
within	IN	O	O
the	DT	O	O
insulin	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
dependent	NN	I_Disease	I_Disease
diabetes	VBZ	I_Disease	I_Disease
mellitus	NNS	E_Disease	E_Disease
(	(	O	O
IDDM	NNP	S_Disease	S_Disease
)	)	O	O
locus	VBZ	O	O
IDDM4	NNP	O	O
on	IN	O	O
chromosome	NN	O	O
11q13	CD	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
its	PRP$	O	O
chromosomal	JJ	O	O
position	NN	O	O
,	,	O	O
this	DT	O	O
gene	NN	O	O
is	VBZ	O	O
a	DT	O	O
candidate	NN	O	O
for	IN	O	O
conferring	VBG	O	O
susceptibility	NN	O	O
to	TO	O	O
diabetes	NNS	S_Disease	S_Disease
.	.	O	O

The	DT	O	O
gene	NN	O	O
,	,	O	O
termed	VBD	O	O
low	JJ	O	O
-	:	O	O
density	NN	O	O
lipoprotein	VBZ	O	O
receptor	NN	O	O
related	JJ	O	O
protein	NN	O	O
5	CD	O	O
(	(	O	O
LRP5	NNP	O	O
)	)	O	O
,	,	O	O
encodes	VBZ	O	O
a	DT	O	O
protein	NN	O	O
of	IN	O	O
1615	CD	O	O
amino	NN	O	O
acids	NNS	O	O
that	WDT	O	O
contains	VBZ	O	O
conserved	VBN	O	O
modules	NNS	O	O
which	WDT	O	O
are	VBP	O	O
characteristic	JJ	O	O
of	IN	O	O
the	DT	O	O
low	JJ	O	O
-	:	O	O
density	NN	O	O
lipoprotein	NN	O	O
(	(	O	O
LDL	NNP	O	O
)	)	O	O
receptor	NN	O	O
family	NN	O	O
.	.	O	O

These	DT	O	O
modules	NNS	O	O
include	VBP	O	O
a	DT	O	O
putative	JJ	O	O
signal	NN	O	O
peptide	NN	O	O
for	IN	O	O
protein	NN	O	O
export	NN	O	O
,	,	O	O
four	CD	O	O
epidermal	JJ	O	O
growth	NN	O	O
factor	NN	O	O
(	(	O	O
EGF	NNP	O	O
)	)	O	O
repeats	VBZ	O	O
with	IN	O	O
associated	JJ	O	O
spacer	NN	O	O
domains	NNS	O	O
,	,	O	O
three	CD	O	O
LDL	NNP	O	O
-	:	O	O
receptor	NN	O	O
(	(	O	O
LDLR	NNP	O	O
)	)	O	O
repeats	VBZ	O	O
,	,	O	O
a	DT	O	O
single	JJ	O	O
transmembrane	NN	O	O
spanning	VBG	O	O
domain	NN	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
cytoplasmic	JJ	O	O
domain	NN	O	O
.	.	O	O

The	DT	O	O
encoded	JJ	O	O
protein	NN	O	O
has	VBZ	O	O
a	DT	O	O
unique	JJ	O	O
organization	NN	O	O
of	IN	O	O
EGF	NNP	O	O
and	CC	O	O
LDLR	NNP	O	O
repeats	NNS	O	O
;	:	O	O
therefore	RB	O	O
,	,	O	O
LRP5	NNP	O	O
likely	JJ	O	O
represents	VBZ	O	O
a	DT	O	O
new	JJ	O	O
category	NN	O	O
of	IN	O	O
the	DT	O	O
LDLR	NNP	O	O
family	NN	O	O
.	.	O	O

Both	DT	O	O
human	JJ	O	O
and	CC	O	O
mouse	NN	O	O
LRP5	NNP	O	O
cDNAs	NN	O	O
have	VBP	O	O
been	VBN	O	O
isolated	VBN	O	O
and	CC	O	O
the	DT	O	O
encoded	JJ	O	O
mature	NN	O	O
proteins	NNS	O	O
are	VBP	O	O
95	CD	O	O
%	NN	O	O
identical	JJ	O	O
,	,	O	O
indicating	VBG	O	O
a	DT	O	O
high	JJ	O	O
degree	NN	O	O
of	IN	O	O
evolutionary	JJ	O	O
conservation	NN	O	O
.	.	O	O
.	.	O	O

9724771	CD	O	O

The	DT	O	O
APC	NNP	S_Disease	S_Disease
variants	NNS	O	O
I1307K	NNP	O	O
and	CC	O	O
E1317Q	NNP	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
colorectal	JJ	B_Disease	B_Disease
tumors	NNS	E_Disease	E_Disease
,	,	O	O
but	CC	O	O
not	RB	O	O
always	RB	O	O
with	IN	O	O
a	DT	O	O
family	NN	O	O
history	NN	O	O
.	.	O	O

Classical	JJ	O	O
familial	NN	B_Disease	B_Disease
adenomatous	JJ	I_Disease	I_Disease
polyposis	NN	E_Disease	E_Disease
(	(	O	O
FAP	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
a	DT	O	O
high	JJ	O	O
-	:	O	O
penetrance	NN	O	O
autosomal	JJ	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
that	WDT	O	O
predisposes	VBZ	O	O
to	TO	O	O
hundreds	NNS	O	O
or	CC	O	O
thousands	NNS	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
adenomas	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
and	CC	O	O
that	IN	O	O
results	NNS	O	O
from	IN	O	O
truncating	VBG	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

A	DT	O	O
variant	NN	O	O
of	IN	O	O
FAP	NNP	S_Disease	S_Disease
is	VBZ	O	O
attenuated	VBN	B_Disease	O
adenomatous	JJ	I_Disease	B_Disease
polyposis	NN	I_Disease	I_Disease
coli	NN	E_Disease	E_Disease
,	,	O	O
which	WDT	O	O
results	NNS	O	O
from	IN	O	O
germ	JJ	O	O
-	:	O	O
line	NN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
5	CD	O	O
and	CC	O	O
3	CD	O	O
regions	NNS	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

Attenuated	NNP	B_Disease	O
adenomatous	JJ	I_Disease	B_Disease
polyposis	NN	I_Disease	I_Disease
coli	NN	E_Disease	E_Disease
patients	NNS	O	O
have	VBP	O	O
"	VBN	O	O
multiple	JJ	O	O
"	NNP	O	B_Disease
colorectal	NN	B_Disease	I_Disease
adenomas	NN	E_Disease	E_Disease
(	(	O	O
typically	RB	O	O
fewer	JJR	O	O
than	IN	O	O
100	CD	O	O
)	)	O	O
without	IN	O	O
the	DT	O	O
florid	JJ	O	O
phenotype	NN	O	O
of	IN	O	O
classical	JJ	O	O
FAP	NNP	S_Disease	S_Disease
.	.	O	O

Another	DT	O	O
group	NN	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
multiple	JJ	O	B_Disease
adenomas	NN	S_Disease	E_Disease
has	VBZ	O	O
no	DT	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
phenotype	NN	O	O
probably	RB	O	O
results	NNS	O	O
from	IN	O	O
variation	NN	O	O
at	IN	O	O
a	DT	O	O
locus	NN	O	O
,	,	O	O
or	CC	O	O
loci	NN	O	O
,	,	O	O
elsewhere	RB	O	O
in	IN	O	O
the	DT	O	O
genome	NN	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
a	DT	O	O
missense	NN	O	O
variant	NN	O	O
of	IN	O	O
APC	NNP	S_Disease	S_Disease
(	(	O	O
I1307K	NNP	O	O
)	)	O	O
was	VBD	O	O
described	VBN	O	O
that	IN	O	O
confers	NNS	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
tumors	NNS	E_Disease	E_Disease
,	,	O	O
including	VBG	O	O
multiple	JJ	O	O
adenomas	NN	S_Disease	S_Disease
,	,	O	O
in	IN	O	O
Ashkenazim	NNP	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
a	DT	O	O
set	NN	O	O
of	IN	O	O
164	CD	O	O
patients	NNS	O	O
with	IN	O	O
multiple	JJ	O	O
colorectal	JJ	B_Disease	B_Disease
adenomas	NN	I_Disease	E_Disease
and	CC	I_Disease	O
/	NN	I_Disease	O
or	CC	I_Disease	O
carcinoma	NN	E_Disease	S_Disease
and	CC	O	O
analyzed	VBD	O	O
codons	NNS	O	O
1263	CD	O	O
-	:	O	O
1377	CD	O	O
(	(	O	O
exon	VB	O	O
15G	CD	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
for	IN	O	O
germ	JJ	O	O
-	:	O	O
line	NN	O	O
variants	NNS	O	O
.	.	O	O

Three	CD	O	O
patients	NNS	O	O
with	IN	O	O
the	DT	O	O
I1307K	NNP	O	O
allele	NN	O	O
were	VBD	O	O
detected	VBN	O	O
,	,	O	O
each	DT	O	O
of	IN	O	O
Ashkenazi	NNP	O	O
descent	NN	O	O
.	.	O	O

Four	CD	O	O
patients	NNS	O	O
had	VBD	O	O
a	DT	O	O
germ	JJ	O	O
-	:	O	O
line	NN	O	O
E1317Q	NNP	O	O
missense	NN	O	O
variant	NN	O	O
of	IN	O	O
APC	NNP	O	S_Disease
that	WDT	O	O
was	VBD	O	O
not	RB	O	O
present	JJ	O	O
in	IN	O	O
controls	NNS	O	O
;	:	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
individuals	NNS	O	O
had	VBD	O	O
an	DT	O	O
unusually	RB	O	O
large	JJ	O	O
number	NN	O	O
of	IN	O	O
metaplastic	JJ	B_Disease	O
polyps	NNS	I_Disease	O
of	IN	I_Disease	O
the	DT	I_Disease	O
colorectum	NN	E_Disease	O
.	.	O	O

There	EX	O	O
is	VBZ	O	O
increasing	VBG	O	O
evidence	NN	O	O
that	IN	O	O
there	EX	O	O
exist	VBP	O	O
germ	SYM	O	O
-	:	O	O
line	NN	O	O
variants	NNS	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
that	WDT	O	O
predispose	VBP	O	O
to	TO	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
multiple	JJ	O	O
colorectal	JJ	B_Disease	B_Disease
adenomas	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
,	,	O	O
but	CC	O	O
without	IN	O	O
the	DT	O	O
florid	JJ	O	O
phenotype	NN	O	O
of	IN	O	O
classical	JJ	O	O
FAP	NNP	S_Disease	S_Disease
,	,	O	O
and	CC	O	O
possibly	RB	O	O
with	IN	O	O
importance	NN	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
risk	NN	O	O
in	IN	O	O
the	DT	O	O
general	JJ	O	O
population	NN	O	O
.	.	O	O
.	.	O	O

9729124	CD	O	O

Genomic	NNP	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
congenital	JJ	B_Disease	B_Disease
chloride	NN	I_Disease	I_Disease
diarrhea	NN	E_Disease	E_Disease
(	(	O	O
CLD	NNP	S_Disease	O
)	)	O	O
gene	NN	O	O
.	.	O	O

Congenital	NNP	B_Disease	B_Disease
chloride	NN	I_Disease	I_Disease
diarrhea	NN	E_Disease	E_Disease
(	(	O	O
CLD	NNP	S_Disease	O
)	)	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
mutations	NNS	O	O
in	IN	O	O
a	DT	O	O
gene	NN	O	O
which	WDT	O	O
encodes	VBZ	O	O
an	DT	O	O
intestinal	JJ	O	O
anion	NN	O	O
transporter	NN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
here	RB	O	O
the	DT	O	O
complete	JJ	O	O
genomic	JJ	O	O
organization	NN	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
CLD	NNP	S_Disease	O
gene	NN	O	O
which	WDT	O	O
spans	VBZ	O	O
approximately	RB	O	O
39kb	CD	O	O
,	,	O	O
and	CC	O	O
comprises	VBZ	O	O
21	CD	O	O
exons	NNS	O	O
.	.	O	O

All	DT	O	O
exon	VBP	O	O
/	NNP	O	O
intron	NN	O	O
boundaries	NNS	O	O
conform	VBP	O	O
to	TO	O	O
the	DT	O	O
GT	NNP	O	O
/	NNP	O	O
AG	NNP	O	O
rule	NN	O	O
.	.	O	O

An	DT	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
putative	JJ	O	O
promoter	NN	O	O
region	NN	O	O
sequence	NN	O	O
shows	VBZ	O	O
a	DT	O	O
putative	JJ	O	O
TATA	NNP	O	O
box	NN	O	O
and	CC	O	O
predicts	VBZ	O	O
multiple	JJ	O	O
transcription	NN	O	O
factor	NN	O	O
binding	VBG	O	O
sites	NNS	O	O
.	.	O	O

The	DT	O	O
genomic	JJ	O	O
structure	NN	O	O
was	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
DNA	NN	O	O
from	IN	O	O
several	JJ	O	O
sources	NNS	O	O
including	VBG	O	O
multiple	JJ	O	O
large	JJ	O	O
-	:	O	O
insert	NN	O	O
libaries	NNS	O	O
and	CC	O	O
genomic	JJ	O	O
DNA	NN	O	O
from	IN	O	O
Finnish	JJ	O	O
CLD	NNP	S_Disease	O
patients	NNS	O	O
and	CC	O	O
controls	NNS	O	O
.	.	O	O

Exon	NNP	O	O
-	:	O	O
specific	JJ	O	O
primers	NNS	O	O
developed	VBD	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
will	MD	O	O
facilitate	VB	O	O
mutation	NN	O	O
screening	VBG	O	O
studies	NNS	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O

Genomic	NNP	O	O
sequencing	NN	O	O
of	IN	O	O
a	DT	O	O
BAC	NNP	O	O
clone	NN	O	O
H	NNP	O	O
_	NNP	O	O
RG364P16	NNP	O	O
revealed	VBD	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
another	DT	O	O
,	,	O	O
highly	RB	O	O
homologous	JJ	O	O
gene	NN	O	O
3	CD	O	O
of	IN	O	O
the	DT	O	O
CLD	NNP	S_Disease	O
gene	NN	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
similar	JJ	O	O
genomic	JJ	O	O
structure	NN	O	O
,	,	O	O
recently	RB	O	O
identified	VBN	O	O
as	IN	O	O
the	DT	O	O
Pendred	NNP	B_Disease	B_Disease
syndrome	JJ	E_Disease	E_Disease
gene	NN	O	O
(	(	O	O
PDS	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O
.	.	O	O

9731533	CD	O	O

The	DT	O	O
APCI1307K	NNP	O	O
allele	NN	O	O
and	CC	O	O
cancer	NN	S_Disease	S_Disease
risk	NN	O	O
in	IN	O	O
a	DT	O	O
community	NN	O	O
-	:	O	O
based	VBN	O	O
study	NN	O	O
of	IN	O	O
Ashkenazi	NNP	O	O
Jews	NNP	O	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
APC	NNP	O	S_Disease
are	VBP	O	O
classically	RB	O	O
associated	VBN	O	O
with	IN	O	O
familial	JJ	B_Disease	B_Disease
adenomatous	JJ	I_Disease	I_Disease
polyposis	NN	E_Disease	E_Disease
(	(	O	O
FAP	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
a	DT	O	O
highly	RB	O	O
penetrant	JJ	O	O
autosomal	JJ	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
characterized	VBN	O	O
by	IN	O	O
multiple	JJ	O	O
intestinal	JJ	O	B_Disease
polyps	NNS	S_Disease	E_Disease
and	CC	O	O
,	,	O	O
without	IN	O	O
surgical	JJ	O	O
intervention	NN	O	O
,	,	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
(	(	O	O
CRC	NNP	S_Disease	O
)	)	O	O
.	.	O	O

APC	NNP	S_Disease	S_Disease
is	VBZ	O	O
a	DT	O	O
tumour	JJ	O	O
-	:	O	O
suppressor	NN	O	O
gene	NN	O	O
,	,	O	O
and	CC	O	O
somatic	JJ	O	O
loss	NN	O	O
occurs	VBZ	O	O
in	IN	O	O
tumours	NNS	S_Disease	S_Disease
.	.	O	O

The	DT	O	O
germline	NN	O	O
T	NNP	O	O
-	:	O	O
to	TO	O	O
-	:	O	O
A	DT	O	O
transversion	NN	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
APC	NNP	O	O
I1307K	NNP	O	O
allele	NN	O	O
converts	VBZ	O	O
the	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
sequence	NN	O	O
to	TO	O	O
a	DT	O	O
homopolymer	NN	O	O
tract	NN	O	O
(	(	O	O
A8	NNP	O	O
)	)	O	O
that	WDT	O	O
is	VBZ	O	O
genetically	RB	O	O
unstable	JJ	O	O
and	CC	O	O
prone	NN	O	O
to	TO	O	O
somatic	JJ	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
I1307K	NNP	O	O
allele	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
6	CD	O	O
.	.	O	O

1	CD	O	O
%	NN	O	O
of	IN	O	O
unselected	JJ	O	O
Ashkenazi	NNP	O	O
Jews	NNPS	O	O
and	CC	O	O
higher	JJR	O	O
proportions	NNS	O	O
of	IN	O	O
Ashkenazim	NNP	O	O
with	IN	O	O
family	NN	O	O
or	CC	O	O
personal	JJ	O	O
histories	NNS	O	O
of	IN	O	O
CRC	NNP	S_Disease	O
(	(	O	O
ref	NN	O	O
.	.	O	O

2	CD	O	O
)	)	O	O
.	.	O	O

To	TO	O	O
evaluate	VB	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
I1307K	NNP	O	O
in	IN	O	O
cancer	NN	S_Disease	S_Disease
,	,	O	O
we	PRP	O	O
genotyped	VBD	O	O
5	CD	O	O
,	,	O	O
081	CD	O	O
Ashkenazi	NNP	O	O
volunteers	NNS	O	O
in	IN	O	O
a	DT	O	O
community	NN	O	O
survey	NN	O	O
.	.	O	O

Risk	NN	O	O
of	IN	O	O
developing	VBG	O	O
colorectal	JJ	B_Disease	B_Disease
,	,	I_Disease	I_Disease
breast	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
other	JJ	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
were	VBD	O	O
compared	VBN	O	O
between	IN	O	O
genotyped	VBN	O	O
I1307K	NNP	O	O
carriers	NNS	O	O
and	CC	O	O
non	SYM	O	O
-	:	O	O
carriers	NNS	O	O
and	CC	O	O
their	PRP$	O	O
first	JJ	O	O
-	:	O	O
degree	NN	O	O
relatives	NNS	O	O
.	.	O	O

9733027	CD	O	O

Sperm	NNP	O	O
DNA	NNP	O	O
analysis	NN	O	O
in	IN	O	O
a	DT	O	O
Friedreich	NNP	B_Disease	B_Disease
ataxia	NN	E_Disease	E_Disease
premutation	NN	O	O
carrier	NN	O	O
suggests	VBZ	O	O
both	DT	O	O
meiotic	JJ	O	O
and	CC	O	O
mitotic	JJ	O	O
expansion	NN	O	O
in	IN	O	O
the	DT	O	O
FRDA	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

Friedreich	NNP	B_Disease	B_Disease
ataxia	NN	E_Disease	E_Disease
is	VBZ	O	O
usually	RB	O	O
caused	VBN	O	O
by	IN	O	O
an	DT	O	O
expansion	NN	O	O
of	IN	O	O
a	DT	O	O
GAA	NNP	O	O
trinucleotide	NN	O	O
repeat	NN	O	O
in	IN	O	O
intron	NN	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
FRDA	NNP	S_Disease	S_Disease
gene	NN	O	O
.	.	O	O

Occasionally	RB	O	O
,	,	O	O
a	DT	O	O
fully	RB	O	O
expanded	VBN	O	O
allele	NN	O	O
has	VBZ	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
arise	VB	O	O
from	IN	O	O
a	DT	O	O
premutation	NN	O	O
of	IN	O	O
100	CD	O	O
or	CC	O	O
less	JJR	O	O
triplet	JJ	O	O
repeats	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
examined	VBN	O	O
the	DT	O	O
sperm	JJ	O	O
DNA	NNP	O	O
of	IN	O	O
a	DT	O	O
premutation	NN	O	O
carrier	NN	O	O
.	.	O	O

This	DT	O	O
mans	VBZ	O	O
leucocyte	JJ	O	O
DNA	NN	O	O
showed	VBD	O	O
one	CD	O	O
normal	JJ	O	O
allele	NN	O	O
and	CC	O	O
one	CD	O	O
allele	NN	O	O
of	IN	O	O
approximately	RB	O	O
100	CD	O	O
repeats	NNS	O	O
.	.	O	O

His	PRP$	O	O
sperm	NN	O	O
showed	VBD	O	O
an	DT	O	O
expanded	VBN	O	O
allele	NN	O	O
in	IN	O	O
a	DT	O	O
tight	JJ	O	O
range	NN	O	O
centering	VBG	O	O
on	IN	O	O
a	DT	O	O
size	NN	O	O
of	IN	O	O
approximately	RB	O	O
320	CD	O	O
trinucleotide	JJ	O	O
repeats	NNS	O	O
.	.	O	O

His	PRP$	O	O
affected	JJ	O	O
son	NN	O	O
has	VBZ	O	O
repeat	NN	O	O
sizes	NNS	O	O
of	IN	O	O
1040	CD	O	O
and	CC	O	O
540	CD	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
expansion	NN	O	O
occurs	NNS	O	O
in	IN	O	O
two	CD	O	O
stages	NNS	O	O
,	,	O	O
the	DT	O	O
first	JJ	O	O
during	IN	O	O
meiosis	NN	O	O
followed	VBN	O	O
by	IN	O	O
a	DT	O	O
second	JJ	O	O
mitotic	JJ	O	O
expansion	NN	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
show	VBP	O	O
that	IN	O	O
in	IN	O	O
all	DT	O	O
informative	JJ	O	O
carrier	NN	O	O
father	NN	O	O
to	TO	O	O
affected	JJ	O	O
child	NN	O	O
transmissions	NNS	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
notable	JJ	O	O
exception	NN	O	O
of	IN	O	O
the	DT	O	O
premutation	NN	O	O
carrier	NN	O	O
,	,	O	O
the	DT	O	O
expansion	NN	O	O
size	NN	O	O
decreases	NNS	O	O
.	.	O	O
.	.	O	O

9744473	CD	O	O

The	DT	O	O
R496H	NNP	O	O
mutation	NN	O	O
of	IN	O	O
arylsulfatase	NN	O	O
A	NNP	O	O
does	VBZ	O	O
not	RB	O	O
cause	VB	O	O
metachromatic	JJ	B_Disease	B_Disease
leukodystrophy	NN	E_Disease	E_Disease
.	.	O	O

Deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
arylsulfatase	NN	I_Disease	I_Disease
A	NNP	E_Disease	E_Disease
(	(	O	O
ARSA	NNP	O	O
)	)	O	O
enzyme	VBP	O	O
activity	NN	O	O
causes	VBZ	O	O
metachromatic	JJ	B_Disease	B_Disease
leukodystrophy	NN	E_Disease	E_Disease
(	(	O	O
MLD	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

A	DT	O	O
number	NN	O	O
of	IN	O	O
ARSA	NNP	O	O
gene	NN	O	O
mutations	NNS	O	O
responsible	JJ	O	O
for	IN	O	O
MLD	NNP	S_Disease	S_Disease
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
the	DT	O	O
R496H	NNP	O	O
mutation	NN	O	O
of	IN	O	O
ARSA	NNP	O	O
was	VBD	O	O
proposed	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
cause	NN	O	O
of	IN	O	O
MLD	NNP	S_Disease	S_Disease
(	(	O	O
Draghia	NNP	O	O
et	RB	O	O
al	RB	O	O
.	.	O	O
,	,	O	O
1997	CD	O	O
)	)	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
investigated	VBN	O	O
the	DT	O	O
R496H	NNP	O	O
mutation	NN	O	O
and	CC	O	O
found	VBD	O	O
this	DT	O	O
mutation	NN	O	O
at	IN	O	O
a	DT	O	O
relatively	RB	O	O
high	JJ	O	O
frequency	NN	O	O
in	IN	O	O
an	DT	O	O
African	JJ	O	O
American	JJ	O	O
population	NN	O	O
(	(	O	O
f	JJ	O	O
=	NN	O	O
0	CD	O	O
.	.	O	O

09	CD	O	O
,	,	O	O
n	RB	O	O
=	VBZ	O	O
61	CD	O	O
subjects	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
ARSA	NNP	O	O
enzyme	NN	O	O
activity	NN	O	O
in	IN	O	O
subjects	NNS	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
the	DT	O	O
R496H	NNP	O	O
mutation	NN	O	O
was	VBD	O	O
determined	VBN	O	O
and	CC	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
normal	JJ	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
therefore	RB	O	O
concluded	VBD	O	O
that	IN	O	O
the	DT	O	O
R496H	NNP	O	O
mutation	NN	O	O
of	IN	O	O
ARSA	NNP	O	O
does	VBZ	O	O
not	RB	O	O
negatively	RB	O	O
influence	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
ARSA	NNP	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
a	DT	O	O
cause	NN	O	O
of	IN	O	O
MLD	NNP	S_Disease	S_Disease

9770531	CD	O	O

Down	NNP	O	O
-	:	O	O
regulation	NN	O	O
of	IN	O	O
transmembrane	NN	O	O
carbonic	JJ	O	O
anhydrases	NNS	O	O
in	IN	O	O
renal	JJ	B_Disease	B_Disease
cell	NN	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
cell	NN	O	O
lines	NNS	O	O
by	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
von	NN	B_Disease	I_Disease
Hippel	NNP	I_Disease	I_Disease
-	:	I_Disease	I_Disease
Lindau	NNP	E_Disease	E_Disease
transgenes	NNS	O	O
.	.	O	O

To	TO	O	O
discover	VB	O	O
genes	NNS	O	O
involved	VBN	O	O
in	IN	O	O
von	NN	B_Disease	B_Disease
Hippel	NNP	I_Disease	I_Disease
-	:	I_Disease	I_Disease
Lindau	NNP	E_Disease	E_Disease
(	(	O	O
VHL	NNP	S_Disease	S_Disease
)	)	O	O
-	:	O	O
mediated	VBN	O	O
carcinogenesis	NN	O	O
,	,	O	O
we	PRP	O	O
used	VBD	O	O
renal	JJ	B_Disease	B_Disease
cell	NN	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
cell	NN	O	O
lines	NNS	O	O
stably	RB	O	O
transfected	VBN	O	O
with	IN	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
VHL	NNP	O	O
-	:	O	O
expressing	VBG	O	O
transgenes	NNS	O	O
.	.	O	O

Large	JJ	O	O
-	:	O	O
scale	NN	O	O
RNA	NNP	O	O
differential	JJ	O	O
display	NN	O	O
technology	NN	O	O
applied	VBN	O	O
to	TO	O	O
these	DT	O	O
cell	NN	O	O
lines	NNS	O	O
identified	VBD	O	O
several	JJ	O	O
differentially	RB	O	O
expressed	VBN	O	O
genes	NNS	O	O
,	,	O	O
including	VBG	O	O
an	DT	O	O
alpha	NN	O	O
carbonic	JJ	O	O
anhydrase	NN	O	O
gene	NN	O	O
,	,	O	O
termed	VBD	O	O
CA12	NNP	O	O
.	.	O	O

The	DT	O	O
deduced	JJ	O	O
protein	NN	O	O
sequence	NN	O	O
was	VBD	O	O
classified	VBN	O	O
as	IN	O	O
a	DT	O	O
one	CD	O	O
-	:	O	O
pass	NN	O	O
transmembrane	NN	O	O
CA	NNP	O	O
possessing	VBG	O	O
an	DT	O	O
apparently	RB	O	O
intact	JJ	O	O
catalytic	JJ	O	O
domain	NN	O	O
in	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
CA	NNP	O	O
module	NN	O	O
.	.	O	O

Reintroduced	NNP	O	O
wild	SYM	O	O
-	:	O	O
type	NN	O	O
VHL	NNP	S_Disease	S_Disease
strongly	RB	O	O
inhibited	VBD	O	O
the	DT	O	O
overexpression	NN	O	O
of	IN	O	O
the	DT	O	O
CA12	NNP	O	O
gene	NN	O	O
in	IN	O	O
the	DT	O	O
parental	JJ	O	O
renal	NN	B_Disease	B_Disease
cell	NN	I_Disease	I_Disease
carcinoma	NN	E_Disease	E_Disease
cell	NN	O	O
lines	NNS	O	O
.	.	O	O

Similar	JJ	O	O
results	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
with	IN	O	O
CA9	NNP	O	O
,	,	O	O
encoding	VBG	O	O
another	DT	O	O
transmembrane	NN	O	O
CA	NNP	O	O
with	IN	O	O
an	DT	O	O
intact	JJ	O	O
catalytic	JJ	O	O
domain	NN	O	O
.	.	O	O

Although	IN	O	O
both	DT	O	O
domains	NNS	O	O
of	IN	O	O
the	DT	O	O
VHL	NNP	S_Disease	S_Disease
protein	NN	O	O
contribute	NN	O	O
to	TO	O	O
regulation	NN	O	O
of	IN	O	O
CA12	NNP	O	O
expression	NN	O	O
,	,	O	O
the	DT	O	O
elongin	NN	O	O
binding	VBG	O	O
domain	NN	O	O
alone	RB	O	O
could	MD	O	O
effectively	RB	O	O
regulate	VB	O	O
CA9	NNP	O	O
expression	NN	O	O
.	.	O	O

We	PRP	O	O
mapped	VBD	O	O
CA12	NNP	O	O
and	CC	O	O
CA9	NNP	O	O
loci	VBP	O	O
to	TO	O	O
chromosome	VB	O	O
bands	NNS	O	O
15q22	CD	O	O
and	CC	O	O
17q21	CD	O	O
.	.	O	O

2	CD	O	O
respectively	RB	O	O
,	,	O	O
regions	NNS	O	O
prone	VBP	O	O
to	TO	O	O
amplification	NN	O	O
in	IN	O	O
some	DT	O	O
human	JJ	O	O
cancers	NNS	S_Disease	S_Disease
.	.	O	O

Additional	JJ	O	O
experiments	NNS	O	O
are	VBP	O	O
needed	VBN	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
CA	NNP	O	O
IX	NNP	O	O
and	CC	O	O
CA	NNP	O	O
XII	NNP	O	O
enzymes	VBZ	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
pH	NN	O	O
in	IN	O	O
the	DT	O	O
extracellular	JJ	O	O
microenvironment	NN	O	O
and	CC	O	O
its	PRP$	O	O
potential	JJ	O	O
impact	NN	O	O
on	IN	O	O
cancer	NN	S_Disease	S_Disease
cell	NN	O	O
growth	NN	O	O
.	.	O	O

9771706	CD	O	O

A	DT	O	O
gene	NN	O	O
encoding	VBG	O	O
a	DT	O	O
transmembrane	NN	O	O
protein	NN	O	O
is	VBZ	O	O
mutated	VBN	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
diabetes	NNS	B_Disease	B_Disease
mellitus	NNS	E_Disease	E_Disease
and	CC	O	O
optic	JJ	B_Disease	B_Disease
atrophy	NN	E_Disease	E_Disease
(	(	O	O
Wolfram	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
)	)	O	O
.	.	O	O

Wolfram	NNP	B_Disease	B_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
WFS	NNP	S_Disease	O
;	:	O	O
OMIM	NNP	O	O
222300	CD	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
neurodegenerative	JJ	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
defined	VBN	O	O
by	IN	O	O
young	JJ	O	O
-	:	O	O
onset	NN	O	O
non	SYM	O	O
-	:	O	O
immune	JJ	O	O
insulin	NN	B_Disease	I_Disease
-	:	I_Disease	I_Disease
dependent	NN	I_Disease	I_Disease
diabetes	VBZ	I_Disease	I_Disease
mellitus	NNS	E_Disease	E_Disease
and	CC	O	O
progressive	JJ	O	O
optic	JJ	B_Disease	B_Disease
atrophy	NN	E_Disease	E_Disease
.	.	O	O

Linkage	NN	O	O
to	TO	O	O
markers	NNS	O	O
on	IN	O	O
chromosome	NN	O	O
4p	CD	O	O
was	VBD	O	O
confirmed	VBN	O	O
in	IN	O	O
five	CD	O	O
families	NNS	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
meiotic	JJ	O	O
recombinants	NNS	O	O
and	CC	O	O
disease	VB	O	O
-	:	O	O
associated	VBN	O	O
haplotypes	NNS	O	O
,	,	O	O
the	DT	O	O
WFS	NNP	S_Disease	O
gene	NN	O	O
was	VBD	O	O
localized	VBN	O	O
to	TO	O	O
a	DT	O	O
BAC	NNP	O	O
/	NNP	O	O
P1	NNP	O	O
contig	NN	O	O
of	IN	O	O
less	JJR	O	O
than	IN	O	O
250	CD	O	O
kb	NN	O	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
a	DT	O	O
novel	JJ	O	O
gene	NN	O	O
(	(	O	O
WFS1	NNP	O	O
)	)	O	O
encoding	VBG	O	O
a	DT	O	O
putative	JJ	O	O
transmembrane	NN	O	O
protein	NN	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
all	DT	O	O
affected	JJ	O	O
individuals	NNS	O	O
in	IN	O	O
six	CD	O	O
WFS	NNP	S_Disease	O
families	NNS	O	O
,	,	O	O
and	CC	O	O
these	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
disease	NN	O	O
phenotype	NN	O	O
.	.	O	O

WFS1	NNP	O	O
appears	VBZ	O	O
to	TO	O	O
function	VB	O	O
in	IN	O	O
survival	NN	O	O
of	IN	O	O
islet	NN	O	O
beta	SYM	O	O
-	:	O	O
cells	NNS	O	O
and	CC	O	O
neurons	NNS	O	O
.	.	O	O
.	.	O	O

9774970	CD	O	O

Stable	JJ	O	O
interaction	NN	O	O
between	IN	O	O
the	DT	O	O
products	NNS	O	O
of	IN	O	O
the	DT	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
tumor	NN	S_Disease	S_Disease
suppressor	NN	O	O
genes	NNS	O	O
in	IN	O	O
mitotic	JJ	O	O
and	CC	O	O
meiotic	JJ	O	O
cells	NNS	O	O
.	.	O	O

BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
account	NN	O	O
for	IN	O	O
most	JJS	O	O
cases	NNS	O	O
of	IN	O	O
familial	JJ	O	O
,	,	O	O
early	JJ	O	O
onset	VBN	O	O
breast	NN	B_Disease	B_Disease
and	CC	I_Disease	I_Disease
/	NN	I_Disease	I_Disease
or	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
encode	NN	O	O
products	NNS	O	O
that	IN	O	O
each	DT	O	O
interact	NN	O	O
with	IN	O	O
hRAD51	NN	O	O
.	.	O	O

Results	NNS	O	O
presented	VBD	O	O
here	RB	O	O
show	VBP	O	O
that	IN	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
coexist	NN	O	O
in	IN	O	O
a	DT	O	O
biochemical	JJ	O	O
complex	NN	O	O
and	CC	O	O
colocalize	NN	O	O
in	IN	O	O
subnuclear	JJ	O	O
foci	NN	O	O
in	IN	O	O
somatic	JJ	O	O
cells	NNS	O	O
and	CC	O	O
on	IN	O	O
the	DT	O	O
axial	JJ	O	O
elements	NNS	O	O
of	IN	O	O
developing	VBG	O	O
synaptonemal	JJ	O	O
complexes	NNS	O	O
.	.	O	O

Like	IN	O	O
BRCA1	NNP	O	O
and	CC	O	O
RAD51	NNP	O	O
,	,	O	O
BRCA2	NNP	O	O
relocates	VBZ	O	O
to	TO	O	O
PCNA	NNP	O	O
+	NNP	O	O
replication	NN	O	O
sites	NNS	O	O
following	VBG	O	O
exposure	NN	O	O
of	IN	O	O
S	NNP	O	O
phase	NN	O	O
cells	NNS	O	O
to	TO	O	O
hydroxyurea	VB	O	O
or	CC	O	O
UV	NNP	O	O
irradiation	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
participate	VB	O	O
,	,	O	O
together	RB	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
pathway	NN	O	O
(	(	O	O
s	PRP	O	O
)	)	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
double	JJ	O	O
-	:	O	O
strand	NN	O	O
break	NN	O	O
repair	NN	O	O
and	CC	O	O
/	NN	O	O
or	CC	O	O
homologous	JJ	O	O
recombination	NN	O	O
.	.	O	O

Dysfunction	NN	O	O
of	IN	O	O
this	DT	O	O
pathway	NN	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
general	JJ	O	O
phenomenon	NN	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
cases	NNS	O	O
of	IN	O	O
hereditary	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
/	NN	I_Disease	I_Disease
or	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O
.	.	O	O

9790667	CD	O	O

A	DT	O	O
novel	JJ	O	O
Arg362Ser	NNP	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
sterol	NN	O	O
27	CD	O	O
-	:	O	O
hydroxylase	NN	O	O
gene	NN	O	O
(	(	O	O
CYP27	NNP	O	O
)	)	O	O
:	:	O	O
its	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
pre	NN	O	O
-	:	O	O
mRNA	NN	O	O
splicing	NN	O	O
and	CC	O	O
enzyme	JJ	O	O
activity	NN	O	O
.	.	O	O

A	DT	O	O
novel	JJ	O	O
C	NNP	O	O
to	TO	O	O
A	DT	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
sterol	NN	O	O
27	CD	O	O
-	:	O	O
hydroxylase	NN	O	O
gene	NN	O	O
(	(	O	O
CYP27	NNP	O	O
)	)	O	O
was	VBD	O	O
identified	VBN	O	O
by	IN	O	O
sequencing	VBG	O	O
amplified	VBN	O	O
CYP27	NNP	O	O
gene	NN	O	O
products	NNS	O	O
from	IN	O	O
a	DT	O	O
patient	NN	O	O
with	IN	O	O
cerebrotendinous	JJ	B_Disease	B_Disease
xanthomatosis	NN	E_Disease	E_Disease
(	(	O	O
CTX	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

The	DT	O	O
mutation	NN	O	O
changed	VBD	O	O
the	DT	O	O
adrenodoxin	NN	O	O
cofactor	NN	O	O
binding	VBG	O	O
residue	JJ	O	O
362Arg	CD	O	O
to	TO	O	O
362Ser	CD	O	O
(	(	O	O
CGT	NNP	O	O
362Arg	CD	O	O
to	TO	O	O
AGT	NNP	O	O
362Ser	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
was	VBD	O	O
responsible	JJ	O	O
for	IN	O	O
deficiency	NN	O	O
in	IN	O	O
the	DT	O	O
sterol	NN	O	O
27	CD	O	O
-	:	O	O
hydroxylase	NN	O	O
activity	NN	O	O
,	,	O	O
as	IN	O	O
confirmed	VBN	O	O
by	IN	O	O
expression	NN	O	O
of	IN	O	O
mutant	JJ	O	O
cDNA	NN	O	O
into	IN	O	O
COS	NNP	O	O
-	:	O	O
1	CD	O	O
cells	NNS	O	O
.	.	O	O

Quantitative	JJ	O	O
analysis	NN	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
CYP27	NNP	O	O
gene	NN	O	O
mRNA	NN	O	O
in	IN	O	O
the	DT	O	O
patient	NN	O	O
represented	VBD	O	O
52	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
level	NN	O	O
.	.	O	O

As	IN	O	O
the	DT	O	O
mutation	NN	O	O
occurred	VBD	O	O
at	IN	O	O
the	DT	O	O
penultimate	NN	O	O
nucleotide	NN	O	O
of	IN	O	O
exon	$	O	O
6	CD	O	O
(	(	O	O
-	:	O	O
2	CD	O	O
position	NN	O	O
of	IN	O	O
exon	$	O	O
6	CD	O	O
-	:	O	O
intron	NN	O	O
6	CD	O	O
splice	NN	O	O
site	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
,	,	O	O
we	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
the	DT	O	O
mutation	NN	O	O
may	MD	O	O
partially	RB	O	O
affect	VB	O	O
the	DT	O	O
normal	JJ	O	O
splicing	JJ	O	O
efficiency	NN	O	O
in	IN	O	O
exon	CC	O	O
6	CD	O	O
and	CC	O	O
cause	VB	O	O
alternative	JJ	O	O
splicing	NN	O	O
elsewhere	RB	O	O
,	,	O	O
which	WDT	O	O
resulted	VBD	O	O
in	IN	O	O
decreased	JJ	O	O
transcript	NN	O	O
in	IN	O	O
the	DT	O	O
patient	NN	O	O
.	.	O	O

Transfection	NN	O	O
of	IN	O	O
constructed	JJ	O	O
minigenes	NNS	O	O
,	,	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
the	DT	O	O
mutation	NN	O	O
,	,	O	O
into	IN	O	O
COS	NNP	O	O
-	:	O	O
1	CD	O	O
cells	NNS	O	O
confirmed	VBD	O	O
that	IN	O	O
the	DT	O	O
mutant	JJ	O	O
minigene	NN	O	O
was	VBD	O	O
responsible	JJ	O	O
for	IN	O	O
a	DT	O	O
mRNA	NN	O	O
species	VBZ	O	O
alternatively	RB	O	O
spliced	VBN	O	O
at	IN	O	O
an	DT	O	O
activated	JJ	O	O
cryptic	JJ	O	O
5	CD	O	O
splice	NN	O	O
site	NN	O	O
88	CD	O	O
bp	NN	O	O
upstream	NN	O	O
from	IN	O	O
the	DT	O	O
3	CD	O	O
end	NN	O	O
of	IN	O	O
exon	JJ	O	O
6	CD	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
C	NNP	O	O
to	TO	O	O
A	DT	O	O
mutation	NN	O	O
at	IN	O	O
the	DT	O	O
penultimate	NN	O	O
nucleotide	NN	O	O
of	IN	O	O
exon	JJ	O	O
6	CD	O	O
of	IN	O	O
the	DT	O	O
CYP27	NNP	O	O
gene	NN	O	O
not	RB	O	O
only	RB	O	O
causes	VBZ	O	O
the	DT	O	O
deficiency	NN	B_Disease	O
in	IN	I_Disease	O
the	DT	I_Disease	O
sterol	NN	I_Disease	O
27	CD	I_Disease	O
-	:	I_Disease	O
hydroxylase	NN	I_Disease	O
activity	NN	E_Disease	O
,	,	O	O
but	CC	O	O
also	RB	O	O
partially	RB	O	O
leads	VBZ	O	O
to	TO	O	O
alternative	VB	O	O
pre	JJ	O	O
-	:	O	O
mRNA	NN	O	O
splicing	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
.	.	O	O

To	TO	O	O
our	PRP$	O	O
knowledge	NN	O	O
,	,	O	O
this	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
report	NN	O	O
regarding	VBG	O	O
effects	NNS	O	O
on	IN	O	O
pre	NN	O	O
-	:	O	O
mRNA	NN	O	O
splicing	NN	O	O
of	IN	O	O
a	DT	O	O
mutation	NN	O	O
at	IN	O	O
the	DT	O	O
-	:	O	O
2	CD	O	O
position	NN	O	O
of	IN	O	O
a	DT	O	O
5	CD	O	O
splice	NN	O	O
site	NN	O	O
.	.	O	O

9792409	CD	O	O

ATM	NNP	O	O
germline	NN	O	O
mutations	NNS	O	O
in	IN	O	O
classical	JJ	O	O
ataxia	NN	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
patients	NNS	O	O
in	IN	O	O
the	DT	O	O
Dutch	JJ	O	O
population	NN	O	O
.	.	O	O

Germline	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
ATM	NNP	O	O
gene	NN	O	O
are	VBP	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
ataxia	SYM	B_Disease	B_Disease
-	:	I_Disease	I_Disease
telangiectasia	NN	E_Disease	E_Disease
(	(	O	O
A	DT	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
)	)	O	O
.	.	O	O

In	IN	O	O
our	PRP$	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
determined	VBN	O	O
the	DT	O	O
ATM	NNP	O	O
mutation	NN	O	O
spectrum	NN	O	O
in	IN	O	O
19	CD	O	O
classical	JJ	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
patients	NNS	O	O
,	,	O	O
including	VBG	O	O
some	DT	O	O
immigrant	JJ	O	O
populations	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
12	CD	O	O
of	IN	O	O
Dutch	NNP	O	O
ethnic	JJ	O	O
origin	NN	O	O
.	.	O	O

Both	DT	O	O
the	DT	O	O
protein	NN	O	O
truncation	NN	O	O
test	NN	O	O
(	(	O	O
PTT	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
restriction	NN	O	O
endonuclease	NN	O	O
fingerprinting	NN	O	O
(	(	O	O
REF	NNP	O	O
)	)	O	O
method	NN	O	O
were	VBD	O	O
used	VBN	O	O
and	CC	O	O
compared	VBN	O	O
for	IN	O	O
their	PRP$	O	O
detection	NN	O	O
efficiency	NN	O	O
,	,	O	O
identifying	VBG	O	O
76	CD	O	O
%	NN	O	O
and	CC	O	O
60	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
mutations	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Most	JJS	O	O
patients	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
compound	JJ	O	O
heterozygote	NN	O	O
.	.	O	O

Seventeen	JJ	O	O
mutations	NNS	O	O
were	VBD	O	O
distinct	JJ	O	O
,	,	O	O
of	IN	O	O
which	WDT	O	O
10	CD	O	O
were	VBD	O	O
not	RB	O	O
reported	VBN	O	O
previously	RB	O	O
.	.	O	O

Mutations	NNS	O	O
are	VBP	O	O
small	JJ	O	O
deletions	NNS	O	O
or	CC	O	O
point	NN	O	O
mutations	NNS	O	O
frequently	RB	O	O
affecting	VBG	O	O
splice	NN	O	O
sites	NNS	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
a	DT	O	O
16	CD	O	O
.	.	O	O

7	CD	O	O
-	:	O	O
kb	NN	O	O
genomic	JJ	O	O
deletion	NN	O	O
of	IN	O	O
the	DT	O	O
3	CD	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
,	,	O	O
most	RBS	O	O
likely	RB	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
recombination	NN	O	O
between	IN	O	O
two	CD	O	O
LINE	NNP	O	O
elements	NNS	O	O
,	,	O	O
was	VBD	O	O
identified	VBN	O	O
.	.	O	O

The	DT	O	O
most	RBS	O	O
frequently	RB	O	O
found	VBN	O	O
mutation	NN	O	O
,	,	O	O
identified	VBN	O	O
in	IN	O	O
three	CD	O	O
unrelated	JJ	O	O
Turkish	PDT	O	O
A	DT	B_Disease	O
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
individuals	NNS	O	O
,	,	O	O
was	VBD	O	O
previously	RB	O	O
described	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
Turkish	JJ	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
founder	NN	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
founder	NN	O	O
mutation	NN	O	O
among	IN	O	O
relatively	RB	O	O
small	JJ	O	O
ethnic	JJ	O	O
population	NN	O	O
groups	NNS	O	O
in	IN	O	O
Western	NNP	O	O
Europe	NNP	O	O
could	MD	O	O
indicate	VB	O	O
a	DT	O	O
high	JJ	O	O
carrier	NN	O	O
frequency	NN	O	O
in	IN	O	O
such	JJ	O	O
communities	NNS	O	O
.	.	O	O

In	IN	O	O
patients	NNS	O	O
of	IN	O	O
Dutch	NNP	O	O
ethnic	JJ	O	O
origin	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
no	DT	O	O
significant	JJ	O	O
founder	NN	O	O
effect	NN	O	O
could	MD	O	O
be	VB	O	O
identified	VBN	O	O
.	.	O	O

The	DT	O	O
observed	JJ	O	O
genetic	JJ	O	O
heterogeneity	NN	O	O
including	VBG	O	O
the	DT	O	O
relative	JJ	O	O
high	JJ	O	O
percentage	NN	O	O
of	IN	O	O
splice	NN	O	O
-	:	O	O
site	NN	O	O
mutations	NNS	O	O
had	VBD	O	O
no	DT	O	O
reflection	NN	O	O
on	IN	O	O
the	DT	O	O
phenotype	NN	O	O
.	.	O	O

All	DT	O	O
patients	NNS	O	O
manifested	VBD	O	O
classical	JJ	O	O
A	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
T	NN	E_Disease	E_Disease
and	CC	O	O
increased	VBD	O	O
cellular	JJ	O	O
radioresistant	NN	O	O
DNA	NNP	O	O
synthesis	NN	O	O
.	.	O	O

9792860	CD	O	O

Determination	NN	O	O
of	IN	O	O
the	DT	O	O
genomic	JJ	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
COL4A4	NNP	O	O
gene	NN	O	O
and	CC	O	O
of	IN	O	O
novel	JJ	O	O
mutations	NNS	O	O
causing	VBG	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
Alport	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
.	.	O	O

Autosomal	NNP	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
Alport	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
is	VBZ	O	O
a	DT	O	O
progressive	JJ	O	B_Disease
hematuric	NN	B_Disease	I_Disease
glomerulonephritis	NN	E_Disease	E_Disease
characterized	VBN	O	O
by	IN	O	O
glomerular	JJ	B_Disease	O
basement	NN	I_Disease	O
membrane	NN	I_Disease	B_Disease
abnormalities	NNS	E_Disease	E_Disease
and	CC	O	O
associated	VBN	O	O
with	IN	O	O
mutations	NNS	O	O
in	IN	O	O
either	CC	O	O
the	DT	O	O
COL4A3	NNP	O	O
or	CC	O	O
the	DT	O	O
COL4A4	NNP	O	O
gene	NN	O	O
,	,	O	O
which	WDT	O	O
encode	VBP	O	O
the	DT	O	O
alpha3	NN	O	O
and	CC	O	O
alpha4	JJ	O	O
type	NN	O	O
IV	NNP	O	O
collagen	NN	O	O
chains	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

To	TO	O	O
date	NN	O	O
,	,	O	O
mutation	NN	O	O
screening	NN	O	O
in	IN	O	O
the	DT	O	O
two	CD	O	O
genes	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
hampered	VBN	O	O
by	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
genomic	JJ	O	O
structure	NN	O	O
information	NN	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
here	RB	O	O
the	DT	O	O
complete	JJ	O	O
characterization	NN	O	O
of	IN	O	O
the	DT	O	O
48	CD	O	O
exons	NNS	O	O
of	IN	O	O
the	DT	O	O
COL4A4	NNP	O	O
gene	NN	O	O
,	,	O	O
a	DT	O	O
comprehensive	JJ	O	O
gene	NN	O	O
screen	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
subsequent	JJ	O	O
detection	NN	O	O
of	IN	O	O
10	CD	O	O
novel	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
eight	CD	O	O
patients	NNS	O	O
diagnosed	VBN	O	O
with	IN	O	O
autosomal	JJ	B_Disease	B_Disease
recessive	JJ	I_Disease	I_Disease
Alport	NNP	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
a	DT	O	O
glycine	NN	O	O
to	TO	O	O
alanine	VB	O	O
substitution	NN	O	O
in	IN	O	O
the	DT	O	O
collagenous	JJ	O	O
domain	NN	O	O
that	WDT	O	O
is	VBZ	O	O
apparently	RB	O	O
silent	JJ	O	O
in	IN	O	O
the	DT	O	O
heterozygous	JJ	O	O
carriers	NNS	O	O
,	,	O	O
in	IN	O	O
11	CD	O	O
.	.	O	O

5	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
control	NN	O	O
individuals	NNS	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
one	CD	O	O
control	NN	O	O
individual	JJ	O	O
homozygous	JJ	O	O
for	IN	O	O
this	DT	O	O
glycine	JJ	O	O
substitution	NN	O	O
.	.	O	O

There	EX	O	O
has	VBZ	O	O
been	VBN	O	O
no	DT	O	O
previous	JJ	O	O
finding	NN	O	O
of	IN	O	O
a	DT	O	O
glycine	JJ	O	O
substitution	NN	O	O
that	WDT	O	O
is	VBZ	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
any	DT	O	O
obvious	JJ	O	O
phenotype	NN	O	O
in	IN	O	O
homozygous	JJ	O	O
individuals	NNS	O	O
.	.	O	O

9792861	CD	O	O

Founder	NNP	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
French	JJ	O	O
Canadian	JJ	O	O
breast	NN	B_Disease	B_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
identified	VBN	O	O
four	CD	O	O
mutations	NNS	O	O
in	IN	O	O
each	DT	O	O
of	IN	O	O
the	DT	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
-	:	O	O
susceptibility	NN	O	O
genes	NNS	O	O
,	,	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
,	,	O	O
in	IN	O	O
French	JJ	O	O
Canadian	JJ	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
breast	NN	B_Disease	B_Disease
/	JJ	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
from	IN	O	O
Quebec	NNP	O	O
.	.	O	O

To	TO	O	O
identify	VB	O	O
founder	NN	O	O
effects	NNS	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
independently	RB	O	O
ascertained	VBN	O	O
French	JJ	O	O
Canadian	JJ	O	O
cancer	NN	S_Disease	S_Disease
families	NNS	O	O
for	IN	O	O
the	DT	O	O
distribution	NN	O	O
of	IN	O	O
these	DT	O	O
eight	CD	O	O
mutations	NNS	O	O
.	.	O	O

Mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
41	CD	O	O
of	IN	O	O
97	CD	O	O
families	NNS	O	O
.	.	O	O

Six	CD	O	O
of	IN	O	O
eight	CD	O	O
mutations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
at	IN	O	O
least	JJS	O	O
twice	RB	O	O
.	.	O	O

The	DT	O	O
BRCA1	NNP	O	O
C4446T	NNP	O	O
mutation	NN	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
mutation	NN	O	O
found	VBD	O	O
,	,	O	O
followed	VBN	O	O
by	IN	O	O
the	DT	O	O
BRCA2	NNP	O	O
8765delAG	CD	O	O
mutation	NN	O	O
.	.	O	O

Together	RB	O	O
,	,	O	O
these	DT	O	O
mutations	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
28	CD	O	O
of	IN	O	O
41	CD	O	O
families	NNS	O	O
identified	VBN	O	O
to	TO	O	O
have	VB	O	O
a	DT	O	O
mutation	NN	O	O
.	.	O	O

The	DT	O	O
odds	NNS	O	O
of	IN	O	O
detection	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
four	CD	O	O
BRCA1	NNP	O	O
mutations	NNS	O	O
was	VBD	O	O
18	CD	O	O
.	.	O	O

7x	CD	O	O
greater	JJR	O	O
if	IN	O	O
one	CD	O	O
or	CC	O	O
more	JJR	O	O
cases	NNS	O	O
of	IN	O	O
ovarian	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
were	VBD	O	O
also	RB	O	O
present	JJ	O	O
in	IN	O	O
the	DT	O	O
family	NN	O	O
.	.	O	O

The	DT	O	O
odds	NNS	O	O
of	IN	O	O
detection	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
four	CD	O	O
BRCA2	NNP	O	O
mutations	NNS	O	O
was	VBD	O	O
5	CD	O	O
.	.	O	O

3x	CD	O	O
greater	JJR	O	O
if	IN	O	O
there	EX	O	O
were	VBD	O	O
at	IN	O	O
least	JJS	O	O
five	CD	O	O
cases	NNS	O	O
of	IN	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
the	DT	O	O
family	NN	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
case	NN	O	O
<	VBZ	O	O
36	CD	O	O
years	NNS	O	O
of	IN	O	O
age	NN	O	O
was	VBD	O	O
strongly	RB	O	O
predictive	JJ	O	O
of	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
any	DT	O	O
of	IN	O	O
the	DT	O	O
eight	CD	O	O
mutations	NNS	O	O
screened	VBD	O	O
.	.	O	O

Carriers	NNS	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
mutation	NN	O	O
,	,	O	O
from	IN	O	O
different	JJ	O	O
families	NNS	O	O
,	,	O	O
shared	VBD	O	O
similar	JJ	O	O
haplotypes	NNS	O	O
,	,	O	O
indicating	VBG	O	O
that	IN	O	O
the	DT	O	O
mutant	JJ	O	O
alleles	NNS	O	O
were	VBD	O	O
likely	JJ	O	O
to	TO	O	O
be	VB	O	O
identical	JJ	O	O
by	IN	O	O
descent	NN	O	O
for	IN	O	O
a	DT	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
founder	NN	O	O
population	NN	O	O
.	.	O	O

The	DT	O	O
identification	NN	O	O
of	IN	O	O
common	JJ	O	O
BRCA1	NNP	O	O
and	CC	O	O
BRCA2	NNP	O	O
mutations	NNS	O	O
will	MD	O	O
facilitate	VB	O	O
carrier	NN	O	O
detection	NN	O	O
in	IN	O	O
French	JJ	O	O
Canadian	JJ	O	O
breast	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
breast	NN	B_Disease	B_Disease
/	JJ	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
families	NNS	O	O
.	.	O	O

9800909	CD	O	O

Are	NNP	O	O
Dp71	NNP	O	O
and	CC	O	O
Dp140	NNP	O	O
brain	NN	O	O
dystrophin	NN	O	O
isoforms	NNS	O	O
related	VBN	O	O
to	TO	O	O
cognitive	JJ	B_Disease	B_Disease
impairment	NN	E_Disease	E_Disease
in	IN	O	O
Duchenne	NNP	B_Disease	B_Disease
muscular	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
?	.	O	O
Molecular	NNP	O	O
study	NN	O	O
and	CC	O	O
neuropsychological	JJ	O	O
analysis	NN	O	O
were	VBD	O	O
performed	VBN	O	O
concurrently	RB	O	O
on	IN	O	O
49	CD	O	O
patients	NNS	O	O
with	IN	O	O
Duchenne	NNP	B_Disease	B_Disease
muscular	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DMD	NNP	S_Disease	S_Disease
)	)	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
find	VB	O	O
a	DT	O	O
molecular	JJ	O	O
explanation	NN	O	O
for	IN	O	O
the	DT	O	O
cognitive	JJ	B_Disease	B_Disease
impairment	NN	E_Disease	E_Disease
observed	VBN	O	O
in	IN	O	O
most	JJS	O	O
DMD	JJ	S_Disease	S_Disease
patients	NNS	O	O
.	.	O	O

Complete	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
dystrophin	JJ	O	O
gene	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
localization	NN	O	O
of	IN	O	O
deletions	NNS	O	O
and	CC	O	O
duplications	NNS	O	O
in	IN	O	O
relation	NN	O	O
to	TO	O	O
the	DT	O	O
different	JJ	O	O
DMD	NNP	S_Disease	S_Disease
promoters	NNS	O	O
.	.	O	O

Qualitative	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
Dp71	NNP	O	O
transcript	NN	O	O
and	CC	O	O
testing	VBG	O	O
for	IN	O	O
the	DT	O	O
specific	NN	O	O
first	JJ	O	O
exon	NN	O	O
of	IN	O	O
Dp140	NNP	O	O
were	VBD	O	O
also	RB	O	O
carried	VBN	O	O
out	RP	O	O
.	.	O	O

Neuropsychological	JJ	O	O
analysis	NN	O	O
assessed	VBD	O	O
verbal	JJ	O	O
and	CC	O	O
visuospatial	JJ	O	O
intelligence	NN	O	O
,	,	O	O
verbal	JJ	O	O
memory	NN	O	O
,	,	O	O
and	CC	O	O
reading	VBG	O	O
skills	NNS	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
molecular	JJ	O	O
and	CC	O	O
psychometric	JJ	O	O
findings	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
deletions	NNS	O	O
and	CC	O	O
duplications	NNS	O	O
that	WDT	O	O
were	VBD	O	O
localized	VBN	O	O
in	IN	O	O
the	DT	O	O
distal	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
seemed	VBD	O	O
to	TO	O	O
be	VB	O	O
preferentially	RB	O	O
associated	VBN	O	O
with	IN	O	O
cognitive	JJ	B_Disease	B_Disease
impairment	NN	E_Disease	E_Disease
.	.	O	O

Two	CD	O	O
altered	VBD	O	O
Dp71	NNP	O	O
transcripts	NNS	O	O
and	CC	O	O
two	CD	O	O
deleted	VBD	O	O
Dp140	NNP	O	O
DNA	NNP	O	O
sequences	NNS	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
four	CD	O	O
patients	NNS	O	O
with	IN	O	O
severe	JJ	O	O
cerebral	JJ	B_Disease	B_Disease
dysfunction	NN	E_Disease	E_Disease
.	.	O	O

These	DT	O	O
findings	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
some	DT	O	O
sequences	NNS	O	O
located	VBN	O	O
in	IN	O	O
the	DT	O	O
distal	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
and	CC	O	O
,	,	O	O
in	IN	O	O
particular	JJ	O	O
,	,	O	O
some	DT	O	O
DMD	NNP	S_Disease	S_Disease
isoforms	NNS	O	O
expressed	VBD	O	O
in	IN	O	O
the	DT	O	O
brain	NN	O	O
may	MD	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
cognitive	JJ	B_Disease	B_Disease
impairment	NN	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
DMD	NNP	S_Disease	S_Disease
.	.	O	O
.	.	O	O

9831355	CD	O	O

I1307K	NNP	O	O
APC	NNP	O	O
and	CC	O	O
hMLH1	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
a	DT	O	O
non	JJ	O	O
-	:	O	O
Jewish	JJ	O	O
family	NN	O	O
with	IN	O	O
hereditary	JJ	B_Disease	B_Disease
non	SYM	I_Disease	I_Disease
-	:	I_Disease	I_Disease
polyposis	NN	I_Disease	I_Disease
colorectal	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
a	DT	O	O
French	JJ	O	O
Canadian	JJ	O	O
hereditary	NN	B_Disease	B_Disease
non	SYM	I_Disease	I_Disease
-	:	I_Disease	I_Disease
polyposis	NN	I_Disease	I_Disease
colorectal	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
(	(	O	O
HNPCC	NNP	S_Disease	S_Disease
)	)	O	O
kindred	VBD	O	O
which	WDT	O	O
carries	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
truncating	VBG	O	O
mutation	NN	O	O
in	IN	O	O
hMLH1	NN	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
the	DT	O	O
I1307K	NNP	O	O
APC	NNP	O	S_Disease
polymorphism	NN	O	O
,	,	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	VBN	O	O
risk	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
,	,	O	O
is	VBZ	O	O
also	RB	O	O
present	JJ	O	O
in	IN	O	O
this	DT	O	O
family	NN	O	O
.	.	O	O

The	DT	O	O
I1307K	NNP	O	O
polymorphism	NN	O	O
has	VBZ	O	O
previously	RB	O	O
only	RB	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
individuals	NNS	O	O
of	IN	O	O
self	NN	O	O
-	:	O	O
reported	VBD	O	O
Ashkenazi	NNP	O	O
Jewish	NNP	O	O
origins	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
in	IN	O	O
this	DT	O	O
family	NN	O	O
,	,	O	O
there	EX	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
no	DT	O	O
relationship	NN	O	O
between	IN	O	O
the	DT	O	O
I1307K	NNP	O	O
polymorphism	NN	O	O
and	CC	O	O
the	DT	O	O
presence	NN	O	O
or	CC	O	O
absence	NN	O	O
of	IN	O	O
cancer	NN	S_Disease	S_Disease
.	.	O	O
.	.	O	O

9843038	CD	O	O

Identification	NN	O	O
of	IN	O	O
a	DT	O	O
novel	JJ	O	O
mutation	NN	O	O
of	IN	O	O
the	DT	O	O
CPO	NNP	O	O
gene	NN	O	O
in	IN	O	O
a	DT	O	O
Japanese	JJ	O	O
hereditary	JJ	B_Disease	O
coproporphyria	NNS	E_Disease	O
family	NN	O	O
.	.	O	O

Hereditary	JJ	B_Disease	B_Disease
coproporphyria	NN	E_Disease	E_Disease
(	(	O	O
HCP	NNP	S_Disease	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
dominant	JJ	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
characterized	VBN	O	O
by	IN	O	O
a	DT	O	O
deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
coproporphyrinogen	NN	I_Disease	I_Disease
oxidase	NN	E_Disease	E_Disease
(	(	O	O
CPO	NNP	O	O
)	)	O	O
caused	VBN	O	O
by	IN	O	O
a	DT	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
CPO	NNP	O	O
gene	NN	O	O
.	.	O	O

Only	RB	O	O
11	CD	O	O
mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
have	VBP	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
HCP	NNP	S_Disease	O
patients	NNS	O	O
.	.	O	O

We	PRP	O	O
report	VBP	O	O
another	DT	O	O
mutation	NN	O	O
in	IN	O	O
a	DT	O	O
Japanese	JJ	O	O
family	NN	O	O
.	.	O	O

Polymerase	NNP	O	O
chain	NN	O	O
reaction	NN	O	O
-	:	O	O
single	JJ	O	O
strand	VBP	O	O
conformational	JJ	O	O
polymorphism	NN	O	O
and	CC	O	O
direct	JJ	O	O
sequence	NN	O	O
analyses	NNS	O	O
demonstrated	VBD	O	O
a	DT	O	O
C	NNP	O	O
to	TO	O	O
T	NNP	O	O
substitution	NN	O	O
in	IN	O	O
exon	JJ	O	O
1	CD	O	O
of	IN	O	O
the	DT	O	O
CPO	NNP	O	O
gene	NN	O	O
at	IN	O	O
nucleotide	JJ	O	O
position	NN	O	O
85	CD	O	O
,	,	O	O
which	WDT	O	O
lies	VBZ	O	O
in	IN	O	O
the	DT	O	O
putative	JJ	O	O
presequence	NN	O	O
for	IN	O	O
targeting	VBG	O	O
to	TO	O	O
mitochondria	NNS	O	O
.	.	O	O

This	DT	O	O
mutation	NN	O	O
changes	VBZ	O	O
the	DT	O	O
codon	NN	O	O
for	IN	O	O
glutamine	NN	O	O
to	TO	O	O
a	DT	O	O
termination	NN	O	O
codon	NN	O	O
at	IN	O	O
amino	NN	O	O
acid	JJ	O	O
position	NN	O	O
29	CD	O	O
.	.	O	O

MaeI	NNP	O	O
restriction	NN	O	O
analysis	NN	O	O
showed	VBD	O	O
two	CD	O	O
other	JJ	O	O
carriers	NNS	O	O
in	IN	O	O
the	DT	O	O
family	NN	O	O
.	.	O	O

The	DT	O	O
C	NNP	O	B_Disease
-	:	O	I_Disease
T	NNP	O	E_Disease
mutation	NN	O	O
is	VBZ	O	O
located	VBN	O	O
within	IN	O	O
a	DT	O	O
recently	RB	O	O
proposed	VBN	O	O
putative	JJ	O	O
alternative	JJ	O	O
translation	NN	O	O
initiation	NN	O	O
codon	NN	O	O
(	(	O	O
TIC	NNP	O	O
-	:	O	O
1	CD	O	O
)	)	O	O
,	,	O	O
supporting	VBG	O	O
that	IN	O	O
TIC	NNP	O	O
-	:	O	O
1	CD	O	O
is	VBZ	O	O
the	DT	O	O
real	JJ	O	O
TIC	NNP	O	O
rather	RB	O	O
than	IN	O	O
TIC	NNP	O	O
-	:	O	O
2	CD	O	O
.	.	O	O
.	.	O	O

9848786	CD	O	O

Human	NNP	B_Disease	O
complement	NN	I_Disease	O
factor	NN	I_Disease	O
H	NNP	I_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
hemolytic	JJ	B_Disease	B_Disease
uremic	JJ	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
.	.	O	O

This	DT	O	O
study	NN	O	O
reports	NNS	O	O
on	IN	O	O
six	CD	O	O
cases	NNS	O	O
of	IN	O	O
deficiency	NN	B_Disease	O
in	IN	I_Disease	O
the	DT	I_Disease	O
human	JJ	I_Disease	O
complement	NN	I_Disease	O
regulatory	JJ	I_Disease	O
protein	NN	I_Disease	O
Factor	NNP	I_Disease	O
H	NNP	E_Disease	O
(	(	O	O
FH	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
context	NN	O	O
of	IN	O	O
an	DT	O	O
acute	JJ	B_Disease	O
renal	JJ	I_Disease	B_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

Five	CD	O	O
of	IN	O	O
the	DT	O	O
cases	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
children	NNS	O	O
presenting	VBG	O	O
with	IN	O	O
idiopathic	JJ	O	B_Disease
hemolytic	JJ	B_Disease	I_Disease
uremic	JJ	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
(	(	O	O
HUS	NNP	S_Disease	O
)	)	O	O
.	.	O	O

Two	CD	O	O
of	IN	O	O
the	DT	O	O
children	NNS	O	O
exhibited	VBD	O	O
a	DT	O	O
homozygous	JJ	O	B_Disease
deficiency	NN	O	E_Disease
characterized	VBN	O	O
by	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
the	DT	O	O
150	CD	O	O
-	:	O	O
kD	NN	O	O
form	NN	O	O
of	IN	O	O
Factor	NNP	O	O
H	NNP	O	O
and	CC	O	O
the	DT	O	O
presence	NN	O	O
,	,	O	O
upon	IN	O	O
immunoblotting	VBG	O	O
,	,	O	O
of	IN	O	O
the	DT	O	O
42	CD	O	O
-	:	O	O
kD	NN	O	O
Factor	NNP	O	O
H	NNP	O	O
-	:	O	O
like	IN	O	O
protein	NN	O	O
1	CD	O	O
(	(	O	O
FHL	NNP	O	O
-	:	O	O
1	CD	O	O
)	)	O	O
and	CC	O	O
other	JJ	O	O
FH	NNP	O	O
-	:	O	O
related	VBN	O	O
protein	NN	O	O
(	(	O	O
FHR	NNP	O	O
)	)	O	O
bands	VBZ	O	O
.	.	O	O

Southern	NNP	O	O
blot	NN	O	O
and	CC	O	O
PCR	NNP	O	O
analysis	NN	O	O
of	IN	O	O
DNA	NN	O	O
of	IN	O	O
one	CD	O	O
patient	NN	O	O
with	IN	O	O
homozygous	JJ	O	B_Disease
deficiency	NN	O	E_Disease
ruled	VBD	O	O
out	RP	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
a	DT	O	O
large	JJ	O	O
deletion	NN	O	O
of	IN	O	O
the	DT	O	O
FH	NNP	O	O
gene	NN	O	O
as	IN	O	O
the	DT	O	O
underlying	VBG	O	O
defect	NN	O	O
for	IN	O	O
the	DT	O	O
deficiency	NN	O	E_Disease
.	.	O	O

The	DT	O	O
other	JJ	O	O
four	CD	O	O
children	NNS	O	O
presented	VBN	O	O
with	IN	O	O
heterozygous	JJ	O	B_Disease
deficiency	NN	O	E_Disease
and	CC	O	O
exhibited	VBD	O	O
a	DT	O	O
normal	JJ	O	O
immunoblotting	NN	O	O
pattern	NN	O	O
of	IN	O	O
proteins	NNS	O	O
of	IN	O	O
the	DT	O	O
FH	NNP	O	O
family	NN	O	O
.	.	O	O

Factor	NN	B_Disease	B_Disease
H	NNP	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
is	VBZ	O	O
the	DT	O	O
only	JJ	O	O
complement	NN	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
HUS	NNP	S_Disease	O
.	.	O	O

These	DT	O	O
observations	NNS	O	O
suggest	VBP	O	O
a	DT	O	O
role	NN	O	O
for	IN	O	O
FH	NNP	O	O
and	CC	O	O
/	NNP	O	O
or	CC	O	O
FH	NNP	O	O
receptors	NNS	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
idiopathic	JJ	O	O
HUS	NNP	S_Disease	O
.	.	O	O
.	.	O	O

9852676	CD	O	O

Further	JJ	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
major	JJ	O	O
ancient	NN	O	O
mutation	NN	O	O
underlying	VBG	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
from	IN	O	O
linkage	NN	O	O
disequilibrium	NN	O	O
studies	NNS	O	O
in	IN	O	O
the	DT	O	O
Japanese	JJ	O	O
population	NN	O	O
.	.	O	O

The	DT	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
mutation	NN	O	O
is	VBZ	O	O
an	DT	O	O
unstable	JJ	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
n	RB	O	O
repeat	NN	O	O
,	,	O	O
present	NN	O	O
at	IN	O	O
a	DT	O	O
copy	NN	O	O
number	NN	O	O
of	IN	O	O
5	CD	O	O
-	:	O	O
37	CD	O	O
repeats	NNS	O	O
on	IN	O	O
normal	JJ	O	O
chromosomes	NNS	O	O
but	CC	O	O
amplified	VBD	O	O
to	TO	O	O
50	CD	O	O
-	:	O	O
3000	CD	O	O
copies	NNS	O	O
on	IN	O	O
DM	NNP	S_Disease	S_Disease
chromosomes	NNS	O	O
.	.	O	O

Previous	JJ	O	O
findings	NNS	O	O
in	IN	O	O
Caucasian	JJ	O	O
populations	NNS	O	O
of	IN	O	O
a	DT	O	O
DM	NNP	S_Disease	S_Disease
founder	NN	O	O
chromosome	NN	O	O
raise	VB	O	O
a	DT	O	O
question	NN	O	O
about	IN	O	O
the	DT	O	O
molecular	JJ	O	O
events	NNS	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
expansion	NN	O	O
mutation	NN	O	O
.	.	O	O

To	TO	O	O
investigate	VB	O	O
whether	IN	O	O
a	DT	O	O
founder	NN	O	O
chromosome	NN	O	O
for	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
mutation	NN	O	O
exists	VBZ	O	O
in	IN	O	O
the	DT	O	O
Japanese	JJ	O	O
population	NN	O	O
,	,	O	O
we	PRP	O	O
genotyped	VBD	O	O
families	NNS	O	O
using	VBG	O	O
polymorphic	JJ	O	O
markers	NNS	O	O
near	IN	O	O
the	DT	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
n	RB	O	O
repeat	JJ	O	O
region	NN	O	O
and	CC	O	O
constructed	VBD	O	O
haplotypes	NNS	O	O
.	.	O	O

Six	CD	O	O
different	JJ	O	O
haplotypes	NNS	O	O
were	VBD	O	O
found	VBN	O	O
and	CC	O	O
DM	NNP	S_Disease	S_Disease
alleles	NNS	O	O
were	VBD	O	O
always	RB	O	O
haplotype	VBN	O	O
A	NNP	O	O
.	.	O	O

To	TO	O	O
find	VB	O	O
an	DT	O	O
origin	NN	O	O
of	IN	O	O
the	DT	O	O
(	(	O	O
CTG	NNP	O	O
)	)	O	O
n	RB	O	O
repeat	JJ	O	O
mutation	NN	O	O
and	CC	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
the	DT	O	O
expansion	NN	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
Japanese	JJ	O	O
population	NN	O	O
we	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
90	CD	O	O
Japanese	JJ	O	O
DM	NNP	S_Disease	S_Disease
families	NNS	O	O
comprising	VBG	O	O
190	CD	O	O
affected	JJ	O	O
and	CC	O	O
130	CD	O	O
unaffected	JJ	O	O
members	NNS	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
a	DT	O	O
few	JJ	O	O
common	JJ	O	O
ancestral	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
both	DT	O	O
Caucasian	NNP	O	O
and	CC	O	O
Japanese	JJ	O	O
populations	NNS	O	O
have	VBP	O	O
originated	VBN	O	O
by	IN	O	O
expansion	NN	O	O
of	IN	O	O
an	DT	O	O
ancestral	JJ	O	O
n	NN	O	O
=	VBD	O	O
5	CD	O	O
repeat	NN	O	O
to	TO	O	O
n	VB	O	O
=	$	O	O
19	CD	O	O
-	:	O	O
37	CD	O	O
copies	NNS	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
support	NN	O	O
multistep	NN	O	O
models	NNS	O	O
of	IN	O	O
triplet	NN	O	O
repeat	NN	O	O
expansion	NN	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
proposed	VBN	O	O
for	IN	O	O
both	DT	O	O
DM	NNP	S_Disease	S_Disease
and	CC	O	O
Friedreichs	NNP	B_Disease	O
ataxia	NN	E_Disease	S_Disease
.	.	O	O
.	.	O	O

9856498	CD	O	O

The	DT	O	O
molecular	JJ	O	O
basis	NN	O	O
of	IN	O	O
C6	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
in	IN	O	O
the	DT	O	O
western	JJ	O	O
Cape	NNP	O	O
,	,	O	O
South	NNP	O	O
Africa	NNP	O	O
.	.	O	O

Deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
sixth	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
human	JJ	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
(	(	O	O
C6	NNP	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
reported	VBN	O	O
in	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
families	NNS	O	O
from	IN	O	O
the	DT	O	O
western	JJ	O	O
Cape	NNP	O	O
,	,	O	O
South	NNP	O	O
Africa	NNP	O	O
.	.	O	O

Meningococcal	JJ	B_Disease	O
disease	NN	E_Disease	O
is	VBZ	O	O
endemic	JJ	O	O
in	IN	O	O
the	DT	O	O
Cape	NNP	O	O
and	CC	O	O
almost	RB	O	O
all	DT	O	O
pedigrees	NNS	O	O
of	IN	O	O
total	JJ	O	O
C6	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
(	(	O	O
C6Q0	NNP	O	O
)	)	O	O
have	VBP	O	O
been	VBN	O	O
ascertained	VBN	O	O
because	IN	O	O
of	IN	O	O
recurrent	JJ	O	B_Disease
disease	NN	O	E_Disease
.	.	O	O

We	PRP	O	O
have	VBP	O	O
sequenced	VBN	O	O
the	DT	O	O
expressed	JJ	O	O
exons	NNS	O	O
of	IN	O	O
the	DT	O	O
C6	NNP	O	O
gene	NN	O	O
from	IN	O	O
selected	VBN	O	O
cases	NNS	O	O
and	CC	O	O
have	VBP	O	O
found	VBN	O	O
three	CD	O	O
molecular	JJ	O	O
defects	NNS	O	O
leading	VBG	O	O
to	TO	O	O
total	JJ	O	B_Disease
deficiency	NN	O	E_Disease
879delG	CD	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
the	DT	O	O
common	JJ	O	O
defect	NN	O	O
in	IN	O	O
the	DT	O	O
Cape	NNP	O	O
and	CC	O	O
hitherto	NN	O	O
unreported	JJ	O	O
,	,	O	O
and	CC	O	O
1195delC	CD	O	O
and	CC	O	O
1936delG	CD	O	O
,	,	O	O
which	WDT	O	O
have	VBP	O	O
been	VBN	O	O
previously	RB	O	O
reported	VBN	O	O
in	IN	O	O
African	NNP	O	O
-	:	O	O
Americans	NNPS	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
879delG	CD	O	O
and	CC	O	O
1195delC	CD	O	O
defects	NNS	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
characteristic	JJ	O	O
C6	NNP	O	B_Disease
/	NNP	O	I_Disease
C7	NNP	O	E_Disease
region	NN	O	O
DNA	NNP	O	O
marker	NN	O	O
haplotypes	NNS	O	O
,	,	O	O
although	IN	O	O
small	JJ	O	O
variations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
.	.	O	O

The	DT	O	O
1936delG	CD	O	O
defect	NN	O	O
was	VBD	O	O
observed	VBN	O	O
only	RB	O	O
once	RB	O	O
in	IN	O	O
the	DT	O	O
Cape	NNP	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
associated	JJ	O	O
haplotype	NN	O	O
could	MD	O	O
be	VB	O	O
deduced	VBN	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
from	IN	O	O
the	DT	O	O
haplotypes	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
these	DT	O	O
three	CD	O	O
molecular	NN	O	O
defects	NNS	O	O
account	VBP	O	O
for	IN	O	O
the	DT	O	O
defects	NNS	O	O
in	IN	O	O
all	PDT	O	O
the	DT	O	O
38	CD	O	O
unrelated	JJ	O	O
C6Q0	NNP	O	O
individuals	NNS	O	O
we	PRP	O	O
have	VBP	O	O
studied	VBN	O	O
from	IN	O	O
the	DT	O	O
Cape	NNP	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
also	RB	O	O
observed	VBN	O	O
the	DT	O	O
879delG	CD	O	O
defect	NN	O	O
in	IN	O	O
two	CD	O	O
Dutch	NNP	O	O
C6	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
deficient	NN	E_Disease	E_Disease
kindreds	NNS	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
879delG	CD	O	O
defect	NN	O	O
in	IN	O	O
the	DT	O	O
Cape	NNP	O	O
probably	RB	O	O
did	VBD	O	O
not	RB	O	O
come	VBN	O	O
from	IN	O	O
The	DT	O	O
Netherlands	NNP	O	O
.	.	O	O
.	.	O	O

9856499	CD	O	O

Complement	NNP	B_Disease	B_Disease
C7	NNP	I_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
:	:	O	O
seven	CD	O	O
further	JJR	O	O
molecular	JJ	O	B_Disease
defects	NNS	O	O
and	CC	O	O
their	PRP$	O	O
associated	VBN	O	O
marker	NN	O	O
haplotypes	NNS	O	O
.	.	O	O

Seven	RB	O	O
further	RBR	O	O
molecular	JJ	O	O
bases	NNS	O	O
of	IN	O	O
C7	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
are	VBP	O	O
described	VBN	O	O
.	.	O	O

All	PDT	O	O
these	DT	O	O
new	JJ	O	O
molecular	NN	O	O
defects	NNS	O	O
involve	VBP	O	O
single	JJ	O	O
-	:	O	O
nucleotide	JJ	O	O
events	NNS	O	O
,	,	O	O
deletions	NNS	O	O
and	CC	O	O
substitutions	NNS	O	O
,	,	O	O
some	DT	O	O
of	IN	O	O
which	WDT	O	O
alter	NN	O	O
splice	NN	O	O
sites	NNS	O	O
,	,	O	O
and	CC	O	O
others	NNS	O	O
codons	NNS	O	O
.	.	O	O

They	PRP	O	O
are	VBP	O	O
distributed	VBN	O	O
along	IN	O	O
the	DT	O	O
C7	NNP	O	O
gene	NN	O	O
,	,	O	O
but	CC	O	O
predominantly	RB	O	O
towards	VBZ	O	O
the	DT	O	O
3	CD	O	O
end	NN	O	O
.	.	O	O

All	DT	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
compound	NN	O	O
heterozygous	JJ	O	O
individuals	NNS	O	O
.	.	O	O

The	DT	O	O
C6	NNP	O	O
/	NNP	O	O
C7	NNP	O	O
marker	NN	O	O
haplotypes	NNS	O	O
associated	VBN	O	O
with	IN	O	O
most	JJS	O	O
C7	NNP	B_Disease	B_Disease
defects	NNS	E_Disease	E_Disease
are	VBP	O	O
tabulated	VBN	O	O
.	.	O	O
.	.	O	O

9861003	CD	O	O

A	DT	O	O
genome	JJ	O	O
-	:	O	O
wide	JJ	O	O
search	NN	O	O
for	IN	O	O
chromosomal	JJ	O	O
loci	NN	O	O
linked	VBN	O	O
to	TO	O	O
mental	JJ	O	O
health	NN	O	O
wellness	NN	O	O
in	IN	O	O
relatives	NNS	O	O
at	IN	O	O
high	JJ	O	O
risk	NN	O	O
for	IN	O	O
bipolar	JJ	B_Disease	B_Disease
affective	JJ	I_Disease	I_Disease
disorder	NN	E_Disease	E_Disease
among	IN	O	O
the	DT	O	O
Old	NNP	O	O
Order	NNP	O	O
Amish	NNP	O	O
.	.	O	O

Bipolar	JJ	B_Disease	O
affective	JJ	I_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
(	(	O	O
BPAD	NNP	S_Disease	O
;	:	O	O
manic	JJ	B_Disease	O
-	:	I_Disease	O
depressive	JJ	I_Disease	O
illness	NN	E_Disease	O
)	)	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
episodes	NNS	O	O
of	IN	O	O
mania	NN	S_Disease	O
and	CC	O	O
/	NN	O	O
or	CC	O	O
hypomania	NN	S_Disease	O
interspersed	VBN	O	O
with	IN	O	O
periods	NNS	O	O
of	IN	O	O
depression	NN	S_Disease	O
.	.	O	O

Compelling	VBG	O	O
evidence	NN	O	O
supports	VBZ	O	O
a	DT	O	O
significant	JJ	O	O
genetic	JJ	O	O
component	NN	O	O
in	IN	O	O
the	DT	O	O
susceptibility	NN	O	O
to	TO	O	O
develop	VB	O	O
BPAD	NNP	S_Disease	S_Disease
.	.	O	O

To	TO	O	O
date	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
linkage	NN	O	O
studies	NNS	O	O
have	VBP	O	O
attempted	VBN	O	O
only	RB	O	O
to	TO	O	O
identify	VB	O	O
chromosomal	JJ	O	O
loci	NN	O	O
that	WDT	O	O
cause	NN	O	O
or	CC	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
developing	VBG	O	O
BPAD	NNP	S_Disease	S_Disease
.	.	O	O

To	TO	O	O
determine	VB	O	O
whether	IN	O	O
there	EX	O	O
could	MD	O	O
be	VB	O	O
protective	JJ	O	O
alleles	NNS	O	O
that	WDT	O	O
prevent	VBP	O	O
or	CC	O	O
reduce	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
developing	VBG	O	O
BPAD	NNP	S_Disease	S_Disease
,	,	O	O
similar	JJ	O	O
to	TO	O	O
what	WP	O	O
is	VBZ	O	O
observed	VBN	O	O
in	IN	O	O
other	JJ	O	O
genetic	JJ	B_Disease	B_Disease
disorders	NNS	E_Disease	E_Disease
,	,	O	O
we	PRP	O	O
used	VBD	O	O
mental	JJ	O	O
health	NN	O	O
wellness	NN	O	O
(	(	O	O
absence	NN	O	O
of	IN	O	O
any	DT	O	O
psychiatric	JJ	B_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
)	)	O	O
as	IN	O	O
the	DT	O	O
phenotype	NN	O	O
in	IN	O	O
our	PRP$	O	O
genome	JJ	O	O
-	:	O	O
wide	JJ	O	O
linkage	NN	O	O
scan	NN	O	O
of	IN	O	O
several	JJ	O	O
large	JJ	O	O
multigeneration	NN	O	O
Old	NNP	O	O
Order	NNP	O	O
Amish	NNP	O	O
pedigrees	NNS	O	O
exhibiting	VBG	O	O
an	DT	O	O
extremely	RB	O	O
high	JJ	O	O
incidence	NN	O	O
of	IN	O	O
BPAD	NNP	S_Disease	S_Disease
.	.	O	O

We	PRP	O	O
have	VBP	O	O
found	VBN	O	O
strong	JJ	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
locus	NN	O	O
on	IN	O	O
chromosome	NN	O	O
4p	CD	O	O
at	IN	O	O
D4S2949	NNP	O	O
(	(	O	O
maximum	JJ	O	O
GENEHUNTER	NNP	O	O
-	:	O	O
PLUS	NNP	O	O
nonparametric	JJ	O	O
linkage	NN	O	O
score	VBD	O	O
=	JJ	O	O
4	CD	O	O
.	.	O	O

05	CD	O	O
,	,	O	O
P	NNP	O	O
=	VBZ	O	O
5	CD	O	O
.	.	O	O

22	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
-	:	O	O
4	CD	O	O
)	)	O	O
;	:	O	O
SIBPAL	NNP	O	O
Pempirical	NNP	O	O
value	NN	O	O
<	VBD	O	O
3	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
-	:	O	O
5	CD	O	O
)	)	O	O
)	)	O	O
and	CC	O	O
suggestive	JJ	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
locus	NN	O	O
on	IN	O	O
chromosome	NN	O	O
4q	CD	O	O
at	IN	O	O
D4S397	NNP	O	O
(	(	O	O
maximum	JJ	O	O
GENEHUNTER	NNP	O	O
-	:	O	O
PLUS	NNP	O	O
nonparametric	JJ	O	O
linkage	NN	O	O
score	VBD	O	O
=	JJ	O	O
3	CD	O	O
.	.	O	O

29	CD	O	O
,	,	O	O
P	NNP	O	O
=	VBZ	O	O
2	CD	O	O
.	.	O	O

57	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
-	:	O	O
3	CD	O	O
)	)	O	O
;	:	O	O
SIBPAL	NNP	O	O
Pempirical	NNP	O	O
value	NN	O	O
<	VBD	O	O
1	CD	O	O
x	JJ	O	O
10	CD	O	O
(	(	O	O
-	:	O	O
3	CD	O	O
)	)	O	O
)	)	O	O
that	WDT	O	O
are	VBP	O	O
linked	VBN	O	O
to	TO	O	O
mental	JJ	O	O
health	NN	O	O
wellness	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
certain	JJ	O	O
alleles	NNS	O	O
could	MD	O	O
prevent	VB	O	O
or	CC	O	O
modify	VB	O	O
the	DT	O	O
clinical	JJ	O	O
manifestations	NNS	O	O
of	IN	O	O
BPAD	NNP	S_Disease	S_Disease
and	CC	O	O
perhaps	RB	O	O
other	JJ	O	O
related	JJ	O	O
affective	JJ	B_Disease	B_Disease
disorders	NNS	E_Disease	E_Disease
.	.	O	O

9863607	CD	O	O

Segregation	NNP	O	O
distortion	NN	O	O
in	IN	O	O
myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
.	.	O	O

Myotonic	JJ	B_Disease	B_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
DM	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
an	DT	O	O
autosomal	JJ	B_Disease	B_Disease
dominant	NN	I_Disease	I_Disease
disease	NN	E_Disease	E_Disease
which	WDT	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
typical	JJ	O	O
pedigree	NN	O	O
,	,	O	O
shows	VBZ	O	O
a	DT	O	O
three	CD	O	O
generation	NN	O	O
anticipation	NN	O	O
cascade	NN	O	O
.	.	O	O

This	DT	O	O
results	NNS	O	O
in	IN	O	O
infertility	NN	S_Disease	S_Disease
and	CC	O	O
congenital	JJ	B_Disease	B_Disease
myotonic	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
CDM	NNP	S_Disease	O
)	)	O	O
with	IN	O	O
the	DT	O	O
disappearance	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
in	IN	O	O
that	DT	O	O
pedigree	NN	O	O
.	.	O	O

The	DT	O	O
concept	NN	O	O
of	IN	O	O
segregation	NN	O	O
distortion	NN	O	O
,	,	O	O
where	WRB	O	O
there	EX	O	O
is	VBZ	O	O
preferential	JJ	O	O
transmission	NN	O	O
of	IN	O	O
the	DT	O	O
larger	JJR	O	O
allele	NN	O	O
at	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
locus	NN	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
put	VBN	O	O
forward	RB	O	O
to	TO	O	O
explain	VB	O	O
partially	RB	O	O
the	DT	O	O
maintenance	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
in	IN	O	O
the	DT	O	O
population	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
survey	NN	O	O
of	IN	O	O
DM	NNP	S_Disease	S_Disease
in	IN	O	O
Northern	NNP	O	O
Ireland	NNP	O	O
,	,	O	O
59	CD	O	O
pedigrees	NNS	O	O
were	VBD	O	O
ascertained	VBN	O	O
.	.	O	O

Sibships	NNP	O	O
where	WRB	O	O
the	DT	O	O
status	NN	O	O
of	IN	O	O
all	PDT	O	O
the	DT	O	O
members	NNS	O	O
had	VBD	O	O
been	VBN	O	O
identified	VBN	O	O
were	VBD	O	O
examined	VBN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
transmission	NN	O	O
of	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
expansion	NN	O	O
from	IN	O	O
affected	JJ	O	O
parents	NNS	O	O
to	TO	O	O
their	PRP$	O	O
offspring	NN	O	O
.	.	O	O

Where	WRB	O	O
the	DT	O	O
transmitting	NN	O	O
parent	NN	O	O
was	VBD	O	O
male	JJ	O	O
,	,	O	O
58	CD	O	O
.	.	O	O

3	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
offspring	NN	O	O
were	VBD	O	O
affected	VBN	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
of	IN	O	O
a	DT	O	O
female	JJ	O	O
transmitting	NN	O	O
parent	NN	O	O
,	,	O	O
68	CD	O	O
.	.	O	O

7	CD	O	O
%	NN	O	O
were	VBD	O	O
affected	VBN	O	O
.	.	O	O

Studies	NNS	O	O
on	IN	O	O
meiotic	JJ	O	O
drive	NN	O	O
in	IN	O	O
DM	NNP	S_Disease	S_Disease
have	VBP	O	O
shown	VBN	O	O
increased	JJ	O	O
transmission	NN	O	O
of	IN	O	O
the	DT	O	O
larger	JJR	O	O
allele	NN	O	O
at	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
locus	NN	O	O
in	IN	O	O
non	JJ	O	O
-	:	O	O
DM	NN	O	S_Disease
heterozygotes	NNS	O	O
for	IN	O	O
CTGn	NNP	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
provides	VBZ	O	O
further	JJ	O	O
evidence	NN	O	O
that	IN	O	O
the	DT	O	O
DM	NNP	S_Disease	S_Disease
expansion	NN	O	O
tends	VBZ	O	O
to	TO	O	O
be	VB	O	O
transmitted	VBN	O	O
preferentially	RB	O	O
.	.	O	O

9867744	CD	O	O

Diagnosis	NN	O	O
of	IN	O	O
hemochromatosis	NN	S_Disease	S_Disease
.	.	O	O

If	IN	O	O
untreated	VBN	O	O
,	,	O	O
hemochromatosis	NN	S_Disease	S_Disease
can	MD	O	O
cause	VB	O	O
serious	JJ	O	O
illness	NN	O	O
and	CC	O	O
early	JJ	B_Disease	O
death	NN	E_Disease	O
,	,	O	O
but	CC	O	O
the	DT	O	O
disease	NN	O	O
is	VBZ	O	O
still	RB	O	O
substantially	RB	O	O
under	IN	O	O
-	:	O	O
diagnosed	VBN	O	O
.	.	O	O

The	DT	O	O
cornerstone	NN	O	O
of	IN	O	O
screening	NN	O	O
and	CC	O	O
case	NN	O	O
detection	NN	O	O
is	VBZ	O	O
the	DT	O	O
measurement	NN	O	O
of	IN	O	O
serum	NN	O	O
transferrin	NN	O	O
saturation	NN	O	O
and	CC	O	O
the	DT	O	O
serum	NN	O	O
ferritin	NN	O	O
level	NN	O	O
.	.	O	O

Once	RB	O	O
the	DT	O	O
diagnosis	NN	O	O
is	VBZ	O	O
suspected	VBN	O	O
,	,	O	O
physicians	NNS	O	O
must	MD	O	O
use	VB	O	O
serum	JJ	O	O
ferritin	NN	O	O
levels	NNS	O	O
and	CC	O	O
hepatic	JJ	O	O
iron	NN	O	O
stores	NNS	O	O
on	IN	O	O
liver	NN	O	O
biopsy	NN	O	O
specimens	VBZ	O	O
to	TO	O	O
assess	VB	O	O
patients	NNS	O	O
for	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
iron	NN	B_Disease	B_Disease
overload	NN	E_Disease	E_Disease
.	.	O	O

Liver	NNP	O	O
biopsy	NN	O	O
is	VBZ	O	O
also	RB	O	O
used	VBN	O	O
to	TO	O	O
establish	VB	O	O
the	DT	O	O
presence	NN	O	O
or	CC	O	O
absence	NN	O	O
of	IN	O	O
cirrhosis	NN	S_Disease	S_Disease
,	,	O	O
which	WDT	O	O
can	MD	O	O
affect	VB	O	O
prognosis	NN	O	O
and	CC	O	O
management	NN	O	O
.	.	O	O

A	DT	O	O
DNA	NNP	O	O
-	:	O	O
based	VBN	O	O
test	NN	O	O
for	IN	O	O
the	DT	O	O
HFE	NNP	O	O
gene	NN	O	O
is	VBZ	O	O
commercially	RB	O	O
available	JJ	O	O
,	,	O	O
but	CC	O	O
its	PRP$	O	O
place	NN	O	O
in	IN	O	O
the	DT	O	O
diagnosis	NN	O	O
of	IN	O	O
hemochromatosis	NN	S_Disease	S_Disease
is	VBZ	O	O
still	RB	O	O
being	VBG	O	O
evaluated	VBN	O	O
.	.	O	O

Currently	RB	O	O
,	,	O	O
the	DT	O	O
most	RBS	O	O
useful	JJ	O	O
role	NN	O	O
for	IN	O	O
this	DT	O	O
test	NN	O	O
is	VBZ	O	O
in	IN	O	O
the	DT	O	O
detection	NN	O	O
of	IN	O	O
hemochromatosis	NN	S_Disease	S_Disease
in	IN	O	O
the	DT	O	O
family	NN	O	O
members	NNS	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
a	DT	O	O
proven	JJ	O	O
case	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
crucial	JJ	O	O
to	TO	O	O
diagnose	VB	O	O
hemochromatosis	NN	S_Disease	S_Disease
before	IN	O	O
hepatic	JJ	B_Disease	B_Disease
cirrhosis	NN	E_Disease	E_Disease
develops	VBZ	O	O
because	IN	O	O
phlebotomy	JJ	O	O
therapy	NN	O	O
can	MD	O	O
avert	VB	O	O
serious	JJ	O	O
chronic	JJ	O	O
disease	NN	O	O
and	CC	O	O
can	MD	O	O
even	RB	O	O
lead	VB	O	O
to	TO	O	O
normal	JJ	O	O
life	NN	O	O
expectancy	NN	O	O
.	.	O	O
.	.	O	O

9869602	CD	O	O

Prevalence	NN	O	O
of	IN	O	O
the	DT	O	O
I1307K	NNP	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
variant	NN	O	O
in	IN	O	O
Israeli	NNP	O	O
Jews	NNP	O	O
of	IN	O	O
differing	VBG	O	O
ethnic	JJ	O	O
origin	NN	O	O
and	CC	O	O
risk	NN	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

BACKGROUND	NNP	O	O
&	CC	O	O
AIMS	NNP	O	O
Israeli	NNP	O	O
Jews	NNP	O	O
of	IN	O	O
European	NNP	O	O
birth	NN	O	O
,	,	O	O
i	NN	O	O
.	.	O	O

e	NN	O	O
.	.	O	O
,	,	O	O
Ashkenazim	NNP	O	O
,	,	O	O
have	VBP	O	O
the	DT	O	O
highest	JJS	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
incidence	NN	O	O
of	IN	O	O
any	DT	O	O
Israeli	NNP	O	O
ethnic	JJ	O	O
group	NN	O	O
.	.	O	O

The	DT	O	O
I1307K	NNP	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
variant	NN	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
6	CD	O	O
.	.	O	O

1	CD	O	O
%	NN	O	O
of	IN	O	O
American	JJ	O	O
Jews	NNP	O	O
,	,	O	O
28	CD	O	O
%	NN	O	O
of	IN	O	O
their	PRP$	O	O
familial	JJ	O	B_Disease
colorectal	NN	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
cases	NNS	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
non	JJ	O	O
-	:	O	O
Jews	NNS	O	O
.	.	O	O

We	PRP	O	O
assessed	VBD	O	O
the	DT	O	O
I1307K	NNP	O	O
prevalence	NN	O	O
in	IN	O	O
Israeli	NNP	O	O
Jews	NNP	O	O
of	IN	O	O
differing	VBG	O	O
ethnic	JJ	O	O
origin	NN	O	O
and	CC	O	O
risk	NN	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

METHODS	NNP	O	O
DNA	NNP	O	O
samples	NNS	O	O
from	IN	O	O
500	CD	O	O
unrelated	JJ	O	O
Jews	NNPS	O	O
of	IN	O	O
European	JJ	O	O
or	CC	O	O
non	JJ	O	O
-	:	O	O
European	JJ	O	O
origin	NN	O	O
,	,	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
a	DT	O	O
personal	JJ	O	O
and	CC	O	O
/	JJ	O	O
or	CC	O	O
family	NN	O	O
history	NN	O	O
of	IN	O	O
neoplasia	NN	S_Disease	S_Disease
,	,	O	O
were	VBD	O	O
examined	VBN	O	O
for	IN	O	O
the	DT	O	O
I1307K	NNP	O	O
variant	NN	O	O
by	IN	O	O
the	DT	O	O
allele	NN	O	O
-	:	O	O
specific	JJ	O	O
oligonucleotide	NN	O	O
(	(	O	O
ASO	NNP	O	O
)	)	O	O
method	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
In	IN	O	O
persons	NNS	O	O
at	IN	O	O
average	JJ	O	O
risk	NN	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
,	,	O	O
I1307K	NNP	O	O
was	VBD	O	O
found	VBN	O	O
in	IN	O	O
5	CD	O	O
.	.	O	O

0	CD	O	O
%	NN	O	O
of	IN	O	O
120	CD	O	O
European	JJ	O	O
and	CC	O	O
1	CD	O	O
.	.	O	O

6	CD	O	O
%	NN	O	O
of	IN	O	O
188	CD	O	O
non	JJ	O	O
-	:	O	O
European	JJ	O	O
Jews	NNP	O	O
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0	CD	O	O
.	.	O	O

08	CD	O	O
)	)	O	O
.	.	O	O

It	PRP	O	O
occurred	VBD	O	O
in	IN	O	O
15	CD	O	O
.	.	O	O

4	CD	O	O
%	NN	O	O
of	IN	O	O
52	CD	O	O
Ashkenazi	NNP	O	O
Israelis	NNP	O	O
with	IN	O	O
familial	JJ	O	B_Disease
cancer	NN	S_Disease	E_Disease
(	(	O	O
P	NNP	O	O
=	VBZ	O	O
0	CD	O	O
.	.	O	O

02	CD	O	O
)	)	O	O
and	CC	O	O
was	VBD	O	O
not	RB	O	O
detected	VBN	O	O
in	IN	O	O
51	CD	O	O
non	JJ	O	O
-	:	O	O
European	JJ	O	O
Jews	NNP	O	O
at	IN	O	O
increased	JJ	O	O
cancer	NN	S_Disease	S_Disease
risk	NN	O	O
.	.	O	O

Colorectal	JJ	B_Disease	B_Disease
neoplasia	NN	E_Disease	E_Disease
occurred	VBD	O	O
personally	RB	O	O
or	CC	O	O
in	IN	O	O
the	DT	O	O
families	NNS	O	O
of	IN	O	O
13	CD	O	O
of	IN	O	O
20	CD	O	O
Ashkenazi	NNP	O	O
I1307K	NNP	O	O
carriers	NNS	O	O
,	,	O	O
8	CD	O	O
of	IN	O	O
whom	WP	O	O
also	RB	O	O
had	VBD	O	O
a	DT	O	O
personal	JJ	O	O
or	CC	O	O
family	NN	O	O
history	NN	O	O
of	IN	O	O
noncolonic	JJ	O	O
neoplasia	NN	S_Disease	E_Disease
.	.	O	O

CONCLUSIONS	NNP	O	O
The	DT	O	O
I1307K	NNP	O	O
APC	NNP	O	S_Disease
variant	NN	O	O
may	MD	O	O
represent	VB	O	O
a	DT	O	O
susceptibility	NN	O	O
gene	NN	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
,	,	I_Disease	I_Disease
or	CC	I_Disease	I_Disease
other	JJ	I_Disease	I_Disease
,	,	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
in	IN	O	O
Ashkenazi	NNP	O	O
Jews	NNP	O	O
,	,	O	O
and	CC	O	O
partially	RB	O	O
explains	VBZ	O	O
the	DT	O	O
higher	JJR	O	O
incidence	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
in	IN	O	O
European	JJ	O	O
Israelis	NNP	O	O
.	.	O	O

9888388	CD	O	O

Systematic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
coproporphyrinogen	NN	O	O
oxidase	NN	O	O
gene	NN	O	O
defects	NNS	O	O
in	IN	O	O
hereditary	JJ	B_Disease	O
coproporphyria	NNS	E_Disease	O
and	CC	O	O
mutation	NN	O	O
update	NN	O	O
.	.	O	O

Hereditary	JJ	B_Disease	B_Disease
coproporphyria	NN	E_Disease	E_Disease
(	(	O	O
HC	NNP	S_Disease	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
acute	JJ	O	O
hepatic	JJ	B_Disease	O
porphyria	NN	E_Disease	O
with	IN	O	O
autosomal	JJ	O	O
dominant	JJ	O	O
inheritance	NN	O	O
caused	VBN	O	O
by	IN	O	O
deficient	JJ	B_Disease	O
activity	NN	I_Disease	O
of	IN	I_Disease	O
coproporphyrinogen	NN	I_Disease	O
III	NNP	I_Disease	O
oxidase	NN	E_Disease	O
(	(	O	O
CPO	NNP	O	O
)	)	O	O
.	.	O	O

Clinical	JJ	O	O
manifestations	NNS	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
are	VBP	O	O
characterized	VBN	O	O
by	IN	O	O
acute	JJ	O	O
attacks	NNS	O	O
of	IN	O	O
neurological	JJ	B_Disease	B_Disease
dysfunction	NN	E_Disease	E_Disease
often	RB	O	O
precipitated	VBN	O	O
by	IN	O	O
drugs	NNS	O	O
,	,	O	O
fasting	NN	O	O
,	,	O	O
cyclical	JJ	O	O
hormonal	NN	O	O
changes	NNS	O	O
,	,	O	O
or	CC	O	O
infectious	JJ	B_Disease	B_Disease
diseases	NNS	E_Disease	E_Disease
.	.	O	O

Skin	NNP	O	O
photosensitivity	NN	O	O
may	MD	O	O
also	RB	O	O
be	VB	O	O
present	JJ	O	O
.	.	O	O

The	DT	O	O
seven	CD	O	O
exons	NNS	O	O
,	,	O	O
the	DT	O	O
exon	NN	O	O
/	NNP	O	O
intron	NN	O	O
boundaries	NNS	O	O
and	CC	O	O
part	NN	O	O
of	IN	O	O
3	CD	O	O
noncoding	VBG	O	O
sequence	NN	O	O
of	IN	O	O
the	DT	O	O
CPO	NNP	O	O
gene	NN	O	O
were	VBD	O	O
systematically	RB	O	O
analyzed	VBN	O	O
by	IN	O	O
an	DT	O	O
exon	JJ	O	O
-	:	O	O
by	IN	O	O
-	:	O	O
exon	NN	O	O
denaturing	VBG	O	O
gradient	JJ	O	O
gel	NN	O	O
electrophoresis	NN	O	O
(	(	O	O
DGGE	NNP	O	O
)	)	O	O
strategy	NN	O	O
followed	VBN	O	O
by	IN	O	O
direct	JJ	O	O
sequencing	NN	O	O
in	IN	O	O
seven	CD	O	O
unrelated	JJ	O	O
heterozygous	JJ	O	O
HC	NNP	S_Disease	O
patients	NNS	O	O
from	IN	O	O
France	NNP	O	O
,	,	O	O
Holland	NNP	O	O
,	,	O	O
and	CC	O	O
Czech	NNP	O	O
Republic	NNP	O	O
.	.	O	O

Seven	NNP	O	O
novel	JJ	O	O
mutations	NNS	O	O
and	CC	O	O
two	CD	O	O
new	JJ	O	O
polymorphisms	NNS	O	O
were	VBD	O	O
detected	VBN	O	O
.	.	O	O

Among	IN	O	O
these	DT	O	O
mutations	NNS	O	O
two	CD	O	O
are	VBP	O	O
missense	JJ	O	O
(	(	O	O
G197W	NNP	O	O
,	,	O	O
W427R	NNP	O	O
)	)	O	O
,	,	O	O
two	CD	O	O
are	VBP	O	O
nonsense	JJ	O	O
(	(	O	O
Q306X	NNP	O	O
,	,	O	O
Q385X	NNP	O	O
)	)	O	O
,	,	O	O
two	CD	O	O
are	VBP	O	O
small	JJ	O	O
deletions	NNS	O	O
(	(	O	O
662de14bp	CD	O	O
;	:	O	O
1168del3bp	CD	O	O
removing	VBG	O	O
a	DT	O	O
glycine	NN	O	O
at	IN	O	O
position	NN	O	O
390	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
one	CD	O	O
is	VBZ	O	O
a	DT	O	O
splicing	VBG	O	O
mutation	NN	O	O
(	(	O	O
IVS1	NNP	O	O
-	:	O	O
15c	CD	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
g	NN	O	O
)	)	O	O
which	WDT	O	O
creates	VBZ	O	O
a	DT	O	O
new	JJ	O	O
acceptor	NN	O	O
splice	NN	O	O
site	NN	O	O
.	.	O	O

The	DT	O	O
pathological	JJ	O	O
significance	NN	O	O
of	IN	O	O
the	DT	O	O
point	NN	O	O
mutations	NNS	O	O
G197W	NNP	O	O
,	,	O	O
W427R	NNP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
in	IN	O	O
-	:	O	O
frame	NN	O	O
deletion	NN	O	O
390delGly	CD	O	O
were	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
their	PRP$	O	O
respective	JJ	O	O
expression	NN	O	O
in	IN	O	O
a	DT	O	O
prokaryotic	JJ	O	O
system	NN	O	O
using	VBG	O	O
site	NN	O	O
-	:	O	O
directed	JJ	O	O
mutagenesis	NN	O	O
.	.	O	O

These	DT	O	O
mutations	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
or	CC	O	O
a	DT	O	O
dramatic	JJ	O	O
decrease	NN	O	O
of	IN	O	O
CPO	NNP	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
two	CD	O	O
polymorphisms	NNS	O	O
were	VBD	O	O
localized	VBN	O	O
in	IN	O	O
noncoding	VBG	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
1	CD	O	O
)	)	O	O
a	DT	O	O
C	NNP	O	O
/	NNP	O	O
G	NNP	O	O
polymorphism	NN	O	O
in	IN	O	O
the	DT	O	O
promotor	NN	O	O
region	NN	O	O
,	,	O	O
142	CD	O	O
bp	NN	O	O
upstream	NN	O	O
from	IN	O	O
the	DT	O	O
transcriptional	JJ	O	O
initiation	NN	O	O
site	NN	O	O
(	(	O	O
-	:	O	O
142C	CD	O	O
/	NNP	O	O
G	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
)	)	O	O
a	DT	O	O
6	CD	O	O
bp	NN	O	O
deletion	NN	O	O
polymorphism	NN	O	O
in	IN	O	O
the	DT	O	O
3	CD	O	O
noncoding	JJ	O	O
part	NN	O	O
of	IN	O	O
the	DT	O	O
CPO	NNP	O	O
gene	NN	O	O
,	,	O	O
574	CD	O	O
bp	NN	O	O
downstream	NN	O	O
of	IN	O	O
the	DT	O	O
last	JJ	O	O
base	NN	O	O
of	IN	O	O
the	DT	O	O
normal	JJ	O	O
termination	NN	O	O
codon	NN	O	O
(	(	O	O
+	JJ	O	O
574	CD	O	O
delATTCTT	NN	O	O
)	)	O	O
.	.	O	O

Five	CD	O	O
intragenic	JJ	O	O
dimorphisms	NNS	O	O
are	VBP	O	O
now	RB	O	O
well	RB	O	O
characterized	VBN	O	O
and	CC	O	O
the	DT	O	O
high	JJ	O	O
degree	NN	O	O
of	IN	O	O
allelic	JJ	O	O
heterogeneity	NN	O	O
in	IN	O	O
HC	NNP	S_Disease	O
is	VBZ	O	O
demonstrated	VBN	O	O
with	IN	O	O
seven	CD	O	O
new	JJ	O	O
different	JJ	O	O
mutations	NNS	O	O
making	VBG	O	O
a	DT	O	O
total	NN	O	O
of	IN	O	O
nineteen	JJ	O	O
CPO	NNP	O	O
gene	NN	B_Disease	O
defects	NNS	E_Disease	O
reported	VBN	O	O
so	RB	O	O
far	RB	O	O
.	.	O	O
.	.	O	O

9888390	CD	O	O

Coincidence	NN	O	O
of	IN	O	O
two	CD	O	O
novel	JJ	O	O
arylsulfatase	VBD	O	O
A	NNP	O	O
alleles	NNS	O	O
and	CC	O	O
mutation	NN	O	O
459	CD	O	O
+	NN	O	O
1G	CD	O	O
>	NN	O	O
A	NNP	O	O
within	IN	O	O
a	DT	O	O
family	NN	O	O
with	IN	O	O
metachromatic	JJ	B_Disease	B_Disease
leukodystrophy	NN	E_Disease	E_Disease
:	:	O	O
molecular	JJ	O	O
basis	NN	O	O
of	IN	O	O
phenotypic	NN	O	O
heterogeneity	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
family	NN	O	O
with	IN	O	O
three	CD	O	O
siblings	NNS	O	O
,	,	O	O
one	CD	O	O
developed	VBD	O	O
classical	JJ	O	O
late	RB	O	O
infantile	JJ	O	B_Disease
metachromatic	JJ	B_Disease	I_Disease
leukodystrophy	NN	E_Disease	E_Disease
(	(	O	O
MLD	NNP	S_Disease	S_Disease
)	)	O	O
,	,	O	O
fatal	JJ	O	O
at	IN	O	O
age	NN	O	O
5	CD	O	O
years	NNS	O	O
,	,	O	O
with	IN	O	O
deficient	JJ	O	O
arylsulfatase	NN	O	O
A	NNP	O	O
(	(	O	O
ARSA	NNP	O	O
)	)	O	O
activity	NN	O	O
and	CC	O	O
increased	VBD	O	O
galactosylsulfatide	NN	O	O
(	(	O	O
GS	NNP	O	O
)	)	O	O
excretion	NN	O	O
.	.	O	O

The	DT	O	O
two	CD	O	O
other	JJ	O	O
siblings	NNS	O	O
,	,	O	O
apparently	RB	O	O
healthy	JJ	O	O
at	IN	O	O
12	CD	O	O
(	(	O	O
1	CD	O	O
/	RB	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
15	CD	O	O
years	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
father	NN	O	O
,	,	O	O
apparently	RB	O	O
healthy	JJ	O	O
as	RB	O	O
well	RB	O	O
,	,	O	O
presented	VBN	O	O
ARSA	NNP	O	O
and	CC	O	O
GS	NNP	O	O
values	NNS	O	O
within	IN	O	O
the	DT	O	O
range	NN	O	O
of	IN	O	O
MLD	NNP	S_Disease	S_Disease
patients	NNS	O	O
.	.	O	O

Mutation	NN	O	O
screening	NN	O	O
and	CC	O	O
sequence	NN	O	O
analysis	NN	O	O
disclosed	VBD	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
three	CD	O	O
different	JJ	O	O
ARSA	NNP	O	O
mutations	NNS	O	O
being	VBG	O	O
the	DT	O	O
molecular	JJ	O	O
basis	NN	O	O
of	IN	O	O
intrafamilial	JJ	O	O
phenotypic	NN	O	O
heterogeneity	NN	O	O
.	.	O	O

The	DT	O	O
late	JJ	O	B_Disease
infantile	NN	O	E_Disease
patient	NN	O	O
inherited	VBN	O	O
from	IN	O	O
his	PRP$	O	O
mother	NN	O	O
the	DT	O	O
frequent	NN	O	O
0	CD	O	O
-	:	O	O
type	NN	O	O
mutation	NN	O	O
459	CD	O	O
+	NN	O	O
1G	CD	O	O
>	NN	O	O
A	NNP	O	O
,	,	O	O
and	CC	O	O
from	IN	O	O
his	PRP$	O	O
father	NN	O	O
a	DT	O	O
novel	NN	O	O
,	,	O	O
single	JJ	O	O
basepair	NN	O	O
microdeletion	NN	O	O
of	IN	O	O
guanine	NN	O	O
at	IN	O	O
nucleotide	JJ	O	O
7	CD	O	O
in	IN	O	O
exon	NN	O	O
1	CD	O	O
(	(	O	O
7delG	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
two	CD	O	O
clinically	RB	O	O
unaffected	JJ	O	O
siblings	NNS	O	O
carried	VBD	O	O
the	DT	O	O
maternal	JJ	O	O
mutation	NN	O	O
459	CD	O	O
+	NN	O	O
1G	CD	O	O
>	NN	O	O
A	DT	O	O
and	CC	O	O
,	,	O	O
on	IN	O	O
their	PRP$	O	O
paternal	JJ	O	O
allele	NN	O	O
,	,	O	O
a	DT	O	O
novel	JJ	O	O
cytosine	NN	O	O
to	TO	O	O
thymidine	VB	O	O
transition	NN	O	O
at	IN	O	O
nucleotide	JJ	O	O
2435	CD	O	O
in	IN	O	O
exon	JJ	O	O
8	CD	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
substitution	NN	O	O
of	IN	O	O
alanine	JJ	O	O
464	CD	O	O
by	IN	O	O
valine	NN	O	O
(	(	O	O
A464V	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
fathers	NNS	O	O
genotype	VBP	O	O
thus	RB	O	O
was	VBD	O	O
7delG	CD	O	O
/	JJ	O	O
A464V	NNP	O	O
.	.	O	O

Mutation	NNP	O	O
A464V	NNP	O	O
was	VBD	O	O
not	RB	O	O
found	VBN	O	O
in	IN	O	O
18	CD	O	O
unrelated	JJ	O	O
MLD	NNP	S_Disease	S_Disease
patients	NNS	O	O
and	CC	O	O
50	CD	O	O
controls	NNS	O	O
.	.	O	O

A464V	NNP	O	O
,	,	O	O
although	IN	O	O
clearly	RB	O	O
modifying	VBG	O	O
ARSA	NNP	O	O
and	CC	O	O
GS	NNP	O	O
levels	NNS	O	O
,	,	O	O
apparently	RB	O	O
bears	VBZ	O	O
little	JJ	O	O
significance	NN	O	O
for	IN	O	O
clinical	JJ	O	O
manifestation	NN	O	O
of	IN	O	O
MLD	NNP	S_Disease	S_Disease
,	,	O	O
mimicking	VBG	O	O
the	DT	O	O
frequent	JJ	O	O
ARSA	NNP	O	O
pseudodeficiency	NN	O	O
allele	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
in	IN	O	O
certain	JJ	O	O
genetic	JJ	O	O
conditions	NNS	O	O
MLD	NNP	S_Disease	O
-	:	O	O
like	IN	O	O
ARSA	NNP	O	O
and	CC	O	O
GS	NNP	O	O
values	NNS	O	O
need	VBP	O	O
not	RB	O	O
be	VB	O	O
paralleled	VBN	O	O
by	IN	O	O
clinical	JJ	O	O
disease	NN	O	O
,	,	O	O
a	DT	O	O
finding	NN	O	O
with	IN	O	O
serious	JJ	O	O
diagnostic	JJ	O	O
and	CC	O	O
prognostic	JJ	O	O
implications	NNS	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
further	JJ	O	O
ARSA	NNP	O	O
alleles	NNS	O	O
functionally	RB	O	O
similar	JJ	O	O
to	TO	O	O
A464V	VB	O	O
might	MD	O	O
exist	VB	O	O
which	WDT	O	O
,	,	O	O
together	RB	O	O
with	IN	O	O
0	CD	O	O
-	:	O	O
type	NN	O	O
mutations	NNS	O	O
,	,	O	O
may	MD	O	O
cause	VB	O	O
pathological	JJ	O	O
ARSA	NNP	O	O
and	CC	O	O
GS	NNP	O	S_Disease
levels	NNS	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
clinical	JJ	O	O
outbreak	NN	O	O
of	IN	O	O
the	DT	O	O
disease	NN	O	O
.	.	O	O
.	.	O	O

9927033	CD	O	O

Human	NNP	O	O
MLH1	NNP	O	B_Disease
deficiency	NN	O	E_Disease
predisposes	NNS	O	O
to	TO	O	O
hematological	JJ	B_Disease	B_Disease
malignancy	NN	E_Disease	E_Disease
and	CC	O	O
neurofibromatosis	NN	B_Disease	O
type	NN	I_Disease	O
1	CD	E_Disease	O
.	.	O	O

Heterozygous	JJ	O	O
germ	SYM	O	O
-	:	O	O
line	NN	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
DNA	NNP	O	O
mismatch	NN	O	O
repair	NN	O	O
genes	NNS	O	O
lead	VBP	O	O
to	TO	O	O
hereditary	JJ	B_Disease	B_Disease
nonpolyposis	NN	I_Disease	I_Disease
colorectal	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
disease	NN	O	O
susceptibility	NN	O	O
of	IN	O	O
individuals	NNS	O	O
who	WP	O	O
constitutionally	RB	O	O
lack	VBP	O	O
both	DT	O	O
wild	JJ	O	O
-	:	O	O
type	NN	O	O
alleles	NNS	O	O
is	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
identified	VBN	O	O
three	CD	O	O
offspring	VBG	O	O
in	IN	O	O
a	DT	O	O
hereditary	JJ	B_Disease	B_Disease
nonpolyposis	NN	I_Disease	I_Disease
colorectal	NN	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
family	NN	O	O
who	WP	O	O
developed	VBD	O	O
hematological	JJ	B_Disease	B_Disease
malignancy	NN	E_Disease	E_Disease
at	IN	O	O
a	DT	O	O
very	RB	O	O
early	JJ	O	O
age	NN	O	O
,	,	O	O
and	CC	O	O
at	IN	O	O
least	JJS	O	O
two	CD	O	O
of	IN	O	O
them	PRP	O	O
displayed	VBD	O	O
signs	NNS	O	O
of	IN	O	O
neurofibromatosis	NN	B_Disease	O
type	NN	I_Disease	O
1	CD	E_Disease	O
(	(	O	O
NF1	NNP	S_Disease	O
)	)	O	O
.	.	O	O

DNA	NN	O	O
sequence	NN	O	O
analysis	NN	O	O
and	CC	O	O
allele	VB	O	O
-	:	O	O
specific	JJ	O	O
amplification	NN	O	O
in	IN	O	O
two	CD	O	O
siblings	NNS	O	O
revealed	VBD	O	O
a	DT	O	O
homozygous	JJ	O	O
MLH1	NNP	O	O
mutation	NN	O	O
(	(	O	O
C676T	NNP	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
Arg226Stop	NNP	O	O
)	)	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
a	DT	O	O
homozygous	JJ	O	O
germ	NN	O	O
-	:	O	O
line	NN	O	O
MLH1	NNP	O	O
mutation	NN	O	O
and	CC	O	O
consequent	JJ	O	O
mismatch	NN	O	O
repair	NN	O	B_Disease
deficiency	NN	O	E_Disease
results	NNS	O	O
in	IN	O	O
a	DT	O	O
mutator	NN	O	O
phenotype	NN	O	O
characterized	VBN	O	O
by	IN	O	O
leukemia	NN	S_Disease	S_Disease
and	CC	O	O
/	NN	O	O
or	CC	O	I_Disease
lymphoma	NN	S_Disease	E_Disease
associated	VBN	O	O
with	IN	O	O
neurofibromatosis	NN	B_Disease	O
type	NN	I_Disease	O
1	CD	E_Disease	O
.	.	O	O
.	.	O	O

9931324	CD	O	O

Missense	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
most	RBS	O	O
ancient	JJ	O	O
residues	NNS	O	O
of	IN	O	O
the	DT	O	O
PAX6	NNP	O	O
paired	VBD	O	O
domain	NN	O	O
underlie	IN	O	O
a	DT	O	O
spectrum	NN	O	O
of	IN	O	O
human	JJ	O	O
congenital	JJ	B_Disease	B_Disease
eye	NN	I_Disease	I_Disease
malformations	NNS	E_Disease	E_Disease
.	.	O	O

Mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
PAX6	NNP	O	O
gene	NN	O	O
underlie	JJ	O	O
aniridia	NN	S_Disease	S_Disease
(	(	O	O
congenital	JJ	B_Disease	B_Disease
absence	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
iris	NN	E_Disease	E_Disease
)	)	O	O
,	,	O	O
a	DT	O	O
rare	JJ	O	O
dominant	JJ	O	O
malformation	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
eye	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
spectrum	NN	O	O
of	IN	O	O
PAX6	NNP	O	O
mutations	NNS	O	O
in	IN	O	O
aniridia	JJ	S_Disease	S_Disease
patients	NNS	O	O
is	VBZ	O	O
highly	RB	O	O
biased	VBN	O	O
,	,	O	O
with	IN	O	O
92	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
reported	VBN	O	O
mutations	NNS	O	O
leading	VBG	O	O
to	TO	O	O
premature	VB	O	O
truncation	NN	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
(	(	O	O
nonsense	JJ	O	O
,	,	O	O
splicing	VBG	O	O
,	,	O	O
insertions	NNS	O	O
and	CC	O	O
deletions	NNS	O	O
)	)	O	O
and	CC	O	O
just	RB	O	O
2	CD	O	O
%	NN	O	O
leading	VBG	O	O
to	TO	O	O
substitution	NN	O	O
of	IN	O	O
one	CD	O	O
amino	NN	O	O
acid	NN	O	O
by	IN	O	O
another	DT	O	O
(	(	O	O
missense	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
extraordinary	JJ	O	O
conservation	NN	O	O
of	IN	O	O
the	DT	O	O
PAX6	NNP	O	O
protein	NN	O	O
at	IN	O	O
the	DT	O	O
amino	NN	O	O
acid	VBP	O	O
level	NN	O	O
amongst	NN	O	O
vertebrates	VBZ	O	O
predicts	NNS	O	O
that	WDT	O	O
pathological	JJ	O	O
missense	NN	O	O
mutations	NNS	O	O
should	MD	O	O
in	IN	O	O
fact	NN	O	O
be	VB	O	O
common	JJ	O	O
even	RB	O	O
though	IN	O	O
they	PRP	O	O
are	VBP	O	O
hardly	RB	O	O
ever	RB	O	O
seen	VBN	O	O
in	IN	O	O
aniridia	JJ	S_Disease	S_Disease
patients	NNS	O	O
.	.	O	O

This	DT	O	O
indicates	VBZ	O	O
that	IN	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
heavy	JJ	O	O
ascertainment	NN	O	O
bias	NN	O	O
in	IN	O	O
the	DT	O	O
selection	NN	O	O
of	IN	O	O
patients	NNS	O	O
for	IN	O	O
PAX6	NNP	O	O
mutation	NN	O	O
analysis	NN	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
missing	VBG	O	O
PAX6	NNP	O	O
missense	NN	O	O
mutations	NNS	O	O
frequently	RB	O	O
may	MD	O	O
underlie	VB	O	O
phenotypes	NNS	O	O
distinct	JJ	O	O
from	IN	O	O
textbook	NN	O	O
aniridia	NN	S_Disease	S_Disease
.	.	O	O

Here	RB	O	O
we	PRP	O	O
present	VBP	O	O
four	CD	O	O
novel	NN	O	O
PAX6	NNP	O	O
missense	NN	O	O
mutations	NNS	O	O
,	,	O	O
two	CD	O	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
atypical	JJ	O	O
phenotypes	NNS	O	O
ectopia	VBP	B_Disease	O
pupillae	NN	E_Disease	O
(	(	O	O
displaced	VBN	B_Disease	O
pupils	NNS	E_Disease	O
)	)	O	O
and	CC	O	O
congenital	JJ	B_Disease	B_Disease
nystagmus	NN	E_Disease	E_Disease
(	(	O	O
searching	VBG	B_Disease	O
gaze	NN	E_Disease	O
)	)	O	O
,	,	O	O
and	CC	O	O
two	CD	O	O
in	IN	O	O
association	NN	O	O
with	IN	O	O
more	RBR	O	O
recognizable	JJ	O	O
aniridia	NN	S_Disease	S_Disease
phenotypes	NNS	O	O
.	.	O	O

Strikingly	RB	O	O
,	,	O	O
all	DT	O	O
four	CD	O	O
mutations	NNS	O	O
are	VBP	O	O
located	VBN	O	O
within	IN	O	O
the	DT	O	O
PAX6	NNP	O	O
paired	VBD	O	O
domain	NN	O	O
and	CC	O	O
affect	VB	O	O
amino	NN	O	O
acids	NNS	O	O
which	WDT	O	O
are	VBP	O	O
highly	RB	O	O
conserved	VBN	O	O
in	IN	O	O
all	DT	O	O
known	VBN	O	O
paired	VBD	O	O
domain	NN	O	O
proteins	NNS	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
support	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
the	DT	O	O
under	IN	O	O
-	:	O	O
representation	NN	O	O
of	IN	O	O
missense	JJ	O	O
mutations	NNS	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
ascertainment	JJ	O	O
bias	NN	O	O
and	CC	O	O
suggest	VBP	O	O
that	IN	O	O
a	DT	O	O
substantial	JJ	O	O
burden	NN	O	O
of	IN	O	O
PAX6	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
related	JJ	I_Disease	O
disease	NN	E_Disease	O
remains	VBZ	O	O
to	TO	O	O
be	VB	O	O
uncovered	VBN	O	O
.	.	O	O
.	.	O	O

993342	CD	O	O

The	DT	O	O
chromosomal	JJ	O	O
order	NN	O	O
of	IN	O	O
genes	NNS	O	O
controlling	VBG	O	O
the	DT	O	O
major	JJ	O	O
histocompatibility	NN	O	O
complex	NN	O	O
,	,	O	O
properdin	NN	O	B_Disease
factor	NN	O	I_Disease
B	NNP	O	E_Disease
,	,	O	O
and	CC	O	O
deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
second	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
relationship	NN	O	O
of	IN	O	O
the	DT	O	O
genes	NNS	O	O
coding	VBG	O	O
for	IN	O	O
HLA	NNP	O	O
to	TO	O	O
those	DT	O	O
coding	VBG	O	O
for	IN	O	O
properdin	NN	O	O
Factor	NNP	O	O
B	NNP	O	O
allotypes	NNS	O	O
and	CC	O	O
for	IN	O	O
deficiency	NN	B_Disease	B_Disease
of	IN	I_Disease	I_Disease
the	DT	I_Disease	I_Disease
second	JJ	I_Disease	I_Disease
component	NN	I_Disease	I_Disease
of	IN	I_Disease	I_Disease
complement	NN	E_Disease	E_Disease
(	(	O	O
C2	NNP	O	O
)	)	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
families	NNS	O	O
of	IN	O	O
patients	NNS	O	O
with	IN	O	O
connective	JJ	O	B_Disease
tissue	NN	O	I_Disease
disorders	NNS	O	E_Disease
.	.	O	O

Patients	NNS	O	O
were	VBD	O	O
selected	VBN	O	O
because	IN	O	O
they	PRP	O	O
were	VBD	O	O
heterozygous	JJ	O	O
or	CC	O	O
homozygous	JJ	O	O
for	IN	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
.	.	O	O

12	CD	O	O
families	NNS	O	O
with	IN	O	O
15	CD	O	O
matings	NNS	O	O
informative	JJ	O	O
for	IN	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
were	VBD	O	O
found	VBN	O	O
.	.	O	O

Of	IN	O	O
57	CD	O	O
informative	JJ	O	O
meioses	NNS	O	O
,	,	O	O
two	CD	O	O
crossovers	NNS	O	O
were	VBD	O	O
noted	VBN	O	O
between	IN	O	O
the	DT	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
gene	NN	O	O
and	CC	O	O
the	DT	O	O
HLA	NNP	O	O
-	:	O	O
B	NNP	O	O
gene	NN	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
recombinant	JJ	O	O
fraction	NN	O	O
of	IN	O	O
0	CD	O	O
.	.	O	O

035	CD	O	O
.	.	O	O

A	DT	O	O
lod	JJ	O	O
score	NN	O	O
of	IN	O	O
13	CD	O	O
was	VBD	O	O
calculated	VBN	O	O
for	IN	O	O
linkage	NN	O	O
between	IN	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
and	CC	O	O
HLA	NNP	O	B_Disease
-	:	O	I_Disease
B	NN	O	O
at	IN	O	O
a	DT	O	O
maximum	JJ	O	O
likelihood	NN	O	O
value	NN	O	O
of	IN	O	O
the	DT	O	O
recombinant	JJ	O	O
fraction	NN	O	O
of	IN	O	O
0	CD	O	O
.	.	O	O

04	CD	O	O
.	.	O	O

18	CD	O	O
families	NNS	O	O
with	IN	O	O
21	CD	O	O
informative	JJ	O	O
matings	NNS	O	O
for	IN	O	O
both	DT	O	O
properdin	JJ	O	B_Disease
Factor	NN	O	O
B	NNP	O	O
allotype	NN	O	O
and	CC	O	O
HLA	NNP	O	O
-	:	O	O
B	NN	O	O
were	VBD	O	O
found	VBN	O	O
.	.	O	O

Of	IN	O	O
72	CD	O	O
informative	JJ	O	O
meioses	NNS	O	O
,	,	O	O
three	CD	O	O
recombinants	NNS	O	O
were	VBD	O	O
found	VBN	O	O
,	,	O	O
giving	VBG	O	O
a	DT	O	O
recombinant	JJ	O	O
fraction	NN	O	O
of	IN	O	O
0	CD	O	O
.	.	O	O

042	CD	O	O
.	.	O	O

A	DT	O	O
lod	JJ	O	O
score	NN	O	O
of	IN	O	O
16	CD	O	O
between	IN	O	O
HLA	NNP	O	O
-	:	O	O
B	NN	O	O
and	CC	O	O
Factor	NNP	O	O
B	NNP	O	O
allotypes	NNS	O	O
was	VBD	O	O
calculated	VBN	O	O
at	IN	O	O
a	DT	O	O
maximum	JJ	O	O
likelihood	NN	O	O
value	NN	O	O
of	IN	O	O
the	DT	O	O
recombinant	JJ	O	O
fraction	NN	O	O
of	IN	O	O
0	CD	O	O
.	.	O	O

04	CD	O	O
.	.	O	O

A	DT	O	O
crossover	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
have	VB	O	O
occurred	VBN	O	O
between	IN	O	O
genes	NNS	O	O
for	IN	O	O
Factor	NNP	O	O
B	NNP	O	O
and	CC	O	O
HLA	NNP	O	O
-	:	O	O
D	NN	O	O
,	,	O	O
in	IN	O	O
which	WDT	O	O
HLA	NNP	O	O
-	:	O	O
D	NN	O	O
segregared	VBD	O	O
with	IN	O	O
HLA	NNP	O	O
-	:	O	O
A	DT	O	O
and	CC	O	O
B	NNP	O	O
.	.	O	O

These	DT	O	O
studies	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
genes	NNS	O	O
for	IN	O	O
Factor	NNP	O	B_Disease
B	NNP	O	I_Disease
and	CC	O	I_Disease
C2	NNP	B_Disease	I_Disease
deficiency	NN	E_Disease	E_Disease
are	VBP	O	O
located	VBN	O	O
outside	IN	O	O
those	DT	O	O
for	IN	O	O
HLA	NNP	O	O
,	,	O	O
that	IN	O	O
the	DT	O	O
order	NN	O	O
of	IN	O	O
genese	NN	O	O
is	VBZ	O	O
HLA	NNP	O	O
-	:	O	O
A	NN	O	O
,	,	O	O
-	:	O	O
B	NN	O	O
,	,	O	O
-	:	O	O
D	NN	O	O
,	,	O	O
Factor	NNP	O	O
B	NNP	O	O
allotype	NN	O	O
,	,	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
,	,	O	O
that	IN	O	O
the	DT	O	O
genes	NNS	O	O
coding	VBG	O	O
for	IN	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
and	CC	O	O
Factor	NNP	O	O
B	NNP	O	O
allotypes	NNS	O	O
are	VBP	O	O
approximately	RB	O	O
3	CD	O	O
-	:	O	O
-	:	O	O
5	CD	O	O
centimorgans	NNS	O	O
from	IN	O	O
the	DT	O	O
HLA	NNP	O	O
-	:	O	O
A	DT	O	O
and	CC	O	O
HLA	NNP	O	O
-	:	O	O
B	NNP	O	O
loci	NN	O	O
,	,	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
apparent	JJ	O	O
lack	NN	O	O
of	IN	O	O
recombinants	NNS	O	O
between	IN	O	O
the	DT	O	O
Factor	NNP	O	O
B	NNP	O	O
gene	NN	O	O
and	CC	O	O
C2	NNP	B_Disease	B_Disease
deficiency	NN	E_Disease	E_Disease
gene	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
these	DT	O	O
two	CD	O	O
genes	NNS	O	O
lie	RBR	O	O
in	IN	O	O
close	JJ	O	O
proximity	NN	O	O
to	TO	O	O
one	CD	O	O
another	DT	O	O
.	.	O	O

9949197	CD	O	O

Distribution	NN	O	O
of	IN	O	O
emerin	NN	O	O
and	CC	O	O
lamins	NNS	O	O
in	IN	O	O
the	DT	O	O
heart	NN	O	O
and	CC	O	O
implications	NNS	O	O
for	IN	O	O
Emery	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Dreifuss	NNP	I_Disease	I_Disease
muscular	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
.	.	O	O

Emerin	NNP	O	O
is	VBZ	O	O
a	DT	O	O
nuclear	JJ	O	O
membrane	NN	O	O
protein	NN	O	O
which	WDT	O	O
is	VBZ	O	O
missing	VBG	O	O
or	CC	O	O
defective	JJ	O	O
in	IN	O	O
Emery	NNP	B_Disease	B_Disease
-	:	I_Disease	I_Disease
Dreifuss	NNP	I_Disease	I_Disease
muscular	JJ	I_Disease	I_Disease
dystrophy	NN	E_Disease	E_Disease
(	(	O	O
EDMD	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
one	CD	O	O
member	NN	O	O
of	IN	O	O
a	DT	O	O
family	NN	O	O
of	IN	O	O
lamina	JJ	O	O
-	:	O	O
associated	VBN	O	O
proteins	NNS	O	O
which	WDT	O	O
includes	VBZ	O	O
LAP1	NNP	O	O
,	,	O	O
LAP2	NNP	O	O
and	CC	O	O
lamin	NN	O	O
B	NNP	O	O
receptor	NN	O	O
(	(	O	O
LBR	NNP	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
panel	NN	O	O
of	IN	O	O
16	CD	O	O
monoclonal	JJ	O	O
antibodies	NNS	O	O
(	(	O	O
mAbs	NN	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
mapped	VBN	O	O
to	TO	O	O
six	CD	O	O
specific	JJ	O	O
sites	NNS	O	O
throughout	IN	O	O
the	DT	O	O
emerin	NN	O	O
molecule	NN	O	O
using	VBG	O	O
phage	NN	O	O
-	:	O	O
displayed	VBN	O	O
peptide	IN	O	O
libraries	NNS	O	O
and	CC	O	O
has	VBZ	O	O
been	VBN	O	O
used	VBN	O	O
to	TO	O	O
localize	VB	O	O
emerin	NN	O	O
in	IN	O	O
human	JJ	O	O
and	CC	O	O
rabbit	JJ	O	O
heart	NN	O	O
.	.	O	O

Several	JJ	O	O
mAbs	NNS	O	O
against	IN	O	O
different	JJ	O	O
emerin	JJ	O	O
epitopes	NNS	O	O
did	VBD	O	O
not	RB	O	O
recognize	VB	O	O
intercalated	JJ	O	O
discs	NN	O	O
in	IN	O	O
the	DT	O	O
heart	NN	O	O
,	,	O	O
though	IN	O	O
they	PRP	O	O
recognized	VBD	O	O
cardiomyocyte	NN	O	O
nuclei	NN	O	O
strongly	RB	O	O
,	,	O	O
both	DT	O	O
at	IN	O	O
the	DT	O	O
rim	NN	O	O
and	CC	O	O
in	IN	O	O
intranuclear	JJ	O	O
spots	NNS	O	O
or	CC	O	O
channels	NNS	O	O
.	.	O	O

A	DT	O	O
polyclonal	JJ	O	O
rabbit	NN	O	O
antiserum	NN	O	O
against	IN	O	O
emerin	NN	O	O
did	VBD	O	O
recognize	VB	O	O
both	DT	O	O
nuclear	JJ	O	O
membrane	NN	O	O
and	CC	O	O
intercalated	JJ	O	O
discs	NN	O	O
but	CC	O	O
,	,	O	O
after	IN	O	O
affinity	NN	O	O
purification	NN	O	O
against	IN	O	O
a	DT	O	O
pure	JJ	O	O
-	:	O	O
emerin	NN	O	O
band	NN	O	O
on	IN	O	O
a	DT	O	O
western	JJ	O	O
blot	NN	O	O
,	,	O	O
it	PRP	O	O
stained	VBD	O	O
only	RB	O	O
the	DT	O	O
nuclear	JJ	O	O
membrane	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
would	MD	O	O
not	RB	O	O
be	VB	O	O
expected	VBN	O	O
if	IN	O	O
immunostaining	NN	O	O
at	IN	O	O
intercalated	JJ	O	O
discs	NN	O	O
were	VBD	O	O
due	JJ	O	O
to	TO	O	O
a	DT	O	O
product	NN	O	O
of	IN	O	O
the	DT	O	O
emerin	JJ	O	O
gene	NN	O	O
and	CC	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
cast	VBD	O	O
some	DT	O	O
doubt	NN	O	O
upon	IN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
cardiac	JJ	B_Disease	B_Disease
defects	NNS	E_Disease	E_Disease
in	IN	O	O
EDMD	NNP	S_Disease	S_Disease
are	VBP	O	O
caused	VBN	O	O
by	IN	O	O
absence	NN	O	O
of	IN	O	O
emerin	NN	O	O
from	IN	O	O
intercalated	VBN	O	O
discs	NN	O	O
.	.	O	O

Although	IN	O	O
emerin	NN	O	O
was	VBD	O	O
abundant	JJ	O	O
in	IN	O	O
the	DT	O	O
membranes	NNS	O	O
of	IN	O	O
cardiomyocyte	NN	O	O
nuclei	NN	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
absent	JJ	O	O
from	IN	O	O
many	JJ	O	O
non	SYM	O	O
-	:	O	O
myocyte	NN	O	O
cells	NNS	O	O
in	IN	O	O
the	DT	O	O
heart	NN	O	O
.	.	O	O

This	DT	O	O
distribution	NN	O	O
of	IN	O	O
emerin	NN	O	O
was	VBD	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
lamin	NN	O	O
A	NNP	O	O
,	,	O	O
a	DT	O	O
candidate	NN	O	O
gene	NN	O	O
for	IN	O	O
an	DT	O	O
autosomal	JJ	O	O
form	NN	O	O
of	IN	O	O
EDMD	NNP	S_Disease	S_Disease
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
lamin	FW	O	O
B1	NNP	O	O
was	VBD	O	O
absent	JJ	O	O
from	IN	O	O
cardiomyocyte	NN	O	O
nuclei	NN	O	O
,	,	O	O
showing	VBG	O	O
that	IN	O	O
lamin	JJ	O	O
B1	NNP	O	O
is	VBZ	O	O
not	RB	O	O
essential	JJ	O	O
for	IN	O	O
localization	NN	O	O
of	IN	O	O
emerin	NN	O	O
to	TO	O	O
the	DT	O	O
nuclear	JJ	O	O
lamina	NN	O	O
.	.	O	O

Lamin	NNP	O	O
B1	NNP	O	O
is	VBZ	O	O
also	RB	O	O
almost	RB	O	O
completely	RB	O	O
absent	JJ	O	O
from	IN	O	O
skeletal	JJ	O	O
muscle	NN	O	O
nuclei	NN	O	O
.	.	O	O

In	IN	O	O
EDMD	NNP	S_Disease	S_Disease
,	,	O	O
the	DT	O	O
additional	JJ	O	O
absence	NN	O	O
of	IN	O	O
lamin	JJ	O	O
B1	NNP	O	O
from	IN	O	O
heart	NN	O	O
and	CC	O	O
skeletal	JJ	O	O
muscle	NN	O	O
nuclei	NN	O	O
which	WDT	O	O
already	RB	O	O
lack	VBP	O	O
emerin	NN	O	O
may	MD	O	O
offer	VB	O	O
an	DT	O	O
alternative	JJ	O	O
explanation	NN	O	O
of	IN	O	O
why	WRB	O	O
these	DT	O	O
tissues	NNS	O	O
are	VBP	O	O
particularly	RB	O	O
affected	VBN	O	O
.	.	O	O
.	.	O	O

9949209	CD	O	O

Genetic	JJ	O	O
mapping	NN	O	O
of	IN	O	O
the	DT	O	O
copper	NN	B_Disease	O
toxicosis	NN	E_Disease	O
locus	NN	O	O
in	IN	O	O
Bedlington	NNP	O	O
terriers	NNS	O	O
to	TO	O	O
dog	VB	O	O
chromosome	NN	O	O
10	CD	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
region	NN	O	O
syntenic	NN	O	O
to	TO	O	O
human	JJ	O	O
chromosome	NN	O	O
region	NN	O	O
2p13	CD	O	O
-	:	O	O
p16	NN	O	O
.	.	O	O

Abnormal	NNP	O	O
hepatic	JJ	B_Disease	O
copper	NN	I_Disease	O
accumulation	NN	E_Disease	O
is	VBZ	O	O
recognized	VBN	O	O
as	IN	O	O
an	DT	O	O
inherited	JJ	B_Disease	B_Disease
disorder	NN	E_Disease	E_Disease
in	IN	O	O
man	NN	O	O
,	,	O	O
mouse	NN	O	O
,	,	O	O
rat	NN	O	O
and	CC	O	O
dog	NN	O	O
.	.	O	O

The	DT	O	O
major	JJ	O	O
cause	NN	O	O
of	IN	O	O
hepatic	JJ	B_Disease	O
copper	NN	I_Disease	O
accumulation	NN	E_Disease	O
in	IN	O	O
man	NN	O	O
is	VBZ	O	O
a	DT	O	O
dysfunctional	JJ	O	O
ATP7B	NNP	O	O
gene	NN	O	O
,	,	O	O
causing	VBG	O	O
Wilson	NNP	B_Disease	B_Disease
disease	NN	E_Disease	E_Disease
(	(	O	O
WD	NNP	S_Disease	S_Disease
)	)	O	O
.	.	O	O

Mutations	NNS	O	O
in	IN	O	O
the	DT	O	O
ATP7B	NNP	O	O
genes	NNS	O	O
have	VBP	O	O
also	RB	O	O
been	VBN	O	O
demonstrated	VBN	O	O
in	IN	O	O
mouse	NN	O	O
and	CC	O	O
rat	NN	O	O
.	.	O	O

The	DT	O	O
ATP7B	NNP	O	O
gene	NN	O	O
has	VBZ	O	O
been	VBN	O	O
excluded	VBN	O	O
in	IN	O	O
the	DT	O	O
much	JJ	O	O
rarer	NN	O	O
human	JJ	O	O
copper	NN	B_Disease	B_Disease
overload	NN	E_Disease	I_Disease
disease	NN	O	E_Disease
non	SYM	B_Disease	O
-	:	I_Disease	O
Indian	JJ	I_Disease	I_Disease
childhood	NN	I_Disease	I_Disease
cirrhosis	NN	E_Disease	E_Disease
,	,	O	O
indicating	VBG	O	O
genetic	JJ	O	O
heterogeneity	NN	O	O
.	.	O	O

By	IN	O	O
investigating	VBG	O	O
the	DT	O	O
common	JJ	O	O
autosomal	JJ	O	O
recessive	JJ	O	O
copper	NN	B_Disease	O
toxicosis	NN	E_Disease	O
(	(	O	O
CT	NNP	S_Disease	O
)	)	O	O
in	IN	O	O
Bedlington	NNP	O	O
terriers	NNS	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
identified	VBN	O	O
a	DT	O	O
new	JJ	O	O
locus	NN	O	O
involved	VBN	O	O
in	IN	O	O
progressive	JJ	O	B_Disease
liver	NN	B_Disease	I_Disease
disease	NN	E_Disease	E_Disease
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
whether	IN	O	O
the	DT	O	O
WD	NNP	S_Disease	S_Disease
gene	NN	O	O
ATP7B	NNP	O	O
was	VBD	O	O
also	RB	O	O
causative	JJ	O	O
for	IN	O	O
CT	NNP	S_Disease	O
by	IN	O	O
investigating	VBG	O	O
the	DT	O	O
chromosomal	JJ	O	O
co	NN	O	O
-	:	O	O
localization	NN	O	O
of	IN	O	O
ATP7B	NNP	O	O
and	CC	O	O
C04107	NNP	O	O
,	,	O	O
using	VBG	O	O
fluorescence	NN	O	O
in	IN	O	O
situ	JJ	O	O
hybridization	NN	O	O
(	(	O	O
FISH	NNP	O	O
)	)	O	O
.	.	O	O

C04107	NNP	O	O
is	VBZ	O	O
an	DT	O	O
anonymous	JJ	O	O
microsatellite	NN	O	O
marker	NN	O	O
closely	RB	O	O
linked	VBN	O	O
to	TO	O	O
CT	NNP	S_Disease	O
.	.	O	O

However	RB	O	O
,	,	O	O
BAC	NNP	O	O
clones	VBZ	O	O
containing	VBG	O	O
ATP7B	NNP	O	O
and	CC	O	O
C04107	NNP	O	O
mapped	VBD	O	O
to	TO	O	O
the	DT	O	O
canine	NN	O	O
chromosome	NN	O	O
regions	NNS	O	O
CFA22q11	NNP	O	O
and	CC	O	O
CFA10q26	NNP	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
demonstrating	VBG	O	O
that	IN	O	O
WD	NNP	S_Disease	S_Disease
cannot	NN	O	O
be	VB	O	O
homologous	JJ	O	O
to	TO	O	O
CT	NNP	S_Disease	O
.	.	O	O

The	DT	O	O
copper	NN	O	O
transport	NN	O	O
genes	NNS	O	O
CTR1	NNP	O	O
and	CC	O	O
CTR2	NNP	O	O
were	VBD	O	O
also	RB	O	O
excluded	VBN	O	O
as	IN	O	O
candidate	NN	O	O
genes	NNS	O	O
for	IN	O	O
CT	NNP	S_Disease	O
since	IN	O	O
they	PRP	O	O
both	DT	O	O
mapped	VBD	O	O
to	TO	O	O
canine	VB	O	O
chromosome	JJ	O	O
region	NN	O	O
CFA11q22	NNP	O	O
.	.	O	O

2	CD	O	O
-	:	O	O
22	CD	O	O
.	.	O	O

5	CD	O	O
.	.	O	O

A	DT	O	O
transcribed	JJ	O	O
sequence	NN	O	O
identified	VBN	O	O
from	IN	O	O
the	DT	O	O
C04107	NNP	O	O
-	:	O	O
containing	VBG	O	O
BAC	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
homologous	JJ	O	O
to	TO	O	O
a	DT	O	O
gene	NN	O	O
expressed	VBN	O	O
from	IN	O	O
human	JJ	O	O
chromosome	NN	O	O
2p13	CD	O	O
-	:	O	O
p16	NN	O	O
,	,	O	O
a	DT	O	O
region	NN	O	O
devoid	NN	O	O
of	IN	O	O
any	DT	O	O
positional	JJ	O	O
candidate	NN	O	O
genes	NNS	O	O
.	.	O	O

9950360	CD	O	O

Molecular	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
in	IN	O	O
205	CD	O	O
families	NNS	O	O
:	:	O	O
extended	VBN	O	O
genotype	NN	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
in	IN	O	O
FAP	NNP	S_Disease	S_Disease
and	CC	O	O
evidence	NN	O	O
for	IN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
APC	NNP	S_Disease	O
amino	NN	O	O
acid	NN	O	O
changes	NNS	O	O
in	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
predisposition	NN	O	O
.	.	O	O

BACKGROUND	NNP	O	O
/	NNP	O	O
AIMS	NNP	O	O
The	DT	O	O
development	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
and	CC	O	O
a	DT	O	O
variable	JJ	O	O
range	NN	O	O
of	IN	O	O
extracolonic	JJ	O	B_Disease
manifestations	NNS	O	E_Disease
in	IN	O	O
familial	JJ	B_Disease	B_Disease
adenomatous	JJ	I_Disease	I_Disease
polyposis	NN	E_Disease	E_Disease
(	(	O	O
FAP	NNP	S_Disease	S_Disease
)	)	O	O
is	VBZ	O	O
the	DT	O	O
result	NN	O	O
of	IN	O	O
the	DT	O	O
dominant	JJ	O	O
inheritance	NN	O	O
of	IN	O	O
adenomatous	JJ	B_Disease	B_Disease
polyposis	NN	I_Disease	I_Disease
coli	NN	E_Disease	E_Disease
(	(	O	O
APC	NNP	S_Disease	S_Disease
)	)	O	O
gene	NN	O	O
mutations	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
direct	JJ	O	O
mutation	NN	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
determine	VB	O	O
genotype	JJ	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
for	IN	O	O
nine	CD	O	O
extracolonic	JJ	O	B_Disease
manifestations	NNS	O	E_Disease
and	CC	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
incidence	NN	O	O
of	IN	O	O
APC	NNP	S_Disease	S_Disease
mutations	NNS	O	O
in	IN	O	O
non	JJ	O	O
-	:	O	O
FAP	NNP	O	B_Disease
colorectal	JJ	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

METHODS	NNP	O	O
The	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
was	VBD	O	O
analysed	VBN	O	O
in	IN	O	O
190	CD	O	O
unrelated	JJ	O	O
FAP	NNP	S_Disease	S_Disease
and	CC	O	O
15	CD	O	O
non	JJ	O	O
-	:	O	O
FAP	NNP	O	B_Disease
colorectal	JJ	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
patients	NNS	O	O
using	VBG	O	O
denaturing	VBG	O	O
gradient	JJ	O	O
gel	NN	O	O
electrophoresis	NN	O	O
,	,	O	O
the	DT	O	O
protein	NN	O	O
truncation	NN	O	O
test	NN	O	O
,	,	O	O
and	CC	O	O
direct	JJ	O	O
sequencing	NN	O	O
.	.	O	O

RESULTS	NNP	O	O
Chain	NNP	O	O
terminating	VBG	O	O
signals	NNS	O	O
were	VBD	O	O
only	RB	O	O
identified	VBN	O	O
in	IN	O	O
patients	NNS	O	O
belonging	VBG	O	O
to	TO	O	O
the	DT	O	O
FAP	NNP	S_Disease	S_Disease
group	NN	O	O
(	(	O	O
105	CD	O	O
patients	NNS	O	O
)	)	O	O
.	.	O	O

Amino	NNP	O	O
acid	NN	O	O
changes	NNS	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
four	CD	O	O
patients	NNS	O	O
,	,	O	O
three	CD	O	O
of	IN	O	O
whom	WP	O	O
belonged	VBD	O	O
to	TO	O	O
the	DT	O	O
non	JJ	O	O
-	:	O	O
FAP	NNP	O	S_Disease
group	NN	O	O
of	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
patients	NNS	O	O
.	.	O	O

Genotype	NNP	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
identified	VBN	O	O
significant	JJ	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
nature	NN	O	O
of	IN	O	O
certain	JJ	O	O
extracolonic	JJ	O	B_Disease
manifestations	NNS	O	E_Disease
in	IN	O	O
FAP	NNP	S_Disease	S_Disease
patients	NNS	O	O
belonging	VBG	O	O
to	TO	O	O
three	CD	O	O
mutation	NN	O	O
subgroups	NNS	O	O
.	.	O	O

CONCLUSIONS	NNP	O	O
Extended	NNP	O	O
genotype	NN	O	O
-	:	O	O
phenotype	NN	O	O
correlations	NNS	O	O
made	VBN	O	O
in	IN	O	O
this	DT	O	O
study	NN	O	O
may	MD	O	O
have	VB	O	O
the	DT	O	O
potential	NN	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
most	RBS	O	O
appropriate	JJ	O	O
surveillance	NN	O	O
and	CC	O	O
prophylactic	JJ	O	O
treatment	NN	O	O
regimens	NNS	O	O
for	IN	O	O
those	DT	O	O
patients	NNS	O	O
with	IN	O	O
mutations	NNS	O	O
associated	VBN	O	O
with	IN	O	O
life	NN	O	O
threatening	VBG	O	O
conditions	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
also	RB	O	O
provided	VBD	O	O
evidence	NN	O	O
for	IN	O	O
the	DT	O	O
pathological	JJ	O	O
nature	NN	O	O
of	IN	O	O
amino	NN	O	O
acid	NN	O	O
changes	NNS	O	O
in	IN	O	O
APC	NNP	O	S_Disease
associated	VBN	O	O
with	IN	O	O
both	DT	O	O
FAP	NNP	S_Disease	S_Disease
and	CC	O	O
non	SYM	O	O
-	:	O	O
FAP	NNP	O	B_Disease
colorectal	JJ	B_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
patients	NNS	O	O
.	.	O	O
.	.	O	O

9973276	CD	O	O

Inherited	VBN	B_Disease	B_Disease
colorectal	JJ	I_Disease	I_Disease
polyposis	NN	E_Disease	E_Disease
and	CC	O	I_Disease
cancer	NN	S_Disease	E_Disease
risk	NN	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
polymorphism	NN	O	O
.	.	O	O

Germ	NNP	O	O
-	:	O	O
line	NN	O	O
and	CC	O	O
somatic	JJ	O	O
truncating	NN	O	O
mutations	NNS	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
are	VBP	O	O
thought	VBN	O	O
to	TO	O	O
initiate	VB	O	O
colorectal	JJ	B_Disease	B_Disease
tumor	NN	E_Disease	E_Disease
formation	NN	O	O
in	IN	O	O
familial	JJ	B_Disease	B_Disease
adenomatous	JJ	I_Disease	I_Disease
polyposis	NN	I_Disease	I_Disease
syndrome	NN	E_Disease	E_Disease
and	CC	O	O
sporadic	JJ	O	O
colorectal	JJ	O	B_Disease
carcinogenesis	NN	O	E_Disease
,	,	O	O
respectively	RB	O	O
.	.	O	O

Recently	RB	O	O
,	,	O	O
an	DT	O	O
isoleucine	NN	O	O
-	:	O	O
-	:	O	O
>	NN	O	O
lysine	JJ	O	O
polymorphism	NN	O	O
at	IN	O	O
codon	NN	O	O
1307	CD	O	O
(	(	O	O
I1307K	NNP	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
APC	NNP	S_Disease	S_Disease
gene	NN	O	O
has	VBZ	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
6	CD	O	O
%	NN	O	O
-	:	O	O
7	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
Ashkenazi	NNP	O	O
Jewish	NNP	O	O
population	NN	O	O
.	.	O	O

To	TO	O	O
assess	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
this	DT	O	O
common	JJ	O	O
APC	NNP	S_Disease	S_Disease
allelic	JJ	O	O
variant	NN	O	O
in	IN	O	O
colorectal	JJ	O	B_Disease
carcinogenesis	NN	O	E_Disease
,	,	O	O
we	PRP	O	O
have	VBP	O	O
analyzed	VBN	O	O
a	DT	O	O
large	JJ	O	O
cohort	NN	O	O
of	IN	O	O
unselected	JJ	O	O
Ashkenazi	NNP	O	O
Jewish	NNP	O	O
subjects	NNS	O	O
with	IN	O	O
adenomatous	JJ	B_Disease	B_Disease
polyps	NNS	E_Disease	E_Disease
and	CC	O	O
.	.	O	O

or	CC	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	I_Disease	E_Disease
,	,	E_Disease	O
for	IN	O	O
the	DT	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
polymorphism	NN	O	O
.	.	O	O

The	DT	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
allele	NN	O	O
was	VBD	O	O
identified	VBN	O	O
in	IN	O	O
48	CD	O	O
(	(	O	O
10	CD	O	O
.	.	O	O

1	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
476	CD	O	O
patients	NNS	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
the	DT	O	O
frequency	NN	O	O
in	IN	O	O
two	CD	O	O
separate	JJ	O	O
population	NN	O	O
control	NN	O	O
groups	NNS	O	O
,	,	O	O
the	DT	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
allele	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
estimated	VBN	O	O
relative	JJ	O	O
risk	NN	O	O
of	IN	O	O
1	CD	O	O
.	.	O	O

5	CD	O	O
-	:	O	O
1	CD	O	O
.	.	O	O

7	CD	O	O
for	IN	O	O
colorectal	JJ	B_Disease	B_Disease
neoplasia	NN	E_Disease	E_Disease
(	(	O	O
both	DT	O	O
P	NNP	O	O
=	NN	O	O
.	.	O	O

01	CD	O	O
)	)	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
noncarriers	NNS	O	O
,	,	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
carriers	NNS	O	O
had	VBD	O	O
increased	VBN	O	O
numbers	NNS	O	O
of	IN	O	O
adenomas	NN	S_Disease	S_Disease
and	CC	O	O
colorectal	JJ	B_Disease	B_Disease
cancers	NNS	E_Disease	E_Disease
per	IN	O	O
patient	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
.	.	O	O

03	CD	O	O
)	)	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
younger	JJR	O	O
age	NN	O	O
at	IN	O	O
diagnosis	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
APC	NNP	O	S_Disease
I1307K	NNP	O	O
variant	JJ	O	O
leads	VBZ	O	O
to	TO	O	O
increased	VBN	O	O
adenoma	NN	S_Disease	S_Disease
formation	NN	O	O
and	CC	O	O
directly	RB	O	O
contributes	VBZ	O	O
to	TO	O	O
3	CD	O	O
%	NN	O	O
-	:	O	O
4	CD	O	O
%	NN	O	O
of	IN	O	O
all	DT	O	O
Ashkenazi	NNP	O	O
Jewish	NNP	O	O
colorectal	NN	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
.	.	O	O

The	DT	O	O
estimated	VBN	O	O
relative	NN	O	O
risk	NN	O	O
for	IN	O	O
carriers	NNS	O	O
may	MD	O	O
justify	VB	O	O
specific	JJ	O	O
clinical	JJ	O	O
screening	NN	O	O
for	IN	O	O
the	DT	O	O
360	CD	O	O
,	,	O	O
000	CD	O	O
Americans	NNPS	O	O
expected	VBN	O	O
to	TO	O	O
harbor	VB	O	O
this	DT	O	O
allele	NN	O	O
,	,	O	O
and	CC	O	O
genetic	JJ	O	O
testing	NN	O	O
in	IN	O	O
the	DT	O	O
setting	NN	O	O
of	IN	O	O
long	JJ	O	O
-	:	O	O
term	NN	O	O
-	:	O	O
outcome	NN	O	O
studies	NNS	O	O
may	MD	O	O
impact	VB	O	O
significantly	RB	O	O
on	IN	O	O
colorectal	JJ	B_Disease	B_Disease
cancer	NN	E_Disease	E_Disease
prevention	NN	O	O
in	IN	O	O
this	DT	O	O
population	NN	O	O
.	.	O	O

9988281	CD	O	O

Localization	NN	O	O
of	IN	O	O
human	JJ	O	O
BRCA1	NNP	O	O
and	CC	O	O
its	PRP$	O	O
loss	NN	O	O
in	IN	O	O
high	JJ	O	O
-	:	O	O
grade	NN	O	O
,	,	O	O
non	SYM	B_Disease	O
-	:	I_Disease	O
inherited	VBN	I_Disease	O
breast	NN	I_Disease	I_Disease
carcinomas	NN	E_Disease	E_Disease
.	.	O	O

Although	IN	O	O
the	DT	O	O
link	NN	O	O
between	IN	O	O
the	DT	O	O
BRCA1	NNP	O	B_Disease
tumour	SYM	S_Disease	E_Disease
-	:	O	O
suppressor	NN	O	O
gene	NN	O	O
and	CC	O	O
hereditary	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancer	NN	E_Disease	E_Disease
is	VBZ	O	O
established	VBN	O	O
,	,	O	O
the	DT	O	O
role	NN	O	O
,	,	O	O
if	IN	O	O
any	DT	O	O
,	,	O	O
of	IN	O	O
BRCA1	NNP	O	O
in	IN	O	O
non	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
familial	JJ	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
is	VBZ	O	O
unclear	JJ	O	O
.	.	O	O

BRCA1	NNP	O	O
mutations	NNS	O	O
are	VBP	O	O
rare	JJ	O	O
in	IN	O	O
sporadic	JJ	B_Disease	B_Disease
cancers	NNS	E_Disease	E_Disease
,	,	O	O
but	CC	O	O
loss	NN	O	O
of	IN	O	O
BRCA1	NNP	O	O
resulting	VBG	O	O
from	IN	O	O
reduced	VBN	O	O
expression	NN	O	O
or	CC	O	O
incorrect	VB	O	O
subcellular	JJ	O	O
localization	NN	O	O
is	VBZ	O	O
postulated	VBN	O	O
to	TO	O	O
be	VB	O	O
important	JJ	O	O
in	IN	O	O
non	JJ	B_Disease	B_Disease
-	:	I_Disease	I_Disease
familial	JJ	I_Disease	I_Disease
breast	NN	I_Disease	I_Disease
and	CC	I_Disease	I_Disease
ovarian	JJ	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
.	.	O	O

Epigenetic	JJ	O	O
loss	NN	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
has	VBZ	O	O
not	RB	O	O
received	VBN	O	O
general	JJ	O	O
acceptance	NN	O	O
due	JJ	O	O
to	TO	O	O
controversy	VB	O	O
regarding	VBG	O	O
the	DT	O	O
subcellular	JJ	O	O
localization	NN	O	O
of	IN	O	O
BRCA1	NNP	O	O
proteins	NNS	O	O
,	,	O	O
reports	NNS	O	O
of	IN	O	O
which	WDT	O	O
have	VBP	O	O
ranged	VBN	O	O
from	IN	O	O
exclusively	RB	O	O
nuclear	JJ	O	O
,	,	O	O
to	TO	O	O
conditionally	RB	O	O
nuclear	JJ	O	O
,	,	O	O
to	TO	O	O
the	DT	O	O
ER	NNP	O	O
/	NNP	O	O
golgi	NN	O	O
,	,	O	O
to	TO	O	O
cytoplasmic	VB	O	O
invaginations	NNS	O	O
into	IN	O	O
the	DT	O	O
nucleus	NN	O	O
.	.	O	O

In	IN	O	O
an	DT	O	O
attempt	NN	O	O
to	TO	O	O
resolve	VB	O	O
this	DT	O	O
issue	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
comprehensively	RB	O	O
characterized	VBN	O	O
19	CD	O	O
anti	JJ	O	O
-	:	O	O
BRCA1	NNP	O	O
antibodies	NNS	O	O
.	.	O	O

These	DT	O	O
reagents	NNS	O	O
detect	VBP	O	O
a	DT	O	O
220	CD	O	O
-	:	O	O
kD	NN	O	O
protein	NN	O	O
localized	VBN	O	O
in	IN	O	O
discrete	JJ	O	O
nuclear	JJ	O	O
foci	NN	O	O
in	IN	O	O
all	DT	O	O
epithelial	JJ	O	O
cell	NN	O	O
lines	NNS	O	O
,	,	O	O
including	VBG	O	O
those	DT	O	O
derived	VBN	O	O
from	IN	O	O
breast	NN	B_Disease	B_Disease
malignancies	NNS	E_Disease	E_Disease
.	.	O	O

Immunohistochemical	JJ	O	O
staining	NN	O	O
of	IN	O	O
human	JJ	O	O
breast	NN	O	O
specimens	NNS	O	O
also	RB	O	O
revealed	VBD	O	O
BRCA1	NNP	O	O
nuclear	JJ	O	O
foci	NN	O	O
in	IN	O	O
benign	JJ	O	B_Disease
breast	NN	O	I_Disease
,	,	O	I_Disease
invasive	JJ	B_Disease	I_Disease
lobular	NN	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
and	CC	O	O
low	JJ	B_Disease	O
-	:	I_Disease	O
grade	NN	I_Disease	O
ductal	JJ	I_Disease	I_Disease
carcinomas	NN	E_Disease	E_Disease
.	.	O	O

Conversely	RB	O	O
,	,	O	O
BRCA1	NNP	O	O
expression	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
or	CC	O	O
undetectable	JJ	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
high	JJ	O	O
-	:	O	O
grade	NN	O	O
,	,	O	O
ductal	JJ	B_Disease	B_Disease
carcinomas	NN	E_Disease	E_Disease
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
absence	NN	O	O
of	IN	O	O
BRCA1	NNP	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
a	DT	O	O
significant	JJ	O	O
percentage	NN	O	O
of	IN	O	O
sporadic	JJ	B_Disease	B_Disease
breast	NN	I_Disease	I_Disease
cancers	NNS	E_Disease	E_Disease
.	.	O	O
.	.	O	O

